

Finnish statistics on medicines 2022

Kela[®] fimea

Finnish Medicines Agency Fimea

Mannerheimintie 166
P.O. Box 55
FI-00034 Fimea
Finland
salesstatistics@fimea.fi
Tel. +358 29 522 3341

Social Insurance Institution

Nordenskiöldinkatu 12
P.O. Box 450
FI-00056 Kela
Finland
tilastot@kela.fi
Tel. +358 20 634 11


ISSN 2737-3592

Key figures for medicine sales and their reimbursement in 2022

Total sales of pharmaceuticals

Sales to hospitals and other health care institutions (at wholesale prices)
865 million euros,
0.4% change from 2021

OTC medicines (at pharmacy prices with VAT)
398 million euros,
10.6% change from 2021




Prescription medicines (at pharmacy prices with VAT)
2,494 million euros,
3.9% change from 2021

Reimbursement of medicine costs

Additional Refunds
257 million euros,
12.5% change from 2021

Basic Refunds
334 million euros,
7.2% change from 2021



Special Refunds
1,182 million euros,
0.9% change from 2021



Contents

List of figures.....	5	7. Tables: Sales statistics according to medicine group	90
List of tables.....	6	A Alimentary tract and metabolism	91
1. Basic information about the compilation of statistics on medicines	10	B Blood and blood forming organs	111
Concepts in Finnish statistics on medicines	11	C Cardiovascular system	121
Material used for the statistics	14	D Dermatologicals	137
Abbreviations, definitions and symbols	14	G Genito urinary system and sex hormones	148
Calculating drug consumption	15	H Systemic hormonal preparations, excl. sex hormones and insulins	157
Structure of the ATC system	16	J Antiinfectives for systemic use	163
2. Current issues in pharmacy	17	L Antineoplastic and immunomodulating agents	176
Key events in the pharmaceutical field in 2022	18	M Musculo-skeletal system	194
Pharmaceutical year 2022	19	N Nervous system	202
Pharmacy economy.....	29	P Antiparasitic products, insecticides and repellents	219
3. Finnish population and hospital districts	33	R Respiratory system	222
4. Drug control and pharmaceutical services	36	S Sensory organs	234
Distribution of medicine sales	37	V Various	242
Pharmacies and hospital pharmacies	38	Nicotine replacement therapy	250
5. National health insurance and reimbursement of medicine expenses	41	OTC medicines in outpatient care	252
The medicine supply chain and the role of various organisations in oversight and reimbursement	42	Figures on sales statistics	276
Medicine reimbursement system and approval of medicine prices	43	Appendices	293
Reimbursable medicines, confirming wholesale prices, and the reference price system.....	51	Appendix 1. Alterations to ATC classification, valid as of January 2023	294
6. Tables: Reimbursement of medicine costs	58	Appendix 2. Alterations to defined daily doses (DDD), valid as of January 2023	295
Medicine costs and their reimbursement annually and according to hospital district	59	Appendix 3. Deflators for converting expenditure items to 2022 money, 2000–2022	296
Medicine costs and their reimbursement in diseases entitling patients to special refund	62		
Medicinal products eligible for restricted basic refund	79		
Clinical nutritional preparations	83		
Medicine costs and their reimbursement according to prescriber	84		



List of figures

1. Basic information about the compilation of statistics on medicines	10	Figure 7.6. Consumption and sales of agents acting on renin-angiotensin system (C09) in 2006–2022	281
2. Current issues in pharmacy	17	Figure 7.7. Consumption of agents acting on renin-angiotensin system (C09) by hospital district in 2022	282
Figure 2.1. Payback payments for conditional reimbursements in 2019–2022	19	Figure 7.8. Consumption and sales of statins (C10AA) in 2006–2022	283
Figure 2.2. Trends in sales of prescription medicines in outpatient care (at retail prices), in the costs forming the basis for reimbursement of prescription medicines in outpatient care, and in reimbursements paid out for prescription medicines in outpatient care, 2010–2022	20	Figure 7.9. Consumption of lipid modifying agents reducers (C10) by hospital district in 2022	284
Figure 2.3. Consumption and sales of nicotine products in 2005–2022	28	Figure 7.10. Consumption of hormonal contraceptives in 2006–2022	284
3. Finnish population and hospital districts	33	Figure 7.11. Consumption of hormone replacement therapy drugs (G03C, G03F) among women aged over 45 by hospital district in 2022	285
Figure 3.2. University hospital regions and hospital districts in 2022	34	Figure 7.12. Consumption of antibacterials (J01) in 2006–2022	285
4. Drug control and pharmaceutical services	36	Figure 7.13. Consumption of antibacterials (J01) by hospital district in 2022	286
Figure 4.1. Distribution of medicine sales between pharmacies and hospitals according to the ATC code, at wholesales prices, in 2022, EUR 1,000	37	Figure 7.14. Consumption of analgesics (M01A, N02A and N02B) in 2006–2022	286
Figure 4.2. Number of pharmacies and prescriptions dispensed in 1990–2022	39	Figure 7.15. Consumption of most common OTC analgesics in 2006–2022	287
Figure 4.3. Number of pharmacies per 10,000 inhabitants by hospital district in 2022	40	Figure 7.16. Consumption of opioids (N02A, N07BC) in 2006–2022	287
5. National health insurance and reimbursement of medicine expenses	41	Figure 7.17. Consumption of most common hypnotics (N05C) in 2006–2022	288
Reimbursements for medicine expenses in 2022	49	Figure 7.18. Consumption of hypnotics (N05C) in outpatient care by hospital district in 2022	288
Figure 5.1. Reimbursement of medicine costs in 2000–2022 according to Refund Category	50	Figure 7.19. Consumption of antidepressants (N06A) in 2006–2022	289
6. Tables: Reimbursement of medicine costs	58	Figure 7.20. Consumption of most common antidepressants (N06A) in 2006–2022	289
Figure 6.1. Percentages of medicine prescribers, 2022	85	Figure 7.21. Consumption of antidepressants (N06A) in outpatient care by hospital district in 2022	290
7. Tables: Sales statistics according to medicine group	90	Figure 7.22. Consumption of inhaled drugs for obstructive airway diseases in 2006–2022	291
Figure 7.1. Consumption and sales of proton pump inhibitors (A02BC) in 2006–2022	276	Figure 7.23. Consumption of drugs for obstructive airway diseases (R03) by hospital district in 2022	292
Figure 7.2. Consumption of drugs for acid related disorders (A02) by hospital district in 2022	277	Appendices	293
Figure 7.3. Consumption and sales of insulins and analogues (A10A) in 2006–2022	278		
Figure 7.4. Consumption and sales of Blood glucose lowering drugs (A10B) in 2006–2022	279		
Figure 7.5. Consumption and sales of most common antihypertensives in 2006–2022	280		



List of tables

1. Basic information about the compilation of statistics on medicines Anatomical Therapeutic Chemical	10	5. National health insurance and reimbursement of medicine expenses	41
2. Current issues in pharmacy	17	Table 5.1. Reimbursement numbers adopted in 2022, basic reimbursement	46
Table 2.1 Top 10 medicines sold in 2022 (wholesale)	21	Table 5.2. Reimbursement numbers discontinued in 2022, basic reimbursement	46
Table 2.2. Top 10 medicines by consumption in 2022	22	Table 5.3. Reimbursement numbers adopted in 2022, special reimbursement	47
Table 2.3. Average turnover of private pharmacies 2008–2022 (EUR million)	29	Table 5.4. Reimbursement numbers discontinued in 2022, special reimbursement	47
Table 2.4. Average gross margin percentages of private pharmacies 2008–2022	30	Table 5.5. Medicines added to existing reimbursement numbers in 2022, basic reimbursement	48
Table 2.5. Average operating profit of private pharmacies before appropriations and taxes in 2008–2022 (EUR thousand)	31	Table 5.6. Medicines added to existing reimbursement numbers in 2022, special reimbursement	48
3. Finnish population and hospital districts	33	Table 5.7. Medicine costs and their reimbursement in 2022	50
Table 3.1. Population according to hospital district, the proportion of elderly people and the proportion of the population in receipt of Special Refunds of medicines of the total population, at the end of 2022	35	Table 5.8. Calculation formula for retail prices, without VAT, of medicinal products in 2022	56
Table 3.2. Population according to university hospital regions by age groups, 31 December 2022	35	Table 5.9. New active substances in 2022	56
4. Drug control and pharmaceutical services	36	Table 5.10. Number of applications for reasonable wholesale prices and reimbursement status processed by the Pharmaceuticals Pricing Board in 2022	57
Table 4.1. Medicine sales to pharmacies and hospitals at wholesale prices according to the ATC code in 2022	37	Table 5.11. Median process times of applications (number of days) approved or rejected by the Pharmaceuticals Pricing Board, according to the type of application, in 2022	57
Table 4.2. Statistics for pharmacies in 2022	38		
Table 4.3. Dispensations dispensed by pharmacies in 2005–2022	39		



6. Tables: Reimbursement of medicine costs	58
Table 6.2. Medicine costs and their reimbursement according to hospital district, in 2022	61
Table 6.3. Payback payments for conditional reimbursements in 2019-2021.....	61
Table 6.4. Patients entitled to reimbursement under the Special Refund Categories, and cost of the diseases per recipient in 2022	62
Table 6.5. Patients receiving reimbursement payments under the Special Refund Categories and total cost and reimbursement payments in the Special Refund Categories in 2022	69
Table 6.6. Drug treatment statistics of the most common diseases entitling the patients to reimbursement under the Special Refund Categories, in 2022	73
Table 6.7. Medicines eligible for restricted basic refund: Number of purchasers and the cost of reimbursed drugs in 2022	79
Table 6.8. Clinical nutritional preparations reimbursable under the Health Insurance Scheme: Number of purchasers and the cost of reimbursed preparations in 2022	83
Table 6.9. Medicine prescribers, 2015–2022	84
Table 6.10. Average number and cost (before reimbursement is deducted) of dispensations per doctor, according to speciality, in 2022 (only those dispensations entitled to reimbursement are included)	86
Table 6.11. Data relating to purchases of reimbursable medicines eligible for generic substitution and savings generated through substitution, in 2016–2022	88

7. Tables: Sales statistics according to medicine group	90
A01 Stomatological preparations	92
A02 Drugs for acid related disorders	93
A03 Drugs for functional gastrointestinal disorders	95
A04 Antiemetics and antinauseants	97
A05 Sapeneritystä lisäävät valmisteet ja maksan suoja-aineet	97
A06 Drugs for constipation	98
A07 Antidiarrheals, intestinal antiinflammatory/antiinfective agents	100
A08 Antiobesity preparations, excl. diet products	102
A09 Digestives, incl. enzymes	102
A10 Drugs used in diabetes	103
A11 Vitamins	106
A12 Mineral supplements	108
A14 Anabolic agents for systemic use	109
A16 Other alimentary tract and metabolism products	109
B01 Antithrombotic agents	112
B02 Antihemorrhagics	114
B03 Antianemic preparations	116
B05 Blood substitutes and perfusion solutions	118
B06 Other hematological agents	120
C01 Cardiac therapy	122
C02 Antihypertensives	125
C03 Diuretics	126
C04 Peripheral vasodilators.....	127
C05 Vasoprotectives	128
C07 Beta blocking agents	129
C08 Calcium channel blockers	131
C09 Agents acting on the renin-angiotensin system	132
C10 Lipid modifying agents	135



D01	Antifungals for dermatological use	138	L01	Antineoplastic agents	177
D02	Emollients and protectives	139	L02	Endocrine therapy	188
D03	Preparations for treatment of wounds and ulcers	139	L03	Immunostimulants	190
D04	Antipruritics, incl. antihistamines, anesthetics, etc.	140	L04	Immunosuppressants	191
D05	Antipsoriatics	140	M01	Antiinflammatory and antirheumatic products	195
D06	Antibiotics and chemotherapeutics for dermatological use	141	M02	Topical products for joint and muscular pain	197
D07	Corticosteroids, dermatological preparations	142	M03	Muscle relaxants	198
D08	Antiseptics and disinfectants	144	M04	Antigout preparations	199
D09	Medicated dressings	144	M05	Drugs for treatment of bone diseases	200
D10	Anti-acne preparations	145	M09	Other drugs for disorders of the musculo-skeletal system	201
D11	Other dermatological preparations	146	N01	Anesthetics	203
G01	Gynecological antiinfectives and antiseptics	149	N02	Analgesics	205
G02	Other gynecologicals	150	N03	Antiepileptics	208
G03	Sex hormones and modulators of the genital system	151	N04	Anti-parkinson drugs	210
G04	Urologicals	155	N05	Psycholeptics	211
H01	Pituitary, hypothalamic hormones and analogues	158	N06	Psychoanaleptics	214
H02	Corticosteroids for systemic use	160	N07	Other nervous system drugs	217
H03	Thyroid therapy	161	P01	Antiprotozoals	220
H04	Haiman hormonit	161	P02	Anthelmintics	221
H05	Calcium homeostasis	162	P03	Ectoparasiticides, incl. scabicides, insecticides and repellents	221
J01	Antibacterials for systemic use	164	R01	Nasal preparations	223
J02	Antimycotics for systemic use	168	R02	Throat preparations	225
J04	Antimycobacterials	169	R03	Drugs for obstructive airway diseases	226
J05	Antivirals for systemic use	170	R05	Cough and cold preparations	230
J06	Immune sera and immunoglobulins	174	R06	Antihistamines for systemic use	232
J07	Vaccines	175	R07	Other respiratory system products	233



S01 Ophthalmologicals	235
S02 Otologicals	240
S03 Ophthalmological and otological preparations	241
V01 Allergens	243
V03 All other therapeutic products	244
V04 Diagnostic agents	246
V07 All other non-therapeutic products	247
V08 Contrast media	248
Appendices	293

1. Basic information
about the compilation
of statistics on
medicines



Concepts in Finnish statistics on medicines

Active substance

The effective ingredient contained in a medicinal product. This is the most detailed (5th) level of ATC classification.

Additional Refund

A patient becomes eligible for Additional Refund payments if his/her personal payments for the non-reimbursed part of his/her medicines, clinical nutritional preparations and basic topical ointments exceed a certain limit during a calendar year. In such a case, the patient pays a fixed deductible of EUR 2.50 per reimbursable medicine purchased, and the rest is refunded in full under the National Health Insurance Scheme.

Annual deductible (ceiling)

This is the upper limit for annual out-of-pocket-cost. If this is exceeded, the customer is entitled to an additional refund. The purpose of the additional refund is to ensure that no individual faces unreasonably high medicine costs.

ATC classification

A pharmaceutical classification system developed and maintained by the World Health Organization (WHO). In this anatomic-therapeutic-chemical (ATC) classification, medicinal agents are divided into different groups according to the organ or system on which they act and their therapeutic, pharmacological and chemical properties. The Finnish statistics on medicines follows the most recent version of ATC classification, which is commonly used for statistics on the consumption of medicines. Please also see the section on the structure of the ATC system.

Basic Refund

The National Health Insurance Scheme reimburses 40% of the cost of medicines in the Basic Refund Category.

Biosimilar

A biological medicine containing the same active substance as the corresponding original biological medicine and designed to be identical and comparable to the original.

Conditional reimbursement

A risk sharing method used in Finland which aims to control the introduction of new pharmaceuticals at the beginning of their life cycle. Conditional reimbursement hinges on confidential agreements between the Pharmaceuticals Pricing Board and pharmaceutical companies. So far, the agreements concluded have been financial agreements concerning a payback payment to Kela.

Cost/Medicine costs

The total cost of a medicine before the deduction of the reimbursement paid under the National Health Insurance Scheme. The costs listed in the register 'Dispensations reimbursable under the National Health Insurance Scheme' from Kela include the costs of medicines purchased at pharmacies, at retail price inclusive of tax, i.e. including the pharmacy markup, delivery fees and VAT. Please also see the figures for wholesale sales of medicines.

Defined Daily Dose (DDD)

The DDD is a unit of measurement of pharmaceutical consumption. Please also see Calculation of consumption of pharmaceuticals.

Direct refundreimbursement

Generally, customers are credited refunds on their medicines at the pharmacy once their initial deductible limit has been met. The pharmacy deducts the refund from the price of the medicine, and the customer pays the rest. Pharmacies verify eligibility for refunds using the Kela's direct reimbursement inquiry service for every purchase of medicines. The query service also informs pharmacies about customers' entitlement to refunds. Pharmacies have access to up-to-date information on the accrual of initial and annual deductibles. As of the beginning of 2020, direct reimbursements also apply to additional refunds. Additional refunds are applied at pharmacies to purchases that exceed the predetermined ceiling.

Dispensation (filled prescriptions)

The batch of a medicinal product dispensed by a pharmacy at any one time. A medicine prescribed for a period of one or two years is recorded as several dispensations, because the National Health Insurance Scheme only permits refunds for purchases of a three-month supply of medicines.



Generic medicine

A medicinal product that entered the market after the expiry of the patent on the original preparation, containing the same active agent as the original and having the same dosage and form. Also referred to as generic preparation.

Generic Substitution

Generic substitution places the pharmacy under an obligation to substitute a prescribed medicinal product with a less expensive alternative containing the same active substance. However, a medicinal product cannot be substituted if the prescriber has forbidden substitution on medical or therapeutic grounds by marking the prescription accordingly or if the customer forbids substitution. The list of substitutable medicinal products is approved by the Finnish Medicines Agency Fimea.

Initial deductible

Customers will be reimbursed for medicines after their combined purchases have exceeded the initial deductible. The initial deductible is EUR 50 per calendar year. It is applicable from the beginning of the year of the customer's 19th birthday.

Marketing authorisation

A new medicinal product can only be sold or otherwise released for consumption with marketing authorisation granted by the Finnish Medicines Agency Fimea or the European Commission.

Medicinal product

The term refers to a medicine released for consumption in the manufacturer's package. A medicinal product may contain one or more chemical entities.

Medicinal Products Eligible for Restricted Basic Refund / Medicinal Products Eligible for Restricted Special Refund

Certain restrictions apply to the Basic and Special Refunds available for a number of particularly expensive medicines. These costly but clinically valuable medicines are reimbursed only when used to treat specified medical conditions where reimbursement is considered medically justifiable. To qualify the patient must provide a doctor's certificate. In certain cases, an addendum to the prescription sheet will suffice.

Medicine

A substance or preparation, the purpose of which is to treat, alleviate or prevent a disease of its symptoms, or which is used in the diagnosis of a health condition or disease.

Out-of-pocket-cost

The amount of a medicine cost payable by the patient. Please also see Initial deductible and Annual deductible.

Prescription

An order, issued by a doctor or dentist, for a pharmacy to supply a medicinal product to a patient. Some licensed nurses also have a limited right to prescribe medicines to a patient. Previously, the term 'prescription' was also used to refer to the batch of a medicine given out by a pharmacy at any one time, but the current term for this is 'dispensation'.

Purchase

A purchase usually refers to the medicines, clinical nutritional preparations and basic topical ointments prescribed for the treatment of chronic skin ailments that are bought from a pharmacy for one person during one transaction. The statistics describing the number of purchases according to refund category, however, consider one purchase being the medicines, clinical nutritional preparations or basic topical ointments in the same refund category that are bought from a pharmacy for one person during one transaction.

Rational pharmacotherapy

Pharmacotherapy that is effective, safe, of high quality, cost-effective and equal.

Reference price system

Under the reference price system the reimbursement payment for a medicinal product is calculated from its reference price. Under the reference price system, substitutable medicinal products containing the same active substance in an equal composition, and being sold in comparable package sizes, are grouped together in the same reference price group. The reference price groups are based on the list for substitutable medicinal products compiled by the Finnish Medicines Agency Fimea. A reference price constitutes of the price of the most inexpensive product within the group and an additional EUR 0.50. Reference prices are determined on a quarterly basis by the Pharmaceuticals Pricing Board. The cost in excess of the reference price is payable by the customer should one/he/she forbid substitution. If the substitution is forbidden by the prescribing doctor, or a product at the reference price is not available nationwide, the customer's reimbursement is calculated from the full purchase price.



Refund/Reimbursement of medicine costs

A reimbursement of medicine costs refers to the proportion of the price of a medicine which is reimbursed by the National Health Insurance Scheme. Prescription-only medicines, deemed necessary for the treatment of an illness, are reimbursed under the National Health Insurance Scheme provided that their reimbursability and reasonable wholesale price have been approved. Some over-the-counter (OTC) medicines are also reimbursable when prescribed by a doctor. In addition to medicines, reimbursement is also paid for clinical nutritional preparations used in some serious illnesses, basic topical ointments used for the treatment of chronic skin ailments as well as for dosage service charges.

Special permit

The Finnish Medicines Agency Fimea may allow drugs without marketing authorisation to be released for consumption in individual cases on special medical grounds. For outpatient care the special permit is issued on a named-patient basis. For inpatient care the permit is issued separately for each institution, and it may cover several patients. The special permit is valid for one year from the day of issue.

Special Refund

Special refunds apply to certain serious and chronic diseases. The diseases qualifying customers for special refunds are divided into a higher special refund category and a lower special refund category. In the lower special refund category, the National Health Insurance Scheme covers 65% of the cost of medications. In the higher special refund category, the patient only pays a deductible of EUR 4.50 per medication, the remainder being reimbursed in full (100%). Patients must apply for eligibility from Kela and provide a doctor's statement.

Wholesale sales of medicines

Wholesale sales means the sales of medicines by pharmaceutical wholesale suppliers to pharmacies and institutions. In this publication, wholesale sales of medicines are presented at recommended wholesale prices exclusive of VAT. See also Cost/Medicine costs.



Material used for the statistics

Drug sales register maintained by the Finnish Medicines Agency (Fimea)

The consumption figures in Finnish statistics on medicines are based on the sales of human medicines with marketing authorisation to pharmacies and hospitals by the three largest medicine wholesalers in Finland, Oriola, Tamro and Magnum Medical. Inpatient care institutions also buy medicines from other wholesalers or directly from pharmaceutical companies. Furthermore, they may import medicines themselves. The recommended wholesale figures of medicines do not include value added tax. Changes in ATC classification and DDD values are considered in the reference data as well as images. The figures for 2020 are not fully comparable to the figures in previous editions of the Finnish Statistics on Medicines. Due to a technical error, some data were missing from the previous editions. Additionally, the current figures no longer include medicines supplied to veterinarians. The figures in this year's edition are comparable with those in the 2020 edition.

Special Refund Entitlement Register of Medicines

The register maintained by Kela includes data both about the patients and the medicine refund entitlements granted by Kela.

Dispensations reimbursable under the National Health Insurance Scheme register (previously Kela's Prescription Register)

A register created from pharmacy accounts, comprising all purchases of medicines directly reimbursed upon purchase at the pharmacy, as well as all purchases of medicines within the reimbursement system made before the initial deductible limit has been met. The register includes information, derived from the prescription, relating to the patient, the medicine, the prescribing doctor as well as the cost and reimbursement paid for the medicine.

Register of Statistical Information on National Health Insurance General Benefit Payments

These statistics comprise data about all reimbursement payments paid during the year and are maintained by Kela. The database includes reimbursements applied for retroactively and not included on the 'Dispensations reimbursable under the NHI scheme' register.

Abbreviations, definitions and symbols

Abbreviations

ATC	Anatomical Therapeutic Chemical classification
DDD	Defined Daily Dose
UD	Unit dose (for example one tablet or 5 ml of mixture)
U	Unit
TU	Thousand units
MU	Million units
mcg	Microgram
I	Inhalative
N	Nasal
O	Oral
P	Parenteral
SL	Sublingual
TD	Transdermal
V	Vaginal

Definitions

0	} Less than half of unit employed
0.0	
0.00	

Symbols

-	Magnitude nil
.	Category not applicable
..	Data no available or too uncertain for presentation, or subject to secrecy



Calculating drug consumption

In Finnish Statistics on Medicines, drug consumption is expressed using the unit Defined Daily Dose (DDD). The calculations are based on the volume of wholesale sales, in other words, the amount of medicine in units of weight or volume as well as an internationally agreed medicine-specific theoretic daily dose. The recommended wholesale figures of medicines do not include value added tax.

The following example shows how simvastatin consumption is calculated:

DDD of simvastatin	0.03 g
Sales	1,745,272g/year
Population	5,572,305

1. Total consumption of simvastatin in grams is first converted into DDDs using the following equation:

$$\frac{1,745,272 \text{ g}}{0.03 \text{ g}} = 58,175,722 \text{ DDD}$$

2. The number of DDDs is then adjusted to the population and the number of days per year.

$$\frac{58,175,722 \text{ DDD}}{\left(\frac{5,572,305}{1,000}\right) * 365} = 28.6 \text{ DDD}/1,000 \text{ inhabitants}/\text{day}$$

The figure of 28.6 DDD/1,000 inh/day indicates how many people (in this case 28.6) per 1,000 of the population may, in theory, have received that standard dose (30 mg) of simvastatin.

When interpreting the figures, it should be remembered that the DDD is only a technical expedient and is not necessarily equal to the real dose. The DDD of a drug can be very difficult to establish, as the drug dose depends on indications, individuals and therapeutic practices. When using sales figures provided by wholesalers, it is worth noting that some drugs sold may still be unused, either in dealer stores or in patient homes. The DDD figure is generally calculated in relation to the total population, although drug use may be concentrated in certain age groups or a particular sex.

In retrospective studies, changes in DDD units and the ATC classification should always be considered. Changes made in each year are listed in Appendices of Finnish Statistics on Medicines. In case the DDD of an active substance has changed, the consumption figures of different years should be altered so that they are comparable. This is done by converting the consumption expressed as DDD back to its initial value, in other words the consumption in units of weight or volume, after which it is possible to calculate the new figure by using the new DDD.



Structure of the ATC system

In the Anatomical Therapeutic Chemical (ATC) classification system, the drugs are divided into different groups according to the organ or system on which they act and their chemical, pharmacological and therapeutic properties.


In the ATC system drugs are classified in groups at five different levels. The drugs are divided into fourteen main groups (1st level), with one pharmacological/therapeutic subgroup (2nd level). The 3rd and 4th levels are chemical/pharmacological/therapeutic subgroups and the 5th level is the chemical substance. The 2nd, 3rd and 4th levels are often used to identify pharmacological subgroups when that is considered more appropriate than therapeutic or chemical subgroups.

The complete classification of simvastatin (C10AA01) illustrates the structure of the code:

ATC code	ATC name
C	Cardiovascular system (1st level, anatomical main group)
C10	Lipid modifying agents (2nd level, pharmacological subgroup)
C10A	Lipid modifying agents, plain (3rd level, pharmacological subgroup)
C10AA	HMG CoA reductase inhibitors (4th level, pharmacological subgroup)
C10AA01	Simvastatin (5th level, chemical substance)

Source: Guidelines for ATC classification and DDD assignment, WHO Collaborating Centre for Drug Statistics Methodology, Oslo 2021.

2. Current issues in pharmacy





Key events in the pharmaceutical field in 2022





Pharmaceutical year 2022

Kati Sarnola, PhD (Pharm.), M.Sc. (Econ.), Senior Researcher, Kela


Tinna Voipio, B.Sc. (Pharm.), Researcher, Fimea

Juho Wedenoja, M.D. Adjunct Professor, Senior Medical Officer, Fimea

Leena K. Saastamoinen, PhD (Pharm.), Adjunct professor, Research Manager, Fimea

In the 2022 pharmaceutical year, total medicine sales continued on the same growth path as in previous years. Measured in euros, the best-selling medicine was once again nicotine, sales of which are concentrated outside pharmacies. The growth in sales was curbed by the introduction of and active price competition from more affordable biosimilars. For example, the sales growth of cancer medicines and immune response modifiers stalled for the first time in years. The increase in conditional reimbursement is reflected in an increase in the amount of payback payments.

Figure 2.1. Payback payments for conditional reimbursements in 2019–2022



Sources: Finnish Medicines Agency Fimea, Drug Sales Register, Dispensations reimbursable under the National Health Insurance Scheme register




Medicine sales

In 2022, medicine sales totalled EUR 3,756 million. This figure consists of retail sales of prescription medicines in outpatient care (EUR 2,494 million) and over-the-counter medicines in outpatient care (EUR 398 million), as well as wholesale sales to hospitals and other institutions (EUR 865 million). Compared to 2021, total sales increased by 3.8%, sales of prescription medicines by 3.9%, sales of over-the-counter medicines by 10.6% and hospital and institutional sales by 0.4%. There was, therefore, a clear upturn in over-the-counter medicine sales, which had decreased by 2.2% in the previous year. Growth in hospital and institutional sales was significantly more moderate this year than in the previous year, when growth was 5%.

The sales of medicines by medicine group described in this article are indicated as wholesale sales in euros. Hospital sales are reported at public wholesale prices not subject to competitive tendering, so sales at actual tendered prices are lower than the reported figures. Currently, no statistics are compiled for sales at actual competitive prices.

Figure 2.2. Trends in sales of prescription medicines in outpatient care (at retail prices), in the costs forming the basis for reimbursement of prescription medicines in outpatient care, and in reimbursements paid out for prescription medicines in outpatient care, 2010–2022



Sources: Finnish Medicines Agency Fimea, Drug Sales Register, Dispensations reimbursable under the National Health Insurance Scheme register

Reimbursements for medicine expenses continued to increase

Kela paid out a total of EUR 1.77 billion in reimbursements for medicine expenses in 2022. Reimbursements increased by 3.6%, or EUR 61 million, from the previous year, also taking into account purchases of medicines for which expenses were retrospectively reimbursed. The increase in claims was lower than in 2021, when claims increased by 4.7%, or EUR 76 million.

A total of 3.87 million consumers purchased reimbursable medicines, with 3.04 million receiving reimbursements for their medicine expenses. The number of recipients of reimbursements for medicines increased by 2.7%, or by slightly under 84,000 consumers.

The costs forming the basis for the reimbursements of medicines were EUR 2.31 billion. Additional reimbursements for costs exceeding the annual deductible were paid to 282,357 consumers, totalling EUR 254 million.

Special refunds were paid in the amount of EUR 1,182 million to 1,261,498 recipients. Special refunds are paid on a discretionary basis for certain illnesses. Higher special refunds totalled EUR 724 million, and their amount decreased for the first time since 2017, when the reimbursement categories for diabetes medicines were changed. The



decrease in refunds is affected by, for example, the transfer of cancer medicines with significant reimbursement costs to the reference price system and price competition from biological medicines. Claims in the lower special refund category, EUR 458 million, continued to grow. Basic refunds accounted for EUR 334 million, paid out to 2,934,286 consumers.

Familiar medicine groups on the top 10 sales list

As in previous years, the highest-selling medicine was nicotine, the sales of which decreased by 3%. As in the previous year, the second and third highest-selling medicines were infliximab, with sales up 2%, and apixaban, up 15%.

During the pharmaceutical year, the highest-selling medicines included the diabetes medicine semaglutide, the sales of which grew by 51%, and the biologic medicine aflibercept, used in the treatment of wet age-related macular degeneration, the sales of which grew by 33%. Aflibercept is administered as an intraocular injection into the vitreous body.

Of the cancer medicines on the list of highest-selling medicines last year, enzalutamide and pembrolizumab remained on the list for 2022. Their sales increased by 2% and 9%, respectively.

Table 2.1 Top 10 medicines sold in 2022 (wholesale)

Medicine	ATC code	Wholesale sales, Change from 2021, % EUR 1,000	
Nicotine	N07BA01	72,858	-3
Infliximab	L04AB02	65,825	+2
Apixaban	B01AF02	65,045	+15
Adalimumab	L04AB04	45,007	+1
Semaglutide	A10BJ06	42,084	+51
Sofosbuvir and velpatasvir	J05AP55	41,541	-17
Rivaroxaban	B01AF01	41,352	+3
Aflibercept	S01LA05	36,796	+33
Enzalutamide	L02BB04	36,677	+2
Pembrolizumab	L01FF02	36,498	+9

Medicines for cardiovascular diseases and analgesics are the most commonly consumed medicines

The top ten medicines in terms of consumption in 2022 were similar to previous years, although the rankings of individual medicines changed slightly. Eight of the top ten medicines by consumption are used to treat cardiovascular diseases. The most widely consumed were the cholesterol medicine atorvastatin, the calcium channel blocker

amlodipine, and the angiotensin II inhibitor ramipril. The consumption of the cholesterol medicine rosuvastatin continued to increase sharply (28%), making rosuvastatin the fourth most consumed medicine. The growth in the consumption of medicines for cardiovascular diseases is likely explained by the approximately 5% annual growth in the population aged 75 or over in Finland (Statistics Finland, StatFin database).

As in previous years, the list of the most consumed medicines also includes the painkillers ibuprofen and paracetamol. Pantoprazole, a proton pump inhibitor, has also been added to the list of the most consumed since last year.

All of the top medicines by consumption have been on the market for a long time, so there are several products on the market with the same active pharmaceutical ingredient. As a result, price competition has significantly reduced their prices. For this reason, the top medicines by consumption, with the exception of ibuprofen and paracetamol, fell far below the top 10 highest-selling medicines in terms of euros.



Table 2.2. Top 10 medicines by consumption in 2022

Medicine	ATC code	Consumption (DDD/1,000 inhabitants/day)	Change from 2021, %
Atorvastatin	C10AA05	75.7	+7
Amlodipine	C08CA01	75.1	+3
Ramipril	C09AA05	71.8	-1
Rosuvastatin	C10AA07	61.5	+28
Candesartan	C09CA06	59.9	+10
Acetylsalicylic acid	B01AC06	58.9	-5
Ibuprofen	M01AE01	56.0	+10
Losartan	C09CA01	53.0	+2
Paracetamol	N02BE01	44.7	+10
Pantoprazole	A02BC02	40.5	+2

The proton pump inhibitor pantoprazole made the list of the most consumed medicines

Sales of medicines for alimentary tract and metabolism diseases increased by 7% (EUR 355 million) and consumption by 1% (337.6 DDD/1000 inhabitants/day). In 2022, a total of 1,097,000 Finns received reimbursements for these medicines.

Sales of proton pump inhibitors for the treatment of hyperacidity (EUR 22 million), decreased by 1% year-on-year, but consumption (71.4 DDD/1000 inhabitants/day) increased by 1%. Pantoprazole was the most consumed proton pump inhibitor, and it

also made the list of top 10 medicines by consumption. Its consumption has increased by 2% to 40.5 DDD/1000 inhabitants/day, and their sales by 3% to EUR 8 million. The highest-selling proton pump inhibitor was esomeprazole, the sales of which (EUR 10 million) decreased by 2% and the consumption of which (16.3 DDD/1000 inhabitants/day) grew by 2%.

Consumption of the diabetes medicine semaglutide continued to increase

Consumption of antidiabetics (111.6 DDD/1000 inhabitants/day) increased by 6% and their sales (EUR 200 million) by 10%. Consumption increased most among GLP-1 analogues, the consumption of which (11.1 DDD/1000 inhabitants/day) increased by 46% and the sales of which (EUR 58 million) rose by 40%.

Growth was particularly strong for semaglutide, the consumption of which (8.0 DDD/1000 inhabitants/day) increased by 54% and the sales of which (EUR 42 million) grew by 51%, and liraglutide, the consumption of which (2.1 DDD/1000 inhabitants/day) increased by 51% and the sales of which (EUR 11 million) grew by 27%. The use of both semaglutide and liraglutide has expanded in recent years to treat obesity. Of these, liraglutide has an official indication for this. In the future, the use of semaglutide in tablet form may be further increased.

The consumption of insulins decreased by 1% to 29.9 DDD/1000 inhabitants/day, and their sales fell by 5% to EUR 52 million. The consumption mainly came from ultra-long-acting insulins (18.2 DDD/1000 inhabitants/day) and short-acting insulins (11.2 DDD/1000 inhabitants/day). Of these, consumption of short-acting insulins increased by 4% and that of over-acting insulins decreased by

3%. Sales in both groups decreased, in short-acting insulins (EUR 12 million) by 12% and in ultra-long-acting ones (EUR 39 million) by 5%.

As a rule, insulins are used in the treatment of type 1 diabetes, which is more common in Finland than in any other country. After a long increase in its incidence, the incidence over the past 20 years has stabilised and even slightly decreased, which may be reflected in insulin consumption. (National Institute for Health and Welfare, 2022.) In addition, new antidiabetic medicines may reduce the need to use insulins in the treatment of type 2 diabetes.

By far the most consumed short-acting insulin was insulin aspart (9.1 DDD/1000 inhabitants/day), the consumption of which increased by 5%, but sales decreased by 14% to less than EUR 10 million. There are also several biosimilars in short-acting products that may affect price competition.

The consumption of ultra-long-acting insulins consisted mainly of insulin glargine (11.1 DDD/1000 inhabitants/day), which decreased by 3%, and insulin degludec (4.2 DDD/1000 inhabitants/day), which in turn increased by 12%. Overall, the consumption of ultra-long-acting insulins has gradually decreased in recent years. In the year under review, their consumption decreased by 3%, to 18.2 DDD/1000 inhabitants/day.



Acetylsalicylic acid and direct anticoagulants the most consumed medicines for blood disorders

Both the consumption (146.4 DDD/1000 inhabitants/day) and sales (EUR 306 million) of blood and blood forming organs medicines grew by 4% on the previous year. The most consumed medicine for blood disorders was acetylsalicylic acid, which was the sixth most consumed medicine in the whole of Finland. Its consumption decreased by 5% to 58.9 DDD/1000 inhabitants/day, and sales fell by 4% to EUR 7 million. This is probably a direct consequence of the proliferation of newer anticoagulants. Of these, the majority of sales came from the sale of direct factor Xa inhibitors apixaban, the sales of which (EUR 65 million) increased by 15%, rivaroxaban (EUR 40 million), the sales of which rose by 3%, and edoxaban, the sales of which (EUR 7 million) increased by 12%. The consumption of apixaban (14.8 DDD/1000 inhabitants/day) increased by 15%, the consumption of rivaroxaban (10.2 DDD/1000 inhabitants/day) by 4% and the consumption of edoxaban (1.7 DDD/1000 inhabitants/day) by 14%. Apixaban was the third highest-selling medicine, as in the previous year.

The consumption of cardiovascular medicines continues to rise, but sales fall

The consumption of cardiovascular medicines (705.5 DDD/1000 inhabitants/day) increased by 3% while their sales (EUR 129 million) decreased by 1%, as in previous years. Reimbursements for cardiovascular medicines were paid to 1,569,195 Finns. In the most-consumed group, medicines affecting the renin-angiotensin system, consumption (287.2 DDD/1 000 inhabitants/day) increased by 2% and sales (EUR 34 million) decreased by 2%. Ramipril, which was the third most consumed medicine in Finland, was consumed the most, although its consumption (71.8 DDD/1000 inhabitants/day) decreased by 1%. Sales nevertheless increased by 1% to EUR 2 million.

The second most consumed group of medicines were lipid medicines, the consumption of which (187.1 DDD/1000 inhabitants/day) increased as in previous years, now by 12%, and sales (EUR 24 million) rose by 7%. This likely reflects the broadening of indications for the pharmaceutical treatment of dyslipidaemia and the treatment targets becoming more stringent in recent years. Angiotensin II receptor blockers were the next most-consumed medicines, the consumption of which (142.1 DDD/1000 inhabitants/day) increased by 6% and the sales of which (EUR 11 million) decreased by 6%, along

with calcium channel blockers, the consumption of which (106.8 DDD/1000 inhabitants/day) increased by 2% and the sales of which (EUR 11 million) by 3%.

Consumption and sales of the dermatological medicine dupilumab are on the rise

Both the consumption (3.2 DDD/1000 inhabitants/day) and sales (EUR 50 million) of dermatological medicines grew by 5% on the previous year. Topical corticosteroids were the highest-selling dermatological medicines, although their sales (EUR 12 million) decreased by 3%. The largest increase in consumption and sales was recorded for dupilumab, which is used, for example, in the treatment of severe asthma and atopic dermatitis. Its consumption (0.1 DDD/1000 inhabitants/day) is still relatively low, but increased by 64%. Sales (EUR 10 million), which increased by 59%, are significant relative to consumption.

The consumption of hormonal preparations remained unchanged

The consumption of medicines for genito urinary system and sex hormones (143.2 DDD/1000 inhabitants/day) remained at the previous year's level and sales (EUR 89 million) decreased by 3%. The largest consumption was mainly in contraceptive sex hormones and substances that affect the genital system, with consumption (85.9 DDD/1000 inhabitants/day) up 1% and sales (EUR 49 million) down 2%, along with medicines for urinary system disorders, with consumption (DDD/1000 inhabitants/day 54.7 DDD/1000 inhabitants/day) down by 1% and sales (EUR 30 million) by 4%.

The consumption of systemic hormonal products (55.1 DDD/1000 inhabitants/day) also remained unchanged. Sales decreased by 7% to EUR 43 million. The majority of consumption comes from the thyroid hormone levothyroxine (35.7 DDD/1000 inhabitants/day). Its consumption and sales (EUR 6 million) remained at the previous year's level.



The consumption of anti-infective medicines is returning to pre-pandemic levels

The consumption of systemic anti-infective medicines (14.6 DDD/1000 inhabitants/day) increased by 9%, while sales (247 million) increased by 1%. During the COVID-19 pandemic, the consumption of these medicines was temporarily lower due to restrictive measures widely in force to reduce the incidence of infectious diseases. In 2019, the consumption of systemic anti-infective medicines was 16.9 DDD/1000 inhabitants/day, suggesting that medicine consumption is gradually returning to the pre-pandemic level. However, the same level may not necessarily be reached, as the consumption of anti-infective medicines, especially antibacterials, had been declining for years before the pandemic.

Since the 2010s, the use of antibiotics in both outpatient and inpatient care has decreased more in Finland than in any other European country and is currently at the European average. Nevertheless, it is estimated that one-third of outpatient antibiotic use is due to viral infections for which they have no therapeutic efficacy. (Vuento, 2020.)

The majority of the consumption of systemic anti-infective medicines comes from systemic antibacterial medicines (12.5 DDD/1000 inhabitants/day), which increased by 11%. The sales in this group were EUR 39 million, up by 1% year-on-year.

The highest-selling anti-infectives, on the other hand, are systemic antivirals, the sales of which (EUR 121 million) correspond to approximately half of the sales of the entire group of medicines, although they decreased by 5% from the previous year. Of these, sales of products specifically intended for the treatment of hepatitis C infection (EUR 74 million) remain high, although they have started to decline from peak years. The consumption of systemic antivirals increased by 2%, to 1.6 DDD/1000 inhabitants/day.

Growth in the sales of cancer medicines and immunomodulating agents stalled for the first time in years

The consumption of antineoplastic and immunomodulating agents (27.3 DDD/1000 inhabitants/day) increased by 5%, but sales (EUR 894 million), which had been increasing for years, remained at the previous year's level. Almost half of the sales in this group come from immunosuppressants (EUR 402 million), which decreased by 3%.

Immunosuppressants include, for example, the TNF- α inhibitors infliximab (sales EUR 66 million, +2%; consumption 2.4 DDD/1000 inhabitants/day, +14%), adalimumab (sales EUR 45 million, +1%; consumption 1.4 DDD/1000 inhabitants/day, +12%), ustekinumab (sales EUR 27 million, +22%; consumption 0.9 DDD/1000 inhabitants/day, +24%), golimumab (sales EUR 22 million, -9%;

consumption 0.6 DDD/1000 inhabitants/day, -5%) and etanercept (sales EUR 20 million, -9 %; consumption 0.6 DDD/1000 inhabitants/day, +2%). The consumption of these medicines increased proportionately more than sales.

Lenalidomide, which was on the highest-selling list last year, was no longer among the highest-selling medicines this year. Lenalidomide's patent protection expired, and the medicine entered the reference price system in April 2022. Its sales (EUR 11 million) decreased by 69%, although consumption increased by 38%. Sales of pomalidomide (EUR 13 million), which is in the group of medicines although used for a different indication, have increased by 24%, exceeding sales of lenalidomide. Pomalidomide has not yet been transferred to the reference price system. Price competition is likely to become more active in many groups of medicines in the future.

Antineoplastic pharmaceuticals were the next highest-selling, up by 2% (EUR 389 million). Antineoplastic medicines include monoclonal antibodies, the sales of which (EUR 180 million) accounted for more than half of the group's sales, although they decreased by 5% on the previous year.

Among individual antineoplastic medicines, sales of biologic medicines administered through infusion

grew, with dostarlimab sales now at EUR 1 million, trastuzumab-derucstecan at EUR 3 million, and isatuximab at EUR 4 million. Sales also increased for daratumumab, which can be administered by infusion but is also available as a health insurance injectable for multiple myeloma. Sales of daratumumab stood at EUR 14 million, showing an increase of 36% on the previous year.

The next highest-selling medicines in this group were protein kinase inhibitors, the sales of which rose by 10% to EUR 112 million. The highest-selling protein kinase inhibitors were palbociclib (EUR 17 million), ibrutinib (EUR 16 million) and cabozantinib (EUR 11 million), with sales up 4%, 8% and 10%, respectively.

The sales of endocrinological medicines grew by 6% on the previous year, to EUR 77 million. The majority of the sales come from medicines used to treat prostate cancer: enzalutamide (sales EUR 37 million, +2%), apalutamide (EUR 6 million, +778%) and darolutamide (EUR 3 million, +194%). For these medicines, consumption increased similarly to sales.



The range of painkillers remains unchanged while consumption grows

The sales (EUR 113 million) of medicines for musculoskeletal disorders decreased by 13% while consumption fell by 6% (105.7 DDD/1000 inhabitants/day). For the first time in a long time, sales and consumption increased significantly. In several previous years, sales have either decreased or increased only slightly.

The sales of NSAIDs and DMARDs grew by 8% on the previous year to EUR 46 million, while consumption increased by 7% to 83.9 DDD per 1000 inhabitants per day. The majority of consumption in this group came from ibuprofen, the sales of which (EUR 33 million) increased by 12% and consumption (56.0 DDD/1000 inhabitants/day) by 10%. Ibuprofen was the seventh highest-selling medicine of all. The second most-used painkiller was paracetamol, the sale (EUR 31 million, +20%) and consumption (44.7 DDD/1000 inhabitants/day, +10%) of which also increased significantly, while last year both sales and consumption decreased. Etoricoxib is the next most widely used analgesic, with sales (EUR 2 million) down by 9%, although consumption (12.8 DDD/1000 inhabitants/day) increased by 4%.

Opioid consumption (12.6 DDD/1000 inhabitants/day) was almost equal to that of etoricoxib. The consumption of opioids has been steadily decreasing since 2012. Most recently, consumption decreased by 3% and sales fell by 5% to EUR 23 million. The consumption of the most-consumed opioid, a combination of codeine and paracetamol, was (5.2 DDD/1000 inhabitants/day), this time down by 3% and sales (EUR 2 million) showed a decrease of 6%.

Of other analgesics and antipyretics, the most widely consumed were pregabalin (6.1 DDD/1000 inhabitants/day, +3%) and gabapentin (5.1 DDD/1000 inhabitants/day, +9%), which are used in the treatment of neuropathic pain and also as antiepileptic medicines, for example. Of these, sales of gabapentin (EUR 7 million) increased by 8% and pregabalin (EUR 4 million) decreased by 15%.

Denosumab is the most widely used medicine against bone loss

The consumption (12.3 DDD/1000 inhabitants/day) of medicines affecting bone structure grew by 3% and their sales (EUR 20 million) rose by 11%. The majority of consumption and sales of medicines affecting bone structure come from denosumab consumption (9.0 DDD/1000 inhabitants/day), which increased by 5%, and sales (EUR 15 million), which rose by 3%. Denosumab has been the most commonly used medicine against bone loss for years. The next highest-selling medicine is zoledronic acid (sales (EUR 2 million, consumption 0.1 DDD/1000 inhabitants/day) and the most consumed is alendronate (2.2 DDD/1000 inhabitants/day).

Sales of migraine medicines are increasing

The sales of central nervous system medicines once again grew by 5% on the previous year to EUR 344 million, while consumption increased by 3% to 304.3 DDD per 1000 inhabitants per day. Reimbursements for these medicines were paid to 1,447,646 Finns. The sales of migraine medicines grew by 6% on the previous year to EUR 30 million, while consumption increased by 2% to 3.6 DDD per 1000 inhabitants per day. The most widely consumed migraine medicine is the selective 5HT1 blocker sumatriptan, the consumption (1.6 DDD/1000 inhabitants/day) and sales (4 million euros) of which decreased by 3% and 14%, respectively.

The majority of migraine medicine sales come from calcitonin gene-related peptide (CGRP) antagonists, such as fremanezumab (sales 10 million, +28%), erenumab (EUR 9 million, -8%), and galkanezumab (EUR 4 million, +48%). The consumption of fremanezumab and galkanezumab (0.4 DDD/1000 inhabitants/day, +45% and 0.2 DDD/1000 inhabitants/day, +63%) is increasing, while the consumption of erenumab (0.6 DDD/1000 inhabitants/day) decreased by 3%.



Melatonin consumption increases while the consumption of other sleep aids decreases

Of medicines affecting the central nervous system, the sales (EUR 35 million) and consumption (14.3 DDD/1000 inhabitants/day) of antiepileptic medicines both fell by 2%. The sales (EUR 15 million) and consumption (5.2 DDD/1000 inhabitants/day) of antiparkinsonian medicines also decreased by 7% and 1%, respectively.

However, Parkinson's disease is the fastest-growing of all neurological diseases: globally, the number of patients has doubled over the past 25 years and is likely to double again by 2040. The consumption of medicines in this group is therefore expected to increase in the future. (Kaasinen & Lokki, 2020.)

The consumption (49,2 DDD/1000 inhabitants/day) and sales (EUR 14 million) of sleep aids remained at the previous year's level. Of these, sales (EUR 3 million, -11% and EUR 2 million, -4%) and consumption (4.3 DDD/1000 inhabitants/day, -12% and 14.0 DDD/1000 inhabitants/day, -6%) of benzodiazepine derivatives and benzodiazepine-like medicines decreased. This development is in line with current treatment guidelines, according to which the long-term use of benzodiazepines should also be avoided as sleep aids and sleeping pills. Of the medicines in the sleep aids group, only melatonin consumption increased (30.7 DDD/1000 inhabitants/day, +4%), but its sales remained at the previous year's level (EUR 6 million). Melatonin is also sold as dietary supplements outside pharmacies, but for the purpose of the present statistics, only melatonin preparations classified as pharmaceutical products are included in these statistics. The consumption of benzodiazepine anti-anxiety medicines (12.8 DDD/1000 inhabitants/day) continued to decrease, this time by 2%, but sales (EUR 6 million) increased by 3%.

Consumption of antidepressants and ADHD medicines is on the rise

The sales (EUR 39 million) of antidepressants used in the treatment of depression and anxiety disorders increased by 2% and consumption (88.9 DDD/1000 inhabitants/day) rose by 4%. About half of the consumption comes from selective serotonin reuptake inhibitors (48.8 DDD/1000 inhabitants/day), which increased by 5%. The most widely consumed individual antidepressants were escitalopram (20.2 DDD/1000 inhabitants/day, +6%) and sertraline (13.5 DDD/1000 inhabitants/day, +5%). The sales of the other antidepressants group grew by 2% on the previous year to EUR 28 million, while consumption increased by 4% to 35.9 DDD per 1000 inhabitants per day. The most widely consumed medicine in this group was venlafaxine, the consumption of which (12.2 DDD/1000 inhabitants/day) increased by 3%, while sales (EUR 7 million) remained at the previous year's level.

As in the previous year, the consumption of antipsychotics used partly for the same indications as antidepressants, but also for the treatment of psychotic disorders, increased by only 1% (23.4 DDD/1000 inhabitants/day) and sales (EUR 53 million) remained unchanged this time.

The sales (EUR 25 million) and consumption (11.0 DDD/1000 inhabitants/day) of central nervous system stimulants, which are mainly used in the

treatment of ADHD, increased by 23% and 27%, respectively, showing a similar clear upward trend as in the previous year. This is directly related to the increase in ADHD diagnoses, which is thought to be related to better recognition of ADHD, especially in adults. On the other hand, the phenomenon has also been criticised as medicalising normal developmental traits. According to the latest estimates, ADHD occurs in 3.6-7.2% of 6-18-year-olds and in 2.5-3.4% of adults (ADHD Current Care Guidelines, Duodecim 2019).

The most widely consumed and highest-selling ADHD medicines were methylphenidate, the sales (EUR 12 million) and consumption (7.7 DDD/1000 inhabitants/day) of which increased by 18% and 24%, respectively, and lisdexamfetamine, the sales (EUR 10 million) and consumption (2.6 DDD/1000 inhabitants/day) of which increased by 38% and 43%, respectively. The sales (EUR 1 million, +18%) and consumption (0.20 DDD/1000 as/day, +18%) of dexamfetamine and the sales (EUR 1 million, +18%) and consumption (0.1 DDD/1000 as/day, +37%) of guanfacine, a centrally acting antiadrenergic, increased. In contrast, the consumption of atomoxetine (0.3 DDD/1000 inhabitants/day) increased by 21%, but sales (EUR 0.7 million) decreased by 19%, largely due to price competition between products.



The value of sales of dementia medicines will increase, although consumption will remain unchanged

The sales (EUR 7 million) of dementia medicines increased by 15%, although consumption (16.5 DDD/1000 inhabitants/day), remained at the previous year's level. The highest-selling medicines were rivastigmine, the sales of which (EUR 3 million) increased by 13%, while consumption (2.3 DDD/1000 inhabitants/day) increased by 1%, and memantine, the sales of which (EUR 2 million) increased by 48%, while consumption (7.1 DDD/1000 inhabitants/day) increased by 2%.

Consumption and sales of combination medicines and biologic medicines are on the rise in respiratory diseases

The sales of medicines for respiratory disorders grew by 12% on the previous year to EUR 169 million, while consumption increased by 4% to 205.6 DDD per 1000 inhabitants per day. Nearly one million (964,584) Finns received reimbursements for medicines for respiratory disorders. The majority of sales and consumption come from the sales (EUR 93 million, +3%) and consumption (83.7 DDD/1000 inhabitants/day, +3%) of medicines for obstructive respiratory diseases, which are used in the treatment of asthma and COPD.

Of these, the sales of adrenergic inhalants were EUR 55 million, up by 2%, and consumption was 50.1 DDD/1000 inhabitants/day, up by 6%. The highest-selling were combinations of adrenergic medicines with either corticosteroids or other medicines. Sales increased by 2% to EUR 36 million, and consumption increased by 4% to 30.6 DDD/1000 inhabitants/day. The second highest-selling combinations were the so-called triple combinations of adrenergic inhalants, anticholinergics and glucocorticoids, with sales of EUR 13 million (+15%) and consumption of 4.1 DDD/1000 inhabitants/day (+12%).

The sales (EUR 11 million, +24%) and consumption (0.2 DDD/1000 inhabitants/day, +14%) of other systemic medicines for obstructive respiratory diseases will also increase, as biologic medicines are also available on the market for asthma. The highest-selling medicines were omalizumab and mepolizumab, both of which generated sales of EUR 4 million, up 11% and 37% year-on-year, respectively. The consumption of omalizumab (0.1 DDD/1000 inhabitants/day) increased by 16% and that of mepolizumab (0.1 DDD/1000 inhabitants/day) by 37%.

The sales of medicines for respiratory disorders grew by 66% on the previous year to EUR 3 million, while consumption increased by 65% to 0.0 DDD per 1000 inhabitants per day. These sales came from sales of ivacaftor and its combination preparations, which are used in the treatment of cystic fibrosis. Cystic fibrosis is very rare in Finland; in 2022, it was estimated that only 100 people in Finland were affected by it. The highest-selling medicines were a combination of ivacaftor and tezacaftor, the sales of which increased 58% (EUR 5 million) and ivacaftor (EUR 3 million), the sales of which increased by 66%. These medicines entered the reimbursement system in 2021 and therefore saw a strong increase in consumption and sales compared to the previous year.

Over-the-counter medicines

The wholesale of over-the-counter medicines grew by 10.6% from the previous year. The sales of over-the-counter medicines made a clear upturn, after their sales in the previous two years had declined by 2.2% and 2.8% respectively. In April 2022, an amendment to the Medicines Act entered into force, allowing pharmacies to decide on the pricing of over-the-counter medicines they sell. The price of an over-the-counter medicine is determined so that it does not exceed the retail price based on

the pharmaceutical tariff, but is no lower than the nationally applicable wholesale price.

The consumption of over-the-counter medicines is also increasing. Among the most widely used painkillers, the sales and consumption of both ibuprofen (sales EUR 33 million, +12% and consumption 56.0 DDD/1000 inhabitants/day, +10%) and paracetamol (sales EUR 31 million, +20% and consumption 44.7 DDD/1000 inhabitants/day, +10%) increased, although the consumption of paracetamol used in self-care still decreased by 13% the previous year.

Nicotine


Nicotine was once again the highest-selling medicine in Finland, with total sales of EUR 73 million. Over 90% were non-pharmacy sales, down by 3% in 2022, while sales from pharmacies showed a decrease (0.2%).

The sale of nicotine replacement therapy products was expanded outside of pharmacies in 2006. Their consumption increased 3.6-fold and wholesale sales in euros rose 4.3-fold between 2005 and 2022.



Figure 2.3. Consumption and sales of nicotine products in 2005–2022

DDD/1,000 inhabitants/day




Source: Finnish Medicines Agency Fimea, Drug Sales Register

References

ADHD (Attention-deficit hyperactivity disorder). Current Care Guidelines. Working group set up by the Finnish Medical Society Duodecim, the Finnish Association of Pediatric Neurology, the Finnish Society for Child and Adolescent Psychiatry and the Finnish Society for Adolescent Psychiatry. Helsinki: The Finnish Medical Society Duodecim, 2019. Available online at: www.kaypahoito.fi. (Referred 12/5/2023.)

Kaasinen, V. & Lokki, M-L. (2020). Uutta tietoa Parkinsonin taudin synnyn ja tupakoinnin välisistä yhteyksistä. <https://www.duodecimlehti.fi/duo15329>. (Referred 12/5/2023.)

Wholesale price (VAT excluded) thousand euros



Source: Finnish Medicines Agency Fimea, Drug Sales Register

National Institute for Health and Welfare. (2022). Prevalence of diabetes. <https://thl.fi/fi/web/kansantaudit/diabetes/diabeteksen-yleisyys>. (Referred 9/20/2023.)

Vuento, R. (2020). Antibiootit. <https://www.terveyskirjasto.fi/dlk01177>. (Referred 12/5/2023.)



Pharmacy economy

Leena Reinikainen, M.Sc. (Pharm.),
Development Specialist, Fimea
Antti Hyvärinen, D.Sc., M.Soc.Sc.,
Pharmacoeconomist, Fimea

Overall, the operations of pharmacies in 2022 were profitable from a business perspective. However, pharmacies differed greatly from one another. The financial operating conditions of a pharmacy depend on, among other things, the type of business location or commuter routes and customer flows along which the pharmacy is located. The above, in turn, depends, for example, on whether the area in question is urban, semi-urban or rural.

In this article, pharmacies are described as whole entities, including information about the main pharmacy as well as any subsidiary pharmacies, service points and remote services. The article discusses the development of the operations of private pharmacies and key financial figures. University pharmacies are excluded from the examination because, due to their large size, they have a significant impact on the above-mentioned key figures.

The turnover of pharmacies consists of the sales of pharmaceuticals, foods, general merchandise and services. Some pharmacies also sell medicines to institutions, contract manufacturing of medicines or dose dispensing, and tax-free sales. Pharmaceutical sales account for an average of 94 per cent of pharmacies' turnover. Turnover includes income from the sale of goods and services minus discounts granted and value added tax. The average turnover of private pharmacies excluding VAT in 2022 was approximately EUR 4.4 million. This was 3.9% more than in 2021 and about 8.6% more than in 2019.

Table 2.3. Average turnover of private pharmacies 2008–2022 (EUR million)

Year	Number of pharmacies in financial data	Million euros	Change from previous year, %
2008	608	3,35	-
2009	608	3,34	- 0,3
2010	608	3,30	- 1,2
2011	604	3,35	+ 1,5
2012	606	3,48	+ 3,9
2013	603	3,55	+ 2,0
2014	594	3,67	+ 3,4
2015	591	3,81	+ 3,8
2016	592	3,91	+ 2,6
2017	602	3,78	- 3,3
2018	608	3,95	+ 4,5
2019	613	4,08	+ 3,3
2020	621	4,16	+ 2,0
2021	620	4,26	+ 2,4
2022	628	4,43 ¹	+ 3,9

1 preliminary information, data review and quality control in progress, Source: Finnish Medicines Agency Fimea

Source: Finnish Medicines Agency Fimea, Drug Sales Register



The gross margin shows how much of the sales revenue remains for the pharmacy after deducting the corresponding purchases of goods. The retail price of medicines, and thereby also the pharmacy's share of the price of medicines, is determined in accordance with the Government Decree on Pharmaceutical Tariffs (713/2013). The medicine price is regressive, which means that the sales margin received by the pharmacy decreases proportionally as the price of the medicine increases. Due to a different calculation formula, the gross margin for prescription medicines is usually lower than for over-the-counter medicines, even though a delivery fee per delivery batch is added to the retail price of prescription medicines. Products that are sold in pharmacies but are not medicines or pharmacy services can be priced freely.

In pharmacy accounting, two gross margin figures are usually examined. Gross margin 1 is obtained by deducting costs that are directly related to the medicine, such as purchases of goods, from turnover. In addition, the paid pharmacy tax (previously the pharmacy fee) has been deducted in gross margin 2. Approximately EUR 211 million (www.vero.fi) in pharmacy tax was remitted to the state for the tax year 2022. In 2022, private pharmacies had an average gross margin percentage 1 of 27.2% and an average gross margin percentage 2 of 21.5%. The gross margin percentage 1 decreased by 1.5% compared to the previous year and by 5.9% compared to 2019. The post-pharmacy tax gross margin per cent 2 appeared to have increased by approximately 2.4% compared to 2021, but decreased by more than 8% compared to 2019. Both gross margin figures have decreased since 2008. Gross margin percentages are typically higher for small pharmacies than for pharmacies with a large turnover. This is explained by the turnover-based progressive pharmacy tax mechanism and the limited liability company activities of larger pharmacies in the sale of general merchandise.

Table 2.4. Average gross margin percentages of private pharmacies 2008–2022.

Year	Number of pharmacies in financial data	Gross margin percentage 1	Gross margin percentage 2
2008	571	31,7	26,2
2009	566	31,9	26,7
2010	576	32,1	27,3
2011	567	32,1	27,4
2012	-	32,1	27,3
2013	-	32,2	27,3
2014	-	32,1	27,2
2015	532	31,8	26,6
2016	592	31,9	26,8
2017	595	31,2	25,9
2018	606	29,6	23,2
2019	612	28,9	23,4
2020	614	27,7	21,1
2021	620	27,6	21,0
2022	628	27,2 ¹	21,5*

¹ preliminary information, data review and quality control in progress, Source: Finnish Medicines Agency Fimea

Source: Finnish Medicines Agency Fimea, Drug Sales Register



Price competition for over-the-counter medicines and discounts on over-the-counter medicines given to all customers in pharmacies have been possible since 1 April 2022 (Decree on Pharmaceutical Tariffs 713/2013). The pharmacy can give a discount to all customers or only to its regular customers. Veteran discounts were possible even earlier than this. However, the retail price of over-the-counter medicines must be the same at all pharmacy locations and online services. The most common over-the-counter medicines for which pharmacies gave discounts based on the amendment to the decree were painkillers, allergy medicines and stomach medicines. However, about three-quarters of pharmacies had not given discounts on over-the-counter medicines. For the time being, the economic significance of discounts on over-the-counter medicines for pharmaceutical consumers and society is small.

Operating profit expresses the company's operating result before interest, appropriation and taxes (Accounting Ordinance 1752/2015). The size of the pharmacy's operating profit is affected not only by direct costs such as income and purchases of goods, but also by other costs. These include, but are not limited to, salaries, personnel costs, personnel leasing costs, depreciation, rental of premises and other operating expenses. However, when calculating the operating profit of pharmacies, neither the pharmacist's salary nor the requirement for interest on equity have been deducted as expenses. The operating profit achieved must therefore be able to provide compensation for the pharmacist's work input, business risk, and return on equity. The average operating profit of private pharmacies before appropriations and taxes was EUR 265,000 in 2022. Compared to the previous year, the average operating profit increased by almost 8%.

Table 2.5. Average operating profit¹ of private pharmacies before appropriations and taxes in 2008–2022 (EUR thousand).

Year	Number of pharmacies in financial data	Average operating profit, thousand EUR	Change from previous year, %
2008	531	275	-
2009	544	253	- 8,0
2010	549	243	- 4,0
2011	523	240	- 1,2
2012	532	249	+ 3,8
2013	546	248	- 0,4
2014	550	263	+ 6,0
2015	532	267	+ 1,5
2016	549	264	- 1,1
2017	554	254	- 3,8
2018	525	253	- 0,3
2019	551	246	- 2,5
2020	553	249	+ 1,2
2021	540	246	- 1,4
2022	547	265 ²	+7,7

1 The concept was operating profit before taxes and salary adjustment in 2008–2010, operating profit before extraordinary items, taxes and salary adjustment in 2011–2016, and operating profit before appropriations, taxes and salary adjustment since 2017.

2 preliminary information, data review and quality control in progress, Source: Finnish Medicines Agency Fimea

Source: Finnish Medicines Agency Fimea, Drug Sales Register



The COVID-19 pandemic and the global political situation have caused uncertainty and created complex challenges in the operating environment of pharmacies. Due to the pharmaceutical tariff and price regulation, pharmacies are not able to pass on the increased costs to the prices of medicines. In times of economic uncertainty, pharmacies may need to adjust their business operations in other ways, such as changing pharmacy opening hours or reducing staff.

Pharmacies and subsidiary pharmacies must be kept open in such a way that the availability of medicines is secured (Medicines Act 395/1987). The opening hours of pharmacies have remained very similar over the past five years, although the COVID-19 pandemic that began in 2020 may have had an impact on pharmacy opening hours. For example, in 2020, approximately 14 per cent of private pharmacies reduced their opening hours by an average of 7 hours per week, and correspondingly, approximately 17 per cent of private pharmacies extended their opening hours by an average of 7 hours per week. Private main and subsidiary pharmacies were open an average of 54 hours per week in 2022, just like in 2019. Of private pharmacies, 78% were open on Saturdays (6.6 hours on average) and 29% on Sundays (5.7 hours on average). On weekdays, pharmacies were open for an average of 9.5 hours. As a rule, the opening hours of main private pharmacies (58 hours/week on average) were wider than those of smaller subsidiary pharmacies (38 hours on average). The task of subsidiary pharmacies is to ensure the availability of medicines and pharmacy services in areas where there are not sufficient operating conditions for an independent pharmacy.

According to the Medicines Act, pharmacies and subsidiary pharmacies must have the necessary number of staff with a degree in pharmacy. In the figures presented, all employees who worked 30 or more hours per week were considered full-time employees and employees who worked less than 30 hours per week were considered part-time. At the end of 2022, private pharmacies employed approximately 6,900 pharmaceutical and technical staff, which was approximately 3% more than in 2021. The proportion of full-time personnel was 79%. Pharmaceutical staff accounted for 69% of the total number of full-time employees. In addition, there were 633 pharmacy owners employed at private pharmacies who were not taken into account in the number of staff. In 2022, 67% of private pharmacies had used temporary agency labour for pharmaceutical staff. Around 50% of private pharmacies had recruited new full-time or part-time pharmaceutical staff during the year, but 33% had not been successful because there had been no applicants.

3. Finnish population and hospital districts





Figure 3.1. Age structure of the Finnish population at the end of 2022



Source: Kela's population data.


Figure 3.2. University hospital regions and hospital districts in 2022

University hospital regions

- A. Helsinki University Central Hospital region (HYKS)
- B. Turku University Central Hospital region (TYKS)
- C. Tampere University Hospital region (TaYS)
- D. Kuopio University Hospital region (KYS)
- E. Oulu University Hospital region (OYS)

Hospital districts

- | | |
|----------------------|--------------------------|
| 0. Åland | 15. South Ostrobothnia |
| 3. Southwest Finland | 16. Vaasa |
| 4. Satakunta | 17. Central Ostrobothnia |
| 5. Kanta-Häme | 18. North Ostrobothnia |
| 6. Pirkanmaa | 19. Kainuu |
| 7. Päijät-Häme | 20. Länsi-Pohja |
| 8. Kymenlaakso | 21. Lapland |
| 9. South Karelia | 25. Helsinki and Uusimaa |
| 10. South Savo | |
| 11. Itä-Savo | |
| 12. North Karelia | |
| 13. North Savo | |
| 14. Central Finland | |



Source: Kela. Suomen karttatiedosto - Map file of Finland.

**Table 3.1. Population according to hospital district, the proportion of elderly people and the proportion of the population in receipt of Special Refunds of medicines of the total population, at the end of 2022**

Hospital district	Total	Male	Female	Population % aged 65 or over	The proportion % of population in receipt of Special Refunds of medicines
Whole country	5,572,305	2,759,066	2,813,239	23.2	22.6
Helsinki and Uusimaa	1,733,343	850,570	882,773	18.2	17.8
Southwest Finland	488,900	240,225	248,675	24.2	21.8
Satakunta	212,779	105,625	107,154	28.4	25.5
Kanta-Häme	169,859	84,228	85,631	26.9	25.3
Pirkanmaa	550,340	271,583	278,757	22.7	22.7
Päijät-Häme	208,313	101,956	106,357	28.1	24.9
Kymenlaakso	160,004	79,343	80,661	29.6	27.4
South Karelia	125,457	62,705	62,752	28.9	25.0
South Savo	95,975	47,600	48,375	32.1	29.5
Itä-Savo	39,133	19,259	19,874	35.1	31.5
North Karelia	162,702	81,084	81,618	28.4	28.7
North Savo	243,320	120,336	122,984	26.7	28.6
Central Finland	253,334	126,156	127,178	23.7	24.0
South Ostrobothnia	190,889	95,453	95,436	26.8	26.6
Vaasa	170,006	86,256	83,750	23.6	21.4
Central Ostrobothnia	76,937	38,564	38,373	25.0	24.4
North Ostrobothnia	414,178	209,241	204,937	20.8	23.8
Kainuu	70,528	35,840	34,688	30.4	30.6
Länsi-Pohja	58,082	29,286	28,796	29.2	27.1
Lapland	117,845	58,671	59,174	26.0	26.8
Åland	30,381	15,085	15,296	23.8	16.6


Source: Kela's population data, Register of Statistical Information on National Health Insurance General Benefit Payments.

Table 3.2. Population according to university hospital regions by age groups, 31 December 2022

Hospital region	Gender	Total	0-15 years	16-64 years	65 or over
A HYKS	Male	5,572,305	902,421	3,375,285	1,294,599
	Female	1,094,574	186,385	712,430	195,759
B TYKS	Male	1,132,543	177,687	693,659	261,197
	Female	394,435	60,191	236,236	98,008
C TaYS	Male	400,029	57,949	224,559	117,521
	Female	371,602	67,582	223,338	80,682
D KYS	Male	365,968	65,000	207,130	93,838
	Female	451,264	74,675	278,142	98,447
E OYS	Male	459,824	71,051	265,588	123,185
	Female	447,191	72,566	273,695	100,930
Total		454,875	69,335	260,508	125,032
Proportion of total population, %		100.0	16.2	60.6	23.2

Source: Kela's population data.

4. Drug control and pharmaceutical services






Distribution of medicine sales

Table 4.1. Medicine sales to pharmacies and hospitals at wholesale prices according to the ATC code in 2022¹

ATC code	Sales at wholesale prices, EUR 1,000	Pharmacies, %	Hospitals, %	Total
A Alimentary tract and metabolism	354,940	11.4 (92.3)	0.9 (7.7)	12.3 (100.0)
B Blood and blood forming organs	305,199	8.0 (75.4)	2.6 (24.6)	10.6 (100.0)
C Cardiovascular system	128,732	4.0 (89.1)	0.5 (10.9)	4.5 (100.0)
D Dermatologicals	49,612	1.6 (95.4)	0.1 (4.6)	1.7 (100.0)
G Genito-urinary system and sex hormones	89,350	2.9 (92.2)	0.2 (7.8)	3.1 (100.0)
H Systemic hormonal preparations, excl. sex hormones and insulines	42,874	1.2 (81.1)	0.3 (18.9)	1.5 (100.0)
J Antiinfectives for systemic use	246,574	2.3 (26.9)	6.3 (73.1)	8.6 (100.0)
L Antineoplastic and immunomodulating agents	893,541	17.7 (57.1)	13.3 (42.9)	31.1 (100.0)
M Musculo-skeletal system	113,008	3.0 (76.7)	0.9 (23.3)	3.9 (100.0)
N Nervous system	344,459	10.0 (83.2)	2.0 (16.8)	12.0 (100.0)
P Antiparasitic products, insecticides and repellents	10,476	0.3 (96.0)	0.0 (4.0)	0.4 (100.0)
R Respiratory system	169,149	5.7 (96.6)	0.2 (3.4)	5.9 (100.0)
S Sensory organs	82,251	1.4 (50.3)	1.4 (49.7)	2.9 (100.0)
V Various	45,168	0.3 (20.5)	1.2 (79.5)	1.6 (100.0)
Total	2,875,333	(69.9)	(30.1)	(100.0)

1 The percentages given in brackets indicate the sales distribution within the group.
Source: Finnish Medicines Agency Fimea, Drug Sales Register.

Figure 4.1. Distribution of medicine sales between pharmacies and hospitals according to the ATC code, at wholesales prices, in 2022, EUR 1,000



Source: Finnish Medicines Agency Fimea, Drug Sales Register.



Pharmacies and hospital pharmacies

In Finland, medicines may be sold to the public by pharmacies, subsidiary pharmacies, pharmacy service points and pharmacies' online services. OTC nicotine products can also be sold from outlets other than pharmacies, e.g. grocery shops and kiosks, under a permit issued by the municipal authorities. A pharmacy will dispense prescription-only medicines against a prescription issued by a doctor, dentist, veterinary surgeon or (in certain cases) nurse.

Pharmacies are privately owned and licensed. After announcing a vacancy, the Finnish Medicines Agency grants a licence to own and operate a pharmacy on the basis of applications. Proprietary pharmacists are required to hold the qualification of a Master of Science (Pharmacy) and be a citizen of any state belonging to the European Economic Area. In addition to the privately owned pharmacies, the University of Helsinki has the statutory right to operate one pharmacy in the city of Helsinki, and up to 16 subsidiary pharmacies with permission granted by the Finnish Medicines Agency. The University of Eastern Finland also has the statutory right to operate one pharmacy in the city of Kuopio.

In addition to paying taxes on earned income, pharmacists pay an annual pharmacy tax based on the pharmacy's turnover. The purpose of the pharmacy tax is to guarantee nationwide access to pharmacy services and to reduce differences in revenue among pharmacies.

The Finnish Medicines Agency may permit health care units to operate a hospital pharmacy or a medicine dispensary. The director of a hospital pharmacy is required to hold the qualification of a Master of Science (Pharmacy) and the director of a medicine dispensary is required to hold the qualification of a Master of Science (Pharmacy) or a Bachelor of Science (Pharmacy).

Hospital pharmacies and medicine dispensaries issue medicines only to their own wards and other departments; they are not allowed to sell medicines to patients or directly to the public. Only on special occasions may patients, who are being discharged or temporarily transferred to outpatient care, be issued medicines from the hospital to ensure the continuation of their medication. These medicines are supplied without charge and normally for one or two days only.

Table 4.2. Statistics for pharmacies in 2022

	Private pharmacies	University pharmacies
Number of pharmacy outlets	810	18
Pharmacies	635	2
Subsidiary pharmacies	175	16
Number of prescriptions in thousands	68,058	7,243

Source: Finnish Medicines Agency Fimea.




Table 4.3. Dispensations dispensed by pharmacies in 2005–2022

Year	Number of pharmacies	Dispensations		
		Number in thousands	Per capita	Per doctor
2005	606	42,161	8.0	1,686
2006	608	43,468	8.2	1,676
2007	610	45,747	8.6	1,721
2008	613	48,252	9.1	1,774
2009	617	48,725	9.1	1,666
2010	618	50,364	9.4	1,668
2011	620	48,498	9.0	1,556
2012	618	51,698	9.5	1,615
2013	616	51,724	9.5	1,586
2014	615	53,381	9.8	1,616
2015	612	55,791	10.2	1,665
2016	613	58,812	10.7	1,560
2017	616	61,250	11.1	1,824
2018	618	63,300	11.4	1,874
2019	623	65,668	11.7	1,857
2020	626	67,120	12.1	1,893
2021	632	71,476	12.9	1,966
2022	637	75,301	13.5	2,020

Source: Finnish Medicines Agency Fimea.


Figure 4.2. Number of pharmacies and prescriptions dispensed in 1990–2022



Source: Finnish Medicines Agency Fimea.




Figure 4.3. Number of pharmacies per 10,000 inhabitants by hospital district in 2022



Hospital pharmacies and medicine dispensaries have not been taken into account.


Source: Finnish Medicines Agency Fimea.

5. National health insurance and reimbursement of medicine expenses



The medicine supply chain and the role of various organisations in oversight and reimbursement

- How medicines reach customers
- Government authority, oversight and marketing authorisations
- Government authority, reimbursement process
- Oversight and marketing authorisations
- Reimbursement process



The chart only includes the organisations relevant in the context of the Finnish Statistics on Medicines.



Medicine reimbursement system and approval of medicine prices

Jaana Kruuti, Chief Pharmaceutical Officer, M.Sc. (Pharm.), Kela

Jaana Harsia-Alatalo, Pharmaceutical Officer, M.Sc. (Pharm.), Kela

Miia Djerf, Pharmaceutical Officer, M.Sc. (Pharm.), Kela

General information

The medicine reimbursement system was first implemented in Finland in 1964 pursuant to the Health Insurance Act (sairausvakuutuslaki 1224/2004). The system covers all residents of Finland, regardless of age, wealth or address. The Health Insurance Scheme is administered by the Social Insurance Institution of Finland (Kela).

The Health Insurance Scheme reimburses some of the necessary costs of prescription-only medicines which are used for the treatment of an illness. An over-the-counter product may also be granted reimbursement status if the product is prescribed by a physician and considered, on medical grounds, to be an indispensable medicinal product. Basic topical ointments prescribed for the treatment of chronic skin ailments are also reimbursable, as are clinical nutritional preparations used in the treatment of a serious illness. Reimbursement is also

paid to a limited group of patients for the dosage service fee charged by pharmacies.

The payment of reimbursement is possible only after the Pharmaceuticals Pricing Board has approved the reimbursement status of the medicine, basic topical ointment or clinical nutritional preparation and confirmed its reasonable wholesale price. The Pharmaceuticals Pricing Board operates under the auspices of the Ministry of Social Affairs and Health.

The Finnish medicine reimbursement system consists of three categories: the Basic Refund Category, and the Lower and Higher Special Refund Categories. The categories are graded according to medical criteria based on the severity of the disease and the necessity of the drug treatment. Up to three months' supply of medicines can be reimbursed at any one transaction. However, a maximum of one month's supply of the medicine is reimbursed at any one time if there is a pack size available on the market whose retail price exceeds EUR 1,000 (inclusive of VAT). The customers usually have their medicine costs refunded directly at the pharmacy, after the pharmacy has verified their eligibility for the reimbursement with Kela's direct reimbursement inquiry service.

In 2015, all pharmacies adopted a real-time data transmission procedure, which applies to medicine purchases. Real-time transmission of data relating to medicine purchases between pharmacies and Kela was a prerequisite for the adoption of the initial deductible limit at the beginning of 2016. The exceptional medicine-specific copayment for Higher Special Refund and Additional Refund categories, charged for each new week of treatment, was adopted at the same time. This also enabled real-time transmission of purchasing data on dose-dispensed medicines from pharmacies to Kela. In addition to dose-dispensed medicines, the exceptional medicine-specific copayment also applies to purchases of medicines containing clozapine, peritoneal dialysis solutions and medicinal oxygen. As of 1 January 2017, the exceptional medicine-specific copayment is also applicable to a supply of a maximum of one month's treatment in case of an expensive medicine, or if a medicinal product is prescribed by a physician, on therapeutic grounds, to be purchased in several batches. The exceptional medicine-specific copayment amounts to 1/12 of the medicine-specific deductible for three months of treatment.

Determining the price of medicines

The Government Decree on the Price List of Drugs regulates the sale prices of medicines and the pharmacy margin for the sale of medicines. The purpose of the price list is to keep the prices of medicines on a reasonable level. In addition, the price list ensures that the prices of medicines are the same in every pharmacy.

The retail price of a medicine is determined on the basis of the price list of drugs and the nationwide wholesale price of the medicine in question. The price list uses separate formulas for calculating the prices of prescription-only medicines and over-the-counter medicines.

A new Government Decree on the Price List of Drugs was issued in 2014. This decree adjusted the principles of calculating the retail prices of prescription-only medicines, reducing the prices of the most expensive prescription-only medicines and increasing the prices at the lower end of the price range. In addition, the processing fee charged by pharmacies increased from EUR 0.43 to EUR 2.39 (inclusive of VAT). The goal of this reform was, for example, to guarantee the continued availability of medicines throughout the country and ensure



that pharmacies have sufficient resources for expert tasks and statutory medication counselling. The changes made to the price list of drugs were anticipated to cut the cost of reimbursement payments made under the Health Insurance Scheme. The savings generated in this way made it possible to reduce the patients' annual deductible, i.e. the maximum limit on annual out-of-pocket medicine expenses, in 2014.

The price list of drugs was adjusted in 2015 in connection with the implementation of real-time transmission of data relating to dose-dispensed medicines. To prevent the total costs of the dosage service fees from exceeding the amount the customer needs to pay for each three-month supply of dose-dispensed medicines, the Government Decree on the Price List of Drugs was amended to include a processing fee for each transaction involving dose-dispensed medicines. The fee is EUR 0.20 (inclusive of VAT) for each new week of treatment. This amounts to 1/12 of the processing fee for a three-month supply of medicine.

Reference Price System

A reference price system was introduced in Finland in 2009 to complement generic substitution, which had started in 2003. Under the reference price system, substitutable medicinal products that contain the same active ingredient and are biologically equivalent are grouped together in the same reference price group. The reference price groups are based on the list of substitutable medicinal products compiled by the Finnish Medicines Agency Fimea. The reference price groups, and the reference price for each group, must be confirmed by the Pharmaceuticals Pricing Board. As of 1 January 2017, the reference price is calculated by adding EUR 0.50 to the price of the most inexpensive product within the group. The reference price is the maximum price used as the basis for calculating reimbursement payments. If the medicine purchased is less expensive than the reference price, reimbursement is calculated from the medicine's purchase price. If a customer does not wish to change the prescribed medicine to an alternative at or below the reference price, the cost in excess of the reference price, in addition to the non-reimbursable portion of the medicine cost, is paid by the customer. The cost in excess of the reference price will not count towards the annual deductible (see Annual deductible). The prescribing physician may only forbid substitution on medical and therapeutic grounds. In that event, the reimbursement to the customer is calculated from the retail price of the medicine.

Drugs in the Basic Refund Category

Forty per cent of the purchase price or reference price (including the pharmacy's processing fee charged for each transaction) of a medicinal product belonging to the Basic Refund Category is reimbursed to the patient. As a general rule, reimbursement for a medicinal product in the Basic Refund Category is paid to all individuals covered by the Finnish Health Insurance Scheme. Decisions relating to medicinal products eligible for reimbursement under the Basic Refund Category are made by the Pharmaceuticals Pricing Board. A medicinal product for the treatment of a disease can only be granted basic reimbursement status to the extent defined in its Summary of Product Characteristics and for the therapeutic indications listed therein. The Pharmaceuticals Pricing Board also has the authority to restrict the basic reimbursement status of certain medicinal products to clearly defined indications. These products form a group known as Medicinal Products Eligible for Restricted Basic Refund, and they will only generate the Basic Refund if the need for such medication can be proved by providing a separate statement, as specified by Kela. The separate statement can either be in the form of a Medical Certificate B or an addendum to the prescription sheet. The reason for creating the sub-group was to target and limit the payment of the Basic Refund to patients who, based on existing knowledge and scientific evidence, are likely to gain most from these costly treatments.

Drugs in the Special Refund Categories

The provisions on diseases that entitle medicinal products used in their treatment to be included in the Special Refund Categories are given by Government decree. The Higher Special Refund Category consists of diseases that are, according to medical criteria, considered to be serious and chronic and where drug treatment is necessary for the patient and where the drug restores or replaces normal bodily functions. Insulin treatment for diabetes mellitus and drugs used to treat malignant diseases are examples of drugs belonging to the Higher Special Refund Category. The purchase price or reference price of a medicinal product is reimbursed to the patient in full (100%), including the pharmacy's processing fee charged for each transaction. The patient pays a non-reimbursable sum of EUR 4.50 per transaction for each medicinal product in the Higher Special Refund Category. In addition, the patient will also pay any part of the medicine price exceeding the reference price.



The Lower Special Refund Category consists of diseases that are, according to medical criteria, considered to be serious and chronic. The most common diseases in this group are hypertension, asthma, coronary heart disease and, since 1 January 2017, also diabetes (other than insulin treatment). Sixty-five per cent of the purchase price or reference price (including the pharmacy's processing fee charged for each transaction) of a medicinal product belonging to the Lower Special Refund Category is reimbursed to the patient.

Decisions relating to medicinal products eligible for reimbursement under the Special Refund Categories are made by the Pharmaceuticals Pricing Board. Special reimbursement status may be granted for a medicinal product that is indicated for the treatment of serious or chronic diseases, which are defined by Government decree. The Pharmaceuticals Pricing Board may also restrict the special reimbursement status of a medicinal product to certain forms or grades of the disease. In such a case the product is eligible for Restricted Special Refund.

Drugs in the Special Refund Categories are only reimbursed if the need for medication can be proved by providing a separate statement, as specified by Kela. The separate statement shall always be in the form of a Medical Certificate B. For certain medicinal products, an addendum to the prescription sheet is also needed.

Clinical nutritional preparations

Either 40% or 65% of the cost of a clinical nutritional preparation, prescribed for the treatment of a serious disease, is reimbursed to the patient, provided that the preparation is used to replace or augment, either fully or partially, the patient's diet. Decisions relating to the reimbursement status of clinical nutritional preparations are made by the Pharmaceuticals Pricing Board. The reimbursement status may be granted for a nutritional preparation used for the treatment of serious or chronic diseases, which are defined by Government decree. Clinical nutritional preparations are only reimbursed if the need for medication can be proved by providing a separate statement, as specified by Kela. In the case of clinical nutritional preparations, the required statement is in the form of a Medical Certificate B.

Initial deductible

A calendar year-specific initial deductible was introduced at the start of 2016. Reimbursement under the medicine reimbursement system is not paid until the sum paid by the customer exceeds the initial deductible, which is EUR 50. Reimbursable medicines, clinical nutritional preparations and basic topical ointments purchased on prescription count towards the initial deductible. The initial deductible is not applicable to children and youth. It is applicable from the beginning of the year during which one turns 19.

Both pharmacies and Kela have real-time data on the amount of each customer's initial deductible. Once the initial deductible is met, the reimbursement is refunded to the customer directly at the pharmacy. The initial deductible counts towards the annual deductible (maximum limit on annual out-of-pocket medicine expenses).

Annual deductible (maximum annual limit on out-of-pocket medicine expenses)

If the total amount spent by the customer on reimbursable medicines, basic topical ointments and clinical nutritional preparations exceeds the annual deductible (the maximum annual limit on out-of-pocket medicine expenses), the customer is entitled to an additional reimbursement. In 2022 the annual deductible was set at EUR 592.16. The cost-of-living index is used to review the limit annually. After the annual deductible is exceeded, the customer pays a fixed non-reimbursable sum of EUR 2.50 per transaction for each reimbursable medicinal product, basic topical ointment and clinical nutritional preparation purchased as well as any portion of the medicine's price exceeding the reference price. Additional Refunds are usually paid to the customers directly at the pharmacy, after the pharmacy has verified their eligibility for Additional Refunds with

Kela's direct reimbursement inquiry service. Until 2019, customers claimed additional reimbursement from Kela for the part of the purchase exceeding the annual maximum. Since the beginning of 2020, customers have received the additional reimbursement in real time at the pharmacy also for purchases exceeding the annual maximum.

Dosage service

Dosage service, or dose dispensing service, refers to a service whereby patients receive up to a fortnight's supply of tablets or capsules from a pharmacy pre-packed into individual single doses. Pharmacies charge from the customer a dose-dispensing fee for the service, which is partially reimbursed by Kela to a specific group of customers in accordance with the Health Insurance Act (sairausvakuutuslaki 1224/2004). The customer is reimbursed 40% of the pharmacy's service fee. However, the maximum fee eligible for reimbursement per week is EUR 3.15. Patients over 75 years of age are entitled to this reimbursement provided that at the start of the service they use at least six reimbursable medicinal products suitable for the dosage service. Moreover, the patient's medication needs to be reviewed in order to eliminate any unnecessary or overlapping medication. The treating physician must also consider the dosage service to be medically justified for the patient.

**Table 5.1. Reimbursement numbers adopted in 2022, basic reimbursement**

Number and name	Disease	Valid from
3057 Alpelisib	Breast cancer	1/3/2022
3058 Vericiguat	Heart failure	1/3/2022
3059 Acalabrutinib	Chronic lymphocytic leukaemia	1/4/2022
3060 Daratumumab	Multiple myeloma	1/5/2022
3061 Sonidegib	Basal cell carcinoma	1/5/2022
3062 Esketamine	Depressive disorder	1/6/2022
3063 Pemigatinib	Cholangiocarcinoma	1/6/2022
3064 Teduglutide	Short-bowel syndrome	1/6/2022
3065 Tucatinib	Breast cancer	1/6/2022
3066 Roxadustat	Anaemia related to chronic kidney disease	1/7/2022
3067 Chlormethine	Cutaneous T-cell lymphoma, specifically mycosis fungoides	1/8/2022
3068 Pralsetinib	Lung cancer	1/8/2022
3069 Cenobamate	Epilepsy	1/8/2022
3070 Talazoparib	Breast cancer	1/8/2022
3071 Finerenone	Chronic kidney disease due to type 2 diabetes	1/10/2022
3072 Selpercatinib	Lung cancer, thyroid cancer	1/10/2022
3073 Abrocitinib	Atopic dermatitis	1/11/2022
3074 Evolocumab for the treatment of familial hypercholesterolaemia (children and adolescents)*	Familial dyslipidemia (children and adolescents)	1/11/2022
3075 Somatrogen	Growth disorder	1/11/2022
3076 Azacitidine tablet	Acute myeloid leukaemia	1/12/2022
3077 Icosapent ethyl ¹	Cardiovascular diseases	1/12/2022

1 Evolocumab has already been eligible for basic reimbursement for this illness for adults under reimbursement number 388.

Table 5.2. Reimbursement numbers discontinued in 2022, basic reimbursement

Number and name	Disease	Valid from
316 Imatinib ¹	Malignant tumours and haematological diseases	1/10/2022

1 *Imatinib has been eligible for basic and special reimbursement starting 1 October 2022, and a reimbursement number is no longer needed for basic reimbursement and special reimbursement is granted under reimbursement numbers 117 and 130.

**Table 5.3. Reimbursement numbers adopted in 2022, special reimbursement**

Number and name	Disease	Valid from
1524 Avatrombopag	Immune thrombocytopenia	1/2/2022
1525 Darolutamide	Prostatic cancer	1/2/2022
1526 Encorafenib (colorectal cancer)	Colorectal cancer	1/4/2022
1527 Lorlatinib	Lung cancer	1/4/2022
1528 Apalutamide	Prostatic cancer	1/5/2022
1529 Ponatinib	Leukaemia	1/7/2022
1530 Cannabidiol	Epilepsy	1/11/2022
1531 Gilteritinib	Acute myeloid leukaemia	1/12/2022
254 Evolocumab for the treatment of familial hypercholesterolaemia (children and adolescents) ¹	Familial dyslipidemia	1/11/2022

1 Evolocumab has already been eligible for special reimbursement for this illness for adults under reimbursement number 292.

Table 5.4. Reimbursement numbers discontinued in 2022, special reimbursement

Number and name	Disease	Valid from
189 Imatinib ¹	Malignant tumours and haematological diseases	1/10/2022

1 Imatinib has been eligible for basic and special reimbursement starting 1 October 2022, and a reimbursement number is no longer needed for basic reimbursement and special reimbursement is granted under reimbursement numbers 117 and 130.

**Table 5.5. Medicines added to existing reimbursement numbers in 2022, basic reimbursement**

Number	Medicinal agent	Disease	Added as of
303	Diroximel fumarate	Multiple sclerosis	1/5/2022
303	Ofatumumab	Multiple sclerosis	1/1/2022
303	Ponesimod	Multiple sclerosis	1/2/2022
313	Risankizumab ¹	Arthropathic psoriasis	1/7/2022
319	Bimekizumab	Cutaneous psoriasis	1/12/2022
3020	Sodium zirconium cyclosilicate	Hyperkalemia	1/2/2022



1 Risankizumab was previously eligible for basic reimbursement under reimbursement number 319 for another illness.

Table 5.6. Medicines added to existing reimbursement numbers in 2022, special reimbursement

Number	Medicinal agent	Disease	Added as of
157	Diroximel fumarate	Multiple sclerosis	1/12/2022
157	Ofatumumab	Multiple sclerosis	1/12/2022
250	Empagliflozin	Heart failure	1/1/2022



Reimbursements for medicine expenses in 2022

EUR 0 Initial deductible	EUR 50 Reimbursement for medicine expenses			EUR 592.16 Additional reimbursement						
<p>Customers pay full price for medicines covered by the reimbursement system up to 50 euros. Persons under 19 are exempt from the initial deductible.</p> 	<p>Once the customer has reached the initial deductible limit, the pharmacy will deduct the reimbursement from the price of purchased medicines. The rate of reimbursement depends on the specific medicine and illness.</p> <table border="0"> <tr> <td data-bbox="899 592 1094 651">Basic rate of reimbursement</td> <td data-bbox="1247 592 1442 651">Lower special rate of reimbursement</td> <td data-bbox="1558 592 1753 651">Higher special rate of reimbursement</td> </tr> <tr> <td data-bbox="899 671 1094 746"></td> <td data-bbox="1247 671 1442 746"></td> <td data-bbox="1558 671 1753 746"></td> </tr> </table>			Basic rate of reimbursement	Lower special rate of reimbursement	Higher special rate of reimbursement				<p>Customers' out-of-pocket payments and the initial deductible count towards an annual maximum limit on medicine expenses. Once customers exceed the annual maximum limit, they are entitled to an additional reimbursement.</p> 
Basic rate of reimbursement	Lower special rate of reimbursement	Higher special rate of reimbursement								
<p>Rate of reimbursement per medicine and per purchase 0%</p> <p>Customer's out-of-pocket share per medicine and per purchase 100%</p>	<table border="0"> <tr> <td data-bbox="899 810 1094 842">40%</td> <td data-bbox="1247 810 1442 842">65%</td> <td data-bbox="1558 810 1753 842">100%</td> </tr> <tr> <td data-bbox="899 906 1094 938">60%</td> <td data-bbox="1247 906 1442 938">35%</td> <td data-bbox="1558 906 1753 938">EUR 4.50 (copayment)</td> </tr> </table>			40%	65%	100%	60%	35%	EUR 4.50 (copayment)	<p>100%</p> <p>EUR 2.50 (copayment)</p>
40%	65%	100%								
60%	35%	EUR 4.50 (copayment)								

Calendar year



Table 5.7. Medicine costs and their reimbursement in 2022

Costs of reimbursed medicines¹

	EUR 1,000
Total cost	2,331,431
Basic Refund Category (40%) ²	617,555
Restricted Basic Refund Category (40%)	247,314
Higher Special Refund Category (100%)	744,646
Lower Special Refund Category (65%)	720,089

Reimbursement of medicine costs

	EUR 1,000
Total reimbursements ³	1,772,423
Basic Refund Category (40%) ²	235,217
Restricted Basic Refund Category (40%)	98,314
Higher Special Refund Category (100%)	724,223
Lower Special Refund Category (65%)	457,507

Number of recipients of reimbursement

	Recipients
Total	3,036,730
Basic Refund Category (40%) ²	2,913,073
Restricted Basic Refund Category (40%)	291,198
Higher Special Refund Category (100%)	500,486
Lower Special Refund Category (65%)	997,135


1 The figures do not include purchases that did not clear the initial deductible limit.

2 Purchases of medicines eligible for restricted basic refund not included.

3 Includes reimbursements for dosage service charges and Additional Refunds.

Source: Register of Statistical Information on National Health Insurance General Benefit Payments.

Figure 5.1. Reimbursement of medicine costs in 2000–2022 according to Refund Category



Source: Register of Statistical Information on National Health Insurance General Benefit Payments.



Reimbursable medicines, confirming wholesale prices, and the reference price system

Kaarina Koskela, Lawyer, Pharmaceuticals Pricing Board

Ulla Kurkijärvi, Principal Pharmaceutical Officer, Pharmaceuticals Pricing Board

A pharmaceutical company can introduce a medicinal product to the market and make it available to consumers once marketing authorisation has been granted. The inclusion of a medicinal product into the system of medicine reimbursement under the Health Insurance Scheme requires a decision by the Pharmaceuticals Pricing Board, which operates under the auspices of the Ministry of Social Affairs and Health. The product will be included in the reimbursement system once its reimbursement status and wholesale price have been approved.

The role of the Pharmaceuticals Pricing Board as a decision-maker

The task of the Pharmaceuticals Pricing Board is to decide which medicinal products are to be included in the reimbursement system and to confirm their wholesale prices and refund categories. The Pricing Board also makes decisions regarding wholesale price increases for reimbursable medicines. The decisions are based on applications submitted by marketing authorisation holders. Moreover, the

Pricing Board makes decisions relating to the reference price system, including decisions regarding the reference price groups, reference prices, and the products to be included in the reference price groups.

The Pharmaceuticals Pricing Board consists of seven members and their deputies nominated by the Ministry of Social Affairs and Health. The Board members represent the Ministry of Social Affairs and Health, the Social Insurance Institution of Finland (Kela), the Finnish Medicines Agency Fimea, the National Institute for Health and Welfare, and the Ministry of Finance. The Board must have members with medical, pharmaceutical, legal and economic expertise. The Pharmaceuticals Pricing Board works closely with a group of experts and the Board's Secretariat. Cases are presented at the Board meetings by the Chief Pharmaceutical Officers and Pharmaceutical Officers of the Board's Secretariat. The Pricing Board's group of experts consists of seven members and their personal deputies, and it comprises experts from the fields of medicine, pharmacology and health insurance. The presenting official of the group of experts is the Senior Medical Officer of the Board's Secretariat.

The decision-making process is based on the application process, and the decision must be issued within a set time period. In turn, the application process is based on the provisions laid down in the Health Insurance Act (sairausvakuutuslaki 1224/2004) and the Administrative Procedure Act (hallintolaki 434/2003). In certain circumstances, as provided in the Health Insurance Act, the Pricing Board may decide to review the wholesale price and reimbursement status of a medicinal product at their own initiative.

A decision issued by the Pharmaceuticals Pricing Board regarding the reimbursement status and reasonable wholesale price of a medicinal product containing a new active substance is valid for up to three years. Decisions regarding all other products are valid for up to five years. Decisions regarding the reimbursement status and maximum wholesale price of products to be included in the reference price system are valid for an indefinite period. The applicant retains the right to appeal against the decisions to the Supreme Administrative Court.

Inclusion of a medicinal product in the reimbursement system

Medicinal products included in the reimbursement system are subject to price regulation. The inclusion of a product into the reimbursement system requires a decision which approves both the reimbursement status of the product and its wholesale price. A medicinal product with a valid marketing authorisation may be marketed in Finland without its wholesale price having been confirmed by the authorities. However, reimbursement for the cost of the medicinal product can only be paid under the Health Insurance Act if the Pharmaceuticals Pricing Board has approved the product for reimbursement and confirmed its wholesale price. A confirmed wholesale price refers to the maximum price at which the product may be sold to pharmacies. The actual reimbursement payment is based on the retail price (inclusive of VAT), which cannot be higher than the confirmed wholesale price plus the pharmacy's profit margin (Table 5.8.) at the rate set out in the Government Decree on the Price List of Drugs (713/2013) and VAT (10%).



The medicine cost will remain fully payable by the patient if the marketing authorisation holder fails to apply for reimbursement status and a wholesale price for the product, or if the product's reimbursement status and wholesale price proposed by the Marketing Authorisation Holder have not been approved. Likewise, the cost remains payable by the patient if the marketing authorisation holder has removed the product from the list of reimbursable medicines, or if its reimbursement status and wholesale price have been removed. The removal of a medicine from the reimbursement system by the marketing authorisation holder is possible on a quarterly basis.

Basic reimbursement status and reasonable wholesale price

An application for basic reimbursement status and a wholesale price is submitted by the marketing authorisation holder. The application must include, in addition to the proposed wholesale prices, a well-grounded evaluation of the benefits and costs incurred should the product be included in the reimbursement system at the proposed prices. Applications for reimbursement status and wholesale price are processed simultaneously by the Pharmaceuticals Pricing Board.

The application must include a statement on the intended use and therapeutic value of the medicinal product and the benefits expected to be gained with reimbursement status as compared with other medicinal products used to treat the same illness. The application must also include a detailed and well-grounded statement regarding the average daily dose and the cost of the drug treatment based on this dose. Moreover, the application must include the validity period of the pharmaceutical patent or the supplementary protection certificate, an estimate of the sales volume and number of users of the product, and the approved prices and grounds for reimbursement of the product in other EEA countries. The application must also include any other trade names under which the product is marketed in other EEA countries, and the respective prices. Applications must contain a health economic evaluation if the medicinal product contains a new active substance or the reimbursement status shall be significantly extended.

A renewal application submitted by the marketing authorisation holder shall contain a description of the changes to the aspects affecting the reasonableness of the wholesale price if a higher wholesale price than the previously confirmed wholesale price is being proposed for the product.

Before reaching decisions regarding basic reimbursement status and a reasonable wholesale price, the Pricing Board may request that Kela submit a statement, if necessary. In the statement, Kela will assess whether the criteria for granting reimbursement status are fulfilled and evaluate the reasonableness of the proposed price in terms of the Health Insurance Scheme. The statement will also include an estimate of the impact of the cost of the product on the Health Insurance Scheme. The Pricing Board may also request an opinion from the group of experts before making a decision, For example, a statement may be requested in the event that a pharmaceutical company applies for basic reimbursement status for a product containing a new active substance, or if the reimbursement status of a medicine is extended to a new indication.

When deciding upon basic reimbursement status, the Pharmaceuticals Pricing Board assesses the therapeutic value of the product. A medicinal product for the treatment of an illness can only be granted basic reimbursement status to the extent defined in its Summary of Product Characteristics and for indications listed therein. The Summary of Product Characteristics must be approved by the marketing authorisation authorities. A medicinal product is not considered eligible for reimbursement under the basic rate of reimbursement if, for example, the therapeutic value of the product is not considered significant, or if the product is used for purposes other than the treatment of an illness. The Pharmaceuticals Pricing Board also has the authority to limit, when necessary, the eligibility for basic reimbursement to clearly defined indications (medicinal products eligible for the limited basic reimbursement).

An over-the-counter product may be granted basic reimbursement status only if the product is considered, on medical grounds, to be an indispensable medicinal product.



When considering the reasonableness of the proposed wholesale price, the Pharmaceuticals Pricing Board takes into account the cost of the drug therapy and the benefits to be gained from its use with regard to both the patient and the overall health care and social costs. The Pricing Board will also consider the benefits and costs of treatment alternatives, the prices of comparable medicinal products in Finland, the price of the medicine in question in other EEA countries, and the funds available for reimbursement payments. It is also possible to consider the medicine's manufacturing, research and development costs in the decision-making, provided that sufficiently detailed, comparable and reliable product-specific data relating to these costs have been submitted.

The wholesale price confirmed for a first generic alternative can be a maximum of 50 per cent of the confirmed wholesale price of the corresponding product, and for a first biosimilar product, a maximum of 70 per cent of the confirmed wholesale price of the corresponding product. For a generic alternative including a new dose-dispensing device, the confirmed wholesale price can be a maximum of 60 per cent of the confirmed wholesale price of the corresponding product.

The use of new medicines is often shadowed by uncertainty around the overall costs, cost effects and therapeutic value. In Finland, a new method to control this uncertainty, known as provisional reimbursement status, has been launched. The possibility of being granted provisional reimbursement status primarily concerns new medicinal therapies. In practice, this refers to new active pharmaceutical substances or new significant indications for pharmaceutical products already included in the reimbursement system. The Pharmaceuticals Pricing Board will assess the preconditions for initiating negotiations concerning provisional reimbursement status on a case-by-case basis. While the negotiations are underway, the processing time of the relevant application will be suspended. If the negotiations produce a positive result, the final decision will be accompanied by an agreement between the marketing authorisation holder and the Pharmaceuticals Pricing Board concerning the terms and conditions for the monitoring and management of the uncertainty surrounding the product. If no agreement is reached through negotiations, the processing of the application will continue in accordance with the normal application procedure. The regulations concerning provisional reimbursement status are valid for a fixed period, until the end of 2025.

Special reimbursement status and reasonable wholesale price

Certain medicines that are used to treat serious and chronic illnesses are eligible for reimbursement payments at special reimbursement rates. Medicinal products granted special reimbursement status attract higher reimbursement payments than those granted basic reimbursement status. The illnesses that make medicinal products used in their treatment eligible for inclusion at special rates of reimbursement are decided by the Finnish Government. The Pharmaceuticals Pricing Board decides which medicinal products are to be granted special reimbursement status. These decisions are product-specific. In order to qualify for special reimbursement status, the medicinal product must be used to treat an illness defined by Government decree, and it must be deemed necessary in the treatment of a serious and chronic illness.

The application for special reimbursement status submitted by the marketing authorisation holder must demonstrate that the product fulfils the criteria for special reimbursement status. Moreover, the application must include a statement regarding the cost-effectiveness of special reimbursement status and a market forecast which takes competing products into account. The application must also include an evaluation of the envisaged impact of costs following the granting of special reimbursement status.

When making decisions on special reimbursement status, the Pharmaceuticals Pricing Board will consider the nature of the illness and the therapeutic value, indispensability, replacement or remedial effects, necessity and cost-effectiveness of the medicine as proven in clinical practice and by research, as well as the funds available for special reimbursement payments. The Board also has the opinions of both the group of experts and Kela at its disposal.

A medicinal product may be granted special reimbursement status if it is already included at the basic rate of reimbursement, and if sufficient clinical experience and research data are available on the product meeting the criteria for special reimbursement (therapeutic value, usefulness in comparison with treatment alternatives, indispensability, replacement or remedial effects, necessity and cost-effectiveness). The special reimbursement status of a medicinal product can also be limited to certain forms or grades of a disease. The reasonableness of the price is always reassessed in connection with applications for special reimbursement.



Reference price system

Under the reference price system, reimbursement for a medicinal product is calculated from a reference price, which is determined separately. If the medicine purchased is more expensive than the reference price, and the patient declines substitution, the cost in excess of the reference price is paid by the patient. Reimbursement under the health insurance scheme can only be paid for the price of a medicine that exceeds the reference price if the prescribing physician forbids substitution on medical or therapeutic grounds.

Under the reference price system, medicines are divided into reference price groups. The reference price groups are based on the list of substitutable medicinal products compiled by the Finnish Medicines Agency Fimea. Medicinal products with a corresponding pharmaceutical form and pack size, and which contain equal amounts of the same active substance, are grouped together in the same reference price group. Products grouped in the same reference price group are interchangeable with each other.

Reference prices are based on the retail price of the medicinal products (inclusive of VAT), and they are updated every three months on the basis of price notifications submitted to the Pharmaceuticals Pricing Board by marketing authorisation holders. The reference price is calculated from the least expensive product within the group by adding EUR 0.50 to its retail price (inclusive of VAT). In December 2022, more than a half (54%) of all reimbursable medicinal product packages with marketing authorisation were included in the reference price system.

Reimbursement status and maximum wholesale price in the reference price system

The application process applied under the reference price system entails the Pharmaceuticals Pricing Board confirming the reimbursement status and maximum wholesale price for a new product to be included in the system. The marketing authorisation holder must apply for reimbursement status for a new medicinal product under the reference price system if the product is eligible for generic substitution and other corresponding products marketed are already included in the reference price system.

The application process in the reference price system places the marketing authorisation holder under an obligation to provide the same documentation, as far as is appropriate, as described above for applications regarding basic and special reimbursement status. The application must also include a proposal for the maximum wholesale price of the product.

The confirmed maximum wholesale price must not exceed the price level of corresponding products. The maximum wholesale price refers to the maximum price at which the product may be sold to pharmacies. When deciding on the reimbursement status of medicinal products to be included in the reference price system, the Pharmaceuticals Pricing Board considers corresponding matters as described above for decisions concerning basic and special reimbursement status.



Matters regarding reimbursement status and price processed in 2022

In 2022, the Pharmaceuticals Pricing Board processed 996 applications for reimbursement status and price (Table 5.10.). Most of the applications, 92.3%, were approved; 2.3% were rejected and 5.4% were withdrawn. The applications processed by the Board refer to a specific product.

The renewal of fixed-term reimbursement status and wholesale price was the most common type of application. There were 321 renewal applications, 312 of which were approved, 4 were rejected, and 5 withdrawn. A total of 49 applications for reimbursement status relating to the reference price system were processed.

There were a total of 73 applications for reimbursement status and price concerning a new active substance or other new pharmaceutical product; 49 of these applications were applications for basic reimbursement status and price, and 24 were for special reimbursement status and price. Of the applications for basic reimbursement status and price, 38 were approved, and 22 applications for special reimbursement status and price were approved. During 2022, a total of 28 new active substances were included in the reimbursement system, and 17 new active substances were granted special reimbursement status (Table 5.9.).

Application processing times

A decision regarding reimbursement status and wholesale price must be issued to the applicant within 180 days of receipt of the application. Should the information supporting the application be insufficient, the Board – and if necessary, the Director – may suspend the application process until the applicant has provided the required information. The final decision must be issued to the applicant within 180 days of the receipt of the requested additional information. If a decision only concerns an increase of a previously confirmed wholesale price, and not the reimbursement status of the medicinal product, the decision must be issued to the applicant within 90 days of receipt of the application. If the number of applications for price increases is exceptionally high, the Board may extend the processing time by 60 days.

The decision issued by the Pharmaceuticals Pricing Board will enter into force at the beginning of the second calendar month following the issue date, unless otherwise specified in the decision.

The average processing times of applications by application type in 2022 are presented in Table 5.11. The median time taken to reach a positive decision ranged from 15 to 132 days, and that of a negative decision from 91 to 132 days depending on the type of application. The median processing time for an application for a new active substance was 128 days for both approved and rejected applications concerning basic reimbursement status and price. Correspondingly, the median processing time for an approved special reimbursement status and price application was 116 days. There were no rejected applications for special reimbursement. Applications that led to conditional reimbursement have not been included in the calculation of processing times (the processing times for these applications are suspended during the negotiations). The median treatment time was 90 days for emollients, 77 days for clinical nutritional products, and 15 days for specially licensed medicinal products.

Prior to a decision being issued, several requests may be submitted to the applicant for detailed additional information to support the application. Moreover, in order to make an assessment, the Board may request the opinion of relevant specialists, and in certain cases, also hear evidence from the applicant. It is also possible for the applicant to request the suspension of the application process.

The Pharmaceuticals Pricing Board is able to transfer the decision-making directly to the Director of the Board in cases where the application refers to a new strength of a medicinal product, generic alternatives, biosimilars, parallel imports, a new pack size, or a new pharmaceutical form. Decisions regarding products in the reference price system may also be transferred to the Director. The processing times of decisions issued by the Director are usually considerably shorter.

**Table 5.8. Calculation formula for retail prices, without VAT, of medicinal products in 2022****Prescription medicine**

Wholesale price euros	Retail price
- 7.49	1,42 x wholesale price
7.50 - 39.99	1,35 x wholesale price + 0,52 €
40.00 - 99.99	1,24 x wholesale price + 4,92 €
100.00 - 399.99	1,15 x wholesale price + 13,92 €
400.00 - 1 499.99	1,10 x wholesale price + 33,92 €
1 500.00 -	1,00 x wholesale price + 183,92 €

Over the counter medicine

Wholesale price euros	Retail price
- 9.25	1,5 x wholesale price + 0,50 €
9.26 - 46.25	1,4 x wholesale price + 1,43 €
46.26 - 100.91	1,3 x wholesale price + 6,05 €
100.92 - 420.47	1,2 x wholesale price + 16,15 €
420.48 -	1,1 x wholesale price + 47,68 €

Source: Government Decree on the Price List of Drugs (713/2013).

Table 5.9. New active substances in 2022

Basic reimbursement, approved	Special reimbursement, approved	Basic reimbursement, approved	Special reimbursement, approved
Abrositinib	Acalabrutinib	Romosozumab	
Acalabrutinib	Apalutamid	Selpercatinib	
Alpelisib	Burosumab	Cenobamate	
Azacitidine	Daratumumab	Somatrogon	
Bertralstat	Diroximel fumarate	Sonidegib	
Bimekizumab	Filgotinib	Talazoparib	
Daratumumab	Gilteritinib	Teduglutide	
Diroximel fumarate	Guselkumab	Tucatinib	
Eptinezumab	Cannabidiol	Vericiguat	
Esketamine	Larotrectinib	Basic reimbursement, rejected	Special reimbursement, rejected
Finerenone	Lorlatinib	Omega-3-triglycerides incl. other esters and acids	-
Follitropin delta	Neratinib	Ozanimod	
Chlormethine	Ofatumumab	Risdiplam	
Omega-3-triglycerides incl. other esters and acids	Opicapone	Foods	
Pegcetacoplan	Ponatinib	Siponimod	
Pemigatinib	Risankizumab	Sotorasib	
Pralsetinib	Ustekinumab	Trientine	
Relugolix, estradiol and norethisterone		Zanubrutinib	
Roxadustat			

Source: Pharmaceuticals Pricing Board.

Table 5.10. Number of applications for reasonable wholesale prices and reimbursement status processed by the Pharmaceuticals Pricing Board in 2022¹

Type of application	Approved	Rejected	Withdrawn
Applications for reimbursement status and price	919	23	54
Medicinal products with marketing authorization	641	16	14
New active substance or other new product, basic reimbursement status	38	9	2
New active substance or other new product, special reimbursement status	22	-	2
New combination of active substances	1	-	-
New pharmaceutical form	7	-	-
New strength	24	-	1
New package size/form	38	-	-
Expansion of reimbursement status	44	3	3
Generic product	76	-	1
Parallel import	27	-	-
Biosimilar	3	-	-
Reimbursement status in reference price system	49	-	-
Price increase application	-	-	-
Renewal of a price and reimbursement status approved for a fixed-period	312	4	5
Clinical nutritional preparations²	151	2	9
Basic topical ointments	24	1	2
Non-registered medicinal products	103	4	29

1 Each application includes all reimbursement categories and subsequent strengths, pharmaceutical forms and package sizes.

2 Includes products belonging to refund categories of 40% and 65%.


Source: Pharmaceuticals Pricing Board.

Table 5.11. Median process times of applications (number of days) approved or rejected by the Pharmaceuticals Pricing Board, according to the type of application, in 2022

Type of application	Approved	Rejected
Applications for reimbursement status and price		
Medicinal products with marketing authorization		
New active substance or other new product, basic reimbursement status	128	128
New active substance or other new product, special reimbursement status	116	-
New combination of active substances	41	-
New pharmaceutical form	32	-
New strength	29	-
New package size/form	15	-
Expansion of reimbursement status	119	91
Generic product	21	-
Parallel import	24	-
Biosimilar	58	-
Reimbursement status in reference price system	34	-
Price increase	-	-
Renewal of a price and reimbursement status approved for a fixed-period	132	132

Source: Pharmaceuticals Pricing Board.

6. Tables: Reimbursement of medicine costs





Medicine costs and their reimbursement annually and according to hospital district

Table 6.1. Medicine costs and their reimbursement in 2005–2022

All refunds¹

Year	Number of recipients	As a proportion of the population, %	Reimbursements EUR 1,000	Total costs ² EUR 1,000	No. of purchases ² , in thousands	No. of dispensations ² , in thousands
2005	3,261,540	62.1	1,076,908	1,598,998	20,872	28,796
2006	3,584,719	67.9	1,100,344	1,588,395	24,583	32,801
2007	3,674,582	69.3	1,142,074	1,638,996	26,417	35,061
2008	3,723,521	69.9	1,242,879	1,744,381	27,515	36,781
2009	3,756,438	70.2	1,244,758	1,768,848	28,890	39,208
2010	3,801,154	70.7	1,225,445	1,719,013	29,255	39,889
2011	3,855,198	71.4	1,262,066	1,753,506	29,646	40,588
2012	3,866,724	71.2	1,303,129	1,812,241	30,267	41,608
2013	3,829,177	70.2	1,273,049	1,811,263	29,574	40,317
2014	3,843,226	70.2	1,306,453	1,860,024	29,945	40,687
2015	3,811,748	69.4	1,377,934	1,948,772	31,268	43,991
2016	3,136,095	56.9	1,411,990	1,947,443	28,033	40,506
2017	3,036,110	55.0	1,386,661	1,938,802	28,758	41,844
2018	3,034,776	54.9	1,460,140	2,003,219	29,482	43,400
2019	3,042,434	54.9	1,550,985	2,088,902	30,376	45,198
2020	2,953,465	53.3	1,634,903	2,168,295	29,972	46,123
2021	2,956,849	53.2	1,711,347	2,251,245	30,543	48,390
2022	3,036,730	54.5	1,772,423	2,331,431	31,890	51,276

Basic Refund Category

Year	Number of recipients	As a proportion of the population, %	Reimbursements EUR 1,000	Total costs ² EUR 1,000	No. of purchases ² , in thousands	No. of dispensations ² , in thousands
2005	3,100,214	59.0	369,861	879,037	14,216	19,635
2006	3,465,440	65.7	366,551	870,280	17,591	23,459
2007	3,563,435	67.2	368,732	877,974	19,114	25,422
2008	3,619,457	68.0	395,494	941,888	20,009	26,924
2009	3,659,959	68.4	402,717	963,650	21,121	29,049
2010	3,705,813	68.9	377,545	908,516	21,347	29,568
2011	3,760,290	69.6	357,149	860,191	21,600	30,048
2012	3,771,227	69.5	354,338	852,663	22,041	30,860
2013	3,729,090	68.4	297,673	827,010	21,356	29,678
2014	3,740,015	68.3	298,518	859,694	21,575	29,916
2015	3,709,187	67.6	310,080	891,529	22,302	32,104
2016	3,022,273	54.9	316,104	837,187	19,097	28,467
2017	2,925,270	53.0	318,145	831,281	19,560	29,171
2018	2,925,818	52.9	307,056	802,044	19,787	29,864
2019	2,934,104	53.0	316,354	822,783	20,222	30,870
2020	2,839,771	51.3	308,455	802,273	19,642	31,183
2021	2,847,500	51.2	311,094	808,921	20,051	32,829
2022	2,934,286	52.7	333,530	864,869	21,051	35,004

1 Includes reimbursements for dosage service charges and Additional Refunds.

2 The figures do not include purchases that did not clear the initial deductible limit.



Table 6.1. continued

Higher Special Refund Category

Year	Number of recipients	As a proportion of the population, %	Reimbursements EUR 1,000	Total costs ² EUR 1,000	No. of purchases ² , in thousands	No. of dispensations ² , in thousands
2005	454,512	8.6	370,102	380,498	2,098	2,738
2006	468,291	8.9	393,324	402,305	2,223	2,820
2007	480,712	9.1	432,580	441,672	2,345	2,950
2008	497,121	9.3	465,619	474,945	2,427	3,029
2009	516,050	9.6	470,530	480,517	2,546	3,160
2010	535,762	10.0	498,984	509,989	2,673	3,313
2011	560,243	10.4	552,042	562,929	2,761	3,415
2012	581,985	10.7	595,277	606,765	2,920	3,602
2013	603,085	11.1	610,419	622,072	3,043	3,747
2014	619,292	11.3	620,592	632,746	3,175	3,896
2015	635,358	11.6	665,822	678,402	3,484	4,361
2016	637,262	11.6	696,153	720,456	3,577	4,547
2017	553,666	10.0	604,660	623,803	2,809	3,560
2018	489,952	8.9	626,444	645,522	2,795	3,548
2019	495,035	8.9	653,167	672,560	2,894	3,680
2020	498,400	9.0	700,049	720,306	2,954	3,792
2021	501,653	9.0	740,205	760,815	3,021	3,952
2022	500,486	9.0	724,223	744,646	3,089	4,093

Lower Special Refund Category

Year	Number of recipients	As a proportion of the population, %	Reimbursements EUR 1,000	Total costs ² EUR 1,000	No. of purchases ² , in thousands	No. of dispensations ² , in thousands
2005	828,191	15.8	237,409	339,464	4,558	6,423
2006	833,665	15.8	226,380	315,580	4,769	6,521
2007	835,283	15.8	229,353	318,920	4,958	6,689
2008	842,503	15.8	235,011	326,833	5,080	6,828
2009	850,307	15.9	230,585	323,452	5,223	7,000
2010	851,717	15.8	210,117	298,539	5,235	7,008
2011	853,920	15.8	230,141	327,432	5,285	7,125
2012	851,478	15.7	246,897	348,884	5,306	7,146
2013	849,208	15.6	233,749	357,237	5,174	6,892
2014	844,440	15.4	235,018	365,194	5,195	6,875
2015	840,877	15.3	243,565	377,463	5,482	7,526
2016	831,193	15.1	245,711	388,649	5,359	7,493
2017	941,101	17.0	305,560	482,557	6,389	9,113
2018	962,071	17.4	352,231	554,415	6,900	9,988
2019	975,518	17.6	376,243	592,235	7,260	10,647
2020	988,705	17.8	408,750	644,233	7,376	11,147
2021	993,098	17.9	431,474	679,845	7,471	11,608
2022	997,135	17.9	457,507	720,089	7,750	12,179

1 Includes reimbursements for dosage service charges and Additional Refunds.

2 The figures do not include purchases that did not clear the initial deductible limit.

Source: Register of Statistical Information on National Health Insurance General Benefit Payments.

**Table 6.2. Medicine costs and their reimbursement according to hospital district, in 2022**

Hospital district	Recipients of reimbursement		Reimbursements		Total costs ¹		No. of dispensations ¹	
	Number of recipients	As a proportion of the population, %	EUR 1,000	EUR per recipient	EUR 1,000	EUR per recipient	In thousands	Per recipient
Whole country	3,036,730	54.5	1,772,096	584	2,329,604	767	51,276	17
Helsinki and Uusimaa	854,152	49.3	442,705	518	587,365	688	12,724	15
Southwest Finland	277,949	56.9	167,632	603	219,980	791	4,492	16
Satakunta	127,968	60.1	74,272	580	98,643	771	2,302	18
Kanta-Häme	98,690	58.1	64,407	653	83,445	846	1,812	18
Pirkanmaa	304,628	55.4	187,820	617	244,545	803	4,923	16
Päijät-Häme	118,574	56.9	70,729	596	93,291	787	2,104	18
Kymenlaakso	95,791	59.9	58,214	608	77,585	810	1,993	21
South Karelia	70,818	56.4	43,586	615	56,826	802	1,167	17
South Savo	59,036	61.5	36,409	617	48,483	821	1,139	19
Itä-Savo	24,926	63.7	14,925	599	19,899	798	500	20
North Karelia	96,640	59.4	59,382	614	78,257	810	1,933	20
North Savo	150,557	61.9	90,483	601	120,412	800	2,969	20
Central Finland	140,048	55.3	82,018	586	108,095	772	2,372	17
South Ostrobothnia	109,468	57.3	69,847	638	90,516	827	1,923	18
Vaasa	83,179	48.9	54,990	661	69,610	837	1,259	15
Central Ostrobothnia	41,695	54.2	25,463	611	33,321	799	795	19
North Ostrobothnia	221,758	53.5	133,759	603	173,891	784	4,012	18
Kainuu	42,699	60.5	25,657	601	33,740	790	830	19
Länsi-Pohja	33,570	57.8	19,432	579	25,620	763	601	18
Lapland	67,170	57.0	42,514	633	55,436	825	1,212	18
Åland	13,576	44.7	6,806	501	9,175	676	192	14

¹ The figures do not include purchases that did not clear the initial deductible limit.

Source: Register of Statistical Information on National Health Insurance General Benefit Payments.

Table 6.3. Payback payments for conditional reimbursements in 2019-2021

Year	Payback payments, euros
2019	13,146,860
2020	32,870,279
2021	38,040,324

Medicine costs and their reimbursement in diseases entitling patients to special refund

Table 6.4. Patients entitled to reimbursement under the Special Refund Categories, and cost of the diseases per recipient in 2022

Reimbursement entitlement	Number of patients entitled to Special Refunds			Average cost, euro		
	Total	Male	Female	Total	Male	Female
Anterior pituitary hypofunction (101)	4,907	3,517	1,390	376	479	124
Diabetes insipidus (102)	1,215	556	659	928	1,061	813
Diabetes, insulin-treated (103)	396,180	215,782	180,398	623	660	571
Thyroid insufficiency (104)	84,199	12,980	71,219	40	44	39
Adrenal cortical hypofunction (105)	1,559	575	984	179	186	175
Hypoparathyroidism (106)	2,244	400	1,844	276	369	253
Pernicious anaemia (107)	13,181	5,020	8,161	32	33	32
Myasthenia gravis (108)	1,735	801	934	477	431	519
Multiple sclerosis (109)	9,869	2,697	7,172	212	259	194
Parkinson's disease and comparable movement disorders (110)	19,829	10,949	8,880	1,236	1,211	1,268
Epilepsy and comparable convulsive disorders (111)	72,125	36,172	35,953	291	306	273
Severe psychotic and other severe mental disorders (112)	97,568	46,264	51,304	862	983	756
Anxiety disorders associated with mental retardation (113)	6,949	4,105	2,844	267	283	236
Glaucoma (114)	102,014	40,250	61,764	266	263	268
Breast cancer (115)	41,960	188	41,772	509	621	509
Prostate cancer (116)	28,292	28,292	0	1,643	1,643	0
Leukaemia and other malignant diseases of the blood and bone marrow, and malignant diseases of the lymphatic tissue (117)	24,223	12,390	11,833	1,261	1,372	1,159
Trigeminal neuralgia or glossopharyngeusneuralgia (119)	2,612	708	1,904	124	141	116

Table continued



Table 6.4. continued

Reimbursement entitlement	Number of patients entitled to Special Refunds			Average cost, euro		
	Total	Male	Female	Total	Male	Female
Hypogammaglobulinaemia (120)	798	332	466	32,963	34,903	31,545
Severe hypofunction of sexual glands (121)	8,890	3,997	4,893	323	526	111
Aplastic anaemia (122)	418	238	180	1,281	1,317	1,229
Chronic disorders of vitamin D metabolism (123)	9,157	5,696	3,461	126	124	130
Inborn metabolic disorders (124)	369	195	174	6,136	4,939	7,159
Chronic coagulation defects (126)	1,140	584	556	69,099	98,552	4,379
Transplant complication (127)	7,140	4,147	2,993	3,333	3,461	3,145
Cancers of female genital organs (128)	5,068	0	5,068	1,469	0	1,469
Idiopathic thrombocytopaenia or granulocytopenia (129)	1,141	495	646	1,945	2,910	1,057
Malignant tumour (130)	31,524	17,982	13,542	2,467	2,277	2,713
Sarcoidosis (132)	3,514	1,749	1,765	37	36	38
Severe chronic pancreatic insufficiency (133)	6,788	4,023	2,765	859	867	845
General erythroderma (134)	2,132	1,398	734	312	332	276
Pemphigus (135)	260	92	168	72	74	71
Uraemia requiring dialysis (137)	2,587	1,566	1,021	22,236	22,636	21,603
Severe anaemia associated with chronic renal failure (138)	8,347	5,054	3,293	2,469	2,550	2,362
Dasatinib (150)	179	101	78	11,824	11,299	12,750
Palbociclib (1501)	1,697	12	1,685	23,589	24,260	23,582
Cabozantinib (1502)	619	409	210	41,029	41,740	39,594
Emicizumab (haemophilia A, with inhibitors) (1503)	14	14	0	131,686	131,686	0
Alectinib (1504)	99	32	67	51,234	49,923	51,660

Table continued



Table 6.4. continued

Reimbursement entitlement	Number of patients entitled to Special Refunds			Average cost, euro		
	Total	Male	Female	Total	Male	Female
Ixazomib (1505)	206	105	101	49,471	56,389	42,207
The combination of trifluridine and tipiracil (1506)	434	250	184	10,462	9,241	11,684
Pomalidomide (1507)	408	197	211	80,222	80,281	80,166
Lenvatinib (1508)	191	131	60	26,672	26,890	26,038
Dabrafenib and trametinib (1509)	334	203	131	79,834	82,460	75,697
Eliglustat, imiglucerase and velaglucerase alfa (151)	14	5	9	220,338	201,832	229,591
Niraparib (1510)	272	0	272	43,799	0	43,799
Olaparib (1511)	165	0	165	62,521	0	62,521
Ibrutinib (1512)	475	307	168	65,289	66,058	63,962
Binimetinib and encorafenib (melanoma) (1513)	137	89	48	85,699	84,491	87,964
Ribociclib (1514)	152	0	152	16,656	0	16,656
Abemaciclib (1515)	346	0	346	22,597	0	22,597
Romiplostim (1516)	123	64	59	29,066	29,279	28,791
Eltrombopag (1517)	342	195	147	19,679	20,293	19,023
Venetoclax (1518)	348	223	125	65,439	65,631	65,055
Osimertinib (1519)	259	88	171	66,314	63,625	67,614
Nilotinib (152)	173	85	88	24,053	23,886	24,194
Emicizumab (haemophilia A, without inhibitors) (1520)	28	27	1	263,564	256,229	380,924
Brigatinib (1521)	10	4	6	31,817	15,576	48,058
Midostaurin (1522)	24	9	15	129,213	0	129,213
Enzalutamide (1523)	2,020	2,020	0	34,784	34,784	0
Avatrombopag (1524)	39	17	22	0	0	0

Table continued



Table 6.4. continued

Reimbursement entitlement	Number of patients entitled to Special Refunds			Average cost, euro		
	Total	Male	Female	Total	Male	Female
Darolutamide (1525)	162	162	0	0	0	0
Encorafenib (colorectal cancer) (1526)	61	28	33	0	0	0
Lorlatinib (1527)	16	6	10	0	0	0
Apalutamide (1528)	418	418	0	0	0	0
Ponatinib (1529)	42	28	14	0	0	0
Lenalidomid (153)	1,966	1,013	953	12,576	12,855	12,279
Cannabidiol (1530)	79	42	37	0	0	0
Gilteritinib (1531)	3	3	0	0	0	0
Afatinib and gefitinib (155)	170	54	116	15,102	15,916	14,704
Lapatinib (156)	58	0	58	18,351	0	18,351
Dimethyl fumarate, diroximel fumarate, glatiramer acetate, interferon beta, ofatumumab and teriflunomid (Multiple sclerosis) (157)	4,815	1,309	3,506	9,464	9,516	9,443
Everolimus (158)	146	83	63	13,945	14,811	13,404
Pazopanib (159)	268	138	130	19,365	20,399	18,295
Exenatide and liraglutide (160)	15,236	8,009	7,227	0	0	0
Preparation with von Willebrand's factor (161)	4	0	4	245,199	0	245,199
Liraglutide (162)	7,713	4,019	3,694	0	0	0
Abiraterone (163)	2,270	2,270	0	23,046	23,046	0
Cladribine and fingolimod (164)	1,268	304	964	17,334	16,797	17,521
Preservative-free combination product containing bimatoprost and timolol (165)	151	35	116	0	0	0
Dalteparin and tinzaparin (treatment for more than 6 months) (166)	1,581	691	890	2,199	2,337	2,105
Vemurafenib (167)	90	48	42	30,094	14,159	35,406
Axitinib (168)	122	72	50	26,089	26,519	25,175
Crizotinib (169)	69	28	41	43,641	53,895	39,155

Table continued



Table 6.4. continued

Reimbursement entitlement	Number of patients entitled to Special Refunds			Average cost, euro		
	Total	Male	Female	Total	Male	Female
Bosutinib (170)	41	23	18	27,453	26,994	28,370
Insulin degludec (171)	1,092	362	730	0	0	0
Blood coagulation factor VIII and von Willebrand factor for desensitisation treatment in inhibitor-positive patients with haemophilia A (172)	3	3	0	0	0	0
Trastuzumab injection (173)	5	0	5	0	0	0
Ruxolitinib (174)	299	150	149	37,798	38,319	37,311
Deferasirox (175)	108	51	57	8,015	9,566	6,464
Regorafenib (176)	271	177	94	16,074	17,150	13,708
Insulin glargine 300 U/ml (177)	15,095	8,608	6,487	0	0	0
Combination product containing tegafur, gimeracil and oteracil (178)	73	46	27	2,141	1,388	2,894
Vismodegib (179)	22	13	9	27,128	21,659	38,067
Interferon alfa (180)	436	229	207	0	0	0
Retigabine and vigabatrin (181)	1,312	633	679	1,007	963	1,059
Brivaracetam, eslikarbazepin, gabapentin, lacosamide, levetiracetam, perampanel, pregabalin, tiagabin and zonisamide (182)	23,575	10,953	12,622	1,276	1,323	1,236
Lamotrigin and topiramate (183)	11,561	4,413	7,148	542	561	530
Paclitaxel (184)	2	0	2	0	0	0
Docetaxel (185)	2	0	2	0	0	0
Growth retardation associated with renal failure (growth hormone) (186)	1,291	841	450	6,606	6,852	6,078
Treatment-resistant psychosis (188)	6,813	3,337	3,476	0	0	0
Imatinib (189)	805	457	348	4,589	5,138	3,804

Table continued



Table 6.4. continued

Reimbursement entitlement	Number of patients entitled to Special Refunds			Average cost, euro		
	Total	Male	Female	Total	Male	Female
Lanthanum carbonate, sevelamer and sucroferric oxyhydroxide (190)	1,574	1,015	559	1,213	1,268	1,128
Erlotinib (191)	92	43	49	2,204	1,466	2,450
Fulvestrant (192)	941	5	936	1,070	1,096	1,070
Rasagiline (193)	2,971	1,629	1,342	93	94	92
Blood coagulation factor VIII and von Willebrand factor for the treatment of von Willebrand disease (194)	53	27	26	128,913	154,433	112,673
Agalsidase alfa, agalsidase beta and migalastat (195)	50	22	28	216,991	249,952	197,458
Paricalcitol and cinacalcet (196)	1,438	869	569	882	917	836
Sunitinib (197)	501	305	196	6,428	6,887	5,842
Sorafenib (198)	263	202	61	10,271	10,262	10,304
Rufinamide (199)	260	156	104	2,795	2,959	2,557
Chronic cardiac insufficiency (201)	31,048	19,420	11,628	133	128	141
Connective tissue diseases, rheumatoid arthritis and comparable disease (202)	128,539	45,427	83,112	347	366	338
Chronic asthma and similar chronic obstructive pulmonary diseases (203)	290,817	118,020	172,797	356	366	350
Chronic hypertension (205)	371,972	181,102	190,870	125	123	128
Chronic coronary artery disease and dyslipidaemia associated with chronic coronary artery disease (206)	181,021	118,220	62,801	115	113	120
Chronic arrhythmias (207)	179,460	91,268	88,192	73	71	75
Ulcerative colitis and Crohn's disease (208)	58,594	30,774	27,820	636	659	612
Severe hereditary disorders of lipid metabolism (familial hypercholesterolaemia and type III dyslipoproteinemia) (211)	4,780	2,230	2,550	74	71	76
Gout (212)	9,446	7,332	2,114	40	40	40
Severe and chronic narcolepsy (214)	581	227	354	1,392	1,422	1,368
Diabetes, non-insulin-treated (215)	396,184	215,788	180,396	419	444	388
Dapagliflozin and empagliflozin (250)	4,677	3,395	1,282	556	553	562
Benralizumab (251)	198	82	116	14,860	14,834	14,884

Table continued



Table 6.4. continued

Reimbursement entitlement	Number of patients entitled to Special Refunds			Average cost, euro		
	Total	Male	Female	Total	Male	Female
Anakinra (252)	106	52	54	10,232	9,792	10,764
Vedolizumab (253)	1,101	596	505	11,296	11,599	10,902
Clopidogrel (280)	22	16	6	0	0	0
Abatacept, adalimumab, certolizumab pegol, etanercept, golimumab, guselkumab, infliximab, ixekizumab, risankizumab, sarilumab, secukinumab and tocilizumab (281)	18,939	7,663	11,276	8,176	8,210	8,151
Sodium oxybat (282)	449	175	274	4,482	4,321	4,608
Ivabradine (283)	54	35	19	0	0	0
Nintedanib and pirfenidone (284)	966	693	273	23,925	24,595	22,239
Dulaglutide, exenatide, liraglutide and semaglutide (type 2 diabetes, adults) (285)	58,536	30,690	27,846	1,323	1,315	1,333
Ciclosporin eye drop (286)	293	14	279	879	888	878
Ticagrelor 60 mg (287)	245	187	58	715	688	789
Febuxostat (288)	2,011	1,394	617	193	192	193
Combination product containing sacubitril and valsartan (289)	4,921	3,828	1,093	2,005	1,986	2,068
Apixaban, dabigatran, edoxaban and rivaroxaban for the treatment of atrial fibrillation (290)	196,719	101,984	94,735	938	928	949
Tofacitinib (291)	889	236	653	9,504	9,734	9,419
Alirocumab and evolocumab for the treatment of familial hypercholesterolaemia (adults) (292)	400	208	192	5,690	5,609	5,786
Baricitinib (293)	723	134	589	10,225	10,433	10,172
Alirocumab and evolocumab for the treatment of hypercholesterolaemia and dyslipidaemia (294)	1,498	943	555	5,634	5,632	5,638
Liraglutide (type 2 diabetes, children and adolescents) (295)	16	8	8	1,346	949	1,544
Rivaroxaban for the treatment of coronary artery disease (296)	334	246	88	746	749	732
Mepolizumab (297)	369	155	214	13,771	13,678	13,845
Upadacitinib (298)	531	124	407	9,412	9,894	9,269
Apremilast (299)	556	269	287	8,434	8,787	8,019

When calculating the average costs, only those persons whose entitlement to special reimbursement for medicines has been in force throughout the year, and who have purchased such medicines, have been included.

Source: Dispensations reimbursable under the National Health Insurance Scheme register (includes purchases falling under the initial deductible) and Special Reimbursement Entitlement Register.

**Table 6.5. Patients receiving reimbursement payments under the Special Refund Categories and total cost and reimbursement payments in the Special Refund Categories in 2022**

Reimbursement entitlement	No. of recipients of reimbursement	Total cost, EUR 1,000 ¹	Reimbursement payments, EUR 1,000
All diseases under the Special Refund Categories	1,250,372	1,458,855	1,248,320
Anterior pituitary hypofunction (101)	3,437	1,267	1,116
Diabetes insipidus (102)	844	761	735
Diabetes, insulin-treated (103)	125,993	75,856	71,792
Thyroid insufficiency (104)	74,641	3,172	1,277
Adrenal cortical hypofunction (105)	1,315	231	175
Hypoparathyroidism (106)	1,419	387	335
Pernicious anaemia (107)	9,578	344	222
Myasthenia gravis (108)	1,318	599	543
Multiple sclerosis (109)	2,260	497	440
Parkinson's disease and comparable movement disorders (110)	16,975	18,832	17,940
Epilepsy and comparable convulsive disorders (111)	36,588	10,275	8,883
Severe psychotic and other severe mental disorders (112)	76,345	65,259	60,308
Anxiety disorders associated with mental retardation (113)	2,619	693	595
Glaucoma (114)	85,753	21,999	18,386
Breast cancer (115)	26,575	16,839	15,862
Dalteparin, enoxaparin and tinzaparin (an addendum to the prescription + 115)	202	124	120
Prostate cancer (116)	17,553	25,695	25,058
Dalteparin, enoxaparin and tinzaparin (an addendum to the prescription + 116)	108	64	62

1 The figures include purchases falling under the initial deductible.

Reimbursement entitlement	No. of recipients of reimbursement	Total cost, EUR 1,000 ¹	Reimbursement payments, EUR 1,000
Leukaemia and other malignant diseases of the blood and bone marrow, and malignant diseases of the lymphatic tissue (117)	11,243	14,378	13,973
Dalteparin, enoxaparin and tinzaparin (an addendum to the prescription + 117)	207	103	99
Trigeminal neuralgia or glossofaryngeusneuralgia (119)	688	86	68
Hypogammaglobulinaemia (120)	599	19,137	19,106
Severe hypofunction of sexual glands (121)	6,050	1,924	1,676
Aplastic anaemia (122)	169	220	213
Chronic disorders of vitamin D metabolism (123)	4,446	520	434
Inborn metabolic disorders (124)	188	1,105	1,099
Chronic coagulation defects (126)	435	33,670	33,652
Transplant complication (127)	5,582	18,012	17,649
Tacrolimus granules (an addendum to the prescription + 127)	21	39	39
Cancers of female genital organs (128)	1,946	2,622	2,548
Dalteparin, enoxaparin and tinzaparin (an addendum to the prescription + 128)	92	55	53
Idiopathic thrombocytopaenia or granulocytopenia (129)	165	298	293
Malignant tumour (130)	14,623	22,713	22,060
Dalteparin, enoxaparin and tinzaparin (an addendum to the prescription + 130)	654	404	390
Sarcoidosis (132)	280	11	7
Severe chronic pancreatic insufficiency (133)	5,383	4,197	4,058

Table continued



Table 6.5. continued

Reimbursement entitlement	No. of recipients of reimbursement	Total cost, EUR 1,000 ¹	Reimbursement payments, EUR 1,000
General erythroderma (134)	649	209	192
Pemphigus (135)	53	4	3
Uraemia requiring dialysis (137)	483	8,618	8,594
Severe anaemia associated with chronic renal failure (138)	3,883	8,427	8,324
Dasatinib (150)	133	1,392	1,386
Palbociclib (1501)	1,056	20,220	20,189
Cabozantinib (1502)	404	13,198	13,187
Emicizumab (haemophilia A, with inhibitors) (1503)	13	1,579	1,579
Alectinib (1504)	80	3,281	3,278
Ixazomib (1505)	88	3,035	3,034
The combination of trifluridine and tipiracil (1506)	246	1,841	1,838
Pomalidomide (1507)	284	15,727	15,712
Lenvatinib (1508)	117	2,015	2,012
Dabrafenib and trametinib (1509)	204	11,888	11,880
Eliglustat, imiglucerase and velaglucerase alfa (151)	12	2,644	2,643
Niraparib (1510)	143	5,272	5,267
Olaparib (1511)	125	5,919	5,914
Ibrutinib (1512)	356	19,282	19,266
Binimetinib and encorafenib (melanoma) (1513)	68	4,328	4,325
Ribociclib (1514)	108	1,036	1,035
Abemaciclib (1515)	236	3,253	3,249
Romiplostim (1516)	79	2,030	2,025

1 The figures include purchases falling under the initial deductible.

Reimbursement entitlement	No. of recipients of reimbursement	Total cost, EUR 1,000 ¹	Reimbursement payments, EUR 1,000
Eltrombopag (1517)	241	4,352	4,343
Venetoclax (1518)	268	11,135	11,128
Osimertinib (1519)	216	10,160	10,154
Nilotinib (152)	141	3,220	3,213
Emicizumab (haemophilia A, without inhibitors) (1520)	23	5,044	5,044
Brigatinib (1521)	6	204	204
Midostaurin (1522)	19	1,167	1,167
Enzalutamide (1523)	1,645	44,506	44,454
Avatrombopag (1524)	27	206	206
Darolutamide (1525)	149	3,605	3,604
Encorafenib (colorectal cancer) (1526)	41	642	642
Lorlatinib (1527)	13	373	372
Apalutamide (1528)	333	6,096	6,094
Ponatinib (1529)	31	723	723
Lenalidomid (153)	1,307	12,240	12,183
Cannabidiol (1530)	58	188	188
Afatinib and gefitinib (155)	109	1,273	1,269
Lapatinib (156)	28	411	410
Dimethyl fumarate, diroximel fumarate, glatiramer acetate, interferon beta, ofatumumab and teriflunomid (Multiple sclerosis) (157)	4,082	37,027	36,818
Everolimus (158)	63	455	454
Pazopanib (159)	139	1,916	1,912

Table continued



Table 6.5. continued

Reimbursement entitlement	No. of recipients of reimbursement	Total cost, EUR 1,000 ¹	Reimbursement payments, EUR 1,000
Preparation with von Willebrand's factor (161)	1	245	245
Abiraterone (163)	806	14,196	14,173
Cladribine and fingolimod (164)	974	17,942	17,889
Dalteparin and tinzaparin (treatment for more than 6 months) (166)	1,030	1,598	1,572
Vemurafenib (167)	4	120	120
Axitinib (168)	72	1,320	1,318
Crizotinib (169)	40	1,438	1,437
Bosutinib (170)	25	577	576
Ruxolitinib (174)	224	6,871	6,862
Deferasirox (175)	46	287	285
Regorafenib (176)	143	1,197	1,195
Combination product containing tegafur, gimeracil and oteracil (178)	44	59	57
Vismodegib (179)	16	436	435
Retigabine and vigabatrin (181)	99	85	83
Brivaracetam, eslikarbazepin, gabapentin, lacosamide, levetiracetam, perampanel, pregabalin, tiagabalin and zonisamide (182)	18,251	21,729	20,992
Lamotrigin and topiramate (183)	7,084	3,732	3,429
Growth retardation associated with renal failure (growth hormone) (186)	1,031	6,414	6,392
Imatinib (189)	655	2,725	2,697

1 The figures include purchases falling under the initial deductible.

Reimbursement entitlement	No. of recipients of reimbursement	Total cost, EUR 1,000 ¹	Reimbursement payments, EUR 1,000
Lanthanum carbonate, sevelamer and sucroferric oxyhydroxide (190)	987	1,021	1,004
Erlotinib (191)	45	64	62
Fulvestrant (192)	518	431	409
Rasagiline (193)	1,481	134	102
Blood coagulation factor VIII and von Willebrand factor for the treatment of von Willebrand disease (194)	19	2,497	2,496
Agalsidase alfa, agalsidase beta and migalastat (195)	46	9,581	9,577
Paricalcitol and cinacalcet (196)	666	536	518
Sunitinib (197)	278	1,173	1,163
Sorafenib (198)	134	896	893
Rufinamide (199)	130	337	334
Chronic cardiac insufficiency (201)	27,610	3,431	2,078
Connective tissue diseases, rheumatoid arthritis and comparable disease (202)	71,317	24,570	16,994
Chronic asthma and similar chronic obstructive pulmonary diseases (203)	231,646	82,097	54,094
Chronic hypertension (205)	344,868	43,494	24,836
Chronic coronary artery disease and dyslipidaemia associated with chronic coronary artery disease (206)	164,410	19,709	11,537
Ticagrelor 90mg (an addendum to the prescription + 206)	3,662	984	606

Table continued



Table 6.5. continued

Reimbursement entitlement	No. of recipients of reimbursement	Total cost, EUR 1,000 ¹	Reimbursement payments, EUR 1,000
Rivaroxaban in the management of acute coronary syndrome (an addendum to the prescription + 206)	9	2	1
Prasugrel (an addendum to the prescription + 206)	149	26	15
Ezetimibe (an addendum to the prescription + 206)	146	2	1
Chronic arrhythmias (207)	94,640	6,521	3,918
Ulcerative colitis and Crohn's disease (208)	38,490	24,307	16,568
Severe hereditary disorders of lipid metabolism (familial hypercholesterolaemia and type III dyslipoproteinemia) (211)	3,008	249	131
Ezetimibe (an addendum to the prescription + 211)	7	0	0
Gout (212)	4,494	177	103
Severe and chronic narcolepsy (214)	286	379	300
Diabetes, non-insulin-treated (215)	304,831	122,932	82,339
Dapagliflozin and empagliflozin (250)	3,085	1,169	865
Benralizumab (251)	167	2,180	2,108
Anakinra (252)	69	629	598
Vedolizumab (253)	728	6,804	6,491
Abatacept, adalimumab, certolizumab pegol, etanercept, golimumab, guselkumab, infliximab, ixekizumab, risankizumab, sarilumab, secukinumab and tocilizumab (281)	15,492	120,988	113,198
Sodium oxybat (282)	140	581	520

Reimbursement entitlement	No. of recipients of reimbursement	Total cost, EUR 1,000 ¹	Reimbursement payments, EUR 1,000
Nintedanib and pirfenidone (284)	759	14,981	14,586
Dulaglutide, exenatide, liraglutide and semaglutide (type 2 diabetes, adults) (285)	46,984	56,699	43,790
Ciclosporin eye drop (286)	174	142	110
Ticagrelor 60 mg (287)	150	91	63
Febuxostat (288)	1,313	240	157
Combination product containing sacubitril and valsartan (289)	3,959	7,032	5,860
Apixaban, dabigatran, edoxaban and rivaroxaban for the treatment of atrial fibrillation (290)	178,909	153,007	105,335
Tofacitinib (291)	613	5,268	4,988
Alirocumab and evolocumab for the treatment of familial hypercholesterolaemia (adults) (292)	317	1,708	1,553
Baricitinib (293)	526	5,063	4,805
Alirocumab and evolocumab for the treatment of hypercholesterolaemia and dyslipidaemia (294)	985	4,914	4,475
Liraglutide (type 2 diabetes, children and adolescents) (295)	12	15	11
Rivaroxaban for the treatment of coronary artery disease (296)	243	162	117
Mepolizumab (297)	329	3,997	3,841
Upadacitinib (298)	383	3,164	3,009
Apremilast (299)	369	2,771	2,604

1 The figures include purchases falling under the initial deductible.

Source: Dispensations reimbursable under the National Health Insurance Scheme register.



Table 6.6. Drug treatment statistics of the most common diseases entitling the patients to reimbursement under the Special Refund Categories, in 2022

Disease/Medication	ATC code	No. of persons who purchased medicines ^{1, 2}	Cost per patient, euro
Diabetes (103, 215, 285, 295)		361,923	706
Metformin	A10BA02	228,861	77
Insulin glargine	A10AE04	68,067	468
Empagliflozin	A10BK03	66,936	497
Insulin aspart	A10AB05	59,807	248
Sitagliptin	A10BH01	42,576	413
Semaglutide	A10BJ06	38,480	1,112
Dapagliflozin	A10BK01	37,777	475
Insulin degludec	A10AE06	31,220	484
Linagliptin	A10BH05	29,674	447
Metformin and sitagliptin	A10BD07	22,742	428
Insulin detemir	A10AE05	21,050	446
Insulin lispro	A10AB04	8,400	315
Metformin and empagliflozin	A10BD20	8,312	483
Liraglutide	A10BJ02	5,978	1,242
Dulaglutide	A10BJ05	5,491	902
Chronic hypertension (205)		353,789	123
Bisoprolol	C07AB07	136,523	41
Amlodipine	C08CA01	114,910	30
Furosemide	C03CA01	62,114	41
Losartan	C09CA01	52,956	35
Candesartan	C09CA06	41,843	46

Disease/Medication	ATC code	No. of persons who purchased medicines ^{1, 2}	Cost per patient, euro
Lercanidipine	C08CA13	41,329	61
Metoprolol	C07AB02	38,159	67
Ramipril	C09AA05	32,845	27
Losartan and diuretics	C09DA01	26,883	66
Enalapril	C09AA02	26,675	44
Spirolactone	C03DA01	22,177	46
Valsartan	C09CA03	21,371	60
Candesartan and diuretics	C09DA06	20,060	116
Felodipine	C08CA02	19,690	85
Enalapril and diuretics	C09BA02	16,045	71
Chronic asthma and similar chronic obstructive pulmonary diseases (203)		236,748	347
Salbutamol	R03AC02	120,991	33
Formoterol and budesonide	R03AK07	52,479	279
Montelukast	R03DC03	45,451	39
Salmeterol and fluticasone	R03AK06	40,763	172
Fluticasone	R03BA05	28,650	160
Prednisolone	H02AB06	28,485	13
Budesonide	R03BA02	25,579	145
Tiotropium bromide	R03BB04	23,629	370
Ciclesonide	R03BA08	23,402	163

Table continued



Table 6.6. continued

Disease/Medication	ATC code	No. of persons who purchased medicines ^{1,2}	Cost per patient, euro
Vilanterol and fluticasone furoate	R03AK10	20,345	409
Formoterol and beclometasone	R03AK08	17,927	367
Terbutaline	R03AC03	15,221	35
Beclometasone	R03BA01	14,689	137
Formoterol, glycopyrronium bromide and beclometasone	R03AL09	8,183	606
Formoterol and fluticasone	R03AK11	6,669	384
Chronic arrhythmias (207, 290)		193,331	825
Apixaban	B01AF02	97,518	841
Bisoprolol	C07AB07	73,753	40
Rivaroxaban	B01AF01	55,165	840
Dabigatran etexilate	B01AE07	16,827	886
Digoxin	C01AA05	15,546	61
Edoxaban	B01AF03	12,348	788
Metoprolol	C07AB02	7,806	59
Flecainide	C01BC04	7,780	172
Amiodarone	C01BD01	3,100	81
Propranolol	C07AA05	1,998	35
Atenolol	C07AB03	1,430	60
Verapamil	C08DA01	1,327	63
Diltiazem	C08DB01	949	122
Sotalol	C07AA07	885	80
Celiprolol	C07AB08	91	55

Disease/Medication	ATC code	No. of persons who purchased medicines ^{1,2}	Cost per patient, euro
Chronic coronary heart disease (206, 294, 296, an addendum to the prescription + 206)		168,146	147
Atorvastatin	C10AA05	73,397	36
Bisoprolol	C07AB07	70,499	35
Rosuvastatin	C10AA07	48,327	40
Ezetimibe	C10AX09	43,483	29
Isosorbide dinitrate	C01DA08	38,171	24
Isosorbide mononitrate	C01DA14	37,146	73
Simvastatin	C10AA01	26,401	40
Amlodipine	C08CA01	23,535	28
Glyceryl trinitrate	C01DA02	19,982	24
Clopidogrel	B01AC04	19,724	30
Metoprolol	C07AB02	15,308	56
Ticagrelor	B01AC24	6,183	465
Pravastatin	C10AA03	2,585	116
Fluvastatin	C10AA04	2,207	126
Rosuvastatin and ezetimibe	C10BA06	1,685	90

Table continued



Table 6.6. continued

Disease/Medication	ATC code	No. of persons who purchased medicines ^{1,2}	Cost per patient, euro
Glaucoma (114)		86,294	254
Timolol, combinations	S01ED51	51,247	202
Latanoprost	S01EE01	22,608	116
Brinzolamide	S01EC04	16,924	74
Tafluprost	S01EE05	14,528	227
Bimatoprost	S01EE03	8,318	156
Travoprost	S01EE04	5,190	162
Brimonidine	S01EA05	4,915	84
Brinzolamide, combinations	S01EC54	4,529	157
Timolol	S01ED01	4,031	108
Dorzolamide	S01EC03	1,815	90
Acetazolamide	S01EC01	1,759	223
Betaxolol	S01ED02	1,016	110

Disease/Medication	ATC code	No. of persons who purchased medicines ^{1,2}	Cost per patient, euro
Disseminated connective tissue diseases, rheumatoid arthritis and comparable conditions (202, 281, 284, 286, 291, 293, 298, 299)		80,625	2,195
Methotrexate	L04AX03	41,510	356
Hydroxychloroquine	P01BA02	25,470	88
Sulfasalazine	A07EC01	20,841	184
Adalimumab	L04AB04	5,630	6,006
Prednisolone	H02AB06	4,882	15
Etanercept	L04AB01	4,469	5,733
Leflunomide	L04AA13	4,410	194
Ursodeoxycholic acid	A05AA02	3,695	461
Azathioprine	L04AX01	2,696	109
Golimumab	L04AB06	2,347	10,329
Methylprednisolone	H02AB04	1,384	54
Certolizumab pegol	L04AB05	925	8,878
Secukinumab	L04AC10	853	9,519
Abatacept	L04AA24	740	8,785
Tocilizumab	L04AC07	679	7,905

Table continued



Table 6.6. continued

Disease/Medication	ATC code	No. of persons who purchased medicines ^{1,2}	Cost per patient, euro
Severe psychotic and other severe mental disorders (112)		78,091	831
Quetiapine	N05AH04	25,055	132
Olanzapine	N05AH03	23,011	555
Aripiprazole	N05AX12	13,439	743
Clozapine	N05AH02	11,093	411
Risperidone	N05AX08	10,542	627
Mirtazapine	N06AX11	10,405	78
Valproic acid	N03AG01	9,175	194
Lamotrigine	N03AX09	7,416	284
Venlafaxine	N06AX16	6,496	209
Sertraline	N06AB06	5,450	72
Escitalopram	N06AB10	5,284	42
Lithium	N05AN01	5,116	144
Citalopram	N06AB04	4,519	60
Perphenazine	N05AB03	4,250	155
Levomepromazine	N05AA02	3,607	68

Disease/Medication	ATC code	No. of persons who purchased medicines ^{1,2}	Cost per patient, euro
Cancers (115–117, 128, 130, 150, 152, 153, 155, 156, 158, 159, 163, 166–170, 173, 174, 176, 178–180, 189, 191, 192, 197, 198, 1501, 1502, 1504–1515, 1518, 1519, 1521–1523, an addendum to the prescription + 115–117, 128 or 130)		74,839	4,345
Letrozole	L02BG04	14,778	90
Oxycodone	N02AA05	13,319	116
Dexamethasone	H02AB02	11,977	119
Leuprorelin	L02AE02	8,739	1,098
Denosumab	M05BX04	6,971	1,623
Prednisolone	H02AB06	5,859	20
Ondansetron	A04AA01	5,644	70
Tamoxifen	L02BA01	5,492	118
Pegfilgrastim	L03AA13	4,705	2,054
Palonosetron, combinations	A04AA55	4,284	367
Hydroxycarbamide	L01XX05	4,241	149
Tramadol	N02AX02	4,108	37
Capecitabine	L01BC06	3,917	220
Triptorelin	L02AE04	3,698	1,016
Bicalutamide	L02BB03	3,526	834

Table continued



Table 6.6. continued

Disease/Medication	ATC code	No. of persons who purchased medicines ^{1,2}	Cost per patient, euro
Epilepsy and comparable convulsive disorders (111, 181-183, 199)		49,622	726
Valproic acid	N03AG01	14,596	207
Levetiracetam	N03AX14	13,513	674
Oxcarbazepine	N03AF02	12,383	348
Carbamazepine	N03AF01	8,252	147
Lamotrigine	N03AX09	5,867	407
Lacosamide	N03AX18	3,901	1,550
Midazolam	N05CD08	3,762	170
Clobazam	N05BA09	3,251	72
Clonazepam	N03AE01	2,148	46
Topiramate	N03AX11	1,653	809
Brivaracetam	N03AX23	1,446	1,945
Gabapentin	N03AX12	1,064	240
Pregabalin	N03AX16	1,061	209
Perampanel	N03AX22	781	1,875
Zonisamide	N03AX15	742	1,527

Disease/Medication	ATC code	No. of persons who purchased medicines ^{1,2}	Cost per patient, euro
Ulcerative colitis and Crohn's disease (208, 253)		39,270	791
Mesalazine	A07EC02	28,965	702
Azathioprine	L04AX01	7,856	132
Budesonide	A07EA06	5,120	273
Mercaptopurine	L01BB02	3,494	122
Prednisolone	H02AB06	3,185	19
Sulfasalazine	A07EC01	1,925	197
Metronidazole	P01AB01	1,621	36
Methotrexate	L04AX03	1,461	339
Vedolizumab	L04AA33	728	9,347
Methylprednisolone	H02AB04	209	48
Hydrocortisone	H02AB09	137	46
Olsalazine	A07EC03	55	350
Dexamethasone	H02AB02	53	54
Ciclosporin	L04AD01	51	706

Table continued



Table 6.6. continued

Disease/Medication	ATC code	No. of persons who purchased medicines ^{1,2}	Cost per patient, euro
Chronic cardiac insufficiency (201, 250, 289)		28,291	411
Bisoprolol	C07AB07	20,241	45
Furosemide	C03CA01	14,847	46
Spironolactone	C03DA01	9,450	40
Ramipril	C09AA05	8,816	27
Valsartan and sacubitril	C09DX04	3,959	1,776
Losartan	C09CA01	3,404	34
Digoxin	C01AA05	3,219	61
Isosorbide dinitrate	C01DA08	3,073	26
Isosorbide mononitrate	C01DA14	2,851	65
Metoprolol	C07AB02	2,532	65
Candesartan	C09CA06	2,313	42
Dapagliflozin	A10BK01	2,224	412
Enalapril	C09AA02	1,851	42
Glyceryl trinitrate	C01DA02	1,711	32
Valsartan	C09CA03	1,434	60

Disease/Medication	ATC code	No. of persons who purchased medicines ^{1,2}	Cost per patient, euro
Parkinson's disease and other comparable movement disorders (110, 193)		17,067	1,110
Levodopa and decarboxylase inhibitor	N04BA02	14,266	776
Pramipexole	N04BC05	3,838	210
Levodopa, decarboxylase inhibitor and comt inhibitor	N04BA03	3,301	1,473
Selegiline	N04BD01	2,262	180
Ropinirole	N04BC04	2,171	170
Rasagiline	N04BD02	1,498	90
Rotigotine	N04BC09	472	1,330
Amantadine	N04BB01	339	129
Opicapone	N04BX04	315	527
Entacapone	N04BX02	312	742
Biperiden	N04AA02	277	63
Apomorphine	N04BC07	34	6,252
Cabergoline	N04BC06	4	77
Cabergoline	N04BC06	6	56
Bromocriptine	G02CB01	1	573

1 The data covers all beneficiaries who in 2020 purchased medicines under the Special Refund Categories for any of the listed diseases, including purchases that did not clear the initial deductible limit.

2 One patient may use medicines from several medicine groups.

Source: Dispensations reimbursable under the National Health Insurance Scheme register.



Medicinal products eligible for restricted basic refund

Table 6.7. Medicines eligible for restricted basic refund: Number of purchasers and the cost of reimbursed drugs in 2022

Reimbursement entitlement	No. of persons who purchased medicines	Average cost per patient, euro	Total cost, EUR 1,000
Medicinal products eligible for restricted basic refund, total	334,447	764	255,627
Alectinib (3001)
Osimertinib (3004)
Tofacitinib (3005)	365	9,582	3,497
Baricitinib (3006)	58	6,000	348
Eptinezumab, erenumab, fremanezumab and galcanezumab (3007)	5,703	5,153	29,389
Tolvaptan (3008)	26	15,009	390
Growth hormone (301)	881	5,727	5,046
Midodrine (3010)	82	867	71
Tafamidis (3011)	33	103,461	3,414
Cabozantinib (3012)	4	32,946	132
Rivaroxaban for the treatment of coronary artery disease and peripheral artery disease (3013)	241	572	138
Alirocumab, evolocumab and inclisiran for the treatment of hypercholesterolaemia and dyslipidaemia (3015)	152	4,678	711
Lenvatinib (3019)
Patiromer and sodium zirconium cyclosilicate (3020)	45	2,425	109
Allergen extract of birch pollen (adults) (3023)	2,141	991	2,122

Reimbursement entitlement	No. of persons who purchased medicines	Average cost per patient, euro	Total cost, EUR 1,000
Calcium carbonate (3025)	26	37	1
Lorlatinib (3026)	4	16,088	64
Benralizumab (3027)
Mepolizumab (3028)	11	5,257	58
Upadacitinib (3029)	137	6,419	879
Dimethyl fumarate, diroximel fumarate, glatiramer acetate, interferon beta, ofatumumab, ponesimod and teriflunomid (Multiple sclerosis) (303)	70	8,346	584
Apalutamide (3031)	112	10,132	1,135
Budesonide tablet, orodispersible (3032)	51	1,157	59
Gilteritinib (3033)	7	93,965	658
Larotrectinib (3034)
Pitolisant and solriamfetol (3035)	116	3,813	442
Darolutamide (3036)	46	3,778	174
Neratinib (3037)
Romiplostim (3038)
Eltrombopag (3039)
Dornase alfa (304)	62	5,561	345

Table continued



Table 6.7. continued

Reimbursement entitlement	No. of persons who purchased medicines	Average cost per patient, euro	Total cost, EUR 1,000
Burosumab (3040)	7	286,027	2,002
Vedolizumab (3042)	19	1,903	36
Combination product containing ivacaftor and lumacaftor (3043)	7	165,499	1,158
Combination therapy with ivacaftor and tezacaftor (3044)	6	161,180	967
Combination therapy with elexacaftor, ivacaftor and tezacaftor (3045)	44	212,772	9,362
Cannabidiol (3046)	68	16,765	1,140
Filgotinib (3048)	54	6,122	331
Encorafenib (colorectal cancer) (3049)	29	8,312	241
Entrectinib (3050)	6	31,050	186
Liraglutide (obesity) (3051)	3,559	1,000	3,557
Anakinra (3053)	5	11,366	57
Enzalutamide (3054)
Combination product containing bupropion and naltrexone (3055)	1,043	332	346
Ataluren (3056)	6	562,794	3,377
Vericiguat (3058)	18	676	12
Acalabrutinib (3059)	6	15,789	95
Erythropoietin and darbepoetin (306)	18	5,769	104
Daratumumab (3060)	32	44,339	1,419
Sonidegib (3061)
Esketamine (3062)	11	9,887	109

Reimbursement entitlement	No. of persons who purchased medicines	Average cost per patient, euro	Total cost, EUR 1,000
Pemigatinib (3063)	5	43,233	216
Teduglutide (3064)	8	31,953	256
Tucatinib (3065)	7	21,567	151
Roxadustat (3066)
Chlormethine (3067)
Pralsetinib (3068)	7	15,983	112
Cenobamate (3069)	31	368	11
Finerenone (3071)
Selpercatinib (3072)
Azacitidine tablet (3076)
Alprostadil, sildenafil and combination product containing aviptadil and phentolamine (308)	2,494	180	449
Nalmefene and naltrexone (309)	317	160	51
Abatacept, adalimumab, certolizumab pegol, etanercept, golimumab, guselkumab, infliximab, ixekizumab, risankizumab, sarilumab, secukinumab, tocilizumab and ustekinumab (rheumatoid diseases) (313)	689	8,880	6,118
Topical pimecrolimus and tacrolimus (317)	3,895	118	461
Teriparatide (318)	320	2,470	791
Adalimumab, bimekizumab, brodalumab, certolizumab pegol, etanercept, guselkumab, infliximab, ixekizumab, risankizumab, secukinumab, tildrakizumab and ustekinumab (skin psoriasis) (319)	2,796	12,108	33,853

Table continued



Table 6.7. continued

Reimbursement entitlement	No. of persons who purchased medicines	Average cost per patient, euro	Total cost, EUR 1,000
Lanthanum carbonate, sevelamer and sucroferric oxyhydroxide (320)
Paricalcitol and cinacalcet (321)	914	743	679
Adalimumab, golimumab, infliximab and ustekinumab (intestinal diseases) (326)	4,534	9,908	44,923
Atomoxetine, dexamphetamine, guanfacine and lisdexamphetamine (331)	15,175	962	14,600
Treprostinil (334)	16	126,246	2,020
Bertralstat, C1-esterase inhibitor, conestat alfa, icatibant and lanadelumab (338)	77	166,386	12,812
Product containing buprenorfine and naloxone (339)	253	940	238
Everolimus (340)	35	27,528	963
Dronedarone (342)	663	497	330
Pazopanib (343)
Omalizumab (344)	483	8,477	4,095
Dulaglutide, exenatide, liraglutide and semaglutide (type 2 diabetes, adults) (346)	316	698	221
Roflumilast (348)	420	532	223
Febuxostat (349)	7	129	1
Capsaicin (350)	30	1,111	33
Apixaban, dabigatran, edoxaban and rivaroxaban for the treatment of atrial fibrillation (351)	418	234	98
Cladribine and fingolimod (353)	4	29,791	119
Dienogest (355)	619	348	215
Nintedanib and pirfenidone (356)	52	11,436	595

Reimbursement entitlement	No. of persons who purchased medicines	Average cost per patient, euro	Total cost, EUR 1,000
Combination product containing naproxen and esomeprazole (366)	83	127	11
Combination product containing docusate sodium and sorbitol (368)	160	1,194	191
Idelalisib (372)	20	22,392	448
Ponatinib (373)	23	21,805	502
Ruxolitinib (374)
Cyanocobalamin (376)	4	52	0
Apremilast and dimethyl fumarate (psoriasis) (377)	307	7,153	2,196
Apixaban, dabigatran, edoxaban and rivaroxaban for the long-term prevention of recurrent deep vein thrombosis and pulmonary embolism (379)	17,295	829	14,339
Adalimumab (hidradenitis suppurativa) (380)	183	14,333	2,623
Combination product containing sacubitril and valsartan (381)	10	364	4
Selexipag (383)	32	44,128	1,412
Asfotase alfa (387)
Alirocumab, evolocumab and inclisiran for the treatment of familial hypercholesterolaemia (adults) (388)	11	4,199	46

Table continued



Table 6.7. continued

Reimbursement entitlement	No. of persons who purchased medicines	Average cost per patient, euro	Total cost, EUR 1,000
Ibrutinib (390)
Obeticholic acid (391)	16	31,032	497
Ferric maltol (392)	9	271	2
Pomalidomide (393)
Palbociclib (394)
Dupilumab (395)	828	12,670	10,490
Idebenone (396)	6	47,405	284
Venetoclax (399)	68	19,292	1,312

Reimbursement entitlement	No. of persons who purchased medicines	Average cost per patient, euro	Total cost, EUR 1,000
(Basic topical ointments) (an addendum to the prescription)	255,901	55	13,955
Apixaban, dabigatran, edoxaban and rivaroxaban (an addendum to the prescription)	19,176	213	4,087
Dalteparin (an addendum to the prescription)	4	159	1
Enoxaparin (an addendum to the prescription)	42	175	7
Fidaxomicin (an addendum to the prescription)	70	2,251	158
Granisetron (an addendum to the prescription)	55	520	29
Letermovir (an addendum to the prescription)	75	21,444	1,608
Other emollients and protectives (an addendum to the prescription)	307	46	14
Prasugrel (an addendum to the prescription)	153	174	27
Tacrolimus (an addendum to the prescription)
Ticagrelor (an addendum to the prescription)	4,001	233	932
Tinzaparin (an addendum to the prescription)	14	385	5
Zolmitriptan (an addendum to the prescription)	703	322	227

Source: Dispensations reimbursable under the National Health Insurance Scheme register.



Clinical nutritional preparations

Table 6.8. Clinical nutritional preparations reimbursable under the Health Insurance Scheme: Number of purchasers and the cost of reimbursed preparations in 2022

Disease	No. of purchasers	Average cost per patient, euro	Total cost, EUR 1,000
Whole group	5,196	1,752	9,105
Inborn metabolic disorders (503)	242	3,138	759
Conditions requiring daily forced enteral nutrition (504)	2,468	2,380	5,874
Allergy to cow's milk in infants (505)	882	803	708
Allergy to cow's milk and hypersensitivity to conventional formula in infants (506)	268	3,343	896
Severe malabsorption of nutrients, mainly fats (601)	895	612	548
Children's severe malnutrition (602)	558	573	320

Source: Dispensations reimbursable under the National Health Insurance Scheme register.



Medicine costs and their reimbursement according to prescriber

Table 6.9. Medicine prescribers, 2015–2022

Doctor

Year	Number of prescribers	Dispensations/prescriber	Costs/prescriber, EUR
2015	27,845	1.576	69.937
2016	28,306	1.642	71.685
2017	28,163	1.720	71.091
2018	28,409	1.781	73.630
2019	29,313	1.811	74.858
2020	29,999	1.817	75.644
2021	30,843	1.854	75.969
2022	31,644	1.912	76.371

Dentist

Year	Number of prescribers	Dispensations/prescriber	Costs/prescriber, EUR
2015	5 466	93	958
2016	5 447	91	928
2017	5 132	87	864
2018	5 058	86	840
2019	5 113	87	826
2020	5 038	74	731
2021	5 032	64	693
2022	5 109	64	708

Table continued




Nurse

Year	Number of prescribers	Dispensations/prescriber	Costs/prescriber, EUR
2015	194	51	853
2016	229	53	914
2017	275	54	924
2018	315	49	751
2019	389	41	562
2020	413	33	486
2021	488	34	535
2022	519	42	690

The figures only include prescriber-specific IDs.
The figures include purchases falling under the initial deductible.

Sources: Dispensations reimbursable under the National Health Insurance Scheme register.

Figure 6.1. Percentages of medicine prescribers, 2022



**Table 6.10. Average number and cost (before reimbursement is deducted) of dispensations per doctor, according to speciality, in 2022 (only those dispensations entitled to reimbursement are included)****Doctors**

Medical speciality	Number of doctors	Dispensation per doctor	Average cost per doctor, euro
No speciality	14,305	2,355	65,893
Specialist emergency medicine	161	796	18,113
Specialist anaesthesiology and intensive care medicin	1,155	166	5,153
Specialist endocrinology	97	2,110	174,457
Specialist phoniatics	29	107	3,059
Specialist physiatrics	244	533	12,829
Specialist gastroenterology	170	1,466	333,637
Specialist surgery: gastroenterology	387	302	8,157
Specialist geriatrics	469	4,867	64,753
Specialist dermatology and allergology	328	1,431	165,416
Specialist infectious diseases	152	504	107,220
Specialist cardiology	382	1,676	95,277
Specialist respiratory medicine and allergology	325	1,178	167,435
Specialist clinical pharmacology	39	819	30,940
Specialist clinical physiology	93	199	8,986
Specialist clinical haematology	120	1,089	861,511

Medical speciality	Number of doctors	Dispensation per doctor	Average cost per doctor, euro
Specialist clinical chemistry	122	325	12,908
Specialist clinical microbiology	82	598	9,629
Specialist clinical neurophysiology	94	50	2,498
Specialist otorhinolaryngology	507	573	14,707
Specialist hand surgery	105	263	3,326
Specialist paediatric surgery	94	222	5,147
Specialist child neurology	142	530	61,927
Specialist child psychiatry	323	299	12,877
Specialist paediatrics	968	613	68,476
Specialist sports medicine	51	948	25,722
Specialist obstetrics and gynaecology	1,078	1,031	40,768
Specialist nephrology	126	1,952	221,214
Specialist neurosurgery	116	181	3,499
Specialist neurology	483	1,303	206,460
Specialist adolescent psychiatry	244	547	19,603
Specialist forensic medicine	51	292	7,772
Specialist forensic psychiatry	59	331	12,586
Specialist surgery: orthopaedics and traumatology	714	516	8,726

Source: Dispensations reimbursable under the National Health Insurance Scheme register.

Table continued



Table 6.10. continued

Medical specialty	Number of doctors	Dispensation per doctor	Average cost per doctor, euro
Specialist pathology	212	82	1,866
Specialist clinical genetics	44	53	1,109
Specialist plastic surgery	165	173	3,749
Specialist psychiatry	1,296	906	36,925
Specialist forensic psychiatry	13	199	9,394
Specialist diagnostic radiology	785	61	1,772
Specialist rheumatology	180	2,624	650,627
Specialist ophthalmology	778	824	37,372
Specialist internal medicine	742	1,325	99,064
Specialist oral and maxillofacial surgery	26	180	4,400
Specialist cardiothoracic surgery	151	169	4,697
Specialist oncology	305	1,323	399,045
Specialist public health	154	621	13,120
Specialist occupational health	1,332	1,148	28,972
Specialist urology	225	1,262	216,413
Specialist vascular surgery	75	245	5,874
Specialist general surgery	186	330	6,954
Specialist general practice	2,978	4,082	110,410
All	31,644	1,911	76,371

Source: Dispensations reimbursable under the National Health Insurance Scheme register.

Dentists

Medical specialty	Number of doctors	Dispensation per doctor	Average cost per doctor, euro
No speciality	4,512	58	647
Specialty dentist dental public health	17	2	26
Dental specialist dental diagnostics	6	16	346
Dental specialist orthodontics	85	4	52
Dental specialist clinical dentistry	379	44	644
Dental specialist oral and maxillofacial surgery	134	316	3,258
Dental specialist public health	30	19	259
All	5,109	63	708

Source: Dispensations reimbursable under the National Health Insurance Scheme register.

**Table 6.11. Data relating to purchases of reimbursable medicines eligible for generic substitution and savings generated through substitution, in 2016–2022****All reimbursed medicines**

	2016	2017	2018	2019	2020	2021	2022
Dispensations, million	47.0	48.9	51.1	53.5	54.9	57.5	60.8
Total cost, EUR million	2,034.5	2,006.9	2,096.3	2,198.8	2,273.2	2,346.9	2,420.7
Refunds, EUR million	1,405.3	1,360.0	1,454.7	1,558.5	1,639.0	1,707.1	1,758.3
Customers	3,817,051	3,805,016	3,842,848	3,861,862	3,730,259	3,771,318	3,871,920

Purchases of products eligible for generic substitution

	2016	2017	2018	2019	2020	2021	2022
Dispensations, million	30.7	31.6	32.3	33.4	32.9	34.4	35.7
Cost, EUR million	1,100.0	972.1	963.6	962.5	954.8	1,130.4	1,205.6
Refunds, EUR million	673.6	538.1	544.2	558.5	572.1	714.2	766.9
Dispensations substituted, %	5.8	6.6	7.4	8.6	9.0	9.4	10.3
Number of patients who accepted substitution for at least one productn	1,712,795	1,814,073	1,929,821	2,074,350	2,110,178	2,159,097	2,249,677

Table continued



Table 6.11. continued

Purchases in reference price system

	2016	2017	2018	2019	2020	2021	2022
Dispensations, million	26.8	28.3	29.6	30.0	29.5	29.7	31.2
Cost, EUR million	628.2	685.7	696.5	647.7	646.8	640.4	622.7
Refunds, EUR million	290.6	337.1	347.6	322.0	336.4	342.1	321.7
Dispensations substituted, %	5.6	6.4	7.2	8.4	8.9	9.0	9.9
Number of patients who accepted substitution for at least one product	1,673,567	1,784,469	1,913,794	2,049,581	2,094,543	2,124,634	2,210,360

Savings generated through generic substitution


	2016	2017	2018	2019	2020	2021	2022
Total, EUR million	78.2	70.1	77.8	75.5	75.1	78.2	102.3
Saving, EUR / each substitution	28.8	23.7	22.9	19.0	18.2	16.7	21.2

Sources: Dispensations reimbursable under the National Health Insurance Scheme register.
Price and reference price information from the Pharmaceutical Database.

The statistics include additional refunds.

The statistics also cover purchases made prior to reaching the initial deductible.

7. Tables: Sales statistics according to medicine group





A Alimentary tract and metabolism

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
A	Alimentary tract and metabolism	308,932	320,857	333,239	354,940	7	7	8	8	314.69	326.04	334.23	337.57	4	3	3	3
A01	Stomatological preparations	1,931	2,086	2,022	2,109	7	8	8	7	12.81	14.27	17.41	19.01	4	3	3	3
A02	Drugs for acid related disorders	32,364	30,560	29,845	30,661	3	3	4	5	71.01	72.92	74.66	75.47	3	3	3	2
A03	Drugs for functional gastrointestinal disorders	5,728	5,337	5,244	5,006	50	44	46	43	2.78	2.71	2.66	2.73	9	9	9	8
A04	Antiemetics and antinauseants	4,185	4,831	5,571	4,445	40	48	54	43	0.29	0.29	0.29	0.29	43	41	40	38
A05	Bile and liver therapy	2,198	1,393	1,595	1,809	2	2	1	1	0.93	0.92	1.02	1.07	2	2	2	1
A06	Drugs for constipation	27,108	29,103	30,234	30,010	12	11	10	9	48.02	51.29	53.33	51.95	9	8	7	6
A07	Antidiarrheals, intestinal antiinflammatory/antiinfective agents	29,633	28,943	29,588	31,161	5	5	5	5	13.58	13.55	13.62	14.12	2	2	2	2
A08	Antiobesity preparations, excl. diet products	638	602	608	864	0	0	0	0	0.08	0.07	0.07	0.07	0	0	0	0
A09	Digestives, incl. enzymes	3,219	3,146	3,339	3,416	4	4	3	3	1.28	1.25	1.32	1.40	4	4	3	3
A10	Drugs used in diabetes	161,244	170,838	180,726	199,662	2	2	1	1	99.88	101.72	105.58	111.64	2	1	1	1
A11	Vitamins	9,120	9,352	7,067	5,431	13	14	19	29	23.52	25.42	22.59	19.42	3	3	3	3
A12	Mineral supplements	15,838	16,449	16,546	16,309	5	4	4	4	40.48	41.60	41.64	40.36	3	3	3	3
A14	Anabolic agents for systemic use	12	12	13	10	17	22	16	13	0.02	0.02	0.02	0.01	17	22	16	13
A16	Other alimentary tract and metabolism products	15,712	18,204	20,842	24,046	34	39	45	51	0.02	0.03	0.03	0.03	29	37	36	39



A01 Stomatological preparations

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
A01	Stomatological preparations	1,931	2,086	2,022	2,109	7	8	8	7	12.81	14.27	17.41	19.01	4	3	3	3
A01A	Stomatological preparations	1,931	2,086	2,022	2,109	7	8	8	7	12.81	14.27	17.41	19.01	4	3	3	3
A01AA	Caries prophylactic agents	610	662	818	927	11	7	6	6	10.47	11.90	15.20	16.88	4	3	2	2
A01AA01	Sodium fluoride	557	610	790	927	12	8	7	6	10.47	11.90	15.20	16.88	4	3	2	2
A01AA03	Olaflur (DDD 1.10 mg)	54	52	28		1	1	1									
A01AB	Antiinfectives for local oral treatment	1,096	1,262	1,176	1,124	6	10	9	8	2.30	2.35	2.20	2.10	6	8	8	7
A01AB03	Chlorhexidine (DDD 30 mg)	880	927	907	931	7	6	6	6	2.09	2.02	1.93	1.91	7	6	6	6
A01AB11	Various	216	335	270	194	0	21	21	13	0.21	0.33	0.27	0.19	0	21	22	13
A01AB22	Doxycycline	0				100											
A01AC	Corticosteroids for local oral treatment	153	113			1	1										
A01AC01	Triamcinolone	153	113			1	1										
A01AD	Other agents for local oral treatment	72	49	28	58	0	0	0	0	0.03	0.02	0.02	0.03				
A01AD02	Benzydamine (DDD 9 mg)	72	49	28	58	0	0	0	0	0.03	0.02	0.02	0.03				

**A02 Drugs for acid related disorders**

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
A02	Drugs for acid related disorders	32,364	30,560	29,845	30,661	3	3	4	5	71.01	72.92	74.66	75.47	3	3	3	2
A02A	Antacids	3,565	3,680	3,853	4,415	1	1	1	1	2.22	2.23	2.26	2.36	1	1	1	1
A02AA	Magnesium compounds	151	141	139	133	22	21	23	26	0.07	0.07	0.07	0.06	22	21	23	26
A02AA04	Magnesium hydroxide (DDD 3 g)	151	141	139	133	22	21	23	26	0.07	0.07	0.07	0.06	22	21	23	26
A02AD	Combinations and complexes of aluminium, calcium and magnesium compounds	3,414	3,539	3,713	4,282	0	0	0	0	2.15	2.17	2.20	2.29	0	0	0	0
A02AD01	Ordinary salt combinations	3,414	3,539	3,713	4,282	0	0	0	0	2.15	2.17	2.20	2.29	0	0	0	0
A02B	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD)	28,799	26,880	25,992	26,246	3	4	4	5	68.79	70.68	72.40	73.12	3	3	3	2
A02BA	H2-receptor antagonists	733	504	473	799	1	1	1	1	0.73	0.16	0.15	0.33	2	1	1	0
A02BA02	Ranitidine (DDD 0.30 g)	393	1	0		2	1	0		0.62	0.00	0.00		2	1		
A02BA03	Famotidine (DDD 40 mg)	339	503	473	440	1	1	1	1	0.10	0.15	0.15	0.13	1	1	1	1
A02BA53	Famotidine, combinations (DDD 2 ED)				359				0				0.20				
A02BB	Prostaglandins	41	61	67	72	66	50	41	39	0.02	0.03	0.03	0.04	66	50	41	38
A02BB01	Misoprostol (DDD 0.80 mg)	41	61	67	72	66	50	41	39	0.02	0.03	0.03	0.04	66	50	41	38

Table continued



ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
A02BC	Proton pump inhibitors	25,406	23,390	22,331	22,160	4	4	4	6	66.87	69.22	70.86	71.37	3	3	3	2
A02BC01	Omeprazole (DDD 20 mg)	2,499	2,370	2,116	1,961	1	1	1	1	8.82	8.59	8.15	7.89	2	1	1	1
A02BC02	Pantoprazole (DDD 40 mg)	9,516	8,047	7,931	8,155	6	8	9	14	35.98	37.89	39.80	40.51	4	4	4	3
A02BC03	Lansoprazole (DDD 30 mg)	2,077	1,205	892	865	0	1	1	1	5.66	5.47	5.20	4.96	0	0	0	0
A02BC04	Rabeprazole (DDD 20 mg)	852	922	953	962	0	0	0	0	1.48	1.59	1.67	1.68	0	0	0	0
A02BC05	Esomeprazole (DDD 30 mg)	10,462	10,847	10,439	10,217	2	2	2	2	14.91	15.67	16.04	16.32	2	2	2	2
A02BD	Combinations for eradication of helicobacter pylori	303	218	259	136	0	0	0	0	0.03	0.02	0.03	0.01	0	0	0	0
A02BD03	Lansoprazole, metronidazole and amoxicillin (DDD 9 ED)	74	23	58	22	0	0	0	0	0.01	0.00	0.01	0.00	0	0	0	0
A02BD07	Lansoprazole, amoxicillin and clarithromycin (DDD 8 ED)	229	196	202	115	0	0	0	0	0.02	0.02	0.02	0.01	0	0	0	0
A02BX	Other drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD)	2,317	2,706	2,861	3,078	3	3	2	2	1.15	1.25	1.33	1.36	3	3	2	2
A02BX02	Sucralfate (DDD 4 g)	380	455	519	562	0	0	0	0	0.23	0.28	0.32	0.34	0	0	0	0
A02BX13	Alginic acid	1,937	2,251	2,343	2,516	3	3	3	3	0.91	0.98	1.02	1.03	4	3	3	3



A03 Drugs for functional gastrointestinal disorders

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
A03	Drugs for functional gastrointestinal disorders	5,728	5,337	5,244	5,006	50	44	46	43	2.78	2.71	2.66	2.73	9	9	9	8
A03A	Drugs for functional gastrointestinal disorders	1,868	1,889	1,719	1,872	20	19	21	19	1.24	1.17	1.15	1.22	7	7	7	6
A03AB	Synthetic anticholinergics, quaternary ammonium compounds	381	370	381	399	88	86	84	81	0.05	0.05	0.05	0.06	88	87	84	82
A03AB02	Glycopyrronium bromide	381	370	381	399	88	86	84	81	0.05	0.05	0.05	0.06	88	87	84	82
A03AX	Other drugs for functional gastrointestinal disorders	1,486	1,519	1,338	1,473	2	2	3	2	1.18	1.12	1.09	1.17	3	3	3	3
A03AX13	Silicones (DDD 0.50 g)	1,468	1,385	1,149	1,200	2	2	3	3	1.18	1.12	1.09	1.17	3	3	3	3
A03AX15	Menthae piperitae aetheroleum	18	134	189	273	0	0	0	0								
A03B	Belladonna and derivatives, plain	624	329	388	310	95	92	92	92	0.06	0.04	0.04	0.05	95	93	91	93
A03BA	Belladonna alkaloids, tertiary amines	541	272	321	261	94	92	92	92	0.06	0.04	0.04	0.04	94	93	91	93
A03BA01	Atropine (DDD 1.50 mg)	541	272	321	261	94	92	92	92	0.06	0.04	0.04	0.04	94	93	91	93
A03BB	Belladonna alkaloids semisynthetic, quaternary ammonium compounds	82	57	66	49	99	95	93	93	0.00	0.00	0.00	0.00	99	97	94	95
A03BB01	Butylscopolamine (DDD 60 mg)	82	57	66	49	99	95	93	93	0.00	0.00	0.00	0.00	99	97	94	95

Table continued



ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
A03C	Antispasmodics in combination with psycholeptics	222	195	179	163	1	1	1	1	0.21	0.18	0.17	0.15	1	0	1	0
A03CA	Synthetic anticholinergic agents in combination with psycholeptics	222	195	179	163	1	1	1	1	0.21	0.18	0.17	0.15	1	0	1	0
A03CA02	Clidinium and psycholeptics (DDD 4 ED)	222	195	179	163	1	1	1	1	0.21	0.18	0.17	0.15	1	0	1	0
A03D	Antispasmodics in combination with analgesics	2,645	2,523	2,441	2,140	68	63	65	65	0.28	0.31	0.29	0.23	9	7	7	5
A03DA	Synthetic anticholinergic agents in combination with analgesics	2,645	2,523	2,441	2,140	68	63	65	65	0.28	0.31	0.29	0.23	9	7	7	5
A03DA02	Pitofenone and analgesics	2,645	2,523	2,441	2,140	68	63	65	65	0.28	0.31	0.29	0.23	9	7	7	5
A03F	Propulsives	369	401	518	521	34	31	25	22	1.00	1.00	1.02	1.08	10	10	9	8
A03FA	Propulsives	369	401	518	521	34	31	25	22	1.00	1.00	1.02	1.08	10	10	9	8
A03FA01	Metoclopramide (DDD 30 mg)	369	401	518	521	34	31	25	22	1.00	1.00	1.02	1.08	10	10	9	8

**A04 Antiemetics and antinauseants**

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
A04	Antiemetics and antinauseants	4,185	4,831	5,571	4,445	40	48	54	43	0.29	0.29	0.29	0.29	43	41	40	38
A04A	Antiemetics and antinauseants	4,185	4,831	5,571	4,445	40	48	54	43	0.29	0.29	0.29	0.29	43	41	40	38
A04AA	Serotonin (5HT3) antagonists	3,337	4,102	4,704	3,547	38	48	55	43	0.23	0.23	0.23	0.22	47	44	44	42
A04AA01	Ondansetron (DDD 16 mg)	996	1,837	2,568	1,556	40	65	73	54	0.15	0.16	0.17	0.17	50	45	44	40
A04AA02	Granisetron	870	850	654	515	44	41	49	56	0.06	0.06	0.04	0.03	35	38	48	54
A04AA05	Palonosetron	294	257	227	231	99	99	100	99	0.01	0.01	0.00	0.00	100	100	100	100
A04AA55	Palonosetron, combinations (DDD 1 ED)	1,178	1,157	1,256	1,245	16	14	13	13	0.01	0.01	0.01	0.01	15	14	13	13
A04AD	Other antiemetics	848	729	867	898	49	49	46	44	0.06	0.06	0.06	0.07	29	28	27	26
A04AD01	Scopolamine (DDD 1 ED)	296	371	535	579	26	26	24	23	0.05	0.06	0.06	0.06	26	26	24	23
A04AD12	Aprepitant	528	359	333	319	62	73	81	83	0.01	0.01	0.01	0.01	47	51	61	66
A04AD14	Rolapitant (DDD 0.18 g)	24				53				0.00				53			

A05 Sapeneritystä lisäävät valmisteet ja maksan suoja-aineet

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
A05	Bile and liver therapy	2,198	1,393	1,595	1,809	2	2	1	1	0.93	0.92	1.02	1.07	2	2	2	1
A05A	Bile therapy	2,198	1,393	1,595	1,809	2	2	1	1	0.93	0.92	1.02	1.07	2	2	2	1
A05AA	Bile acids and derivatives	2,198	1,393	1,595	1,809	2	2	1	1	0.93	0.92	1.02	1.07	2	2	2	1
A05AA02	Ursodeoxycholic acid (DDD 0.75 g)	2,164	1,321	1,331	1,396	2	2	2	1	0.93	0.92	1.02	1.07	2	2	2	1
A05AA04	Obeticholic acid (DDD 10 mg)	35	72	264	413	0	4	0	0	0.00	0.00	0.00	0.00		4		

**A06 Drugs for constipation**

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
A06	Drugs for constipation	27,108	29,103	30,234	30,010	12	11	10	9	48.02	51.29	53.33	51.95	9	8	7	6
A06A	Drugs for constipation	27,108	29,103	30,234	30,010	12	11	10	9	48.02	51.29	53.33	51.95	9	8	7	6
A06AB	Contact laxatives	3,784	3,739	3,510	3,226	9	7	7	7	6.21	6.31	6.01	5.22	6	5	5	4
A06AB02	Bisacodyl (DDD 10 mg)	363	265	248	243	5	2	1	1	0.91	0.71	0.66	0.62	4	2	1	1
A06AB06	Senna glycosides	60	52	51	55	0	0	0	0	0.15	0.13	0.12	0.12	0	0	0	0
A06AB08	Sodium picosulfate (DDD 5 mg)	2,688	2,819	2,572	2,325	6	4	4	4	5.15	5.48	5.22	4.47	7	6	5	5
A06AB56	Senna glycosides, combinations	169	163	145	133	0	0	0	0								
A06AB58	Sodium picosulfate, combinations (DDD 33 ED)	505	441	493	470	31	31	28	26	0.00	0.00	0.00	0.00	31	30	28	26
A06AC	Bulk-forming laxatives	5,287	5,843	6,260	6,150	2	2	2	2	10.75	11.98	12.85	12.47	0	0	0	0
A06AC01	Ispaghula (psylla seeds) (DDD 7 g)	5,050	5,613	6,040	5,940	2	2	2	2	10.15	11.39	12.29	11.94	0	0	0	0
A06AC51	Ispaghula, combinations (DDD 15 ED)	238	230	220	209	1	1	1	1	0.61	0.59	0.56	0.53	1	1	1	1
A06AD	Osmotically acting laxatives	14,745	16,135	17,040	17,334	14	12	11	11	29.55	31.51	32.99	32.78	12	11	10	9
A06AD11	Lactulose (DDD 6.70 g)	2,711	2,628	2,558	2,396	10	9	8	8	13.46	13.23	12.77	12.00	10	9	9	8
A06AD15	Macrogol (DDD 10 g)	10,211	11,750	12,806	13,350	14	12	11	10	14.85	17.20	19.29	19.98	14	12	11	10
A06AD17	Sodium phosphate (DDD 50 g)	55	41	26	16	16	18	26	11								
A06AD65	Macrogol, combinations	1,768	1,716	1,651	1,573	20	21	22	23	1.24	1.08	0.93	0.80	3	3	3	3

Table continued



ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
A06AG	Enemas	2,510	2,411	2,414	2,390	21	17	16	14	1.36	1.30	1.30	1.30	16	10	9	8
A06AG02	Bisacodyl (DDD 1 ED)	419	411	408	360	36	31	29	28	0.25	0.24	0.24	0.21	37	32	30	29
A06AG10	Docusate sodium, incl. combinations (DDD 1 ED)	588	551	563	512	48	45	45	42	0.06	0.05	0.06	0.05	51	48	49	45
A06AG11	Laurilsulfate, incl. combinations (DDD 1 ED)	1,504	1,449	1,443	1,518	7	2	2	1	1.06	1.01	1.00	1.04	9	3	2	2
A06AH	Peripheral opioid receptor antagonists	623	756	773	677	44	39	37	35	0.11	0.13	0.14	0.12	33	28	26	22
A06AH01	Methylnaltrexone bromide (DDD 6 mg)	118	133	137	132	95	97	97	98	0.00	0.00	0.00	0.00	95	97	97	98
A06AH03	Naloxegol (DDD 25 mg)	505	624	636	546	32	26	24	20	0.11	0.13	0.13	0.11	31	26	24	19
A06AX	Other drugs for constipation	159	218	236	232	4	5	3	3	0.04	0.05	0.06	0.06	4	4	2	2
A06AX04	Linaclotide (DDD 0.29 mg)	66	111	120	125	2	1	1	1	0.02	0.03	0.03	0.04	2	1	1	1
A06AX05	Prucalopride (DDD 2 mg)	93	107	116	107	6	9	4	5	0.02	0.02	0.02	0.03	5	8	4	5

**A07 Antidiarrheals, intestinal antiinflammatory/antiinfective agents**

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
A07	Antidiarrheals, intestinal antiinflammatory/antiinfective agents	29,633	28,943	29,588	31,161	5	5	5	5	13.58	13.55	13.62	14.12	2	2	2	2
A07A	Intestinal antiinfectives	2,397	2,666	3,060	3,291	40	33	32	34	0.14	0.17	0.20	0.20	25	21	19	18
A07AA	Antibiotics	2,397	2,666	3,060	3,291	40	33	32	34	0.14	0.17	0.20	0.20	25	21	19	18
A07AA02	Nystatin (DDD 1.50 MU)	668	679	648	667	22	18	18	18	0.07	0.07	0.07	0.07	21	18	18	17
A07AA09	Vancomycin (DDD 2 g)	702	687	722	930	59	53	47	61	0.01	0.01	0.01	0.01	59	53	47	61
A07AA11	Rifaximin (DDD 0.60 g)	735	1,026	1,293	1,334	24	20	18	15	0.07	0.09	0.12	0.12	24	20	18	15
A07AA12	Fidaxomicin (DDD 0.40 g)	292	274	397	359	78	73	72	65	0.00	0.00	0.00	0.00	78	73	72	65
A07B	Intestinal adsorbents	617	620	550	603	48	51	48	45	0.12	0.13	0.11	0.12	54	52	50	48
A07BA	Charcoal preparations	617	620	550	603	48	51	48	45	0.12	0.13	0.11	0.12	54	52	50	48
A07BA01	Medicinal charcoal (DDD 5 g)	617	620	550	603	48	51	48	45	0.12	0.13	0.11	0.12	54	52	50	48
A07C	Electrolytes with carbohydrates	228	138	143	40	5	5	5	6	0.01	0.01	0.01	0.00	5	5	5	6
A07CA	Oral rehydration salt formulations	456	275	287	80	9	9	11	12	0.02	0.01	0.02	0.00	9	9	11	12
A07D	Antipropulsives	4,426	3,787	3,919	4,578	1	1	1	1	1.37	1.20	1.22	1.47	2	2	1	1
A07DA	Antipropulsives	4,426	3,787	3,919	4,578	1	1	1	1	1.37	1.20	1.22	1.47	2	2	1	1
A07DA02	Opium			0	1			0	100			0.00	0.00				100
A07DA03	Loperamide (DDD 10 mg)	3,407	2,962	3,115	3,942	1	1	1	1	1.37	1.20	1.22	1.47	2	2	1	1
A07DA06	Eluxadolone (DDD 0.20 g)	0				0				0.00							
A07DA53	Loperamide, combinations	1,019	825	804	635	0	0	0	0								

Table continued



ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
A07E	Intestinal antiinflammatory agents	17,944	18,961	19,282	19,254	1	1	1	1	10.75	11.23	11.29	11.34	1	1	1	1
A07EA	Corticosteroids acting locally	1,834	1,976	2,084	1,903	2	3	3	3	0.32	0.35	0.36	0.37	3	3	3	3
A07EA06	Budesonide	1,834	1,976	2,084	1,903	2	3	3	3	0.32	0.35	0.36	0.37	3	3	3	3
A07EC	Aminosalicylic acid and similar agents	16,110	16,985	17,197	17,351	1	1	1	1	10.42	10.88	10.93	10.97	1	1	1	1
A07EC01	Sulfasalazine (DDD 2 g)	2,883	2,926	2,841	2,782	1	1	1	1	3.21	3.25	3.15	3.08	1	1	1	1
A07EC02	Mesalazine (DDD 1.50 g)	13,207	14,046	14,341	14,557	1	1	1	1	7.20	7.63	7.77	7.88	1	1	1	1
A07EC03	Olsalazine (DDD 1 g)	20	14	16	12	0	0	0	0	0.01	0.01	0.01	0.01	0	0	0	0
A07F	Antidiarrheal microorganisms	3,568	2,472	2,374	3,057	4	4	4	2	1.19	0.82	0.79	0.99	4	4	4	3
A07FA	Antidiarrheal microorganisms	3,568	2,472	2,374	3,057	4	4	4	2	1.19	0.82	0.79	0.99	4	4	4	3
A07FA01	Lactic acid producing organisms (DDD 3 ED)	0				1991				0.00				499			
A07FA02	Saccharomyces boulardii (DDD 1 g)	3,568	2,472	2,374	3,057	4	4	4	2	1.19	0.82	0.79	0.99	4	4	4	3
A07X	Other antidiarrheals	454	299	261	338	5	7	7	6								
A07XA	Other antidiarrheals	454	299	261	338	5	7	7	6								
A07XA04	Racecadotril	454	299	261	338	5	7	7	6								

**A08 Antiobesity preparations, excl. diet products**

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
A08	Antiobesity preparations, excl. diet products	638	602	608	864	0	0	0	0	0.08	0.07	0.07	0.07	0	0	0	0
A08A	Antiobesity preparations, excl. diet products	638	602	608	864	0	0	0	0	0.08	0.07	0.07	0.07	0	0	0	0
A08AA	Centrally acting antiobesity products	355	334	337	561	0	0	0	0								
A08AA62	Bupropion and naltrexone	355	334	337	561	0	0	0	0								
A08AB	Peripherally acting antiobesity products	283	268	270	303	0	0	0	0	0.08	0.07	0.07	0.07	0	0	0	0
A08AB01	Orlistat (DDD 0.36 g)	283	268	270	303	0	0	0	0	0.08	0.07	0.07	0.07	0	0	0	0

A09 Digestives, incl. enzymes

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
A09	Digestives, incl. enzymes	3,219	3,146	3,339	3,416	4	4	3	3	1.28	1.25	1.32	1.40	4	4	3	3
A09A	Digestives, incl. enzymes	3,219	3,146	3,339	3,416	4	4	3	3	1.28	1.25	1.32	1.40	4	4	3	3
A09AA	Enzyme preparations	3,219	3,146	3,339	3,416	4	4	3	3	1.28	1.25	1.32	1.40	4	4	3	3
A09AA02	Multienzymes (lipase, protease etc.)	3,219	3,146	3,339	3,416	4	4	3	3	1.28	1.25	1.32	1.40	4	4	3	3

**A10 Drugs used in diabetes**

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
A10	Drugs used in diabetes	161,244	170,838	180,726	199,662	2	2	1	1	99.88	101.72	105.58	111.64	2	1	1	1
A10A	Insulins and analogues	61,128	58,293	54,639	51,847	3	2	2	2	32.33	31.23	30.18	29.92	3	3	3	2
A10AB	Insulins and analogues for injection, fast-acting (DDD 40 U)	15,441	15,324	13,750	12,164	3	3	3	2	10.70	10.66	10.71	11.15	3	3	3	2
A10AB01	Insulin (human) (DDD 40 U)	81	70	58	58	38	40	36	41	0.07	0.06	0.05	0.05	38	40	37	41
A10AB04	Insulin lispro (DDD 40 U)	2,003	1,774	1,703	1,741	2	2	1	1	1.67	1.56	1.51	1.54	1	2	1	1
A10AB05	Insulin aspart (DDD 40 U)	12,590	12,730	11,264	9,743	3	3	3	2	8.45	8.53	8.66	9.07	3	3	3	2
A10AB06	Insulin glulisine (DDD 40 U)	767	750	725	623	2	2	2	2	0.51	0.49	0.49	0.48	2	2	2	2
A10AC	Insulins and analogues, intermediate-acting (DDD 40 U)	879	720	651	557	10	7	11	9	0.63	0.51	0.46	0.39	10	7	11	9
A10AC01	Insulin (human) (DDD 40 U)	879	720	651	557	10	7	11	9	0.63	0.51	0.46	0.39	10	7	11	9
A10AD	Insulins and analogues, intermediate-acting combined with fast-acting (DDD 40 U)	593	466	354	263	5	4	5	5	0.36	0.28	0.22	0.17	5	4	5	5
A10AD04	Insulin lispro (DDD 40 U)	34	26	19	8	3	3	3	9	0.02	0.02	0.01	0.01	3	3	3	9
A10AD05	Insulin aspart (DDD 40 U)	560	441	335	255	5	4	5	5	0.34	0.27	0.20	0.16	5	4	5	5
A10AE	Insulins and analogues, long-acting	44,215	41,782	39,884	38,863	2	2	2	2	20.64	19.78	18.79	18.21	2	2	2	2
A10AE04	Insulin glargine (DDD 40 U)	26,163	24,511	22,865	22,199	3	3	2	2	13.03	12.26	11.43	11.07	3	3	2	2
A10AE05	Insulin detemir (DDD 40 U)	13,167	9,760	7,930	6,485	2	2	3	2	5.59	4.39	3.56	2.91	2	2	3	2
A10AE06	Insulin degludec (DDD 40 U)	4,884	7,511	9,089	10,179	2	1	2	1	2.03	3.14	3.79	4.24	2	1	2	1
A10AE54	Insulin glargine and lixisenatide (DDD 40 U)	0				0				0.00							

Table continued



ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
A10B	Blood glucose lowering drugs, excl. insulins	100,116	112,544	126,087	147,815	1	1	1	1	67.55	70.49	75.40	81.72	1	1	1	1
A10BA	Biguanides	11,666	11,386	11,229	11,827	1	1	1	1	33.50	33.60	34.41	34.59	1	1	1	1
A10BA02	Metformin (DDD 2 g)	11,666	11,386	11,229	11,827	1	1	1	1	33.50	33.60	34.41	34.59	1	1	1	1
A10BB	Sulfonylureas	110	87	69	51	2	2	2	2	1.12	0.88	0.69	0.49	1	1	1	2
A10BB12	Glimepiride (DDD 2 mg)	110	87	69	51	2	2	2	2	1.12	0.88	0.69	0.49	1	1	1	2
A10BD	Combinations of oral blood glucose lowering drugs	13,556	13,689	13,372	12,963	0	0	0	0	6.22	6.28	6.19	6.19	0	0	0	0
A10BD05	Metformin and pioglitazone (DDD 2 ED)	6				0				0.01				0			
A10BD07	Metformin and sitagliptin (DDD 2 ED)	8,930	8,464	7,670	6,755	1	0	1	0	4.25	4.08	3.79	3.56	0	0	0	0
A10BD08	Metformin and vildagliptin (DDD 2 ED)	1,311	1,221	1,085	968	0	0	0	0	0.59	0.55	0.49	0.46	0	0	0	0
A10BD09	Pioglitazone and alogliptin (DDD 1 ED)	20	18	20	20	0	0	1	0	0.01	0.01	0.01	0.01	0	0	1	
A10BD10	Metformin and saxagliptin (DDD 2 ED)	37	34	28	26	0	0	0	0	0.02	0.02	0.01	0.01				
A10BD11	Metformin and linagliptin (DDD 2 ED)	452	471	460	426	0	0	0	0	0.20	0.21	0.21	0.19	0	0	0	0
A10BD13	Metformin and alogliptin (DDD 2 ED)	22	12			0	0			0.01	0.01						
A10BD15	Metformin and dapagliflozin (DDD 2 ED)	983	1,156	1,377	1,514	0	0	0	0	0.43	0.50	0.60	0.65	0	0	0	0
A10BD19	Linagliptin and empagliflozin (DDD 1 ED)	249	292	299	327	0	0	0	0	0.06	0.07	0.07	0.07	0	0	0	0
A10BD20	Metformin and empagliflozin (DDD 2 ED)	1,505	1,976	2,371	2,867	0	0	0	0	0.64	0.84	1.01	1.22	0	0	0	0
A10BD21	Saxagliptin and dapagliflozin (DDD 1 ED)	37	38	44	45	0	0	0	0	0.01	0.01	0.01	0.01				
A10BD23	Metformin and ertugliflozin (DDD 2 ED)	1	2	4	0	0	0	0	0	0.00	0.00	0.00	0.00				
A10BD24	Sitagliptin and ertugliflozin (DDD 1 ED)	5	7	14	14	0	0	0	0	0.00	0.00	0.00	0.00				0
A10BG	Thiazolidinediones	710	707	667	629	1	1	1	1	0.53	0.51	0.47	0.43	1	1	1	1
A10BG03	Pioglitazone (DDD 30 mg)	710	707	667	629	1	1	1	1	0.53	0.51	0.47	0.43	1	1	1	1

Table continued



ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
A10BH	Dipeptidyl peptidase 4 (DPP-4) inhibitors	28,602	27,074	26,638	23,762	2	2	2	2	13.43	12.70	12.52	12.19	2	2	2	2
A10BH01	Sitagliptin (DDD 0.10 g)	17,083	16,187	14,910	12,478	2	2	2	2	7.86	7.44	6.86	6.71	2	1	2	1
A10BH02	Vildagliptin (DDD 0.10 g)	1,999	1,792	1,558	1,265	2	2	2	2	0.98	0.87	0.76	0.67	2	2	2	2
A10BH03	Saxagliptin (DDD 5 mg)	120	108	95	86	2	1	2	2	0.05	0.05	0.04	0.04	1	1	1	1
A10BH04	Alogliptin (DDD 25 mg)	69	61	58	49	1	0	0	0	0.03	0.03	0.03	0.02	1	0	0	0
A10BH05	Linagliptin (DDD 5 mg)	9,331	8,926	10,019	9,884	3	3	3	3	4.51	4.31	4.84	4.76	3	3	3	3
A10BJ	Glucagon-like peptide-1 (GLP-1) analogues	23,934	32,819	41,474	58,046	1	1	1	1	3.80	5.42	7.60	11.11	1	1	1	1
A10BJ01	Exenatide	2,545	2,073	1,481	1,131	1	1	1	1	0.47	0.38	0.28	0.21	1	1	1	1
A10BJ02	Liraglutide (DDD 1.50 mg)	14,175	12,084	8,755	11,155	1	1	1	1	2.08	1.77	1.40	2.12	1	1	1	1
A10BJ03	Lixisenatide (DDD 20 mcg)	30	22	6		1	2	0		0.00	0.00	0.00		1	2		
A10BJ05	Dulaglutide (DDD 0.16 mg)	3,080	3,761	3,429	3,675	1	1	1	1	0.64	0.79	0.75	0.83	1	1	1	1
A10BJ06	Semaglutide	4,104	14,879	27,804	42,084	0	1	1	1	0.61	2.48	5.17	7.95	0	0	1	1
A10BK	Sodium-glucose co-transporter 2 (SGLT2) inhibitors	21,470	26,698	32,563	40,463	1	1	1	1	8.79	10.96	13.39	16.59	1	1	1	1
A10BK01	Dapagliflozin (DDD 10 mg)	7,142	8,383	10,482	14,483	1	1	1	1	3.07	3.57	4.38	6.04	1	1	1	1
A10BK02	Canagliflozin (DDD 0.20 g)	46	572	1,057	1,090	0	0	1	1	0.01	0.19	0.36	0.40	0	0	0	0
A10BK03	Empagliflozin (DDD 17.50 mg)	14,258	17,711	20,981	24,848	1	1	1	1	5.71	7.19	8.63	10.13	1	1	1	1
A10BK04	Ertugliflozin (DDD 10 mg)	24	32	43	41	0	0	1	2	0.01	0.01	0.02	0.02	0	0	1	1
A10BX	Other blood glucose lowering drugs, excl. insulins	69	84	74	75	2	1	1	1	0.15	0.14	0.12	0.11	1	1	1	1
A10BX02	Repaglinide (DDD 4 mg)	69	84	74	75	2	1	1	1	0.15	0.14	0.12	0.11	1	1	1	1



A11 Vitamins

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
A11	Vitamins	9,120	9,352	7,067	5,431	13	14	19	29	23.52	25.42	22.59	19.42	3	3	3	3
A11C	Vitamin A and D, incl. combinations of the two	918	1,043	1,608	1,718	3	2	1	1	4.20	6.10	10.22	11.45	1	1	1	0
A11CC	Vitamin D and analogues	918	1,043	1,608	1,718	3	2	1	1	4.20	6.10	10.22	11.45	1	1	1	0
A11CC01	Ergocalciferol (vitamin D ₂)	4				1											
A11CC02	Dihydrotachysterol (DDD 1 mg)	69	19			2	2			0.05	0.01			2	2		
A11CC03	Alfacalcidol (DDD 1 mcg)	396	433	476	469	5	4	3	3	0.42	0.46	0.50	0.49	5	3	3	3
A11CC05	Colecalciferol (vitamin D ₃) (DDD 20 mcg)	450	591	1,133	1,249	1	1	0	0	3.72	5.63	9.72	10.95	1	0	0	0
A11D	Vitamin B ₁ , plain and in combination with vitamin B ₆ and B ₁₂	2,215	2,246	2,170	2,304	50	54	58	65	5.05	4.64	4.26	3.86	12	12	12	13
A11DA	Vitamin B ₁ , plain	1,072	1,204	1,263	1,503	99	99	99	99	0.48	0.50	0.48	0.48	99	99	99	99
A11DA01	Thiamine (vitamin B ₁) (DDD 50 mg)	1,072	1,204	1,263	1,503	99	99	99	99	0.48	0.50	0.48	0.48	99	99	99	99
A11DB	Vitamin B ₁ in comb. with vitamin B ₆ and/or vitamin B ₁₂	2,287	2,085	1,813	1,601	8	5	3	2	9.13	8.29	7.57	6.76	6	4	3	2

Table continued



ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
A11E	Vitamin B-complex, incl. combinations	5,667	5,697	2,978	1,119	1	1	1	4	12.41	12.41	6.57	2.67	1	1	2	4
A11EA	Vitamin B-complex (DDD 1 ED)	2,022	1,990	1,965	1,964	8	8	8	8	5.35	5.25	5.18	5.16	8	8	8	8
A11EX	Vitamin B-complex, other combinations	9,311	9,405	3,991	274	0	0	0	3	19.47	19.57	7.95	0.19	0	0	0	3
A11G	Ascorbic acid (vitamin C), incl. Combinations	108	138	89	83	1	1	1	1	1.61	2.06	1.33	1.23	1	1	1	0
A11GA	Ascorbic acid (vitamin C), plain	108	138	89	83	1	1	1	1	1.61	2.06	1.33	1.23	1	1	1	0
A11GA01	Ascorbic acid (vitamin C) (DDD 0.20 g)	108	138	89	83	1	1	1	1	1.61	2.06	1.33	1.23	1	1	1	0
A11H	Other plain vitamin preparations	212	227	221	207	4	4	4	4	0.26	0.21	0.21	0.20	9	8	7	8
A11HA	Other plain vitamin preparations	212	227	221	207	4	4	4	4	0.26	0.21	0.21	0.20	9	8	7	8
A11HA02	Pyridoxine (vitamin B ₆) (DDD 0.16 g)	49	43	44	43	14	12	11	13	0.15	0.13	0.14	0.13	14	12	11	13
A11HA03	Tocopherol (vitamin E) (DDD 0.20 g)	23	18	17	16	1	2	1	1	0.11	0.08	0.07	0.07	1	2	1	1
A11HA08	Tocofersolan (DDD 0.20 g)		3	1	0		100	100	100		0.00	0.00	0.00		100	100	100
A11HA30	Dexpanthenol	140	164	160	148	1	1	1	1								



A12 Mineral supplements

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
A12	Mineral supplements	15,838	16,449	16,546	16,309	5	4	4	4	40.48	41.60	41.64	40.36	3	3	3	3
A12A	Calcium	10,841	11,382	11,312	10,911	2	2	2	2	34.58	35.49	35.38	34.04	2	2	2	2
A12AA	Calcium	816	852	846	837	2	1	1	1	1.09	1.13	1.13	1.11	2	1	1	1
A12AA04	Calcium carbonate (DDD 3 g)	801	846	846	837	2	1	1	1	1.08	1.13	1.13	1.11	2	1	1	1
A12AA06	Calcium lactate gluconate (DDD 3 g)	15	6			6	6			0.01	0.00			6	6		
A12AX	Calcium, combinations with vitamin D and/or other drugs	20,050	21,059	20,932	20,149	5	4	4	3	66.99	68.72	68.50	65.85	5	4	4	4
A12B	Potassium	4,906	4,982	5,190	5,283	9	9	8	8	5.78	6.00	6.21	6.17	7	7	7	6
A12BA	Potassium	4,906	4,982	5,190	5,283	9	9	8	8	5.78	6.00	6.21	6.17	7	7	7	6
A12BA01	Potassium chloride (DDD 3 g)	4,801	4,982	5,190	5,283	9	9	8	8	5.74	6.00	6.21	6.17	7	7	7	6
A12BA51	Potassium chloride, combinations (DDD 6 ED)	105				3				0.04				3			
A12C	Other mineral supplements	92	86	44	115	39	32	31	27	0.12	0.11	0.06	0.15	39	32	31	27
A12CA	Sodium	92	86	44	115	39	32	31	27	0.12	0.11	0.06	0.15	39	32	31	27
A12CA01	Sodium chloride (DDD 1 g)	92	86	44	115	39	32	31	27	0.12	0.11	0.06	0.15	39	32	31	27

**A14 Anabolic agents for systemic use**

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
		A14	Anabolic agents for systemic use	12	12	13	10	17	22	16	13	0.02	0.02	0.02	0.01	17	22
A14A	Anabolic steroids	12	12	13	10	17	22	16	13	0.02	0.02	0.02	0.01	17	22	16	13
A14AB	Estren derivatives	12	12	13	10	17	22	16	13	0.02	0.02	0.02	0.01	17	22	16	13
A14AB01	Nandrolone (DDD 2 mg)	12	12	13	10	17	22	16	13	0.02	0.02	0.02	0.01	17	22	16	13

A16 Other alimentary tract and metabolism products

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
		A16	Other alimentary tract and metabolism products	15,712	18,204	20,842	24,046	34	39	45	51	0.02	0.03	0.03	0.03	29	37
A16A	Other alimentary tract and metabolism products	15,712	18,204	20,842	24,046	34	39	45	51	0.02	0.03	0.03	0.03	29	37	36	39
A16AA	Amino acids and derivatives	4	162	211	239	100	83	87	85	0.00	0.00	0.00	0.00	100	63	67	66
A16AA04	Mercaptamine (DDD 2 g)		22	21	29		0	0	0		0.00	0.00	0.00				
A16AA05	Carglumic acid (DDD 0.20 g)	4	135	183	200	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100
A16AA06	Betaine (DDD 6 g)		6	8	10		0	6	18		0.00	0.00	0.00			6	18
A16AB	Enzymes	12,383	13,404	15,373	18,206	41	44	46	54	0.01	0.01	0.01	0.01	42	44	40	43
A16AB02	Imiglucerase (DDD 300 U)	904	662	758	872	12	15	42	48	0.00	0.00	0.00	0.00	12	15	42	48
A16AB03	Agalsidase alfa (DDD 1 mg)	1,847	1,670	1,372	1,334	48	47	31	33	0.00	0.00	0.00	0.00	48	47	31	33
A16AB04	Agalsidase beta (DDD 5 mg)	8,249	9,230	9,533	9,731	41	45	39	39	0.01	0.01	0.01	0.01	41	45	39	39

Table continued



ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
A16AB05	Laronidase (DDD 1 TU)	259	258	263	257	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100
A16AB07	Alglucosidase alfa (DDD 0.10 g)	396	619	663	631	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100
A16AB09	Idursulfase			219	79			100	100								
A16AB10	Velaglucerase alfa (DDD 300 U)	728	965	855	713	5	0	0	0	0.00	0.00	0.00	0.00	5			
A16AB13	Asfotase alfa			202	430			0	0								
A16AB14	Sebelipase alfa (DDD 5 mg)			1,509	4,158			100	100			0.00	0.00			100	100
A16AX	Various alimentary tract and metabolism products	3,326	4,638	5,258	5,602	8	25	37	40	0.01	0.01	0.01	0.01	11	24	26	31
A16AX03	Sodium phenylbutyrate (DDD 20 g)	223	220	238	211	3	1	4	0	0.00	0.00	0.00	0.00	3	1	4	0
A16AX04	Nitisinone (DDD 20 mg)	462	510	487	439	1	1	1	2	0.00	0.00	0.00	0.00	0	1	0	2
A16AX05	Zinc acetate (DDD 0.15 g)		1	2	3		67	100	59		0.00	0.00	0.00		67	100	58
A16AX06	Miglustat (DDD 0.30 g)	208	236	375	377	0	0	0	1	0.00	0.00	0.00	0.00				1
A16AX08	Teduglutide (DDD 5 mg)	152	616	1,283	1,783	100	100	100	88	0.00	0.00	0.00	0.00	100	100	100	89
A16AX09	Glycerol phenylbutyrate (DDD 15 g)	142	175	196	205	1	0	1	1	0.00	0.00	0.00	0.00	1	0	1	1
A16AX10	Eliglustat (DDD 0.17 g)	1,058	1,114	1,211	969	0	0	0	0	0.00	0.00	0.00	0.00				
A16AX12	Trientine (DDD 0.45 g)	15	488	657	606	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100
A16AX14	Migalastat (DDD 61.50 mg)	1,002	1,217	793	974	1	0	0	0	0.00	0.00	0.00	0.00	1			
A16AX15	Telotristat (DDD 0.75 g)	64	60	15	35	98	96	83	89	0.00	0.00	0.00	0.00	98	96	83	89
A16AX10	Eliglustat (DDD 0.17,g)	208	1,058	1,114	1,211	0	0	0	0	0.00	0.00	0.00	0.00	0	0	0	0
A16AX12	Trientine (DDD 0.45,g)		15	488	657		100	100	100		0.00	0.00	0.00		100	100	100
A16AX14	Migalastat (DDD 61.50 mg)	100	1,002	1,217	793	0	1	0	0	0.00	0.00	0.00	0.00	0	1	0	0
A16AX15	Telotristat (DDD 0.75,g)	40	64	60	15	100	98	96	83	0.00	0.00	0.00	0.00	100	98	96	83
A16AX14	Migalastaatti (DDD 61.50 mg)		100	1,002	1,217			1			0.00	0.00	0.00			1	
A16AX15	Telotrastaatti (DDD 0.75,g)		40	64	60		100	98	96		0.00	0.00	0.00		100	98	96



B Blood and blood forming organs

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
B	Blood and blood forming organs	267,916	284,632	295,792	305,199	28	27	25	25	136.61	140.78	146.10	146.37	4	4	4	4
B01	Antithrombotic agents	138,493	155,554	162,730	170,145	14	12	10	10	115.37	116.20	116.93	113.15	4	4	3	3
B02	Antihemorrhagics	56,157	55,131	54,554	54,162	28	27	27	25	0.29	0.34	0.38	0.38	24	21	20	19
B03	Antianemic preparations	35,208	35,604	36,814	37,179	39	41	45	47	20.95	24.25	28.78	32.84	6	5	5	5
B05	Blood substitutes and perfusion solutions	30,853	30,276	30,339	31,566	79	80	81	81								
B06	Other hematological agents	7,205	8,067	11,356	12,147	20	34	13	14	0.00	0.00	0.01	0.01	21	40	15	12

**B01 Antithrombotic agents**

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
B01	Antithrombotic agents	138,493	155,554	162,730	170,145	14	12	10	10	115.37	116.20	116.93	113.15	4	4	3	3
B01A	Antithrombotic agents	138,493	155,554	162,730	170,145	14	12	10	10	115.37	116.20	116.93	113.15	4	4	3	3
B01AA	Vitamin K antagonists	2,313	1,877	1,547	1,283	1	1	1	1	10.09	8.18	6.76	5.60	1	1	1	1
B01AA03	Warfarin (DDD 7.50 mg)	2,313	1,877	1,547	1,283	1	1	1	1	10.09	8.18	6.76	5.60	1	1	1	1
B01AB	Heparin group	24,682	23,306	19,520	20,068	41	39	38	41	6.71	6.63	5.78	5.65	36	36	34	40
B01AB01	Heparin (DDD 10 TU)	757	814	729	596	99	99	99	99	0.08	0.08	0.07	0.06	99	99	99	99
B01AB02	Antithrombin (DDD 2.10 TU)	399	381	356	406	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100
B01AB04	Dalteparin (DDD 2.50 TU)	1,221	1,272	1,611	1,811	5	8	18	38	0.47	0.48	0.63	0.68	5	7	16	34
B01AB05	Enoxaparin	15,840	14,592	7,945	8,431	43	41	42	44	5.11	5.01	3.52	3.85	41	40	41	43
B01AB09	Danaparoid (DDD 1.50 TU)	210	160	238	75	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100
B01AB10	Tinzaparin (DDD 3.50 TU)	6,254	6,086	8,642	8,749	30	28	28	32	1.05	1.06	1.56	1.06	23	21	22	32
B01AC	Platelet aggregation inhibitors excl. heparin	19,744	20,398	19,719	18,652	7	5	5	5	78.84	77.47	77.53	72.60	2	1	1	1
B01AC04	Clopidogrel (DDD 75 mg)	1,394	1,565	1,569	1,411	19	21	19	18	9.49	10.34	10.84	9.59	3	3	3	3
B01AC06	Acetylsalicylic acid (DDD 1 ED)	7,317	7,323	7,383	7,105	1	1	1	1	63.89	62.32	62.22	58.92	1	1	1	1
B01AC07	Dipyridamole	320	156	92	76	2	2	2	2	0.37	0.18	0.11	0.09	2	2	2	2
B01AC11	Iloprost	297	256	176	137	42	47	45	71	0.00	0.00	0.00	0.00	68	72	66	88
B01AC13	Abciximab (DDD 25 mg)	90	-13			100	100			0.00	0.00			100	100		
B01AC16	Eptifibatide (DDD 0.20 g)	109	90	112	81	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100
B01AC17	Tirofiban (DDD 10 mg)	34	27	23	19	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100
B01AC21	Treprostinil (DDD 4.30 mg)	2,048	2,158	1,558	1,741	10	3	3	4	0.00	0.00	0.00	0.00	8	2	3	3
B01AC22	Prasugrel (DDD 10 mg)	74	119	146	120	19	15	11	13	0.02	0.03	0.04	0.04	18	14	11	12

Table continued



ATC classification	Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
	2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
B01AC24 Ticagrelor (DDD 0.18 g)	3,480	3,538	3,343	3,008	5	4	4	4	0.84	0.85	0.81	0.77	4	4	4	4
B01AC25 Cangrelor (DDD 50 mg)	182	147	193	165	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100
B01AC27 Selexipag (DDD 1.80 mg)	776	788	1,142	1,165	4	0	2	1	0.00	0.00	0.00	0.01	1	0	1	0
B01AC30 Combinations (DDD 2 ED)	3,623	4,245	3,982	3,624	2	1	2	2	4.23	3.74	3.51	3.18	2	1	2	2
B01AD Enzymes	4,726	5,035	4,699	3,870	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100
B01AD02 Alteplase (DDD 0.10 g)	4,036	4,075	4,206	3,521	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100
B01AD11 Tenecteplase (DDD 40 mg)	690	960	493	349	99	99	99	98	0.00	0.00	0.00	0.00	99	99	99	98
B01AE Direct thrombin inhibitors	12,414	12,618	12,032	11,039	4	3	3	3	2.79	2.87	2.74	2.58	2	1	1	1
B01AE03 Argatroban (DDD 0.20 g)	54	83	78	48	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100
B01AE06 Bivalirudin (DDD 0.25 g)	186	104	147	110	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100
B01AE07 Dabigatran etexilate (DDD 0.30 g)	12,173	12,431	11,808	10,881	2	2	1	1	2.79	2.87	2.74	2.58	2	1	1	1
B01AF Direct factor xa inhibitors	73,796	91,106	104,249	114,389	3	3	2	2	16.91	21.02	24.11	26.70	3	2	2	2
B01AF01 Rivaroxaban (DDD 20 mg)	32,952	37,647	40,303	41,352	2	2	2	2	7.95	9.11	9.72	10.15	2	2	2	1
B01AF02 Apixaban (DDD 10 mg)	36,986	47,651	56,798	65,045	4	3	3	3	8.13	10.67	12.86	14.81	3	3	2	2
B01AF03 Edoxaban (DDD 60 mg)	3,858	5,808	7,148	7,991	3	3	3	3	0.83	1.24	1.53	1.74	2	2	2	2
B01AX Other antithrombotic agents	818	1,214	963	845	78	85	77	86	0.03	0.03	0.02	0.01	10	10	19	16
B01AX01 Defibrotide (DDD 1.75 g)	613	716	592	247	100	100	86	100	0.00	0.00	0.00	0.00	100	100	86	100
B01AX05 Fondaparinux (DDD 2.50 mg)	205	193	166	136	10	9	18	13	0.03	0.03	0.02	0.01	10	9	18	16
B01AX07 Caplacizumab (DDD 10 mg)		305	205	462		100	100	100		0.00	0.00	0.00		100	100	100

**B02 Antihemorrhagics**

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
B02	Antihemorrhagics	56,157	55,131	54,554	54,162	28	27	27	25	0.29	0.34	0.38	0.38	24	21	20	19
B02A	Antifibrinolytics	1,915	2,264	2,009	1,736	76	75	69	64	0.23	0.27	0.31	0.31	21	18	17	16
B02AA	Amino acids	1,744	2,014	1,741	1,420	74	72	65	56	0.23	0.27	0.31	0.31	21	17	16	15
B02AA02	Tranexamic acid (DDD 2 g)	1,744	2,014	1,741	1,420	74	72	65	56	0.23	0.27	0.31	0.31	21	17	16	15
B02AB	Proteinase inhibitors	171	250	268	317	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100
B02AB01	Aprotinin (DDD 500 TU)	118	190	217	276	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100
B02AB02	Alfa1 antitrypsin (DDD 0.60 g)	54	61	51	41	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100
B02B	Vitamin K and other hemostatics	54,242	52,867	52,544	52,425	26	25	26	24	0.06	0.07	0.07	0.07	36	32	35	33
B02BA	Vitamin K	134	107	106	112	88	87	86	90	0.02	0.02	0.02	0.02	88	89	88	91
B02BA01	Phytomenadione (DDD 20 mg)	134	107	106	112	88	87	86	90	0.02	0.02	0.02	0.02	88	89	88	91
B02BB	Fibrinogen	1,869	1,867	1,993	1,948	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100
B02BB01	Fibrinogen, human (DDD 5 g)	1,869	1,867	1,993	1,948	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100
B02BC	Local hemostatics	3,441	3,172	3,304	2,701	100	100	100	100								
B02BC30	Combinations	3,441	3,172	3,304	2,701	100	100	100	100								

Table continued



ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
B02BD	Blood coagulation factors	43,110	40,028	38,247	35,847	20	19	19	19								
B02BD01	Coagulation factor ix, ii, vii and x in combination	4,627	4,420	3,946	3,570	100	100	100	100								
B02BD02	Coagulation factor viii	25,579	24,213	23,854	22,434	4	5	3	3								
B02BD03	Factor viii inhibitor bypassing activity	1,949	831	602	682	48	37	100	100								
B02BD04	Coagulation factor ix	5,806	5,447	5,437	5,060	11	7	8	6								
B02BD06	Von willebrand factor and coagulation factor viii in combination	4,192	3,851	2,861	2,732	17	17	22	28								
B02BD07	Coagulation factor xiii	611	730	779	777	40	37	35	40								
B02BD08	Coagulation factor viia	347	483	488	409	82	79	72	86								
B02BD10	Von willebrand factor		52	280	181		67	59	59								
B02BX	Other systemic hemostatics	5,688	7,694	8,894	11,818	8	7	10	8	0.04	0.05	0.05	0.05	9	8	14	12
B02BX04	Romiplostim (DDD 30 mcg)	1,379	1,805	1,978	1,930	9	8	18	16	0.01	0.01	0.02	0.02	9	9	18	16
B02BX05	Eltrombopag (DDD 50 mg)	3,751	4,518	4,008	4,093	9	9	12	11	0.03	0.03	0.03	0.03	9	9	12	11
B02BX06	Emicizumab (DDD 15 mg)	559	1,371	2,907	5,586	0	2	1	2	0.00	0.00	0.00	0.00		2	1	3
B02BX08	Avatrombopag (DDD 20 mg)			1	209			100	20			0.00	0.00			100	20

**B03 Antianemic preparations**

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
B03	Antianemic preparations	35,208	35,604	36,814	37,179	39	41	45	47	20.95	24.25	28.78	32.84	6	5	5	5
B03A	Iron preparations	16,696	16,411	18,096	18,450	69	77	83	85	6.07	5.94	5.59	4.95	5	5	6	7
B03AA	Iron bivalent, oral preparations	3,498	2,332	1,710	1,527	2	2	3	3	4.15	4.14	3.85	3.48	3	3	3	3
B03AA01	Ferrous glycine sulfate (DDD 0.20 g)	2,912	1,903	1,358	1,217	2	2	3	3	3.05	3.24	3.00	2.73	3	3	3	3
B03AA07	Ferrous sulfate (DDD 0.20 g)	586	428	352	311	3	2	2	2	1.10	0.90	0.85	0.75	3	2	2	2
B03AB	Iron trivalent, oral preparations	1,417	1,348	1,283	1,068	3	3	3	3	1.75	1.63	1.54	1.26	2	2	2	2
B03AB05	Ferric oxide polymaltose complexes (DDD 90 mg)	1,413	1,343	1,273	1,045	3	3	3	3	1.75	1.63	1.53	1.25	2	2	2	2
B03AB10	Ferric maltol (DDD 60 mg)	4	6	10	23	0	0	0	0	0.00	0.00	0.00	0.01				0
B03AC	Iron, parenteral preparations (DDD 0.10 g)	23,542	25,461	30,206	31,708	195	196	197	197	0.33	0.34	0.40	0.42	196	197	197	197
B03AD	Iron in combination with folic acid	10				2											
B03AD01	Ferrous amino acid complex and folic acid	10				2											

Table continued



ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
B03B	Vitamin B ₁₂ and folic acid	2,009	2,161	2,573	2,567	5	5	4	6	13.70	17.08	21.92	26.60	6	5	4	4
B03BA	Vitamin B ₁₂ (cyanocobalamin and derivatives)	1,144	1,080	1,210	1,083	5	4	3	5	5.96	5.59	5.88	5.25	5	4	4	5
B03BA01	Cyanocobalamin	385	369	531	472	5	1	1	6	1.16	1.10	1.59	1.41	5	1	1	6
B03BA03	Hydroxocobalamin (DDD 20 mcg)	759	711	679	611	5	5	5	4	4.81	4.49	4.29	3.84	5	5	5	4
B03BB	Folic acid, combinations	865	1,082	1,363	1,484	5	6	6	7	7.74	11.49	16.05	21.35	6	6	5	4
B03BB01	Folic acid	865	1,082	1,363	1,484	5	6	6	7	7.74	11.49	16.05	21.35	6	6	5	4
B03X	Other antianemic preparations	16,503	17,032	16,145	16,163	12	11	10	11	1.18	1.23	1.27	1.28	12	11	10	11
B03XA	Other antianemic preparations	16,503	17,032	16,145	16,163	12	11	10	11	1.18	1.23	1.27	1.28	12	11	10	11
B03XA01	Erythropoietin (DDD 1 TU)	2,094	2,439	2,335	2,399	15	18	20	22	0.19	0.21	0.23	0.24	14	17	19	20
B03XA02	Darbepoetin alfa (DDD 4.50 mcg)	11,850	12,361	11,878	11,954	11	10	9	9	0.82	0.85	0.89	0.90	11	10	9	9
B03XA03	Methoxy polyethylene glycolepoetin beta (DDD 4 mcg)	2,559	2,232	1,933	1,806	12	9	7	9	0.18	0.17	0.16	0.15	12	9	7	9
B03XA05	Roxadustat (DDD 43 mg)				4				66				0.00				66

**B05 Blood substitutes and perfusion solutions**

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
B05	Blood substitutes and perfusion solutions	30,853	30,276	30,339	31,566	79	80	81	81								
B05A	Blood and related products	5,175	5,765	5,953	6,347	100	100	100	100								
B05AA	Blood substitutes and plasma protein fractions	5,175	5,765	5,953	6,347	100	100	100	100								
B05AA01	Albumin	5,158	5,758	5,950	6,342	100	100	100	100								
B05AA06	Gelatin agents	12	7	3	5	96	95	95	83								
B05AA07	Hydroxyethylstarch	4				100											
B05B	I.v. solutions	17,452	16,960	16,992	17,699	99	99	99	99								
B05BA	Solutions for parenteral nutrition	5,102	5,403	5,297	5,120	100	100	100	100								
B05BA01	Amino acids	95	76	88	62	100	100	100	100								
B05BA02	Fat emulsions	39	37	48	46	95	95	99	99								
B05BA03	Carbohydrates	417	415	402	435	99	99	99	99								
B05BA10	Combinations	4,552	4,874	4,759	4,577	100	100	100	100								
B05BB	Solutions affecting the electrolyte balance	12,324	11,528	11,672	12,544	99	99	99	99								
B05BB01	Electrolytes	11,409	10,707	10,859	11,583	99	99	99	99								
B05BB02	Electrolytes with carbohydrates	915	821	812	961	100	100	100	100								
B05BC	Solutions producing osmotic diuresis	26	30	24	35	99	98	96	97								
B05BC01	Mannitol	26	30	24	35	99	98	96	97								
B05D	Peritoneal dialytics	6,774	6,108	5,954	6,102	7	6	6	6								
B05DA	Isotonic solutions	5,348	4,945	5,133	5,283	13	11	11	11								
B05DB	Hypertonic solutions	8,199	7,270	6,775	6,921	15	11	11	11								

Table continued



ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
B05X	I.v. solution additives	1,251	1,202	1,198	1,171	99	99	98	98								
B05XA	Electrolyte solutions	820	777	786	803	98	98	97	97								
B05XA01	Potassium chloride	275	225	225	211	99	99	98	98								
B05XA03	Sodium chloride	176	131	129	148	94	92	90	91								
B05XA05	Magnesium sulfate	81	107	99	97	99	100	100	99								
B05XA06	Potassium phosphate, incl. comb. with other potassium salts	31	33	29	32	98	99	99	100								
B05XA07	Calcium chloride		27	53	65		100	100	100								
B05XA14	Sodium glycerophosphate	65	58	57	73	94	96	95	95								
B05XA31	Electrolytes in combination with other drugs	191	197	195	177	100	100	100	100								
B05XB	Amino acids	31	27	21	27	100	100	100	100								
B05XB02	Alanyl glutamine	31	27	21	27	100	100	100	100								
B05XC	Vitamins	800	794	781	683	199	199	199	200								
B05Z	Hemodialytics and hemofiltrates	202	242	242	248	100	100	100	100								
B05ZB	Hemofiltrates	403	484	484	495	200	200	200	200								



B06 Other hematological agents

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
B06	Other hematological agents	7,205	8,067	11,356	12,147	20	34	13	14	0.00	0.00	0.01	0.01	21	40	15	12
B06A	Other hematological agents	7,205	8,067	11,356	12,147	20	34	13	14	0.00	0.00	0.01	0.01	21	40	15	12
B06AB	Heme products		15	43	74		100	100	100								
B06AB01	Hemin		15	43	74		100	100	100								
B06AC	Drugs used in hereditary angioedema	7,205	8,052	11,229	11,962	20	34	12	12	0.00	0.00	0.00	0.01	21	40	10	8
B06AC01	C1-inhibitor, plasma derived (DDD 1.40 TU)	3,952	4,425	3,712	3,527	20	20	16	36	0.00	0.00	0.00	0.00	19	20	16	36
B06AC02	Icatibant (DDD 30 mg)	2,837	2,025	2,661	1,055	12	11	9	9	0.00	0.00	0.00	0.00	12	11	6	5
B06AC04	Conestat alfa (DDD 3.50 TU)	273	96	100	100	69	100	100	100	0.00	0.00	0.00	0.00	69	100	100	100
B06AC05	Lanadelumab (DDD 21.40 mg)	143	1,506	4,756	7,279	100	100	9	0	0.00	0.00	0.00	0.00	100	100	8	0
B06AX	Other hematological agents			84	112			100	100			0.00	0.00			100	100
B06AX01	Crizanlizumab (DDD 12.50 mg)			84	112			100	100			0.00	0.00			100	100
B06AX01	Crizanlizumab				84				100				0.00				100



C Cardiovascular system

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
C	Cardiovascular system	150,662	138,176	130,578	128,732	12	13	13	11	626.11	655.05	682.93	705.45	2	2	1	1
C01	Cardiac therapy	22,056	22,397	21,102	18,916	57	61	61	55	13.97	13.44	12.91	12.10	8	8	9	7
C02	Antihypertensives	7,864	9,119	9,156	9,370	7	7	7	5	3.23	3.18	3.32	3.34	3	3	3	3
C03	Diuretics	8,669	9,142	9,217	8,893	20	21	19	16	51.42	50.49	50.16	48.28	6	5	5	5
C04	Peripheral vasodilators	76	76	67	63	2	2	1	1	0.10	0.10	0.09	0.09	2	2	1	1
C05	Vasoprotectives	4,469	4,515	4,887	4,976	5	5	5	4								
C07	Beta blocking agents	20,279	19,267	18,397	17,769	4	4	4	4	64.37	65.65	63.93	60.59	2	2	2	2
C08	Calcium channel blockers	12,799	11,381	11,080	11,436	4	4	3	3	95.51	99.50	104.32	106.76	1	1	1	1
C09	Agents acting on the renin-angiotensin system	43,195	38,543	34,466	33,628	1	1	1	1	264.30	274.79	280.96	287.23	1	1	1	1
C10	Lipid modifying agents	31,255	23,735	22,207	23,681	1	1	1	1	133.20	147.89	167.25	187.05	1	1	1	1

**C01 Cardiac therapy**

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
C01	Cardiac therapy	22,056	22,397	21,102	18,916	57	61	61	55	13.97	13.44	12.91	12.10	8	8	9	7
C01A	Cardiac glycosides	1,106	1,052	1,051	836	14	15	19	3	2.08	1.91	1.79	1.66	4	4	4	3
C01AA	Digitalis glycosides	1,106	1,052	1,051	836	14	15	19	3	2.08	1.91	1.79	1.66	4	4	4	3
C01AA05	Digoxin (DDD 0.25 mg)	1,106	1,052	1,051	836	14	15	19	3	2.08	1.91	1.79	1.66	4	4	4	3
C01B	Antiarrhythmics, class i and iii	3,730	2,862	2,511	2,583	37	41	38	40	2.01	1.97	1.92	1.89	3	3	3	3
C01BB	Antiarrhythmics, class ib	360	283	164	237	97	97	98	98	0.00	0.00	0.00	0.00	97	97	98	98
C01BB01	Lidocaine (DDD 3 g)	360	283	164	237	97	97	98	98	0.00	0.00	0.00	0.00	97	97	98	98
C01BC	Antiarrhythmics, class ic	1,644	1,177	1,145	1,125	1	2	2	1	1.42	1.40	1.36	1.34	1	1	1	1
C01BC04	Flecainide (DDD 0.20 g)	1,644	1,177	1,145	1,125	1	2	2	1	1.42	1.40	1.36	1.34	1	1	1	1
C01BD	Antiarrhythmics, class iii	948	668	550	538	24	23	21	21	0.58	0.57	0.56	0.54	9	10	10	8
C01BD01	Amiodarone (DDD 0.20 g)	307	260	255	244	37	28	26	21	0.46	0.46	0.45	0.44	11	12	12	10
C01BD05	Ibutilide (DDD 1 mg)	109	77	48	58	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100
C01BD07	Dronedarone (DDD 0.80 g)	532	331	247	236	1	1	1	1	0.12	0.11	0.11	0.11	1	1	1	1
C01BG	Other antiarrhythmics, class i and iii	778	733	652	684	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100
C01BG11	Vernakalant (DDD 0.20 g)	778	733	652	684	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100

Table continued



ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
C01C	Cardiac stimulants excl. cardiac glycosides	11,743	13,209	11,956	10,206	84	85	83	78	0.61	0.69	0.77	0.52	83	83	87	78
C01CA	Adrenergic and dopaminergic agents	6,568	8,062	7,417	6,064	70	75	73	63	0.61	0.68	0.77	0.51	83	83	87	78
C01CA01	Etilefrine (DDD 50 mg)	417	259	301	261	77	62	73	62	0.06	0.06	0.05	0.06	23	23	25	19
C01CA02	Isoprenaline (DDD 90 mg)		138	416	538		100	100	100		0.00	0.00	0.00		100	100	100
C01CA03	Norepinephrine (DDD 6 mg)	1,359	2,294	1,291	466	99	100	99	97	0.06	0.08	0.05	0.06	99	99	99	99
C01CA04	Dopamine (DDD 0.50 g)	70	120	21	20	89	91	62	70	0.00	0.00	0.00	0.00	89	91	64	68
C01CA06	Phenylephrine (DDD 4 mg)	595	675	635	389	99	99	100	100	0.02	0.02	0.02	0.01	100	99	100	100
C01CA07	Dobutamine (DDD 0.50 g)	51	84	36	55	99	100	100	100	0.00	0.00	0.00	0.00	99	100	100	100
C01CA17	Midodrine (DDD 30 mg)	41	65	84	94	14	17	18	12	0.00	0.01	0.01	0.01	11	15	16	11
C01CA24	Epinephrine (DDD 0.50 mg)	3,730	4,140	4,350	3,951	52	56	58	48	0.47	0.52	0.65	0.37	88	88	91	85
C01CA26	Ephedrine	304	288	283	290	99	98	98	98								
C01CE	Phosphodiesterase inhibitors	738	819	633	594	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100
C01CE02	Milrinone (DDD 50 mg)	738	819	633	594	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100
C01CX	Other cardiac stimulants	4,438	4,328	3,906	3,549	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100
C01CX08	Levosimendan (DDD 11 mg)	4,438	4,328	3,906	3,539	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100
C01CX09	Angiotensin ii				10				100								
C01D	Vasodilators used in cardiac diseases	4,599	4,561	4,631	4,473	10	12	16	15	9.23	8.85	8.38	7.99	4	4	4	4
C01DA	Organic nitrates	4,599	4,561	4,630	4,462	10	12	16	15	9.23	8.85	8.38	7.99	4	4	4	4
C01DA02	Glyceryl trinitrate	989	1,018	1,176	1,049	30	40	53	54	0.69	0.65	0.60	0.48	16	22	24	18
C01DA08	Isosorbide dinitrate	1,043	991	927	970	10	8	7	7	1.57	1.49	1.41	1.42	6	5	6	6
C01DA14	Isosorbide mononitrate (DDD 40 mg)	2,566	2,553	2,527	2,443	3	2	2	2	6.96	6.71	6.37	6.09	3	2	2	2

Table continued



ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
C01DX	Other vasodilators used in cardiac diseases			0	11			0	6			0.00	0.00				4
C01DX22	Vericiguat (DDD 10 mg)			0	11			0	6			0.00	0.00				4
C01E	Other cardiac preparations	879	714	954	818	95	95	96	96	0.03	0.03	0.04	0.04	60	49	59	54
C01EA	Prostaglandins	329	287	331	243	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100
C01EA01	Alprostadil (DDD 0.50 mg)	329	287	331	243	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100
C01EB	Other cardiac preparations	550	427	622	575	91	92	94	95	0.03	0.03	0.04	0.04	60	48	58	54
C01EB10	Adenosine (DDD 15 mg)	363	222	364	348	96	98	98	99	0.02	0.01	0.02	0.02	96	99	98	100
C01EB16	Ibuprofen (DDD 30 mg)		9	12	15		100	100	100		0.00	0.00	0.00		100	100	100
C01EB17	Ivabradine (DDD 10 mg)	36	33	34	30	3	4	4	6	0.01	0.02	0.02	0.02	2	3	3	4
C01EB21	Regadenoson (DDD 0.40 mg)	151	162	212	183	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100



C02 Antihypertensives

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day				
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022	
C02	Antihypertensives	7,864	9,119	9,156	9,370	7	7	7	5	3.23	3.18	3.32	3.34	3	3	3	3	
C02A	Antiadrenergic agents, centrally acting	1,419	1,523	1,571	1,603	26	31	25	14	2.70	2.61	2.70	2.70	3	3	2	2	
C02AC	Imidazoline receptor agonists	1,419	1,523	1,571	1,603	26	31	25	14	2.70	2.61	2.70	2.70	3	3	2	2	
C02AC01	Clonidine (DDD 0.45 mg)	363	460	355	193	86	89	87	75	0.07	0.06	0.06	0.07	36	35	34	35	
C02AC02	Guanfacine (DDD 3 mg)	310	439	606	805	14	13	11	9	0.04	0.07	0.09	0.12	15	14	12	10	
C02AC05	Moxonidine (DDD 0.30 mg)	745	624	610	606	2	1	1	1	2.59	2.48	2.55	2.51	2	1	1	1	
C02C	Antiadrenergic agents, peripherally acting	379	403	462	505	4	4	4	3	0.48	0.51	0.55	0.58	4	3	3	3	
C02CA	Alpha-adrenoceptor blocking agents	379	403	462	505	4	4	4	3	0.48	0.51	0.55	0.58	4	3	3	3	
C02CA01	Prazosin (DDD 5 mg)	379	403	462	505	4	4	4	3	0.48	0.51	0.55	0.58	4	3	3	3	
C02D	Arteriolar smooth muscle, agents acting on			67	53				100	100			0.00	0.00			100	100
C02DD	Nitroferricyanide derivatives			67	53				100	100			0.00	0.00			100	100
C02DD01	Nitroprusside (DDD 50 mg)			67	53				100	100			0.00	0.00			100	100
C02K	Other antihypertensives	6,066	7,193	7,056	7,209	3	2	2	3	0.05	0.06	0.06	0.07	2	2	2	2	
C02KX	Antihypertensives for pulmonary arterial hypertension	6,066	7,193	7,056	7,209	3	2	2	3	0.05	0.06	0.06	0.07	2	2	2	2	
C02KX01	Bosentan (DDD 0.25 g)	810	1,317	1,297	914	4	3	4	4	0.01	0.01	0.01	0.01	4	3	3	3	
C02KX02	Ambrisentan (DDD 7.50 mg)	783	797	343	303	2	1	2	1	0.01	0.01	0.00	0.01	1	1	1	0	
C02KX04	Macitentan (DDD 10 mg)	3,094	3,416	3,586	4,036	3	2	1	3	0.02	0.02	0.03	0.03	3	2	1	3	
C02KX05	Riociguat (DDD 4.50 mg)	1,378	1,664	1,830	1,957	1	2	1	2	0.01	0.02	0.02	0.02	1	1	1	1	

**C03 Diuretics**

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
C03	Diuretics	8,669	9,142	9,217	8,893	20	21	19	16	51.42	50.49	50.16	48.28	6	5	5	5
C03A	Low-ceiling diuretics, thiazides	1,301	1,429	1,497	1,561	2	2	2	1	6.68	7.11	7.18	7.20	2	2	2	2
C03AA	Thiazides, plain	1,301	1,429	1,497	1,561	2	2	2	1	6.68	7.11	7.18	7.20	2	2	2	2
C03AA03	Hydrochlorothiazide (DDD 25 mg)	1,301	1,429	1,497	1,561	2	2	2	1	6.68	7.11	7.18	7.20	2	2	2	2
C03B	Low-ceiling diuretics, excl. thiazides	185	235	306	292	1	14	21	19	0.48	0.49	0.49	0.49	1	3	4	4
C03BA	Sulfonamides, plain	185	235	306	292	1	14	21	19	0.48	0.49	0.49	0.49	1	3	4	4
C03BA08	Metolazone (DDD 5 mg)		52	130	117		60	48	46		0.01	0.04	0.03		60	48	46
C03BA11	Indapamide (DDD 2.50 mg)	185	183	176	176	1	1	1	1	0.48	0.48	0.46	0.46	1	1	1	1
C03C	High-ceiling diuretics	5,055	5,238	5,026	4,505	33	35	32	28	35.24	34.93	34.61	32.88	8	7	6	6
C03CA	Sulfonamides, plain	5,055	5,238	5,026	4,505	33	35	32	28	35.24	34.93	34.61	32.88	8	7	6	6
C03CA01	Furosemide (DDD 40 mg)	5,055	5,238	5,026	4,505	33	35	32	28	35.24	34.93	34.61	32.88	8	7	6	6
C03D	Aldosterone antagonists and other potassium-sparing agents	1,374	1,496	1,594	1,686	3	2	2	2	2.70	2.92	3.11	3.29	3	2	2	2
C03DA	Aldosterone antagonists	1,374	1,496	1,594	1,686	3	2	2	2	2.70	2.92	3.11	3.29	3	2	2	2
C03DA01	Spironolactone (DDD 75 mg)	1,300	1,412	1,498	1,592	3	2	2	2	2.69	2.90	3.09	3.28	3	2	2	2
C03DA04	Eplerenone (DDD 50 mg)	74	84	95	92	3	2	3	4	0.01	0.01	0.02	0.01	3	2	3	3
C03DA05	Finerenone				1				0								

Table continued



ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
C03E	Diuretics and potassium-sparing agents in combination	722	609	535	494	2	1	1	1	6.32	5.03	4.76	4.41	2	1	1	1
C03EA	Low-ceiling diuretics and potassium-sparing agents	585	487	426	401	1	1	1	1	5.57	4.37	4.16	3.90	1	1	1	1
C03EA01	Hydrochlorothiazide and potassium-sparing agents (DDD 1 ED)	585	487	426	401	1	1	1	1	5.57	4.37	4.16	3.90	1	1	1	1
C03EB	High-ceiling diuretics and potassium-sparing agents	137	122	109	93	5	4	5	4	0.75	0.67	0.60	0.51	5	4	5	4
C03EB01	Furosemide and potassium-sparing agents (DDD 1 ED)	137	122	109	93	5	4	5	4	0.75	0.67	0.60	0.51	5	4	5	4
C03X	Other diuretics	31	135	260	355	68	20	10	11	0.00	0.00	0.01	0.01	32	1	1	1
C03XA	Vasopressin antagonists	31	135	260	355	68	20	10	11	0.00	0.00	0.01	0.01	32	1	1	1
C03XA01	Tolvaptan (DDD 30 mg)	31	135	260	355	68	20	10	11	0.00	0.00	0.01	0.01	32	1	1	1

C04 Peripheral vasodilators

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
C04	Peripheral vasodilators	76	76	67	63	2	2	1	1	0.10	0.10	0.09	0.09	2	2	1	1
C04A	Peripheral vasodilators	76	76	67	63	2	2	1	1	0.10	0.10	0.09	0.09	2	2	1	1
C04AD	Purine derivatives	76	76	67	63	2	2	1	1	0.10	0.10	0.09	0.09	2	2	1	1
C04AD03	Pentoxifylline	76	76	67	63	2	2	1	1	0.10	0.10	0.09	0.09	2	2	1	1

**C05 Vasoprotectives**

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
C05	Vasoprotectives	4,469	4,515	4,887	4,976	5	5	5	4								
C05A	Agents for treatment of hemorrhoids and anal fissures for topical use	2,785	2,786	3,096	3,111	2	2	2	1								
C05AA	Corticosteroids	2,559	2,648	2,969	2,995	2	2	2	1								
C05AA01	Hydrocortisone	59	79	58		27	29	36									
C05AA04	Prednisolone	2,049	2,131	2,449	2,518	1	1	1	1								
C05AA08	Fluocortolone	451	437	462	477	2	1	1	3								
C05AE	Muscle relaxants	134	139	128	117	1	1	3	2								
C05AE01	Glyceryl trinitrate	134	139	128	117	1	1	3	2								
C05AX	Other agents for treatment of hemorrhoids and anal fissures for topical use	92				0											
C05AX03	Other preparations, combinations	92				0											
C05B	Antivaricose therapy	1,684	1,729	1,790	1,864	11	11	11	9								
C05BA	Heparins or heparinoids for topical use	1,515	1,537	1,593	1,695	2	2	2	2								
C05BA01	Organo-heparinoid	1,515	1,537	1,593	1,695	2	2	2	2								
C05BB	Sclerosing agents for local injection	169	192	197	169	90	87	87	78								
C05BB02	Polidocanol	169	192	197	169	90	87	87	78								

**C07 Beta blocking agents**

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
C07	Beta blocking agents	20,279	19,267	18,397	17,769	4	4	4	4	64.37	65.65	63.93	60.59	2	2	2	2
C07A	Beta blocking agents	17,820	17,205	16,601	16,225	5	5	4	4	59.56	61.27	60.10	57.29	2	2	2	2
C07AA	Beta blocking agents, non-selective	1,387	1,443	1,501	1,634	2	2	2	2	2.73	2.68	2.68	2.79	2	1	1	1
C07AA05	Propranolol (DDD 0.16 g)	1,240	1,307	1,370	1,509	2	2	2	2	2.23	2.22	2.24	2.37	2	1	1	1
C07AA07	Sotalol (DDD 0.16 g)	147	136	131	125	1	1	2	2	0.49	0.46	0.44	0.42	1	1	2	2
C07AB	Beta blocking agents, selective	15,259	14,716	14,205	13,822	3	3	2	3	54.69	56.57	55.49	52.67	2	2	2	2
C07AB02	Metoprolol (DDD 0.15 g)	4,663	3,881	3,560	3,376	5	5	4	5	10.03	9.70	8.99	8.28	2	2	1	1
C07AB03	Atenolol (DDD 75 mg)	365	383	335	313	2	2	2	2	1.83	1.91	1.69	1.56	2	2	2	2
C07AB04	Acebutolol (DDD 0.40 g)	73	59	58	43	3	2	3	2	0.14	0.11	0.11	0.08	3	2	3	2
C07AB05	Betaxolol (DDD 20 mg)	227	90			1	1			0.63	0.25			1	1		
C07AB07	Bisoprolol (DDD 10 mg)	9,244	9,665	9,681	9,558	2	2	2	2	39.56	42.15	42.25	40.34	2	2	2	2
C07AB08	Celiprolol (DDD 0.20 g)	175	148	146	132	2	1	1	1	0.77	0.65	0.64	0.58	2	1	1	1
C07AB09	Esmolol (DDD 2.50 g)	26	26	38	34	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100
C07AB12	Nebivolol (DDD 5 mg)	484	463	385	360	1	1	1	1	1.74	1.79	1.81	1.83	1	1	1	1
C07AB14	Landiolol	2	1	1	5	100	100	100	100								
C07AG	Alpha and beta blocking agents	1,174	1,047	896	770	37	41	36	33	2.14	2.03	1.93	1.83	2	2	2	2
C07AG01	Labetalol (DDD 0.60 g)	593	503	442	370	73	83	71	64	0.09	0.05	0.07	0.07	7	13	7	8
C07AG02	Carvedilol (DDD 37.50 mg)	581	543	454	399	1	1	1	4	2.05	1.98	1.86	1.76	1	1	1	1

Table continued



ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
C07B	Beta blocking agents and thiazides	1,194	1,048	873	742	0	0	0	0	3.40	3.06	2.61	2.20	0	0	0	0
C07BB	Beta blocking agents, selective, and thiazides	1,194	1,048	873	742	0	0	0	0	3.40	3.06	2.61	2.20	0	0	0	0
C07BB02	Metoprolol and thiazides (DDD 1 ED)	227	142	50		0	0	0		0.49	0.32	0.11		0	0		
C07BB07	Bisoprolol and thiazides (DDD 1 ED)	923	867	784	704	0	0	0	0	2.91	2.74	2.50	2.20	0	0	0	0
C07BB12	Nebivolol and thiazides	44	38	38	38	0	0	0	0								
C07F	Beta blocking agents, other combinations	1,264	1,014	922	802	0	0	0	0	1.41	1.32	1.21	1.11	0	0	0	0
C07FB	Beta blocking agent and calcium channel blockers	1,264	1,014	922	802	0	0	0	0	1.41	1.32	1.21	1.11	0	0	0	0
C07FB02	Metoprolol and felodipine (DDD 1 ED)	1,264	1,014	922	802	0	0	0	0	1.41	1.32	1.21	1.11	0	0	0	0



C08 Calcium channel blockers

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
C08	Calcium channel blockers	12,799	11,381	11,080	11,436	4	4	3	3	95.51	99.50	104.32	106.76	1	1	1	1
C08C	Selective calcium channel blockers with mainly vascular effects	11,820	10,496	10,254	10,656	4	4	3	3	94.05	98.04	102.94	105.43	1	1	1	1
C08CA	Dihydropyridine derivatives	11,820	10,496	10,254	10,656	4	4	3	3	94.05	98.04	102.94	105.43	1	1	1	1
C08CA01	Amlodipine (DDD 5 mg)	4,208	4,357	4,632	4,830	1	1	1	1	66.49	69.36	72.79	75.06	1	1	1	1
C08CA02	Felodipine (DDD 5 mg)	2,712	2,250	1,878	1,690	1	1	1	1	7.58	7.56	7.92	7.49	1	1	1	1
C08CA03	Isradipine (DDD 5 mg)	13				1				0.02				1			
C08CA05	Nifedipine (DDD 30 mg)	735	506	407	430	2	2	2	2	1.02	0.68	0.54	0.57	2	2	2	2
C08CA06	Nimodipine	286	305	247	207	95	95	95	94	0.01	0.00	0.00	0.00	84	81	83	83
C08CA07	Nisoldipine (DDD 20 mg)	3				6				0.00				6			
C08CA10	Nilvadipine (DDD 8 mg)	434	427	440	381	1	1	1	1	0.72	0.71	0.73	0.63	1	1	1	1
C08CA13	Lercanidipine (DDD 10 mg)	3,430	2,652	2,650	3,117	1	1	1	1	18.21	19.73	20.96	21.68	1	1	1	1
C08D	Selective calcium channel blockers with direct cardiac effects	979	885	826	781	10	2	2	2	1.46	1.45	1.38	1.33	2	2	2	2
C08DA	Phenylalkylamine derivatives	309	243	244	246	25	1	2	2	0.72	0.75	0.74	0.74	3	2	2	2
C08DA01	Verapamil (DDD 0.24 g)	309	243	244	246	25	1	2	2	0.72	0.75	0.74	0.74	3	2	2	2
C08DB	Benzothiazepine derivatives	670	641	582	534	2	2	2	2	0.75	0.71	0.64	0.59	2	2	2	2
C08DB01	Diltiazem (DDD 0.24 g)	670	641	582	534	2	2	2	2	0.75	0.71	0.64	0.59	2	2	2	2

**C09 Agents acting on the renin-angiotensin system**

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
C09	Agents acting on the renin-angiotensin system	43,195	38,543	34,466	33,628	1	1	1	1	264.30	274.79	280.96	287.23	1	1	1	1
C09A	Ace inhibitors, plain	8,175	6,223	5,212	4,950	1	1	1	1	103.84	103.85	101.22	99.80	1	1	1	1
C09AA	Ace inhibitors, plain	8,175	6,223	5,212	4,950	1	1	1	1	103.84	103.85	101.22	99.80	1	1	1	1
C09AA02	Enalapril (DDD 10 mg)	2,049	2,003	1,829	1,783	1	1	1	1	22.02	21.93	20.86	20.33	1	1	1	1
C09AA03	Lisinopril (DDD 10 mg)	680	557	310	247	2	1	2	1	3.63	3.48	3.31	3.22	1	1	1	1
C09AA04	Perindopril (DDD 4 mg)	1,711	1,575	1,138	960	1	1	1	1	4.69	4.59	4.45	4.42	1	1	1	1
C09AA05	Ramipril (DDD 2.50 mg)	3,736	2,079	1,930	1,958	2	1	1	1	73.49	73.82	72.59	71.83	1	1	1	1
C09AA06	Quinapril (DDD 15 mg)		8	4	1		2	0	3		0.03	0.01	0.00		2	0	3
C09AA15	Zofenopril (DDD 30 mg)	0				0				0.00							
C09B	Ace inhibitors, combinations	4,028	3,519	3,080	3,329	0	0	0	0	11.55	11.24	10.79	10.14	0	0	0	0
C09BA	Ace inhibitors and diuretics	2,990	2,433	1,976	2,149	0	0	0	0	9.53	9.09	8.61	7.84	0	0	0	0
C09BA02	Enalapril and diuretics (DDD 1 ED)	1,664	1,223	870	1,113	0	0	0	0	6.34	6.02	5.73	5.14	0	0	0	0
C09BA03	Lisinopril and diuretics (DDD 1 ED)	634	529	470	438	0	0	0	0	1.24	1.13	1.04	0.97	0	0	0	0
C09BA04	Perindopril and diuretics (DDD 1 ED)	523	505	473	448	0	0	0	0	1.00	0.97	0.93	0.89	0	0	0	0
C09BA05	Ramipril and diuretics (DDD 1 ED)	168	165	157	149	0	0	0	0	0.96	0.94	0.89	0.84	0	0	0	0
C09BA06	Quinapril and diuretics (DDD 1 ED)		11	6	1		1	0	0		0.03	0.02	0.00		1		
C09BB	Ace inhibitors and calcium channel blockers	747	777	799	844	0	0	0	0	1.60	1.67	1.72	1.80	0	0	0	0
C09BB02	Enalapril and lercanidipine (DDD 1 ED)	126	123	121	121	0	0	0	0	0.36	0.36	0.35	0.35	0	0	0	0
C09BB04	Perindopril and amlodipine (DDD 1 ED)	621	654	677	722	0	0	0	0	1.24	1.32	1.36	1.45	0	0	0	0
C09BX	Ace inhibitors, other combinations	291	309	305	336	0	0	0	0	0.41	0.47	0.46	0.50	0	0	0	0

Table continued



ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
C09BX01	Perindopril, amlodipine and indapamide (DDD 1 ED)	275	293	299	336	0	0	0	0	0.38	0.43	0.44	0.50	0	0	0	0
C09BX02	Perindopril and bisoprolol (DDD 1 ED)	16	17	6		0	0	0		0.04	0.04	0.02					
C09C	Angiotensin ii receptor blockers (ARBs), PLAIN	14,030	13,100	11,377	10,696	1	1	1	1	115.66	125.67	134.63	142.08	1	1	1	1
C09CA	Angiotensin ii receptor blockers (ARBs), plain	14,030	13,100	11,377	10,696	1	1	1	1	115.66	125.67	134.63	142.08	1	1	1	1
C09CA01	Losartan (DDD 50 mg)	6,533	5,458	3,486	3,327	1	1	1	1	47.21	49.44	52.12	52.99	1	1	1	1
C09CA02	Eprosartan (DDD 0.60 g)	288	202	75	88	1	2	2	3	0.35	0.27	0.11	0.13	1	2	2	3
C09CA03	Valsartan (DDD 80 mg)	1,940	2,146	2,094	1,950	1	1	1	1	14.79	16.00	16.68	17.54	1	1	1	1
C09CA06	Candesartan (DDD 8 mg)	4,199	3,927	3,915	3,750	1	1	1	1	43.16	49.04	54.38	59.85	1	1	1	1
C09CA07	Telmisartan (DDD 40 mg)	886	986	1,369	1,262	2	1	1	1	9.06	9.80	10.30	10.55	1	1	1	1
C09CA08	Olmesartan medoxomil (DDD 20 mg)	185	381	438	318	1	1	1	1	1.09	1.12	1.04	1.02	1	0	0	1
C09D	Angiotensin ii receptor blockers (ARBs), COMBINATIONS	16,962	15,700	14,798	14,653	1	1	1	1	33.26	34.03	34.32	35.21	0	0	0	0
C09DA	Angiotensin ii receptor blockers (ARBs) and diuretics	9,564	9,391	8,170	7,680	0	0	0	0	28.70	29.11	29.03	29.46	0	0	0	0
C09DA01	Losartan and diuretics (DDD 1 ED)	3,837	3,748	2,970	2,706	0	0	0	0	12.77	12.51	12.44	12.84	0	0	0	0
C09DA02	Eprosartan and diuretics (DDD 1 ED)	291	240	215	169	0	0	0	0	0.35	0.32	0.30	0.24	0	0	0	0
C09DA03	Valsartan and diuretics (DDD 1 ED)	1,137	1,103	1,035	1,022	0	0	0	0	4.42	4.53	4.50	4.47	0	0	0	0
C09DA06	Candesartan and diuretics (DDD 1 ED)	3,380	3,352	2,980	2,844	0	0	0	0	7.21	7.52	7.62	7.77	0	0	0	0
C09DA07	Telmisartan and diuretics (DDD 1 ED)	775	785	820	797	0	0	0	0	3.60	3.89	3.84	3.84	0	0	0	0
C09DA08	Olmesartan medoxomil and diuretics (DDD 1 ED)	145	164	149	142	0	0	0	0	0.35	0.35	0.32	0.31	0	0	0	0

Table continued



ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
C09DB	Angiotensin ii receptor blockers (ARBs) and calcium channel blockers	2,452	1,369	935	581	0	0	0	0	2.67	2.81	2.99	3.22	0	0	0	0
C09DB01	Valsartan and amlodipine (DDD 1 ED)	2,384	1,284	864	513	0	0	0	0	2.56	2.68	2.86	3.10	0	0	0	0
C09DB02	Olmesartan medoxomil and amlodipine (DDD 1 ED)	68	85	71	69	0	0	0	0	0.11	0.14	0.12	0.13	0	0	0	0
C09DX	Angiotensin ii receptor blockers (ARBs), other combinations	4,946	4,941	5,693	6,392	2	2	2	2	1.89	2.11	2.30	2.54	1	1	1	0
C09DX01	Valsartan, amlodipine and hydrochlorothiazide (DDD 1 ED)	2,193	1,183	1,056	953	0	0	0	0	1.58	1.68	1.77	1.91	0	0	0	0
C09DX04	Valsartan and sacubitril (DDD 2 ED)	2,753	3,758	4,637	5,439	3	3	2	2	0.31	0.42	0.53	0.62	3	3	2	2

**C10 Lipid modifying agents**

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
C10	Lipid modifying agents	31,255	23,735	22,207	23,681	1	1	1	1	133.20	147.89	167.25	187.05	1	1	1	1
C10A	Lipid modifying agents, plain	31,136	23,544	21,825	23,074	2	1	1	1	133.10	147.59	166.53	185.81	1	1	1	1
C10AA	Hmg coa reductase inhibitors	27,758	19,190	15,960	14,968	1	1	1	1	125.96	138.43	153.84	169.13	1	1	1	1
C10AA01	Simvastatin (DDD 30 mg)	11,269	6,678	4,589	3,999	1	1	1	1	35.62	33.39	31.30	28.60	1	1	1	1
C10AA02	Lovastatin (DDD 45 mg)	211	229	70		1	1	1		0.30	0.31	0.09		1	1	1	
C10AA03	Pravastatin (DDD 30 mg)	1,205	1,029	942	945	2	2	1	1	2.17	1.83	1.78	1.77	2	2	1	1
C10AA04	Fluvastatin (DDD 60 mg)	737	600	730	788	2	2	1	1	1.85	1.76	1.64	1.61	1	1	1	1
C10AA05	Atorvastatin (DDD 20 mg)	8,406	6,166	5,478	4,883	2	1	1	1	56.15	63.09	70.99	75.66	1	1	1	1
C10AA07	Rosuvastatin (DDD 10 mg)	5,929	4,488	4,150	4,353	1	1	1	1	29.86	38.06	48.05	61.49	1	1	1	1
C10AB	Fibrates	398	417	413	394	2	1	1	2	0.49	0.52	0.52	0.53	2	1	1	2
C10AB02	Bezafibrate (DDD 0.60 g)	86	88	98	93	1	1	1	1	0.07	0.07	0.08	0.08	1	1	1	1
C10AB04	Gemfibrozil (DDD 1.20 g)	22	17			2	3			0.03	0.02			2	3		
C10AB05	Fenofibrate (DDD 0.20 g)	290	311	315	301	2	1	2	2	0.39	0.42	0.44	0.45	2	1	2	2
C10AC	Bile acid sequestrants	244	15	142	178	3	0	2	3	0.09	0.00	0.05	0.07	3		2	3
C10AC01	Colestyramine (DDD 14 g)	232		135	178	3		2	3	0.09		0.05	0.07	3		2	3
C10AC04	Colesevelam (DDD 3.75 g)	12	15	7		0	0	2		0.00	0.00	0.00				2	

Table continued



ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
C10AX	Other lipid modifying agents	2,736	3,922	5,310	7,535	3	1	1	1	6.56	8.64	12.12	16.08	1	1	1	1
C10AX06	Omega-3-triglycerides incl. other esters and acids (DDD 4 g)				1				40				0.00				43
C10AX09	Ezetimibe (DDD 10 mg)	1,831	1,561	1,388	1,426	3	2	1	1	6.53	8.54	11.96	15.83	1	1	1	1
C10AX13	Evolocumab (DDD 10 mg)	687	1,790	3,078	4,773	3	1	1	0	0.03	0.07	0.11	0.18	3	1	1	0
C10AX14	Alirocumab (DDD 5.40 mg)	218	571	823	1,096	0	1	0	0	0.01	0.03	0.05	0.06		1	0	0
C10AX16	Inclisiran (DDD 1.60 mg)			22	238			41	5			0.00	0.01			40	5
C10B	Lipid modifying agents, combinations	120	191	382	606	0	0	0	0	0.10	0.30	0.72	1.24	0		0	0
C10BA	Combinations of various lipid modifying agents	12	58	232	453	1	0	0	0	0.00	0.15	0.55	1.07	1		0	
C10BA02	Simvastatin and ezetimibe (DDD 1 ED)	12				1				0.00				1			
C10BA06	Rosuvastatin and ezetimibe (DDD 1 ED)		58	232	453		0	0	0		0.15	0.55	1.07			0	
C10BX	Lipid modifying agents in combination with other drugs	108	134	149	153	0	0	0	0	0.10	0.15	0.16	0.17			0	0
C10BX11	Atorvastatin, amlodipine and perindopril (DDD 1 ED)	105	117	139	153	0	0	0	0	0.09	0.13	0.15	0.17			0	0
C10BX15	Atorvastatin and perindopril (DDD 1 ED)	2	17	10		0	0	0		0.00	0.02	0.01				0	



D Dermatologicals

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
D	Dermatologicals	43,205	43,110	47,210	49,612	4	4	5	5	2.97	2.89	3.04	3.19	1	1	1	1
D01	Antifungals for dermatological use	5,919	5,939	5,923	6,134	3	3	3	3	1.58	1.43	1.49	1.52	1	1	1	1
D02	Emollients and protectives	2,376	49	53	48	1	0	0	1								
D03	Preparations for treatment of wounds and ulcers	6,688	6,809	7,128	6,885	3	2	2	1								
D04	Antipruritics, incl. antihistamines, anesthetics, etc.	425	379	644	499	0	0	0	0								
D05	Antipsoriatics	2,151	2,215	2,038	1,680	2	2	2	2	0.15	0.17	0.16	0.18	2	2	1	1
D06	Antibiotics and chemotherapeutics for dermatological use	4,980	4,719	4,737	4,855	3	3	3	3								
D07	Corticosteroids, dermatological preparations	11,804	12,266	12,537	12,125	3	3	3	3								
D08	Antiseptics and disinfectants	980	967	1,039	1,014	66	67	71	71								
D09	Medicated dressings	141	132	134	113	22	18	21	19								
D10	Anti-acne preparations	3,531	3,672	3,746	3,603	1	1	1	1	1.15	1.19	1.24	1.30	1	1	1	1
D11	Other dermatological preparations	4,210	5,964	9,231	12,656	1	5	6	6	0.09	0.11	0.15	0.20	0	3	4	5

**D01 Antifungals for dermatological use**

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
D01	Antifungals for dermatological use	5,919	5,939	5,923	6,134	3	3	3	3	1.58	1.43	1.49	1.52	1	1	1	1
D01A	Antifungals for topical use	4,752	4,885	4,871	5,170	4	3	3	3								
D01AA	Antibiotics	44	47	44	50	2	2	2	2								
D01AA02	Natamycin	44	47	44	50	2	2	2	2								
D01AC	Imidazole and triazole derivatives	3,139	3,292	3,288	3,514	5	4	4	4								
D01AC01	Clotrimazole	250	224	214	191	1	1	1	1								
D01AC02	Miconazole	982	993	999	1,073	8	7	7	7								
D01AC07	Tioconazole	20	43	40	41	1	0	0	0								
D01AC08	Ketoconazole	1,062	1,159	1,168	1,305	2	1	1	1								
D01AC10	Bifonazole		39	29	39		0	0	0								
D01AC20	Imidazoles/triazoles in combination with corticosteroids	825	834	837	866	7	6	6	6								
D01AE	Other antifungals for topical use	1,568	1,546	1,539	1,605	1	1	1	1								
D01AE14	Ciclopirox	61	47	49	50	0	0	0	0								
D01AE15	Terbinafine	1,303	1,311	1,282	1,337	1	1	1	1								
D01AE16	Amorolfine	204	188	208	218	0	1	1	1								
D01B	Antifungals for systemic use	1,168	1,054	1,052	964	1	1	1	1	1.58	1.43	1.49	1.52	1	1	1	1
D01BA	Antifungals for systemic use	1,168	1,054	1,052	964	1	1	1	1	1.58	1.43	1.49	1.52	1	1	1	1
D01BA02	Terbinafine (DDD 0.25 g)	1,168	1,054	1,052	964	1	1	1	1	1.58	1.43	1.49	1.52	1	1	1	1



D02 Emollients and protectives

ATC classification	Wholesale price (VAT excluded), thousand euros	Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
D02 Emollients and protectives	2,376	49	53	48	1	0	0	1					
D02A Emollients and protectives	2,376	49	53	48	1	0	0	1					
D02AE Carbamide products	1,287	29	32	32	1	0	1	1					
D02AE01 Carbamide	1,287	29	32	32	1	0	1	1					
D02AX Other emollients and protectives	2,178	40	42	32	1	0	0	0					

D03 Preparations for treatment of wounds and ulcers

ATC classification	Wholesale price (VAT excluded), thousand euros	Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
D03 Preparations for treatment of wounds and ulcers	6,688	6,809	7,128	6,885	3	2	2	1					
D03A Cicatrizants	6,688	6,809	7,128	6,885	3	2	2	1					
D03AX Other cicatrizants	6,688	6,809	7,128	6,885	3	2	2	1					
D03AX03 Dexpanthenol	6,688	6,809	7,128	6,885	3	2	2	1					

**D04 Antipruritics, incl. antihistamines, anesthetics, etc.**

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
D04	Antipruritics, incl. antihistamines, anesthetics, etc.	425	379	644	499	0	0	0	0								
D04A	Antipruritics, incl. antihistamines, anesthetics, etc.	425	379	644	499	0	0	0	0								
D04AA	Antihistamines for topical use	425	379	644	499	0	0	0	0								
D04AA04	Tripelennamine	425	379	644	499	0	0	0	0								

D05 Antipsoriatics

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
D05	Antipsoriatics	2,151	2,215	2,038	1,680	2	2	2	2	0.15	0.17	0.16	0.18	2	2	1	1
D05A	Antipsoriatics for topical use	1,860	1,908	1,739	1,362	3	2	2	2								
D05AX	Other antipsoriatics for topical use	1,860	1,908	1,739	1,362	3	2	2	2								
D05AX02	Calcipotriol	42	44	43	43	3	2	2	1								
D05AX03	Calcitriol	38	29	26	25	3	2	1	1								
D05AX52	Calcipotriol, combinations	1,779	1,836	1,670	1,294	3	2	2	2								
D05B	Antipsoriatics for systemic use	291	306	300	319	2	2	1	1	0.15	0.17	0.16	0.18	2	2	1	1
D05BB	Retinoids for treatment of psoriasis	291	306	300	319	2	2	1	1	0.15	0.17	0.16	0.18	2	2	1	1
D05BB02	Acitretin (DDD 35 mg)	291	306	300	319	2	2	1	1	0.15	0.17	0.16	0.18	2	2	1	1

**D06 Antibiotics and chemotherapeutics for dermatological use**

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
D06	Antibiotics and chemotherapeutics for dermatological use	4,980	4,719	4,737	4,855	3	3	3	3								
D06A	Antibiotics for topical use	2,289	2,221	2,311	2,441	5	5	5	4								
D06AX	Other antibiotics for topical use	2,289	2,221	2,311	2,441	5	5	5	4								
D06AX01	Fusidic acid	1,046	1,016	996	1,000	9	9	9	9								
D06AX04	Neomycin	1,216	1,180	1,293	1,424	1	1	1	1								
D06AX09	Mupirocin	26	26	23	18	16	16	18	16								
D06B	Chemotherapeutics for topical use	2,691	2,498	2,425	2,415	1	1	1	1								
D06BB	Antivirals	2,182	2,151	2,099	2,075	1	1	1	1								
D06BB03	Aciclovir	1,158	1,129	1,136	1,164	1	1	1	1								
D06BB06	Penciclovir	245	195	190	192	0	0	0	0								
D06BB10	Imiquimod	516	631	590	512	1	1	1	1								
D06BB53	Aciclovir, combinations	262	196	183	207	0	0	0	0								
D06BX	Other chemotherapeutics	509	347	326	340	0	0	0	0								
D06BX01	Metronidazole	353	342	326	340	0	0	0	0								
D06BX02	Ingenol mebutate	156	5			0	0										

**D07 Corticosteroids, dermatological preparations**

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
D07	Corticosteroids, dermatological preparations	11,804	12,266	12,537	12,125	3	3	3	3								
D07A	Corticosteroids, plain	8,137	8,632	8,905	8,620	3	3	3	2								
D07AA	Corticosteroids, weak (group I)	3,589	3,724	3,995	3,974	2	1	1	1								
D07AA02	Hydrocortisone	3,589	3,724	3,995	3,974	2	1	1	1								
D07AB	Corticosteroids, moderately potent (group II)	1,305	1,508	1,509	1,319	3	3	3	3								
D07AB01	Clobetasone	9	9	1		0	0	0									
D07AB02	Hydrocortisone butyrate	861	929	872	981	2	2	2	2								
D07AB08	Desonide	435	570	636	338	5	4	4	5								
D07AC	Corticosteroids, potent (group III)	2,626	2,624	2,594	2,475	5	4	4	4								
D07AC01	Betamethasone	1,622	1,666	1,813	1,778	6	5	5	4								
D07AC03	Desoximetasone	81	32			6	10										
D07AC13	Mometasone	884	890	749	672	2	2	2	2								
D07AC14	Methylprednisolone aceponate	40	36	32	26	0	0	0	0								
D07AD	Corticosteroids, very potent (group IV)	617	776	806	852	4	3	3	3								
D07AD01	Clobetasol	617	776	806	852	4	3	3	3								

Table continued



ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
D07B	Corticosteroids, combinations with antiseptics	1,232	1,247	1,237	1,210	3	3	3	3								
D07BA	Corticosteroids, weak, combinations with antiseptics	748	727	714	691	2	2	2	2								
D07BA04	Hydrocortisone and antiseptics	748	727	714	691	2	2	2	2								
D07BB	Corticosteroids, moderately potent, combinations with antiseptics	349	349	349	349	3	3	3	3								
D07BB04	Hydrocortisone butyrate and antiseptics	349	349	349	349	3	3	3	3								
D07BC	Corticosteroids, potent, combinations with antiseptics	135	171	174	171	6	5	5	5								
D07BC01	Betamethasone and antiseptics	135	171	174	171	6	5	5	5								
D07C	Corticosteroids, combinations with antibiotics	1,625	1,591	1,608	1,521	4	4	4	4								
D07CA	Corticosteroids, weak, combinations with antibiotics	949	925	933	861	4	4	4	4								
D07CA01	Hydrocortisone and antibiotics	949	925	933	861	4	4	4	4								
D07CC	Corticosteroids, potent, combinations with antibiotics	676	666	675	660	4	4	4	4								
D07CC01	Betamethasone and antibiotics	676	666	675	660	4	4	4	4								
D07X	Corticosteroids, other combinations	809	796	787	774	2	2	2	2								
D07XA	Corticosteroids, weak, other combinations	300	272	274	264	0	0	0	0								
D07XA01	Hydrocortisone	300	272	274	264	0	0	0	0								
D07XC	Corticosteroids, potent, other combinations	509	524	512	510	3	2	3	3								
D07XC01	Betamethasone, combinations	509	524	512	510	3	2	3	3								



D08 Antiseptics and disinfectants

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
D08	Antiseptics and disinfectants	980	967	1,039	1,014	66	67	71	71								
D08A	Antiseptics and disinfectants	980	967	1,039	1,014	66	67	71	71								
D08AC	Biguanides and amidines	655	635	721	694	96	99	99	100								
D08AC02	Chlorhexidine	64	41	40		55	90	89									
D08AC52	Chlorhexidine, combinations	591	593	680	694	100	100	100	100								
D08AG	Iodine products	326	332	318	320	7	6	7	8								
D08AG02	Povidone-iodine	326	332	318	320	7	6	7	8								

D09 Medicated dressings

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
D09	Medicated dressings	141	132	134	113	22	18	21	19								
D09A	Medicated dressings	141	132	134	113	22	18	21	19								
D09AB	Zinc bandages	141	132	134	113	22	18	21	19								
D09AB01	Zinc bandage without supplements	141	132	134	113	22	18	21	19								
D10	Anti-acne preparations	3,531	3,672	3,746	3,603	1	1	1	1	1.15	1.19	1.24	1.30	1	1	1	1
D10A	Anti-acne preparations for topical use	2,144	2,317	2,378	2,240	1	1	1	1								

**D10 Anti-acne preparations**

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
D10AD	Retinoids for topical use in acne	908	882	919	962	2	2	2	2								
D10AD01	Tretinoin	206	235	223	268	0	1	0	1								
D10AD03	Adapalene	190	167	155	151	1	1	1	1								
D10AD06	Trifarotene				47				0								
D10AD53	Adapalene, combinations	512	480	542	496	3	3	3	3								
D10AE	Peroxides	452	461	461	435	0	0	0	0								
D10AE01	Benzoyl peroxide	452	461	461	435	0	0	0	0								
D10AF	Antiinfectives for treatment of acne	606	790	805	660	1	1	1	1								
D10AF01	Clindamycin	219	221	216	202	2	1	1	1								
D10AF51	Clindamycin, combinations	387	570	589	458	1	1	1	1								
D10AX	Other anti-acne preparations for topical use	177	183	193	184	0	1	0	0								
D10AX03	Azelaic acid	177	183	193	184	0	1	0	0								
D10B	Anti-acne preparations for systemic use	1,387	1,356	1,367	1,363	1	1	1	1	1.15	1.19	1.24	1.30	1	1	1	1
D10BA	Retinoids for treatment of acne	1,387	1,356	1,367	1,363	1	1	1	1	1.15	1.19	1.24	1.30	1	1	1	1
D10BA01	Isotretinoin (DDD 30 mg)	1,387	1,356	1,367	1,363	1	1	1	1	1.15	1.19	1.24	1.30	1	1	1	1

**D11 Other dermatological preparations**

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
D11	Other dermatological preparations	4,210	5,964	9,231	12,656	1	5	6	6	0.09	0.11	0.15	0.20	0	3	4	5
D11A	Other dermatological preparations	4,210	5,964	9,231	12,656	1	5	6	6	0.09	0.11	0.15	0.20	0	3	4	5
D11AA	Antihidrotics				2				0								
D11AA01	Glycopyrronium				2				0								
D11AC	Medicated shampoos	107	113	107		0	0	0									
D11AC03	Selenium compounds	107	113	107		0	0	0									
D11AH	Agents for dermatitis, excluding corticosteroids	2,679	4,318	7,487	11,016	2	7	8	7	0.03	0.05	0.09	0.13	1	7	7	7
D11AH01	Tacrolimus	884	993	979	955	2	2	2	2								
D11AH02	Pimecrolimus	579	438	447	508	1	1	1	1								
D11AH04	Alitretinoin (DDD 20 mg)	316	340	187	202	0	0	0	0	0.02	0.02	0.02	0.02	0	0		0
D11AH05	Dupilumab (DDD 21.40 mg)	899	2,548	5,874	9,339	2	11	10	8	0.01	0.03	0.07	0.11	2	11	10	8
D11AH08	Abrocitinib (DDD 0.15 g)				13				100				0.00				100

Table continued



ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
D11AX	Other dermatologicals	1,424	1,532	1,637	1,637	0	0	0	0	0.06	0.06	0.06	0.07	0	0	0	
D11AX01	Minoxidil	780	887	971	919	0	0	0	0								
D11AX10	Finasteride (DDD 1 mg)	212	205	217	218	0	0	0	0	0.06	0.06	0.06	0.07	0	0	0	
D11AX16	Eflornithine	56	44	39	46	0	0	0	0								
D11AX18	Diclofenac	5	5	3	1	3	0	0	0								
D11AX21	Brimonidine	112	95	97	106	0	0	1	0								
D11AX22	Ivermectin	251	295	305	348	0	0	0	0								
D11AX24	Deoxycholic acid	8	2	5		33	0	0									
D11AX18	Diclofenac	5	5	5	3	5	3	0	0								
D11AX21	Brimonidine	106	112	95	97	0	0	0	1								
D11AX22	Ivermectin	208	251	295	305	0	0	0	0								
D11AX24	Deoxycholic acid	8	8	2	5	20	33	0	0								
D11AX16	Eflornitiini	41	33	56	44	0	0		0								
D11AX18	Diklofenaakki	5	5	5	5	2	5	3									
D11AX21	Brimonidiini	119	106	112	95	0	0	0	1								
D11AX22	Ivermektiini	187	208	251	295	0	0	0	1								
D11AX24	Deoksikoolihappo	13	8	8	2	20	20	33									



G Genito urinary system and sex hormones

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
G	Genito urinary system and sex hormones	112,664	104,274	91,992	89,350	6	6	7	8	138.42	139.24	142.73	143.24	8	8	8	10
G01	Gynecological antiinfectives and antiseptics	3,425	3,223	3,162	3,144	1	1	1	1	0.81	0.75	0.75	0.75	1	1	1	1
G02	Other gynecologicals	8,154	7,702	7,594	7,284	37	39	39	41	2.77	2.38	2.18	1.89	12	12	11	12
G03	Sex hormones and modulators of the genital system	59,593	56,738	50,332	49,254	6	5	6	7	83.16	82.64	84.60	85.86	12	12	12	15
G04	Urologicals	41,493	36,611	30,904	29,668	2	2	2	2	51.68	53.46	55.19	54.73	2	2	2	2

**G01 Gynecological antiinfectives and antiseptics**

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
G01	Gynecological antiinfectives and antiseptics	3,425	3,223	3,162	3,144	1	1	1	1	0.81	0.75	0.75	0.75	1	1	1	1
G01A	Antiinfectives and antiseptics, excl. combinations with corticosteroids	3,425	3,223	3,162	3,144	1	1	1	1	0.81	0.75	0.75	0.75	1	1	1	1
G01AA	Antibiotics	408	426	391	342	0	0	0	0	0.06	0.07	0.06	0.06	0	1	0	0
G01AA10	Clindamycin (DDD 0.10 g)	408	426	391	342	0	0	0	0	0.06	0.07	0.06	0.06	0	1	0	0
G01AC	Quinoline derivatives	216	229	229	195	0	0	0	0	0.01	0.02	0.02	0.02	0	0	0	0
G01AC05	Dequalinium (DDD 20 mg)	216	229	229	195	0	0	0	0	0.01	0.02	0.02	0.02	0	0	0	0
G01AF	Imidazole derivatives	2,801	2,567	2,543	2,607	1	1	1	1	0.73	0.67	0.67	0.67	1	1	1	1
G01AF01	Metronidazole	831	769	723	676	1	1	1	1	0.17	0.16	0.15	0.15	1	1	1	1
G01AF02	Clotrimazole (DDD 0.10 g)	1,790	1,674	1,716	1,844	0	1	1	1	0.42	0.42	0.43	0.46	0	1	1	1
G01AF04	Miconazole (DDD 0.10 g)	180	124	104	87	2	2	2	3	0.14	0.10	0.08	0.07	2	2	2	3

**G02 Other gynecologicals**

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
G02	Other gynecologicals	8,154	7,702	7,594	7,284	37	39	39	41	2.77	2.38	2.18	1.89	12	12	11	12
G02A	Uterotonics	75	72	121	30	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100
G02AD	Prostaglandins	75	72	121	30	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100
G02AD02	Dinoprostone (DDD 0.50 mg)	7	12	10	15	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100
G02AD06	Misoprostol (DDD 0.20 mg)	69	60	111	14	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100
G02B	Contraceptives for topical use	7,702	7,195	7,136	6,919	34	35	36	38	2.74	2.35	2.16	1.88	12	12	11	12
G02BA	Intrauterine contraceptives	6,074	5,914	6,000	5,942	41	42	42	43								
G02BA03	Plastic iud with progestogens	6,074	5,914	6,000	5,942	41	42	42	43								
G02BB	Intravaginal contraceptives	1,627	1,280	1,137	977	7	5	5	6	2.74	2.35	2.16	1.88	12	12	11	12
G02BB01	Vaginal ring with progestogen and estrogen (DDD 0.04 ED)	1,627	1,280	1,137	977	7	5	5	6	2.74	2.35	2.16	1.88	12	12	11	12
G02C	Other gynecologicals	377	435	336	336	87	87	85	87	0.03	0.03	0.02	0.01	10	10	12	12
G02CB	Prolactine inhibitors	54	60	55	46	10	9	10	8	0.02	0.03	0.02	0.01	8	9	11	8
G02CB01	Bromocriptine (DDD 5 mg)	18	20	15		7	9	11		0.02	0.02	0.02		7	9	11	
G02CB03	Cabergoline (DDD 0.50 mg)	35	40	40	46	11	9	10	8	0.01	0.01	0.01	0.01	11	9	10	8
G02CX	Other gynecologicals	323	376	282	290	100	99	99	100	0.00	0.00	0.00	0.00	100	99	99	100
G02CX01	Atosiban (DDD 165 mg)	323	376	282	290	100	99	99	100	0.00	0.00	0.00	0.00	100	99	99	100

**G03 Sex hormones and modulators of the genital system**

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
G03	Sex hormones and modulators of the genital system	59,593	56,738	50,332	49,254	6	5	6	7	83.16	82.64	84.60	85.86	12	12	12	15
G03A	Hormonal contraceptives for systemic use	18,635	17,760	17,871	17,770	16	15	15	17	45.38	44.82	46.67	48.04	21	21	22	26
G03AA	Progestogens and estrogens, fixed combinations	10,467	9,633	9,221	8,559	15	13	14	15	25.62	24.51	24.17	23.77	19	19	21	25
G03AA07	Levonorgestrel and ethinylestradiol	170	227	233	248	4	12	17	21	0.60	0.81	0.94	1.07	5	20	24	28
G03AA09	Desogestrel and ethinylestradiol	886	779	694	563	7	4	5	5	3.08	2.90	2.75	2.34	10	15	18	19
G03AA10	Gestodene and ethinylestradiol	1,327	1,173	1,023	930	5	4	5	7	5.25	4.62	4.11	3.93	15	15	16	21
G03AA11	Norgestimate and ethinylestradiol	7	0			1	0			0.02	0.00			1			
G03AA12	Drospirenone and ethinylestradiol	6,506	5,762	5,264	4,578	18	15	16	16	13.14	12.10	11.45	10.77	21	20	21	25
G03AA13	Norelgestromin and ethinylestradiol (DDD 0.11 ED)	265	253	238	255	8	10	11	22	0.44	0.42	0.40	0.41	8	10	11	22
G03AA14	Nomegestrol and estradiol (DDD 1 ED)	860	770	960	1,070	20	13	13	19	1.51	1.30	1.62	1.80	23	14	13	19
G03AA16	Dienogest and ethinylestradiol	446	669	810	871	20	15	14	15	1.58	2.37	2.90	3.45	37	31	31	39
G03AA18	Drospirenone and estetrol				45				8								
G03AB	Progestogens and estrogens, sequential preparations	1,097	996	881	837	8	9	7	6	1.75	1.58	1.39	1.31	8	9	7	6
G03AB03	Levonorgestrel and ethinylestradiol (DDD 0.75 ED)	0				0				0.00							
G03AB05	Desogestrel and ethinylestradiol	2				0				0.00							
G03AB06	Gestodene and ethinylestradiol (DDD 0.75 ED)	2				0				0.00							
G03AB08	Dienogest and estradiol (DDD 1 ED)	1,092	996	881	837	8	9	7	6	1.74	1.58	1.39	1.31	8	9	7	6

Table continued



ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
G03AC	Progestogens	5,995	6,173	6,900	7,418	22	21	21	22	17.96	18.68	21.06	22.92	25	25	25	27
G03AC01	Norethisterone	228	165	60	99	2	3	4	6	0.89	0.71	0.26	0.43	2	3	4	6
G03AC03	Levonorgestrel (DDD 1 ED)	274	267	247	74	18	22	15	41	0.46	0.41	0.41	0.00	8	8	6	41
G03AC08	Etonogestrel (DDD 67 mcg)	1,031	985	1,059	1,096	56	59	58	60	4.69	4.50	4.91	5.15	55	59	58	60
G03AC09	Desogestrel (DDD 1 ED)	4,462	4,100	3,586	3,037	16	12	12	10	11.92	11.91	12.07	11.87	16	15	14	16
G03AC10	Drospirenone (DDD 1 ED)		656	1,948	3,111		22	18	21		1.16	3.42	5.46		23	20	23
G03AD	Emergency contraceptives	1,077	958	869	956	2	2	2	2	0.05	0.04	0.04	0.04	2	2	2	2
G03AD01	Levonorgestrel	521	464	428	463	3	2	2	2	0.03	0.02	0.02	0.03	3	2	3	2
G03AD02	Ulipristal (DDD 30 mg)	556	494	441	493	1	2	2	2	0.02	0.02	0.02	0.02	1	1	1	2
G03B	Androgens	5,809	5,915	5,971	6,570	0	0	0	0	2.31	2.43	2.50	2.75	0	0	0	0
G03BA	3-oxoandrostens (4) derivatives	5,809	5,915	5,971	6,570	0	0	0	0	2.31	2.43	2.50	2.75	0	0	0	0
G03BA03	Testosterone	5,809	5,915	5,971	6,570	0	0	0	0	2.31	2.43	2.50	2.75	0	0	0	0
G03C	Estrogens	23,582	22,134	14,885	13,381	1	1	1	1	20.08	20.84	21.13	21.07	1	1	1	1
G03CA	Natural and semisynthetic estrogens, plain	23,348	21,922	14,704	13,123	1	1	1	1	19.44	20.22	20.59	20.57	1	1	1	1
G03CA03	Estradiol	20,944	18,980	12,042	10,627	1	0	0	0	13.63	14.61	15.45	15.76	0	0	0	0
G03CA04	Estriol	2,404	2,942	2,662	2,496	1	1	1	2	5.81	5.62	5.14	4.81	1	2	2	2
G03CC	Estrogens, combinations with other drugs	15	7			0	0										
G03CC07	Conjugated estrogens and bazedoxifene	15	7			0	0										
G03CX	Other estrogens	219	205	180	258	0	0	0	0	0.65	0.62	0.54	0.49	0	0	0	0
G03CX01	Tibolone (DDD 2.50 mg)	219	205	180	258	0	0	0	0	0.65	0.62	0.54	0.49	0	0	0	0

Table continued



ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
G03D	Progestogens	1,462	1,490	1,503	1,581	0	0	0	0	2.30	2.23	2.38	2.61	0	0	0	0
G03DA	Pregnen (4) derivatives	449	427	449	497	0	0	0	0	0.46	0.54	0.59	0.63	1	0	0	0
G03DA02	Medroxyprogesterone	55	69	64	68	1	0	1	1	0.29	0.37	0.34	0.37	1	0	1	1
G03DA04	Progesterone	393	357	385	429	0	0	0	0	0.17	0.17	0.24	0.26	0	0	0	0
G03DB	Pregnadien derivatives	490	619	611	579	0	0	0	0	0.54	0.71	0.72	0.75	0	0	0	0
G03DB01	Dydrogesterone (DDD 10 mg)	240	317	311	310	0	0	0	0	0.44	0.58	0.57	0.56	0	0	0	0
G03DB08	Dienogest (DDD 2 mg)	250	302	300	270	0	0	0	0	0.10	0.13	0.15	0.19	0	0	0	0
G03DC	Estren derivatives	524	445	443	505	0	1	1	1	1.30	0.98	1.08	1.23	0	1	1	1
G03DC02	Norethisterone (DDD 5 mg)	478	445	397	442	0	1	1	0	1.11	0.98	0.88	0.96	0	1	0	0
G03DC03	Lynestrenol (DDD 5 mg)	47		46	63	1		1	1	0.20		0.20	0.27	1		1	1
G03F	Progestogens and estrogens in combination	4,236	3,935	4,192	4,248	0	0	0	0	9.79	9.45	9.53	9.38	0	0	0	0
G03FA	Progestogens and estrogens, combinations	3,458	3,249	3,458	3,502	0	0	0	0	7.78	7.59	7.68	7.59	0	0	0	0
G03FA01	Norethisterone and estrogen	1,366	1,085	1,422	1,519	0	0	0	0	3.07	2.63	3.03	3.06	0	0	0	0
G03FA12	Medroxyprogesterone and estrogen (DDD 1 ED)	527	515	500	493	0	0	0	0	1.18	1.15	1.12	1.10	0	0	0	0
G03FA14	Dydrogesterone and estrogen (DDD 1 ED)	1,250	1,403	1,297	1,259	0	0	0	0	3.11	3.48	3.22	3.11	0	0	0	0
G03FA17	Drospirenone and estrogen (DDD 1 ED)	315	246	238	231	0	0	0	0	0.42	0.33	0.32	0.31	0		0	0
G03FB	Progestogens and estrogens, sequential preparations	778	686	735	745	0	0	0	0	2.01	1.86	1.85	1.79	0	0	0	0
G03FB05	Norethisterone and estrogen	287	185	266	317	0	0	0	0	0.66	0.51	0.58	0.64	0	0	0	0
G03FB06	Medroxyprogesterone and estrogen	28	21	16	15	0	0	0	1	0.13	0.09	0.08	0.07	0	0	0	1
G03FB08	Dydrogesterone and estrogen (DDD 1 ED)	464	479	452	413	0	0	0	0	1.22	1.26	1.19	1.08	0	0	0	0

Table continued



ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
G03G	Gonadotrophins and other ovulation stimulants	4,392	4,302	4,832	4,658	0	1	1	1	0.17	0.24	0.28	0.16	0	0	0	1
G03GA	Gonadotrophins	4,392	4,302	4,832	4,658	0	1	1	1	0.17	0.24	0.28	0.16	0	0	0	1
G03GA01	Chorionic gonadotrophin (DDD 250 U)	59	109	125	43	0	0	0	0	0.08	0.16	0.18	0.06	0	0	0	0
G03GA02	Human menopausal gonadotrophin (DDD 75 U)	1,214	1,327	1,667	1,523	0	0	0	0	0.03	0.03	0.05	0.04	0	0	0	0
G03GA04	Urofollitropin (DDD 75 U)	26	38	24	16	0	0	0	0	0.00	0.00	0.00	0.00				
G03GA05	Follitropin alfa (DDD 75 U)	1,860	1,783	1,962	1,939	0	1	2	2	0.05	0.05	0.05	0.05	0	1	2	2
G03GA06	Follitropin beta (DDD 75 U)	43	13			0	0			0.00	0.00						
G03GA07	Lutropin alfa (DDD 75 U)	1	1		0	0	0		0	0.00	0.00		0.00				
G03GA08	Choriogonadotropin alfa (DDD 0.25 mg)	235	191	206	299	0	0	0	0	0.00	0.00	0.00	0.00	0	0	0	0
G03GA09	Corifollitropin alfa (DDD 0.15 mg)	249	177	176	97	0	0	0	0	0.00	0.00	0.00	0.00				
G03GA30	Combinations	706	662	672	741	0	0	0	0								
G03H	Antiandrogens	1,152	938	592	505	1	1	1	2	3.10	2.56	1.95	1.66	3	3	3	4
G03HA	Antiandrogens, plain preparations	121	103	90	80	5	5	6	6	0.05	0.04	0.04	0.03	5	5	6	6
G03HA01	Cyproterone (DDD 0.10 g)	121	103	90	80	5	5	6	6	0.05	0.04	0.04	0.03	5	5	6	6
G03HB	Antiandrogens and estrogens	1,031	835	503	425	1	1	1	1	3.05	2.51	1.92	1.63	3	3	3	4
G03HB01	Cyproterone and estrogen (DDD 0.75 ED)	1,031	835	503	425	1	1	1	1	3.05	2.51	1.92	1.63	3	3	3	4
G03X	Other sex hormones and modulators of the genital system	323	264	485	541	48	73	64	59	0.03	0.06	0.15	0.19	19	9	4	3
G03XB	Progesterone receptor modulators	311	203	323	332	50	95	97	97	0.02	0.01	0.01	0.01	25	84	87	88
G03XB01	Mifepristone (DDD 0.20 g)	155	194	316	326	99	99	99	98	0.01	0.01	0.01	0.01	99	99	99	98
G03XB02	Ulipristal (DDD 5 mg)	156	9	7	6	0	-3	0	0	0.02	0.00	0.00	0.00	0	-3		
G03XX	Other sex hormones and modulators of the genital system	12	61	162	209	0	0	0	0	0.01	0.05	0.14	0.18			0	0
G03XX01	Prasterone (DDD 6.50 mg)	12	61	162	209	0	0	0	0	0.01	0.05	0.14	0.18			0	0



G04 Urologicals

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
G04	Urologicals	41,493	36,611	30,904	29,668	2	2	2	2	51.68	53.46	55.19	54.73	2	2	2	2
G04B	Urologicals	20,964	19,732	18,728	18,460	2	2	2	2	18.67	19.26	20.03	20.68	1	2	1	1
G04BD	Drugs for urinary frequency and incontinence	12,301	11,975	12,478	12,825	2	2	2	2	7.15	7.30	7.66	8.12	2	2	2	2
G04BD04	Oxybutynin	211	202	134	142	2	2	2	3	0.13	0.13	0.09	0.11	2	2	2	2
G04BD07	Tolterodine (DDD 4 mg)	310	289	229	204	3	3	3	3	0.25	0.24	0.21	0.20	3	2	3	2
G04BD08	Solifenacin (DDD 5 mg)	1,463	670	548	536	3	3	2	1	1.49	1.35	1.37	1.47	1	2	2	1
G04BD09	Tropium (DDD 40 mg)	205	194	189	182	1	1	1	1	0.19	0.18	0.18	0.17	1	1	1	1
G04BD10	Darifenacin (DDD 7.50 mg)	51	38	39	42	3	2	2	2	0.04	0.03	0.03	0.03	2	2	2	2
G04BD11	Fesoterodine (DDD 4 mg)	718	611	559	378	2	2	2	2	0.49	0.44	0.41	0.40	2	1	2	1
G04BD12	Mirabegron (DDD 50 mg)	9,343	9,971	10,781	11,341	2	2	2	2	4.56	4.94	5.38	5.74	2	2	2	2
G04BE	Drugs used in erectile dysfunction	7,613	6,668	5,184	4,621	1	1	1	1	8.39	8.68	9.16	9.52	0	0	0	0
G04BE01	Alprostadil	666	419	560	624	0	0	0	1	0.04	0.04	0.03	0.03	0	0	0	1
G04BE03	Sildenafil (DDD 50 mg)	2,161	2,285	2,238	2,254	2	2	1	2	7.56	7.63	7.73	7.56	0	0	0	0
G04BE08	Tadalafil (DDD 10 mg)	4,516	3,678	2,153	1,451	0	0	0	0	0.77	0.99	1.38	1.91	0	0	0	0
G04BE09	Vardenafil (DDD 10 mg)	105	76	66	59	0	0	0	0	0.02	0.01	0.01	0.01				
G04BE10	Avanafil (DDD 0.10 g)	60	56	51	44	0	0	0	0	0.01	0.01	0.01	0.01				
G04BE30	Combinations (DDD 1 ED)	105	155	115	189	2	0	1	1	0.00	0.00	0.00	0.00	2	0	1	1
G04BX	Other urologicals	1,051	1,089	1,066	1,014	2	4	4	4	3.13	3.28	3.22	3.03	2	4	4	4
G04BX01	Magnesium hydroxide (DDD 0.50 g)	1,007	1,042	1,023	973	2	4	4	4	3.12	3.27	3.21	3.03	2	4	4	4
G04BX14	Dapoxetine (DDD 30 mg)	44	47	43	41	0	0	0	0	0.01	0.01	0.01	0.01				0

Table continued



ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
G04C	Drugs used in benign prostatic hypertrophy	20,528	16,880	12,176	11,208	2	2	2	2	33.01	34.20	35.15	34.06	2	2	2	2
G04CA	Alpha-adrenoreceptor antagonists	14,681	11,227	7,141	6,372	1	1	1	2	23.73	24.79	26.05	25.72	2	2	1	2
G04CA01	Alfuzosin (DDD 7.50 mg)	1,981	1,901	1,371	1,444	1	1	1	1	5.79	6.08	6.27	6.56	1	1	1	1
G04CA02	Tamsulosin (DDD 0.40 mg)	3,494	3,489	3,473	3,026	2	2	2	2	11.69	12.07	12.70	11.36	2	2	2	2
G04CA52	Tamsulosin and dutasteride (DDD 1 ED)	9,126	5,773	2,229	1,843	1	1	2	2	6.22	6.62	7.05	7.78	1	1	1	1
G04CA53	Tamsulosin and solifenacin (DDD 1 ED)	81	64	68	61	0	0	0	0	0.03	0.03	0.03	0.03	0	0	0	0
G04CB	Testosterone-5-alpha reductase inhibitors	5,353	5,231	4,674	4,681	2	2	2	2	8.64	8.85	8.60	8.11	2	2	2	2
G04CB01	Finasteride (DDD 5 mg)	4,865	4,787	4,255	2,794	2	2	2	2	6.18	6.05	5.71	5.11	2	2	2	2
G04CB02	Dutasteride (DDD 0.50 mg)	487	444	419	1,888	2	2	2	2	2.46	2.79	2.89	3.00	2	2	2	2
G04CX	Other drugs used in benign prostatic hypertrophy	495	421	361	154	0	0	0	0	0.64	0.56	0.51	0.23				
G04CX02	Sabalıs serrulatae fructus (DDD 0.32 g)	495	421	361	154	0	0	0	0	0.64	0.56	0.51	0.23				
G04CX	Other drugs used in benign prostatic hypertrophy	618	495	421	361	0	0	0	0	0.85	0.64	0.56	0.51	0	0	0	0
G04CX02	Sabalıs serrulatae fructus (DDD 0.32,g)	618	495	421	361	0	0	0	0	0.85	0.64	0.56	0.51	0	0	0	0
G04CB02	Dutasteridi (DDD 0.50 mg)	1,312	702	487	444	3	3	2	2	1.90	2.05	2.46	2.79	3	3	2	2
G04CX	Muut hyvänlaatuisen eturauhasen liikakasvun lääkkeet	547	618	495	421					0.74	0.85	0.64	0.56				
G04CX02	Sabalıs serrulatae fructus (DDD 0.32,g)	547	618	495	421					0.74	0.85	0.64	0.56				



H Systemic hormonal preparations, excl. sex hormones and insulins

ATC classification	Wholesale price (VAT excluded), thousand euros	Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a pro- portion (%) of consumption, DDD/1,000 inhabitants/day							
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
H	Systemic hormonal preparations, excl. sex hormones and insulins	48,211	49,497	45,878	42,874	18	18	19	19	55.96	55.49	55.06	55.13	6	5	5	5
H01	Pituitary, hypothalamic hormones and analogues	28,230	29,255	25,358	23,045	9	9	10	10	1.30	1.40	1.46	1.51	4	3	3	3
H02	Corticosteroids for systemic use	10,084	10,260	10,872	10,759	56	54	52	48	18.69	17.61	17.07	17.22	14	15	14	15
H03	Thyroid therapy	6,888	6,959	6,927	6,904	1	1	1	1	35.72	36.22	36.27	36.15	1	1	1	1
H04	Pancreatic hormones	264	225	302	352	61	60	47	48	0.01	0.01	0.01	0.01	64	67	65	67
H05	Calcium homeostasis	2,745	2,797	2,419	1,813	12	11	13	19	0.24	0.25	0.25	0.24	10	9	10	10



H01 Pituitary, hypothalamic hormones and analogues

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
H01	Pituitary, hypothalamic hormones and analogues	28,230	29,255	25,358	23,045	9	9	10	10	1.30	1.40	1.46	1.51	4	3	3	3
H01A	Anterior pituitary lobe hormones and analogues	9,637	9,957	9,905	10,030	13	11	10	9	0.29	0.32	0.33	0.34	1	0	0	0
H01AB	Thyrotrophin	1,220	1,103	992	862	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100
H01AB01	Thyrotrophin alfa (DDD 0.90 mg)	1,220	1,103	992	862	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100
H01AC	Somatropin and somatropin agonists	7,936	8,324	8,395	8,609	0	0	0	0	0.29	0.31	0.33	0.34	0	0	0	0
H01AC01	Somatropin (DDD 2 U)	7,936	8,324	8,395	8,609	0	0	0	0	0.29	0.31	0.33	0.34	0	0	0	0
H01AX	Other anterior pituitary hormones and analogues	480	530	518	559	0	0	1	0	0.00	0.00	0.00	0.00	0		1	
H01AX01	Pegvisomant (DDD 10 mg)	480	530	518	559	0	0	1	0	0.00	0.00	0.00	0.00	0		1	
H01B	Posterior pituitary lobe hormones	2,667	2,608	2,715	2,623	28	33	36	34	0.72	0.78	0.81	0.85	5	5	3	4
H01BA	Vasopressin and analogues	2,491	2,399	2,460	2,313	23	27	30	25	0.71	0.75	0.79	0.83	3	2	1	1
H01BA01	Vasopressin (argipressin) (DDD 40 U)	85	137	128	158	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100
H01BA02	Desmopressin	2,036	1,872	1,811	1,805	6	6	5	4	0.70	0.75	0.78	0.83	2	2	1	1
H01BA04	Terlipressin (DDD 12 mg)	370	391	521	349	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100
H01BB	Oxytocin and analogues	176	209	255	310	100	100	100	100	0.02	0.02	0.02	0.02	100	100	100	100
H01BB02	Oxytocin	125	99	55	61	100	100	100	100	0.02	0.02	0.01	0.02	100	100	100	100
H01BB03	Carbetocin (DDD 0.10 mg)	51	110	201	250	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100

Table continued



ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
H01C	Hypothalamic hormones	15,926	16,689	12,738	10,392	4	4	4	6	0.29	0.31	0.32	0.32	2	3	2	3
H01CA	Gonadotrophin-releasing hormones	215	245	298	255	0	0	0	0	0.04	0.04	0.05	0.05	0	0	0	0
H01CA02	Nafarelin (DDD 0.40 mg)	215	245	298	255	0	0	0	0	0.04	0.04	0.05	0.05	0	0	0	0
H01CB	Somatostatin and analogues	15,404	16,152	12,102	9,745	4	5	5	6	0.24	0.25	0.26	0.26	3	3	3	3
H01CB02	Octreotide (DDD 0.70 mg)	7,507	7,430	3,873	3,631	8	9	13	15	0.12	0.12	0.12	0.11	5	6	5	6
H01CB03	Lanreotide (DDD 3 mg)	7,853	8,697	8,176	6,039	1	1	1	1	0.12	0.13	0.14	0.15	1	1	1	1
H01CB05	Pasireotide (DDD 1.20 mg)	45	25	53	74	0	40	32	0	0.00	0.00	0.00	0.00		40	30	
H01CC	Anti gonadotropin releasing hormones	306	292	338	393	0	1	2	1	0.01	0.01	0.01	0.01	0	1	2	2
H01CC01	Ganirelix (DDD 0.25 mg)	287	278	329	324	0	1	2	2	0.01	0.01	0.01	0.01	0	1	2	2
H01CC02	Cetrorelix (DDD 0.25 mg)	19	13	9	4	0	0	0	0	0.00	0.00	0.00	0.00				
H01CC54	Relugolix, estradiol and norethisterone			0	65			0	0								

**H02 Corticosteroids for systemic use**

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
H02	Corticosteroids for systemic use	10,084	10,260	10,872	10,759	56	54	52	48	18.69	17.61	17.07	17.22	14	15	14	15
H02A	Corticosteroids for systemic use, plain	7,721	8,181	8,692	8,586	53	51	49	44	18.59	17.52	16.98	17.13	14	14	14	14
H02AA	Mineralocorticoids	151	147	129	133	6	6	5	5	0.67	0.65	0.57	0.59	6	6	5	5
H02AA02	Fludrocortisone (DDD 0.10 mg)	151	147	129	133	6	6	5	5	0.67	0.65	0.57	0.59	6	6	5	5
H02AB	Glucocorticoids	7,570	8,034	8,563	8,452	54	52	49	45	17.92	16.87	16.41	16.54	14	15	15	15
H02AB01	Betamethasone	171	170	160	156	82	83	82	79	0.28	0.27	0.26	0.24	71	72	71	69
H02AB02	Dexamethasone (DDD 1.50 mg)	1,514	2,429	2,891	2,421	77	58	56	49	2.18	2.32	2.37	2.35	37	39	40	39
H02AB04	Methylprednisolone	1,752	1,720	1,712	2,013	72	74	69	75	1.09	1.08	1.01	1.08	36	38	36	41
H02AB06	Prednisolone (DDD 10 mg)	1,571	1,314	1,430	1,858	19	12	12	10	12.42	11.39	11.00	11.22	7	6	6	6
H02AB07	Prednisone (DDD 10 mg)	88	82	92	93	2	2	2	2	0.57	0.54	0.49	0.45	2	2	2	2
H02AB08	Triamcinolone (DDD 7.50 mg)	833	874	827	476	76	71	70	68	0.09	0.09	0.09	0.05	76	71	69	68
H02AB09	Hydrocortisone (DDD 30 mg)	1,640	1,446	1,452	1,435	37	39	38	35	1.29	1.17	1.20	1.15	15	15	15	16
H02AB13	Deflazacort (DDD 15 mg)				0				0				0.00				
H02B	Corticosteroids for systemic use, combinations	2,361	2,070	2,179	2,172	65	64	62	60	0.10	0.09	0.09	0.09	65	64	62	60
H02BX	Corticosteroids for systemic use, combinations	2,361	2,070	2,179	2,172	65	64	62	60	0.10	0.09	0.09	0.09	65	64	62	60
H02BX01	Methylprednisolone, combinations (DDD 0.50 ED)	2,361	2,070	2,179	2,172	65	64	62	60	0.10	0.09	0.09	0.09	65	64	62	60
H02C	Antiadrenal preparations	1	9	1	1	100	0	100	50	0.00	0.00	0.00	0.00	100		100	50
H02CA	Anticorticosteroids	1	9	1	1	100	0	100	50	0.00	0.00	0.00	0.00	100		100	50
H02CA03	Ketoconazole (DDD 0.60 g)	1	9	1	1	100	0	100	50	0.00	0.00	0.00	0.00	100		100	50



H03 Thyroid therapy

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
H03	Thyroid therapy	6,888	6,959	6,927	6,904	1	1	1	1	35.72	36.22	36.27	36.15	1	1	1	1
H03A	Thyroid preparations	6,229	6,317	6,318	6,299	1	1	1	1	35.17	35.70	35.77	35.65	1	1	1	1
H03AA	Thyroid hormones	6,229	6,317	6,318	6,299	1	1	1	1	35.17	35.70	35.77	35.65	1	1	1	1
H03AA01	Levothyroxine sodium (DDD 0.15 mg)	6,229	6,317	6,318	6,299	1	1	1	1	35.17	35.70	35.77	35.65	1	1	1	1
H03B	Antithyroid preparations	658	642	609	606	3	2	3	3	0.54	0.53	0.50	0.50	3	2	3	3
H03BB	Sulphur-containing imidazole derivatives	658	642	609	606	3	2	3	3	0.54	0.53	0.50	0.50	3	2	3	3
H03BB01	Carbimazole (DDD 15 mg)	658	642	609	606	3	2	3	3	0.54	0.53	0.50	0.50	3	2	3	3

H04 Haiman hormonit

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
H04	Pancreatic hormones	264	225	302	352	61	60	47	48	0.01	0.01	0.01	0.01	64	67	65	67
H04A	Glycogenolytic hormones	264	225	302	352	61	60	47	48	0.01	0.01	0.01	0.01	64	67	65	67
H04AA	Glycogenolytic hormones	264	225	302	352	61	60	47	48	0.01	0.01	0.01	0.01	64	67	65	67
H04AA01	Glucagon	264	225	302	352	61	60	47	48	0.01	0.01	0.01	0.01	64	67	65	67

**H05 Calcium homeostasis**

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
H05	Calcium homeostasis	2,745	2,797	2,419	1,813	12	11	13	19	0.24	0.25	0.25	0.24	10	9	10	10
H05A	Parathyroid hormones and analogues	1,225	817	721	712	7	7	11	16	0.06	0.05	0.05	0.04	7	7	11	8
H05AA	Parathyroid hormones and analogues	1,225	817	721	712	7	7	11	16	0.06	0.05	0.05	0.04	7	7	11	8
H05AA02	Teriparatide (DDD 20 mcg)	1,225	817	721	656	7	7	11	9	0.06	0.05	0.05	0.04	7	7	11	8
H05AA03	Parathyroid hormone (DDD 0.10 mg)				56				100				0.00				100
H05B	Anti-parathyroid agents	1,519	1,981	1,698	1,101	16	12	14	21	0.19	0.19	0.20	0.20	11	10	9	10
H05BA	Calcitonin preparations	55	28	38	31	97	98	97	98	0.00	0.00	0.00	0.00	97	98	97	98
H05BA01	Calcitonin (salmon synthetic)	55	28	38	31	97	98	97	98	0.00	0.00	0.00	0.00	97	98	97	98
H05BX	Other anti-parathyroid agents	1,464	1,953	1,660	1,070	13	11	12	19	0.19	0.19	0.20	0.20	11	10	9	10
H05BX01	Cinacalcet (DDD 60 mg)	1,310	1,779	1,502	871	9	6	6	5	0.16	0.17	0.18	0.18	7	6	6	5
H05BX02	Paricalcitol (DDD 2 mcg)	136	155	124	145	50	59	62	69	0.02	0.02	0.01	0.02	46	46	49	55
H05BX04	Etelcalcetide (DDD 2.10 mg)	18	18	34	54	98	100	100	100	0.00	0.00	0.00	0.00	98	100	100	100



J Antiinfectives for systemic use

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
J	Antiinfectives for systemic use	267,785	256,579	244,852	246,574	77	77	77	73	16.79	13.92	13.34	14.60	19	21	21	20
J01	Antibacterials for systemic use	44,542	41,360	38,760	38,962	49	57	56	48	14.64	11.86	11.27	12.50	14	16	16	16
J02	Antimycotics for systemic use	17,941	13,191	12,507	11,253	81	76	75	74	0.38	0.35	0.35	0.34	16	15	14	16
J04	Antimycobacterials	977	759	735	1,154	85	87	89	92	0.16	0.16	0.13	0.14	85	86	86	85
J05	Antivirals for systemic use	140,120	127,743	127,767	121,276	94	94	93	93	1.62	1.54	1.58	1.62	56	53	53	52
J06	Immune sera and immunoglobulins	43,065	51,949	49,823	53,213	80	80	73	71								

**J01 Antibacterials for systemic use**

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
J01	Antibacterials for systemic use	44,542	41,360	38,760	38,962	49	57	56	48	14.64	11.86	11.27	12.50	14	16	16	16
J01A	Tetracyclines	2,276	1,724	1,572	1,756	30	25	19	20	3.11	2.48	2.30	2.57	5	5	4	5
J01AA	Tetracyclines	2,276	1,724	1,572	1,756	30	25	19	20	3.11	2.48	2.30	2.57	5	5	4	5
J01AA02	Doxycycline (DDD 0.10 g)	1,124	709	645	831	16	8	7	8	1.93	1.29	1.17	1.50	6	8	7	8
J01AA04	Lymecycline (DDD 0.60 g)	453	469	482	467	1	1	1	1	0.79	0.82	0.84	0.81	1	1	1	1
J01AA07	Tetracycline (DDD 1 g)	189	185	204	186	2	2	2	2	0.39	0.36	0.29	0.25	2	2	2	2
J01AA12	Tigecycline (DDD 0.10 g)	510	362	241	272	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100
J01C	Beta-lactam antibacterials, penicillins	16,832	16,560	16,176	15,566	47	63	60	43	4.95	3.64	3.52	4.41	12	15	15	13
J01CA	Penicillins with extended spectrum	6,691	4,774	4,762	6,244	15	22	24	22	2.64	1.81	1.77	2.27	8	10	9	9
J01CA01	Ampicillin	612	712	838	968	100	100	100	100	0.01	0.01	0.01	0.01	100	100	100	100
J01CA04	Amoxicillin	4,437	2,612	2,689	4,095	7	9	9	8	1.95	1.20	1.19	1.71	8	10	9	9
J01CA08	Pivmecillinam (DDD 0.60 g)	1,642	1,450	1,235	1,181	6	6	7	7	0.68	0.61	0.58	0.56	7	7	8	7
J01CE	Beta-lactamase sensitive penicillins	2,038	1,562	1,672	1,666	53	46	40	26	1.25	1.01	0.90	1.01	9	10	11	10
J01CE01	Benzympenicillin (DDD 3.60 g)	1,055	722	646	419	100	94	95	88	0.06	0.05	0.05	0.07	99	94	94	85
J01CE02	Phenoxymethylpenicillin (DDD 2 g)	983	840	1,025	1,247	3	5	5	5	1.19	0.96	0.85	0.94	4	5	5	5
J01CF	Beta-lactamase resistant penicillins	1,028	993	1,282	1,680	61	59	58	47	0.20	0.19	0.24	0.32	54	51	50	40
J01CF02	Cloxacillin (DDD 2 g)	574	534	744	875	100	100	91	82	0.10	0.08	0.12	0.13	100	100	91	82
J01CF05	Flucloxacillin (DDD 2 g)	454	459	538	805	11	12	11	9	0.10	0.10	0.12	0.18	11	12	11	9

Table continued



ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
J01CR	Combinations of penicillins, incl. beta-lactamase inhibitors	7,074	9,230	8,460	5,977	74	88	84	68	0.87	0.62	0.61	0.81	20	27	25	19
J01CR02	Amoxicillin and beta-lactamase inhibitor	2,004	1,288	1,451	2,041	9	13	10	8	0.78	0.53	0.52	0.72	11	15	12	10
J01CR05	Piperacillin and beta-lactamase inhibitor (DDD 14 g)	5,071	7,942	7,008	3,937	100	100	100	99	0.09	0.09	0.09	0.09	100	100	99	97
J01D	Other beta-lactam antibacterials	12,633	11,170	10,308	10,692	60	62	62	61	2.62	2.27	2.19	2.21	33	35	35	37
J01DB	First-generation cephalosporins	5,190	4,369	4,043	4,369	6	6	7	7	1.86	1.56	1.51	1.50	6	6	7	7
J01DB01	Cefalexin (DDD 2 g)	5,188	4,364	4,037	4,357	6	6	7	7	1.85	1.56	1.51	1.49	6	6	7	7
J01DB04	Cefazolin (DDD 3 g)	2	5	6	12	100	100	91	96	0.00	0.00	0.00	0.00	100	100	97	98
J01DC	Second-generation cephalosporins	3,880	3,155	2,828	2,746	98	98	98	99	0.65	0.57	0.56	0.61	96	97	97	99
J01DC02	Cefuroxime	3,880	3,155	2,828	2,746	98	98	98	99	0.65	0.57	0.56	0.61	96	97	97	99
J01DD	Third-generation cephalosporins	1,246	1,391	1,350	1,129	95	95	93	92	0.08	0.09	0.07	0.07	98	98	97	96
J01DD01	Cefotaxime (DDD 4 g)	2	2	2	2	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100
J01DD02	Ceftazidime (DDD 4 g)	108	68	63	77	100	100	100	100	0.01	0.01	0.00	0.01	100	100	100	100
J01DD04	Ceftriaxone (DDD 2 g)	958	1,121	1,009	827	94	94	93	89	0.07	0.08	0.06	0.06	97	98	97	96
J01DD52	Ceftazidime and beta-lactamase inhibitor (DDD 6 g)	178	200	276	222	100	99	93	100	0.00	0.00	0.00	0.00	100	99	93	100
J01DE	Fourth-generation cephalosporins	4	6	32	185	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100
J01DE01	Cefepime (DDD 4 g)	4	6	32	185	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100
J01DF	Monobactams	41	32	49	45	100	95	100	100	0.00	0.00	0.00	0.00	100	95	100	100
J01DF01	Aztreonam	41	32	49	45	100	95	100	100	0.00	0.00	0.00	0.00	100	95	100	100
J01DH	Carbapenems	2,059	1,921	1,922	2,015	100	100	99	100	0.04	0.04	0.04	0.04	100	100	100	100
J01DH02	Meropenem (DDD 3 g)	1,049	910	816	911	100	100	100	100	0.03	0.03	0.03	0.03	100	100	100	100
J01DH03	Ertapenem (DDD 1 g)	1,010	1,011	1,007	997	100	100	100	100	0.01	0.01	0.01	0.01	100	100	100	100

Table continued



ATC classification	Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day						
	2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022			
J01DH51	Imipenem and cilastatin (DDD 4 ED)			38	68			100	100			0.00	0.00			100	100		
J01DH52	Meropenem and vaborbactam (DDD 3 g)			3	14			100	100										
J01DH56	Imipenem, cilastatin and relebactam (DDD 2 g)			58	25			86	100										
J01DI	Other cephalosporins and penems			214	297	85	203	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100
J01DI02	Ceftaroline fosamil (DDD 1.20 g)			83	127	119	91	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100
J01DI54	Ceftolozane and beta-lactamase inhibitor (DDD 3 ED)			131	170	-34	113	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100
J01E	Sulfonamides and trimethoprim			1,525	1,352	1,373	1,395	6	7	7	6	1.14	1.02	1.01	0.97	7	8	8	7
J01EA	Trimethoprim and derivatives			879	817	807	787	6	6	6	5	0.77	0.70	0.68	0.64	6	7	7	6
J01EA01	Trimethoprim (DDD 0.40 g)			879	817	807	787	6	6	6	5	0.77	0.70	0.68	0.64	6	7	7	6
J01EE	Combinations of sulfonamides and trimethoprim, incl. derivatives			646	535	565	609	7	8	8	7	0.36	0.33	0.34	0.33	9	9	10	8
J01EE01	Sulfamethoxazole and trimethoprim			175	203	227	182	14	11	10	12	0.15	0.16	0.17	0.13	12	11	10	12
J01EE02	Sulfadiazine and trimethoprim			471	332	338	427	5	6	7	5	0.21	0.17	0.17	0.20	8	8	9	6
J01F	Macrolides, lincosamides and streptogramins			3,060	2,488	2,259	2,209	35	47	52	45	0.75	0.55	0.49	0.58	17	22	22	18
J01FA	Macrolides			1,502	1,095	1,025	1,248	29	44	48	40	0.49	0.32	0.27	0.35	14	22	22	17
J01FA01	Erythromycin			77	93	96	117	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100
J01FA06	Roxithromycin (DDD 0.30 g)			165	100	70	93	12	11	12	11	0.07	0.04	0.03	0.04	10	11	12	10
J01FA09	Clarithromycin			365	209	173	211	18	28	32	14	0.10	0.06	0.05	0.06	16	26	29	12
J01FA10	Azithromycin			895	693	687	827	30	46	49	41	0.31	0.21	0.19	0.25	13	22	22	19
J01FF	Lincosamides			1,558	1,393	1,234	961	42	49	55	52	0.26	0.24	0.23	0.23	22	22	22	21
J01FF01	Clindamycin			1,558	1,393	1,234	961	42	49	55	52	0.26	0.24	0.23	0.23	22	22	22	21

Table continued



ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
J01G	Aminoglycoside antibacterials	1,193	1,074	837	906	49	49	47	57	0.02	0.02	0.01	0.01	49	48	49	50
J01GB	Other aminoglycosides	1,193	1,074	837	906	49	49	47	57	0.02	0.02	0.01	0.01	49	48	49	50
J01GB01	Tobramycin	848	725	595	513	28	25	26	25	0.01	0.01	0.01	0.01	41	37	38	33
J01GB03	Gentamicin (DDD 0.24 g)	155	118	120	143	98	97	93	95	0.00	0.00	0.00	0.00	97	95	95	94
J01GB06	Amikacin	190	230	123	250	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100
J01M	Quinolone antibacterials	2,604	2,441	1,814	1,867	45	52	42	41	0.63	0.55	0.49	0.52	25	29	25	27
J01MA	Fluoroquinolones	2,604	2,441	1,814	1,867	45	52	42	41	0.63	0.55	0.49	0.52	25	29	25	27
J01MA02	Ciprofloxacin	1,442	1,235	1,087	1,040	35	37	30	25	0.38	0.32	0.32	0.33	17	18	18	20
J01MA12	Levofloxacin	778	808	547	621	52	59	53	55	0.18	0.18	0.14	0.14	35	44	39	35
J01MA14	Moxifloxacin (DDD 0.40 g)	385	398	180	206	70	86	81	75	0.07	0.05	0.03	0.05	35	47	43	44
J01MA23	Delafloxacin				1				100				0.00				100
J01X	Other antibacterials	4,421	4,552	4,421	4,571	63	64	63	66	1.42	1.35	1.26	1.23	9	10	10	9
J01XA	Glycopeptide antibacterials	1,083	1,051	1,031	690	100	98	97	96	0.02	0.03	0.03	0.03	99	98	97	97
J01XA01	Vancomycin (DDD 2 g)	799	749	768	353	100	97	96	92	0.02	0.03	0.03	0.03	99	98	97	97
J01XA02	Teicoplanin (DDD 0.40 g)	193	188	42	18	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100
J01XA04	Dalbavancin (DDD 1.50 g)	90	115	220	315	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100
J01XA05	Oritavancin				4				100								
J01XB	Polymyxins	160	177	147	145	22	8	3	3	0.00	0.00	0.00	0.00	22	8	3	3
J01XB01	Colistin	160	177	147	145	22	8	3	3	0.00	0.00	0.00	0.00	22	8	3	3
J01XC	Steroid antibacterials	12	1			13	10			0.00	0.00			13	10		
J01XC01	Fusidic acid (DDD 1.50 g)	12	1			13	10			0.00	0.00			13	10		
J01XD	Imidazole derivatives	689	1,031	916	1,553	100	100	100	100	0.04	0.05	0.05	0.04	100	100	100	100
J01XD01	Metronidazole (DDD 1.50 g)	689	1,031	916	1,553	100	100	100	100	0.04	0.05	0.05	0.04	100	100	100	100

**J02 Antimycotics for systemic use**

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
J01XE	Nitrofurantoin derivatives	471	558	558	554	4	3	3	3	0.27	0.31	0.32	0.32	6	5	4	4
J01XE01	Nitrofurantoin (DDD 0.20 g)	471	558	558	554	4	3	3	3	0.27	0.31	0.32	0.32	6	5	4	4
J01XX	Other antibacterials	2,006	1,734	1,769	1,629	47	47	49	47	1.08	0.96	0.87	0.84	4	4	4	4
J01XX01	Fosfomycin	11	9	9	19	100	100	98	100	0.00	0.00	0.00	0.00	100	100	98	100
J01XX05	Methenamine	931	840	849	827	4	3	3	3	1.07	0.94	0.86	0.83	4	3	3	3
J01XX08	Linezolid (DDD 1.20 g)	552	434	359	314	70	74	79	83	0.01	0.01	0.01	0.01	61	57	60	58
J01XX09	Daptomycin (DDD 0.28 g)	511	450	552	468	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100
J02	Antimycotics for systemic use	17,941	13,191	12,507	11,253	81	76	75	74	0.38	0.35	0.35	0.34	16	15	14	16
J02A	Antimycotics for systemic use	17,941	13,191	12,507	11,253	81	76	75	74	0.38	0.35	0.35	0.34	16	15	14	16
J02AA	Antibiotics	2,691	1,778	1,925	1,999	100	100	100	100	0.01	0.01	0.01	0.01	100	100	100	100
J02AA01	Amphotericin (DDD 35 mg)	2,691	1,778	1,925	1,999	100	100	100	100	0.01	0.01	0.01	0.01	100	100	100	100
J02AC	Triazole and tetrazole derivatives	4,694	4,095	3,816	3,692	29	24	19	20	0.36	0.34	0.33	0.33	11	11	10	12
J02AC01	Fluconazole (DDD 0.20 g)	2,506	2,080	1,883	1,892	12	14	11	13	0.26	0.23	0.22	0.23	14	13	12	14
J02AC02	Itraconazole (DDD 0.20 g)	373	378	385	351	1	1	1	1	0.09	0.08	0.08	0.08	1	1	1	1
J02AC03	Voriconazole (DDD 0.40 g)	661	235	234	301	71	54	40	62	0.01	0.01	0.01	0.01	25	22	20	22
J02AC04	Posaconazole (DDD 0.30 g)	688	718	534	337	47	45	44	38	0.00	0.01	0.01	0.01	48	39	33	35
J02AC05	Isavuconazole (DDD 0.20 g)	466	684	779	812	51	38	24	22	0.00	0.00	0.00	0.00	36	25	19	14
J02AX	Other antimycotics for systemic use	10,555	7,318	6,766	5,562	100	100	100	100	0.01	0.01	0.01	0.01	100	100	100	100
J02AX04	Caspofungin (DDD 50 mg)	4,377	1,848	1,108	558	100	100	100	100	0.00	0.00	0.00	0.01	100	100	100	100
J02AX05	Micafungin (DDD 0.10 g)	4,388	2,587	2,521	1,533	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100
J02AX06	Anidulafungin (DDD 0.10 g)	1,790	2,883	3,137	3,471	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100



J04 Antimycobacterials

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
J04	Antimycobacterials	977	759	735	1,154	85	87	89	92	0.16	0.16	0.13	0.14	85	86	86	85
J04A	Drugs for treatment of tuberculosis	977	759	735	1,154	85	87	89	92	0.16	0.16	0.13	0.14	85	86	86	85
J04AA	Aminosalicylic acid and derivatives	-3	2			100	100			0.00	0.00			100	100		
J04AA01	Aminosalicylic acid (DDD 12 g)	-3	2			100	100			0.00	0.00			100	100		
J04AB	Antibiotics	387	362	354	343	75	74	78	75	0.08	0.07	0.07	0.07	71	71	74	71
J04AB02	Rifampicin (DDD 0.60 g)	294	298	253	262	68	70	70	68	0.07	0.07	0.06	0.06	68	70	70	68
J04AB04	Rifabutin (DDD 0.15 g)	93	64	101	80	96	94	98	97	0.01	0.01	0.01	0.01	96	94	98	97
J04AC	Hydrazides	98	109	86	103	98	98	97	99	0.05	0.05	0.03	0.04	98	98	97	99
J04AC01	Isoniazid	98	109	86	103	98	98	97	99	0.05	0.05	0.03	0.04	98	98	97	99
J04AK	Other drugs for treatment of tuberculosis	496	285	296	708	90	100	100	100	0.04	0.04	0.03	0.03	98	99	100	100
J04AK01	Pyrazinamide (DDD 1.50 g)	61	85	62	87	98	100	99	100	0.01	0.01	0.01	0.01	98	100	99	100
J04AK02	Ethambutol (DDD 1.20 g)	179	154	165	157	99	99	100	99	0.03	0.02	0.02	0.02	99	99	100	99
J04AK05	Bedaquiline (DDD 86 mg)	255	46	70	464	82	100	100	100	0.00	0.00	0.00	0.00	82	100	100	100

**J05 Antivirals for systemic use**

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
J05	Antivirals for systemic use	140,120	127,743	127,767	121,276	94	94	93	93	1.62	1.54	1.58	1.62	56	53	53	52
J05A	Direct acting antivirals	140,120	127,743	127,767	121,276	94	94	93	93	1.62	1.54	1.58	1.62	56	53	53	52
J05AB	Nucleosides and nucleotides excl. reverse transcriptase inhibitors	11,151	10,486	10,688	10,212	35	37	36	34	0.70	0.72	0.76	0.78	7	7	7	6
J05AB01	Aciclovir (DDD 4 g)	2,729	2,873	2,605	2,869	20	28	21	29	0.31	0.32	0.33	0.34	3	3	3	4
J05AB06	Ganciclovir	251	174	143	162	100	100	100	99	0.00	0.00	0.00	0.00	100	100	100	99
J05AB09	Famciclovir (DDD 0.75 g)	131	126	108	99	1	2	1	0	0.01	0.01	0.01	0.01	1	2	1	
J05AB11	Valaciclovir (DDD 3 g)	5,059	4,511	4,784	4,699	3	3	2	2	0.35	0.36	0.39	0.41	3	3	3	2
J05AB12	Cidofovir (DDD 25 mg)				27				100				0.00				100
J05AB14	Valganciclovir (DDD 0.90 g)	2,980	2,802	3,048	2,356	99	100	100	100	0.03	0.03	0.03	0.02	99	100	100	100
J05AE	Protease inhibitors	1,878	496	298	235	100	100	100	100	0.05	0.03	0.03	0.02	100	100	100	100
J05AE01	Saquinavir (DDD 1.80 g)	8				100				0.00				100			
J05AE03	Ritonavir (DDD 1.20 g)	141	104	88	74	100	99	100	100	0.00	0.00	0.00	0.00	100	99	100	100
J05AE08	Atazanavir (DDD 0.30 g)	451	142	69	32	100	100	100	100	0.02	0.01	0.01	0.00	100	100	100	100
J05AE10	Darunavir (DDD 1.20 g)	1,277	250	141	130	100	100	100	100	0.03	0.02	0.02	0.01	100	100	100	100
J05AF	Nucleoside and nucleotide reverse transcriptase inhibitors	1,277	1,142	1,219	585	100	100	100	99	0.07	0.07	0.08	0.06	100	100	99	99
J05AF01	Zidovudine (DDD 0.60 g)	4		2	5	100		100	97	0.00		0.00	0.00	100		100	97
J05AF05	Lamivudine (DDD 0.30 g)	65	50	38	40	97	100	100	100	0.01	0.00	0.00	0.00	97	100	100	100

Table continued



ATC classification	Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day				
	2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022	
J05AF06	Abacavir (DDD 0.60 g)	69	45	39	30	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100
J05AF07	Tenofovir disoproxil (DDD 0.25 g)	695	655	768	202	100	100	100	99	0.05	0.05	0.06	0.04	100	100	100	99
J05AF08	Adefovir dipivoxil (DDD 10 mg)	38	31	30	20	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100
J05AF09	Emtricitabine (DDD 0.20 g)	11	8	8	8	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100
J05AF10	Entecavir (DDD 0.50 mg)	167	117	106	96	100	99	97	97	0.01	0.01	0.01	0.01	100	99	96	96
J05AF13	Tenofovir alafenamide (DDD 25 mg)	229	235	226	185	100	100	100	100	0.01	0.01	0.01	0.01	100	100	100	100
J05AG	Non-nucleoside reverse transcriptase inhibitors	885	761	959	1,032	100	100	100	100	0.04	0.04	0.05	0.06	100	100	100	100
J05AG01	Nevirapine (DDD 0.40 g)	475	207	180	111	100	100	100	100	0.02	0.02	0.02	0.02	100	100	100	100
J05AG03	Efavirenz (DDD 0.60 g)	81	115	111	74	100	100	100	100	0.01	0.01	0.01	0.01	100	100	100	100
J05AG04	Etravirine (DDD 0.40 g)	160	83	53	24	100	100	100	100	0.01	0.00	0.00	0.00	100	100	100	100
J05AG05	Rilpivirine	117	133	210	308	100	100	100	100	0.01	0.01	0.01	0.02	100	100	100	100
J05AG06	Doravirine (DDD 0.10 g)	52	223	405	515	100	100	100	100	0.00	0.01	0.01	0.01	100	100	100	100
J05AH	Neuraminidase inhibitors	783	358	16	161	37	14	42	3	0.08	0.04	0.00	0.02	37	15	35	2
J05AH02	Oseltamivir (DDD 0.15 g)	783	358	16	161	37	14	42	3	0.08	0.04	0.00	0.02	37	15	35	2
J05AJ	Integrase inhibitors	7,179	7,045	7,516	8,309	100	100	100	100	0.19	0.19	0.20	0.21	100	100	100	100
J05AJ01	Raltegravir (DDD 0.80 g)	2,232	2,179	2,094	1,919	100	100	100	100	0.07	0.07	0.07	0.06	100	100	100	100
J05AJ03	Dolutegravir (DDD 50 mg)	4,946	4,866	5,295	6,002	100	100	100	100	0.12	0.12	0.13	0.14	100	100	100	100
J05AJ04	Cabotegravir			127	388			100	100			0.00	0.01			100	100

Table continued



ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
J05AP	Antivirals for treatment of hcv infections	90,287	84,527	82,773	74,301	100	100	100	100	0.08	0.08	0.07	0.07	100	100	100	100
J05AP01	Ribavirin	281	42	6		100	99	100		0.01	0.00	0.00		100	99	100	
J05AP08	Sofosbuvir (DDD 0.40 g)	42	126			100	100			0.00	0.00			100	100		
J05AP51	Sofosbuvir and ledipasvir (DDD 1 ED)	49	361	148	508	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100
J05AP54	Elbasvir and grazoprevir (DDD 1 ED)	17,130	4,388	2,023	1,043	100	100	100	100	0.02	0.01	0.00	0.00	100	100	100	100
J05AP55	Sofosbuvir and velpatasvir (DDD 1 ED)	63,353	58,351	50,135	41,541	100	100	100	100	0.05	0.05	0.04	0.03	100	100	100	100
J05AP56	Sofosbuvir, velpatasvir and voxilaprevir (DDD 1 ED)	216	1,205	1,582	1,187	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100
J05AP57	Glecaprevir and pibrentasvir (DDD 3 ED)	9,215	20,054	28,879	30,022	100	100	100	100	0.01	0.02	0.03	0.03	100	100	100	100
J05AR	Antivirals for treatment of hiv infections, combinations	26,192	21,672	22,149	24,083	100	100	100	100	0.41	0.37	0.39	0.40	98	94	94	96
J05AR01	Zidovudine and lamivudine (DDD 2 ED)	30	12			100	100			0.00	0.00			100	100		
J05AR02	Lamivudine and abacavir (DDD 1 ED)	401	155	131	109	99	99	100	100	0.03	0.03	0.03	0.02	99	99	100	100
J05AR03	Tenofovir disoproxil and emtricitabine (DDD 1 ED)	2,281	1,215	1,499	1,738	99	94	95	97	0.09	0.13	0.18	0.22	92	82	86	93
J05AR04	Zidovudine, lamivudine and abacavir (DDD 2 ED)	4				100				0.00				100			
J05AR06	Emtricitabine, tenofovir disoproxil and efavirenz (DDD 1 ED)	736	194	123	76	100	97	100	99	0.01	0.01	0.01	0.01	100	96	100	100
J05AR08	Emtricitabine, tenofovir disoproxil and rilpivirine (DDD 1 ED)	198	137	112	112	98	100	93	90	0.00	0.00	0.00	0.00	98	100	93	90
J05AR09	Emtricitabine, tenofovir disoproxil, elvitegravir and cobicistat (DDD 1 ED)	156	96	60	35	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100
J05AR10	Lopinavir and ritonavir (DDD 0.80 g)	79	27	3	9	100	98	100	100	0.00	0.00	0.00	0.00	100	98	100	100
J05AR13	Lamivudine, abacavir and dolutegravir (DDD 1 ED)	7,385	6,124	5,220	4,140	100	100	100	100	0.10	0.08	0.07	0.05	100	100	100	100

Table continued



ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
J05AR14	Darunavir and cobicistat (DDD 1 ED)	218	242	153	132	100	100	100	100	0.01	0.01	0.00	0.00	100	100	100	100
J05AR17	Emtricitabine and tenofovir alafenamide (DDD 1 ED)	3,810	2,651	2,331	1,749	100	100	100	100	0.10	0.07	0.06	0.05	100	100	100	100
J05AR18	Emtricitabine, tenofovir alafenamide, elvitegravir and cobicistat (DDD 1 ED)	1,416	1,092	859	535	100	100	100	100	0.02	0.01	0.01	0.01	100	100	100	100
J05AR19	Emtricitabine, tenofovir alafenamide and rilpivirine (DDD 1 ED)	1,896	1,420	1,057	699	100	100	100	100	0.03	0.02	0.02	0.01	100	100	100	100
J05AR20	Emtricitabine, tenofovir alafenamide and bictegravir	5,411	4,632	4,889	6,854	100	100	100	100								
J05AR21	Dolutegravir and rilpivirine	182	215	195	163	100	100	100	100								
J05AR22	Emtricitabine, tenofovir alafenamide, darunavir and cobicistat (DDD 1 ED)	1,458	1,010	892	1,231	100	100	100	100	0.02	0.02	0.02	0.01	100	100	100	100
J05AR24	Lamivudine, tenofovir disoproxil and doravirine	456	1,901	3,013	3,598	100	100	100	100								
J05AR25	Lamivudine and dolutegravir	74	549	1,612	2,902	100	100	100	100								
J05AX	Other antivirals	488	1,256	2,150	2,358	100	65	32	44	0.00	0.00	0.00	0.00	100	74	46	52
J05AX09	Maraviroc (DDD 0.60 g)	83	82	87	64	100	97	100	100	0.00	0.00	0.00	0.00	100	98	100	100
J05AX18	Letermovir (DDD 0.48 g)	405	1,173	2,062	2,293	100	62	29	42	0.00	0.00	0.00	0.00	100	61	29	42
J05AX25	Baloxavir marboxil (DDD 40 mg)			1	0			0	100			0.00	0.00				100

**J06 Immune sera and immunoglobulins**

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
J06	Immune sera and immunoglobulins	43,065	51,949	49,823	53,213	80	80	73	71								
J06B	Immunoglobulins	43,065	51,949	49,823	53,213	80	80	73	71								
J06BA	Immunoglobulins, normal human	41,450	50,568	48,282	49,773	79	80	72	70								
J06BA01	Immunoglobulins, normal human, for extravascular adm.	8,816	10,595	13,884	15,456	3	3	3	2								
J06BA02	Immunoglobulins, normal human, for intravascular adm.	32,634	39,972	34,397	34,317	100	100	100	100								
J06BB	Specific immunoglobulins	617	645	691	634	100	100	100	100								
J06BB01	Anti-d (rh) immunoglobulin	617	645	691	634	100	100	100	100								
J06BC	Antibacterial monoclonal antibodies	204	186	313	230	100	100	100	97								
J06BC03	Bezlotoxumab	204	186	313	230	100	100	100	97								
J06BD	Antiviral monoclonal antibodies	794	550	537	2,576	100	100	100	100								
J06BD01	Palivizumab	794	550	537	526	100	100	100	100								
J06BD03	Tixagevimab and cilgavimab				2,050				100								



J07 Vaccines

ATC classification		Doses per year			
		2019	2020	2021	2022
J07	Vaccines	4,054,300	6,015,500	16,312,400	13,319,000
J07A	Bacterial vaccines	585,800	626,200	559,700	701,000
J07AE	Cholera vaccines	5,700	2,200	2,000	4,500
J07AG	Haemophilus influenzae B vaccines	900	900	900	800
J07AH	Meningococcal vaccines	56,100	55,000	40,100	15,400
J07AJ	Pertussis vaccines	118,500	108,800	115,900	174,800
J07AL	Pneumococcal vaccines	196,200	275,600	167,000	213,000
J07AM	Tetanus vaccines	162,000	153,200	211,400	237,000
J07AN	Tuberculosis vaccines	25,400	24,800	18,300	20,900
J07AP	Typhoid vaccines	20,900	5,700	4,000	10,100
J07B	Viral vaccines	3,088,000	5,060,600	15,552,100	12,325,000
J07BA	Encephalitis vaccines	241,100	232,300	254,400	254,000
J07BB	Influenza vaccines	2,082,100	4,050,800	4,322,400	3,935,300
J07BC	Hepatitis vaccines	264,400	138,000	93,700	132,000
J07BD	Measles vaccines	190,700	153,400	170,000	271,400
J07BF	Poliomyelitis vaccines	13,400	11,700	7,600	18,000
J07BH	Rota virus diarrhea vaccines	132,800	135,300	145,000	192,400
J07BK	Varicella zoster vaccines	77,000	75,000	68,100	129,500
J07BL	Yellow fever vaccines	8,800	3,100	2,300	5,200
J07BM	Papillomavirus vaccines	77,700	215,000	144,700	213,000
J07BN	covid-19 vaccines	0	45,800	10,344,000	7,194,300
J07C	Bacterial and viral vaccines, combined	380,500	328,700	200,700	293,300
J07CA	Bacterial and viral vaccines, combined	380,500	328,700	200,700	293,300



L Antineoplastic and immunomodulating agents

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
L	Antineoplastic and immunomodulating agents	782,967	813,257	895,552	893,541	44	42	44	43	23.86	24.63	26.00	27.25	11	12	13	12
L01	Antineoplastic agents	308,365	328,298	381,940	389,281	70	68	68	65	0.41	0.44	0.48	0.54	3	3	3	3
L02	Endocrine therapy	65,173	70,383	72,991	77,226	3	2	2	2	7.87	7.75	7.78	7.94	3	3	3	3
L03	Immunostimulants	31,836	31,137	27,498	24,842	13	16	16	18	0.70	0.68	0.66	0.63	5	7	7	8
L04	Immunosuppressants	377,594	383,439	413,122	402,192	32	30	31	31	14.88	15.76	17.09	18.14	16	17	17	16

**L01 Antineoplastic agents**

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
L01	Antineoplastic agents	308,365	328,298	381,940	389,281	70	68	68	65	0.41	0.44	0.48	0.54	3	3	3	3
L01A	Alkylating agents	6,108	6,213	6,388	5,255	69	73	75	72								
L01AA	Nitrogen mustard analogues	2,665	2,803	2,605	2,158	94	95	97	97								
L01AA01	Cyclophosphamide	752	710	705	595	96	96	95	95								
L01AA02	Chlorambucil	112	96	33	20	14	14	12	10								
L01AA03	Melphalan	65	457	400	189	40	93	96	95								
L01AA05	Chlormethine		10		2		100		0								
L01AA06	Ifosfamide	501	451	361	352	100	100	100	100								
L01AA09	Bendamustine	1,235	1,080	1,105	1,000	100	100	100	100								
L01AB	Alkyl sulphonates	224	646	721	642	100	100	100	100								
L01AB01	Busulfan	108	120	197	98	100	100	100	100								
L01AB02	Treosulfan	116	525	523	544	100	100	100	100								
L01AC	Ethylene imines	537	460	743	499	100	100	100	100								
L01AC01	Thiotepa	537	460	743	499	100	100	100	100								
L01AD	Nitrosoureas	784	633	616	387	100	99	100	99								
L01AD01	Carmustine	716	547	533	304	100	100	100	100								
L01AD02	Lomustine	18	28	30	31	93	85	94	89								
L01AD04	Streptozocin	51	57	54	53	100	100	100	100								
L01AX	Other alkylating agents	1,899	1,672	1,704	1,569	10	8	10	11								
L01AX03	Temozolomide	1,802	1,603	1,622	1,492	5	4	5	6								
L01AX04	Dacarbazine	97	69	82	77	100	100	100	100								

Table continued



ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
L01B	Antimetabolites	17,659	17,391	16,331	10,777	84	82	82	76								
L01BA	Folic acid analogues	6,420	6,349	6,887	3,677	98	98	99	100								
L01BA01	Methotrexate	475	421	444	303	69	70	82	100								
L01BA04	Pemetrexed	5,944	5,928	6,443	3,374	100	100	100	100								
L01BB	Purine analogues	646	537	616	608	47	39	36	33								
L01BB02	Mercaptopurine	250	299	371	393	5	6	4	3								
L01BB04	Cladribine	62	94	64	58	90	100	100	100								
L01BB05	Fludarabine	179	103	114	100	44	57	71	78								
L01BB06	Clofarabine	119	38	14	13	100	100	100	100								
L01BB07	Nelarabine	35	4	53	45	100	100	100	89								
L01BC	Pyrimidine analogues	10,594	10,505	8,829	6,491	78	74	72	67								
L01BC01	Cytarabine	98	156	151	153	100	100	100	100								
L01BC02	Fluorouracil	359	403	320	315	100	100	99	100								
L01BC05	Gemcitabine	997	531	651	879	100	100	100	100								
L01BC06	Capecitabine	1,145	955	800	578	2	2	2	2								
L01BC07	Azacitidine	6,353	6,417	4,922	2,883	100	100	100	100								
L01BC08	Decitabine	386	216	257	67	100	100	100	100								
L01BC52	Fluorouracil, combinations	2	6	5	4	0	0	0	0								
L01BC53	Tegafur, combinations	127	100	96	113	8	9	8	21								
L01BC59	Trifluridine, combinations	1,126	1,720	1,627	1,499	0	1	0	0								

Table continued



ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
L01C	Plant alkaloids and other natural products	14,740	13,967	14,652	14,061	90	94	95	96								
L01CA	Vinca alkaloids and analogues	1,843	1,183	1,060	942	36	52	58	55								
L01CA01	Vinblastine	26	34	54	45	100	95	100	100								
L01CA02	Vincristine	103	174	243	241	99	99	100	100								
L01CA04	Vinorelbine	1,570	810	661	595	25	30	33	28								
L01CA05	Vinflunine	145	165	103	60	100	100	100	100								
L01CB	Podophyllotoxin derivatives	350	452	402	357	72	76	72	71								
L01CB01	Etoposide	350	452	402	357	72	76	72	71								
L01CD	Taxanes	11,010	11,102	11,772	11,504	100	100	100	100								
L01CD01	Paclitaxel	5,410	6,198	6,689	6,917	100	100	100	100								
L01CD02	Docetaxel	922	739	726	453	100	100	100	100								
L01CD04	Cabazitaxel	4,679	4,165	4,357	4,133	100	100	100	100								
L01CE	Topoisomerase 1 (TOP1) inhibitors	951	700	871	809	84	85	85	90								
L01CE01	Topotecan	238	185	175	120	35	45	30	34								
L01CE02	Irinotecan	713	515	697	688	100	100	99	100								
L01CX	Other plant alkaloids and other natural products	585	530	546	449	100	100	100	100								
L01CX01	Trabectedin	585	530	546	449	100	100	100	100								
L01D	Cytotoxic antibiotics and related substances	3,244	2,561	2,581	2,845	99	99	100	99								

Table continued



ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
L01DB	Anthracyclines and related substances	2,680	2,173	2,070	2,358	100	100	100	100								
L01DB01	Doxorubicin	1,769	1,487	1,420	1,714	100	100	100	100								
L01DB03	Epirubicin	490	274	229	240	100	100	100	100								
L01DB06	Idarubicin	257	268	299	304	100	100	100	100								
L01DB07	Mitoxantrone	97	111	113	100	100	100	99	99								
L01DB11	Pixantrone	67	32	8		100	100	100									
L01DC	Other cytotoxic antibiotics	564	389	511	487	97	98	98	95								
L01DC01	Bleomycin	81	101	151	106	100	100	100	99								
L01DC03	Mitomycin	482	287	360	381	96	97	97	94								
L01E	Protein kinase inhibitors	82,710	91,282	101,910	112,326	4	4	4	5	0.41	0.44	0.48	0.54	3	3	3	3
L01EA	Bcr-abl tyrosine kinase inhibitors	11,942	10,865	9,764	7,741	2	3	2	2	0.12	0.12	0.12	0.13	1	2	2	2
L01EA01	Imatinib (DDD 0.40 g)	5,501	4,913	4,031	2,372	1	0	0	0	0.09	0.09	0.09	0.09	1	1	1	2
L01EA02	Dasatinib (DDD 0.10 g)	2,752	2,174	1,885	1,172	3	6	4	4	0.01	0.01	0.01	0.01	2	5	4	7
L01EA03	Nilotinib (DDD 0.60 g)	2,548	2,576	2,668	2,663	0	1	1	1	0.02	0.02	0.02	0.02	0	1	1	1
L01EA04	Bosutinib (DDD 0.40 g)	293	342	444	466	0	0	0	1	0.00	0.00	0.00	0.00				1
L01EA05	Ponatinib (DDD 45 mg)	849	860	735	1,068	8	20	4	5	0.00	0.00	0.00	0.00	7	20	5	5
L01EB	Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors	4,873	5,257	6,926	9,521	1	1	1	0	0.03	0.03	0.03	0.04	1	1	1	1
L01EB01	Gefitinib (DDD 0.25 g)	618	232	65	46	2	1	2	5	0.01	0.01	0.00	0.00	2	1	2	1
L01EB02	Erlotinib (DDD 0.15 g)	992	553	144	49	1	3	1	2	0.01	0.01	0.00	0.00	1	2	1	1
L01EB03	Afatinib (DDD 40 mg)	1,729	1,806	1,341	988	1	0	1	0	0.01	0.01	0.01	0.01	1	0	1	0
L01EB04	Osimertinib (DDD 80 mg)	1,533	2,666	5,375	8,439	2	1	1	0	0.00	0.01	0.02	0.02	2	1	1	0

Table continued



ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
L01EC	B-raf serine-threonine kinase (BRAF) inhibitors	6,324	5,820	6,799	8,801	2	1	1	2	0.02	0.01	0.02	0.02	2	1	1	2
L01EC01	Vemurafenib (DDD 1.92 g)	400	225	138	118	1	1	2	20	0.00	0.00	0.00	0.00	1	1	2	20
L01EC02	Dabrafenib (DDD 0.30 g)	5,675	4,694	5,006	6,098	2	1	1	2	0.01	0.01	0.01	0.02	2	1	1	2
L01EC03	Encorafenib (DDD 0.45 g)	249	900	1,656	2,585	8	0	1	0	0.00	0.00	0.00	0.01	8	0	1	0
L01ED	Anaplastic lymphoma kinase (ALK) inhibitors	2,690	3,592	3,964	4,722	3	7	5	6	0.01	0.01	0.01	0.02	3	6	5	6
L01ED01	Crizotinib (DDD 0.50 g)	1,468	1,169	966	1,223	2	4	5	4	0.00	0.00	0.00	0.00	2	4	5	4
L01ED03	Alectinib (DDD 1.20 g)	1,174	2,061	2,532	2,749	2	2	2	2	0.00	0.01	0.01	0.01	2	2	2	2
L01ED04	Brigatinib (DDD 0.18 g)	48	223	163	217	56	68	62	27	0.00	0.00	0.00	0.00	58	67	63	29
L01ED05	Lorlatinib (DDD 0.10 g)		139	302	532		0	0	28		0.00	0.00	0.00				28
L01EE	Mitogen-activated protein kinase (MEK) inhibitors	3,168	3,695	4,831	6,784	3	1	2	19	0.01	0.01	0.02	0.02	2	1	2	4
L01EE01	Trametinib (DDD 2 mg)	2,939	2,892	3,418	3,937	2	1	3	5	0.01	0.01	0.01	0.02	2	1	3	5
L01EE03	Binimetinib (DDD 90 mg)	229	803	1,413	1,762	9	1	1	1	0.00	0.00	0.00	0.01	8	1	1	1
L01EE04	Selumetinib				1,085				100								
L01EF	Cyclin-dependent kinase (CDK) inhibitors	11,040	14,586	17,321	20,134	0	0	0	0	0.06	0.08	0.09	0.11	0	0	0	0
L01EF01	Palbociclib (DDD 94 mg)	11,002	14,439	15,952	16,544	0	0	0	0	0.06	0.08	0.09	0.09	0	0	0	0
L01EF02	Ribociclib (DDD 0.45 g)	38	76	103	863	0	0	0	0	0.00	0.00	0.00	0.01				
L01EF03	Abemaciclib (DDD 0.30 g)		72	1,266	2,727		0	0	0		0.00	0.01	0.01			0	1

Table continued



ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
L01EG	Mammalian target of rapamycin (mTOR) kinase inhibitors	1,613	1,609	1,495	1,211	9	8	2	3	0.01	0.01	0.01	0.01	8	9	2	3
L01EG01	Temsirolimus (DDD 3.57 mg)	59	61	25	12	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100
L01EG02	Everolimus (DDD 10 mg)	1,554	1,548	1,469	1,199	5	5	1	2	0.01	0.01	0.01	0.01	5	5	1	3
L01EH	Human epidermal growth factor receptor 2 (HER2) tyrosine kinase inhibitors	541	436	477	564	0	3	9	8	0.00	0.00	0.00	0.00	0	3	6	10
L01EH01	Lapatinib (DDD 1.25 g)	541	436	417	368	0	3	1	11	0.00	0.00	0.00	0.00	0	3	1	11
L01EH02	Neratinib (DDD 0.24 g)			60	60			69	13			0.00	0.00			69	13
L01EH03	Tucatinib (DDD 0.60 g)				136				0				0.00				
L01EJ	Janus-associated kinase (JAK) inhibitors	4,720	5,631	6,561	7,046	17	17	21	21	0.02	0.03	0.03	0.03	14	15	18	19
L01EJ01	Ruxolitinib (DDD 30 mg)	4,720	5,631	6,561	7,046	17	17	21	21	0.02	0.03	0.03	0.03	14	15	18	19
L01EK	Vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors	1,102	911	970	1,075	0	0	0	0	0.00	0.00	0.00	0.00		0	0	
L01EK01	Axitinib (DDD 10 mg)	1,102	911	970	1,075	0	0	0	0	0.00	0.00	0.00	0.00		0	0	
L01EL	Bruton's tyrosine kinase (BTK) inhibitors	10,349	12,908	14,833	16,058	1	1	1	1	0.03	0.04	0.04	0.05	1	1	1	1
L01EL01	Ibrutinib (DDD 0.42 g)	10,349	12,908	14,833	15,975	1	1	1	1	0.03	0.04	0.04	0.05	1	1	1	1
L01EL02	Acalabrutinib (DDD 0.20 g)				83				6				0.00				6
L01EM	Phosphatidylinositol-3-kinase (Pi3K) inhibitors	1,490	1,024	821	383	2	1	10	5	0.01	0.00	0.00	0.00	2	1	8	6
L01EM01	Idelalisib (DDD 0.30 g)	1,490	1,024	729	373	2	1	1	2	0.01	0.00	0.00	0.00	2	1	1	2
L01EM03	Alpelisib (DDD 0.30 g)			92	11			79	100			0.00	0.00			73	100
L01EN	Fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitors				178				0				0.00				
L01EN02	Pemigatinib (DDD 9 mg)				178				0				0.00				

Table continued



ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
L01EX	Other protein kinase inhibitors	22,859	24,947	27,149	28,108	7	6	6	8	0.09	0.09	0.10	0.11	4	3	4	4
L01EX01	Sunitinib (DDD 33 mg)	5,547	3,792	3,203	982	1	1	2	4	0.03	0.02	0.02	0.02	1	1	2	2
L01EX02	Sorafenib (DDD 0.80 g)	1,882	1,880	1,578	934	15	14	13	22	0.01	0.01	0.01	0.01	14	14	13	12
L01EX03	Pazopanib (DDD 0.80 g)	2,411	2,045	1,613	1,604	2	2	2	2	0.01	0.01	0.01	0.01	2	2	2	2
L01EX04	Vandetanib (DDD 0.30 g)	108	30	44	59	100	100	67	100	0.00	0.00	0.00	0.00	100	100	67	100
L01EX05	Regorafenib (DDD 0.12 g)	1,145	926	708	1,050	1	0	2	7	0.01	0.01	0.00	0.01	1	0	2	7
L01EX07	Cabozantinib (DDD 60 mg)	6,350	8,588	10,078	11,071	4	2	2	1	0.01	0.02	0.02	0.02	4	1	3	2
L01EX08	Lenvatinib (DDD 18 mg)	543	1,106	1,667	1,711	3	4	0	3	0.00	0.00	0.01	0.01	3	5	0	4
L01EX09	Nintedanib (DDD 0.38 g)	3,841	4,562	5,298	6,927	1	1	1	1	0.02	0.03	0.03	0.04	1	1	1	1
L01EX10	Midostaurin (DDD 0.10 g)	1,031	1,813	1,723	2,414	77	44	53	60	0.00	0.00	0.00	0.00	76	44	53	60
L01EX12	Larotrectinib (DDD 0.20 g)		86	253	349		85	4	1		0.00	0.00	0.00		85	4	1
L01EX13	Gilteritinib (DDD 0.12 g)		119	952	576		14	11	6		0.00	0.00	0.00		14	11	6
L01EX14	Entrectinib (DDD 0.60 g)				176				4				0.00				4
L01EX22	Selpercatinib (DDD 0.32 g)			32	255			100	83			0.00	0.00			100	80
L01F	Monoclonal antibodies and antibody drug conjugates	153,457	162,695	188,799	179,926	100	100	100	199								
L01FA	Cd20 (Clusters of Differentiation 20) inhibitors	37,411	30,374	34,449	32,886	100	100	100	100								
L01FA01	Rituximab	35,693	28,912	32,063	29,663	100	100	100	100								
L01FA02	Ofatumumab	13				100											
L01FA03	Obinutuzumab	1,705	1,461	2,386	3,223	100	100	100	100								

Table continued



ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
L01FB	Cd22 (Clusters of Differentiation 22) inhibitors	309	399	229	140	100	100	100	100								
L01FB01	Inotuzumab ozogamicin	309	399	229	140	100	100	100	100								
L01FC	Cd38 (Clusters of Differentiation 38) inhibitors	5,670	6,187	11,053	18,057	100	100	100	94								
L01FC01	Daratumumab	5,670	6,187	10,535	14,362	100	100	100	92								
L01FC02	Isatuximab			518	3,695			100	100								
L01FD	Her2 (Human Epidermal Growth Factor Receptor 2) inhibitors	43,521	48,908	43,841	32,951	100	100	100	100								
L01FD01	Trastuzumab	27,840	30,979	27,361	19,480	100	100	100	100								
L01FD02	Pertuzumab	10,894	12,253	9,934	3,519	100	100	100	100								
L01FD03	Trastuzumab emtansine	4,787	5,676	6,396	7,260	100	100	100	100								
L01FD04	Trastuzumab deruxtecan			151	2,693			100	99								
L01FE	Egfr (Epidermal Growth Factor Receptor) inhibitors	7,667	6,879	7,053	8,491	100	100	100	100								
L01FE01	Cetuximab	3,053	2,104	2,143	2,949	100	100	100	100								
L01FE02	Panitumumab	4,613	4,775	4,910	5,542	100	100	100	100								
L01FF	Pd-1/pdL-1 (Programmed cell death protein 1/death ligand 1) inhibitors	28,765	39,612	54,923	61,593	100	100	100	100								
L01FF01	Nivolumab	10,989	12,347	15,351	16,926	100	100	100	100								
L01FF02	Pembrolizumab	14,753	22,396	33,503	36,498	100	100	100	100								
L01FF03	Durvalumab	346	863	1,622	1,680	100	100	99	100								
L01FF04	Avelumab	63	2	219	881	100	0	100	100								
L01FF05	Atezolizumab	2,591	3,894	4,094	3,784	100	100	100	100								
L01FF06	Cemiplimab	23	109	121	754	100	100	100	100								
L01FF07	Dostarlimab			14	1,070			100	100								

Table continued



ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
L01FG	Vegf/vegfr (Vascular Endothelial Growth Factor) inhibitors	25,763	26,535	30,352	18,428	100	100	100	100								
L01FG01	Bevacizumab	25,352	25,984	29,801	18,027	100	100	100	100								
L01FG02	Ramucirumab	411	551	551	402	100	100	100	100								
L01FX	Other monoclonal antibodies and antibody drug conjugates	4,352	3,801	6,899	7,340	100	100	100	100								
L01FX02	Gemtuzumab ozogamicin	101	137	43	87	100	100	100	100								
L01FX04	Ipilimumab	840	1,240	2,328	3,242	100	100	100	100								
L01FX05	Brentuximab vedotin	1,063	1,160	1,926	1,524	100	100	100	100								
L01FX07	Blinatumomab	2,050	1,156	1,652	1,188	100	100	100	100								
L01FX08	Elotuzumab	199	42	125	82	100	100	100	100								
L01FX09	Mogamulizumab			33					100								
L01FX10	Olaratumab	99				100											
L01FX12	Tafasitamab				61												
L01FX13	Enfortumab vedotin				10												
L01FX14	Polatuzumab vedotin		66	792	651		100	100	99								
L01FX17	Sacituzumab govitecan				439				100								
L01FX18	Amivantamab				56				100								
L01X	Other antineoplastic agents	30,446	34,189	51,279	64,112	77	67	60	64								
L01XA	Platinum compounds	1,086	1,317	1,313	1,480	100	100	100	100								
L01XA01	Cisplatin	249	273	254	241	100	100	100	100								
L01XA02	Carboplatin	334	467	501	488	100	100	100	100								
L01XA03	Oxaliplatin	503	577	558	751	100	100	100	100								

Table continued



ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
L01XD	Sensitizers used in photodynamic/radiation therapy	1,005	1,051	947	795	99	99	99	98								
L01XD03	Methyl aminolevulinate	751	820	730	609	99	99	99	98								
L01XD04	Aminolevulinic acid	254	231	217	186	100	100	100	100								
L01XF	Retinoids for cancer treatment	385	391	336	441	100	100	100	100								
L01XF01	Tretinoin	31	32	46	67	100	99	100	100								
L01XF03	Bexarotene	354	359	290	375	100	100	100	100								
L01XG	Proteasome inhibitors	19,761	17,723	17,968	13,761	90	88	84	82								
L01XG01	Bortezomib	10,295	8,001	7,003	1,708	100	100	100	100								
L01XG02	Carfilzomib	7,348	7,531	8,051	9,505	100	100	100	100								
L01XG03	Ixazomib	2,119	2,190	2,914	2,548	5	3	3	2								
L01XJ	Hedgehog pathway inhibitors	293	319	499	412	10	4	3	1								
L01XJ01	Vismodegib	293	319	499	362	10	4	3	1								
L01XJ02	Sonidegib				51				0								
L01XK	Poly (ADP-ribose) polymerase (PARP) inhibitors	1,813	4,683	9,588	9,274	0	0	0	1								
L01XK01	Olaparib	1,513	2,249	3,504	4,950	0	1	1	2								
L01XK02	Niraparib	300	2,433	6,084	4,323	0	0	0	0								
L01XL	Antineoplastic cell and gene therapy	55	347	552	683	100	100	100	100								
L01XL02	Talimogene laherparepvec	55	347	552	683	100	100	100	100								

Table continued



ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
L01XX	Other antineoplastic agents	5,835	7,992	12,094	16,468	51	50	39	33								
L01XX01	Amsacrine				14				100								
L01XX05	Hydroxycarbamide	493	533	476	452	2	2	2	2								
L01XX11	Estramustine	3	1	1		8	19	13									
L01XX23	Mitotane	178	197	196	252	5	4	6	9								
L01XX24	Pegaspargase	486	622	486	489	96	100	100	100								
L01XX27	Arsenic trioxide	341	298	357	487	100	100	100	100								
L01XX35	Anagrelide	395	351	221	135	1	1	1	1								
L01XX41	Eribulin	1,078	1,358	1,612	1,535	99	100	100	100								
L01XX44	Aflibercept	380	295	350	434	100	100	100	100								
L01XX52	Venetoclax	2,482	4,338	8,394	11,972	28	32	22	15								
L01XX73	Sotorasib				699				98								
L01XY	Combinations of antineoplastic agents	213	366	7,982	20,798	100	100	100	100								
L01XY01	Cytarabine and daunorubicin	213	366	284	519	100	100	100	100								
L01XY02	Pertuzumab and trastuzumab			7,698	20,279			100	100								

**L02 Endocrine therapy**

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
L02	Endocrine therapy	65,173	70,383	72,991	77,226	3	2	2	2	7.87	7.75	7.78	7.94	3	3	3	3
L02A	Hormones and related agents	12,182	12,168	11,772	12,232	5	5	4	4	1.81	1.85	1.90	1.95	5	4	4	4
L02AB	Progestogens	94	89	92	96	6	8	9	5	0.01	0.01	0.01	0.01	6	8	9	5
L02AB02	Medroxyprogesterone (DDD 1 g)	94	89	92	96	6	8	9	5	0.01	0.01	0.01	0.01	6	8	9	5
L02AE	Gonadotrophin releasing hormone analogues	12,089	12,079	11,680	12,136	5	5	4	4	1.80	1.84	1.88	1.94	5	4	4	4
L02AE01	Buserelin	16				0				0.00							
L02AE02	Leuprorelin	8,835	8,531	7,994	8,169	5	5	5	5	1.32	1.31	1.30	1.30	5	5	5	5
L02AE03	Goserelin (DDD 0.13 mg)	1,342	1,213	991	872	6	4	4	3	0.19	0.18	0.16	0.14	6	4	4	3
L02AE04	Triptorelin	1,896	2,335	2,695	3,096	2	2	1	2	0.28	0.35	0.43	0.50	2	2	1	2
L02B	Hormone antagonists and related agents	52,991	58,215	61,219	64,994	2	2	2	2	6.06	5.90	5.88	5.99	3	3	3	3
L02BA	Anti-estrogens	3,543	3,661	2,032	935	6	6	8	4	1.23	1.20	1.10	1.12	2	2	2	1
L02BA01	Tamoxifen (DDD 20 mg)	549	515	453	492	1	1	1	1	1.06	1.02	0.93	0.94	1	1	1	1
L02BA02	Toremifene (DDD 60 mg)	11	7	8	14	0	0	0	0	0.01	0.00	0.00	0.01			0	
L02BA03	Fulvestrant (DDD 8.30 mg)	2,983	3,138	1,570	429	7	7	10	8	0.17	0.17	0.17	0.17	6	7	5	3
L02BB	Anti-androgens	32,374	34,846	40,221	48,222	1	1	1	1	1.68	1.56	1.48	1.47	2	2	2	3
L02BB01	Flutamide (DDD 0.75 g)	27	16	14	7	5	4	2	3	0.00	0.00	0.00	0.00	5	4	2	3
L02BB03	Bicalutamide (DDD 50 mg)	1,308	1,949	2,676	2,428	2	3	3	6	1.53	1.39	1.29	1.24	2	2	2	3
L02BB04	Enzalutamide (DDD 0.16 g)	31,039	32,729	35,784	36,677	1	1	1	1	0.15	0.16	0.18	0.18	1	1	1	1
L02BB05	Apalutamid (DDD 0.24 g)		114	681	5,982		2	1	0		0.00	0.00	0.03		2	1	0
L02BB06	Darolutamide (DDD 1.20 g)		38	1,065	3,129		0	0	0		0.00	0.01	0.02			0	0

Table continued



ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
L02BG	Aromatase inhibitors	2,758	2,882	2,379	1,804	2	2	2	3	2.83	2.78	2.92	3.01	2	1	1	1
L02BG03	Anastrozole (DDD 1 mg)	330	278	243	199	3	3	3	5	0.29	0.24	0.22	0.21	3	2	1	2
L02BG04	Letrozole (DDD 2.50 mg)	1,983	2,031	1,551	985	1	1	2	2	2.28	2.26	2.40	2.47	1	1	1	1
L02BG06	Exemestane (DDD 25 mg)	445	573	584	620	3	3	2	2	0.26	0.28	0.30	0.33	2	2	2	2
L02BX	Other hormone antagonists and related agents	14,316	16,825	16,587	14,034	4	3	4	4	0.32	0.36	0.39	0.40	21	21	24	24
L02BX02	Degarelix (DDD 2.70 mg)	1,938	2,138	2,162	2,110	19	19	22	23	0.25	0.29	0.32	0.31	25	26	29	30
L02BX03	Abiraterone (DDD 1 g)	12,378	14,688	14,425	11,924	1	1	1	1	0.06	0.07	0.07	0.09	1	1	1	1

**L03 Immunostimulants**

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
L03	Immunostimulants	31,836	31,137	27,498	24,842	13	16	16	18	0.70	0.68	0.66	0.63	5	7	7	8
L03A	Immunostimulants	31,836	31,137	27,498	24,842	13	16	16	18	0.70	0.68	0.66	0.63	5	7	7	8
L03AA	Colony stimulating factors	15,703	16,115	14,053	12,080	16	15	12	12	0.24	0.29	0.31	0.31	15	13	11	12
L03AA02	Filgrastim (DDD 0.35 mg)	2,606	2,704	2,176	1,923	37	33	29	25	0.04	0.04	0.05	0.05	31	25	23	20
L03AA10	Lenograstim (DDD 0.35 mg)	18	29	21		49	23	29		0.00	0.00	0.00		49	23	29	
L03AA13	Pegfilgrastim (DDD 0.30 mg)	9,299	9,916	8,429	8,592	17	15	12	12	0.15	0.18	0.19	0.23	16	14	13	13
L03AA14	Lipegfilgrastim (DDD 0.30 mg)	3,780	3,467	3,427	1,565	1	1	1	1	0.06	0.07	0.07	0.04	1	1	1	1
L03AB	Interferons	8,998	7,863	7,080	6,580	2	8	13	14	0.36	0.29	0.26	0.24	1	3	4	6
L03AB04	Interferon alfa-2a (DDD 2 MU)	669				1				0.03				1			
L03AB05	Interferon alfa-2b (DDD 2 MU)	57				1				0.00				1			
L03AB07	Interferon beta-1a (DDD 4.30 mcg)	5,684	4,793	4,084	3,507	0	0	0	0	0.27	0.22	0.20	0.18	0	0	0	0
L03AB08	Interferon beta-1b (DDD 4 MU)	790	713	482	455	0	0	0	0	0.02	0.02	0.02	0.01		0		
L03AB11	Peginterferon alfa-2a (DDD 26 mcg)	145	607	776	865	97	99	99	99	0.00	0.01	0.01	0.01	97	99	99	99
L03AB13	Peginterferon beta-1a (DDD 8.90 mcg)	1,653	1,712	1,621	1,671	0	0	0	0	0.03	0.04	0.04	0.04		0	0	0
L03AB15	Ropeginterferon alfa-2b		37	117	83		100	100	100								
L03AX	Other immunostimulants	7,135	7,159	6,365	6,181	20	27	29	33	0.10	0.10	0.09	0.08	0	0	0	0
L03AX03	Bcg vaccine (DDD 1.80 mg)	627	918	977	1,218	100	100	100	100								
L03AX13	Glatiramer acetate (DDD 20 mg)	5,684	5,213	4,508	4,152	0	0	0	0	0.10	0.10	0.09	0.08	0	0	0	0
L03AX16	Plerixafor (DDD 16.80 mg)	824	1,028	880	812	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100

**L04 Immunosuppressants**

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
L04	Immunosuppressants	377,594	383,439	413,122	402,192	32	30	31	31	14.88	15.76	17.09	18.14	16	17	17	16
L04A	Immunosuppressants	377,594	383,439	413,122	402,192	32	30	31	31	14.88	15.76	17.09	18.14	16	17	17	16
L04AA	Selective immunosuppressants	82,246	89,486	100,388	106,664	44	44	46	48	1.88	2.04	2.17	2.30	18	19	19	19
L04AA04	Antithymocyte immunoglobulin (DDD 0.10 g)	166	104	148	86	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100
L04AA06	Mycophenolic acid (DDD 2 g)	4,743	4,839	4,847	4,610	5	4	5	4	0.47	0.49	0.50	0.51	3	3	3	2
L04AA10	Sirolimus (DDD 3 mg)	191	193	255	265	16	15	16	11	0.01	0.01	0.01	0.01	16	15	16	11
L04AA13	Leflunomide (DDD 20 mg)	416	611	632	590	2	1	2	1	0.54	0.56	0.53	0.52	2	1	2	1
L04AA18	Everolimus (DDD 1.50 mg)	157	172	149	206	97	97	97	75	0.00	0.00	0.00	0.01	97	97	97	59
L04AA23	Natalizumab (DDD 10 mg)	7,444	7,027	7,902	8,366	100	100	100	100	0.05	0.05	0.05	0.05	100	100	100	100
L04AA24	Abatacept (DDD 27 mg)	7,430	7,512	8,065	7,497	37	34	32	31	0.08	0.09	0.10	0.09	41	36	33	32
L04AA25	Eculizumab (DDD 64 mg)			557	1,302			100	100			0.00	0.00			100	100
L04AA26	Belimumab (DDD 25 mg)	412	478	562	557	100	100	100	100	0.01	0.01	0.01	0.01	100	100	100	100
L04AA27	Fingolimod (DDD 0.50 mg)	13,974	12,807	11,654	5,694	0	0	0	0	0.13	0.12	0.12	0.07	0	0	0	0
L04AA28	Belatacept (DDD 12.50 mg)		5				100				0.00				100		
L04AA29	Tofacitinib (DDD 10 mg)	5,226	5,574	6,438	7,182	4	1	2	3	0.09	0.10	0.13	0.15	4	1	2	4
L04AA31	Teriflunomide (DDD 14 mg)	7,417	7,721	7,699	7,539	0	0	0	0	0.13	0.15	0.15	0.15	0	0	0	0
L04AA32	Apremilast (DDD 60 mg)	2,847	3,601	3,660	3,943	0	0	1	1	0.06	0.07	0.08	0.09	0	0	1	1
L04AA33	Vedolizumab (DDD 5.40 mg)	19,173	20,271	22,508	24,532	100	100	93	78	0.18	0.21	0.26	0.33	100	100	85	60
L04AA34	Alemtuzumab (DDD 0.13 mg)	427	83	69		100	100	100		0.00	0.00	0.00		100	100	100	
L04AA36	Ocrelizumab (DDD 3.29 mg)	5,118	8,537	11,186	13,193	100	100	100	100	0.04	0.06	0.08	0.10	100	100	100	100
L04AA37	Baricitinib (DDD 4 mg)	4,049	4,477	4,154	4,328	1	1	1	1	0.07	0.07	0.07	0.08	1	1	1	1

Table continued



ATC classification	Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day								
	2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022					
L04AA40	Cladribine (DDD 0.34 mg)				3,057	5,240	6,396	7,342	0	0	0	0	0.02	0.04	0.05	0.05	0				
L04AA43	Ravulizumab (DDD 58.90 mg)						1,721	5,341			100	100			0.00	0.00	100	100			
L04AA44	Upadacitinib (DDD 15 mg)					235	1,751	3,221		0	0	0		0.00	0.03	0.06		0	0		
L04AA45	Filgotinib (DDD 0.20 g)						14	265				1			0.00	0.01			1		
L04AA50	Ponesimod (DDD 20 mg)							94				0				0.00					
L04AA51	Anifrolumab							2				100									
L04AA52	Ofatumumab (DDD 0.67 mg)						20	509			100	0			0.00	0.01			100		
L04AB	Tumor necrosis factor alpha (TNF-a) inhibitors				177,797	163,610	161,533	159,251	43	39	40	37	3.85	4.20	4.68	5.12	45	47	46	39	
L04AB01	Etanercept (DDD 7 mg)				23,508	24,182	22,092	20,121	0	0	0	0	0.53	0.55	0.58	0.59	0	0	0	0	
L04AB02	Infliximab (DDD 3.75 mg)				75,481	63,663	64,429	65,825	100	100	100	89	1.70	1.94	2.14	2.44	100	100	99	81	
L04AB04	Adalimumab (DDD 2.90 mg)				50,241	47,071	44,756	45,007	1	1	1	1	1.00	1.07	1.22	1.36	1	1	1	1	
L04AB05	Certolizumab pegol (DDD 14 mg)				6,895	6,606	6,523	6,796	1	0	0	0	0.13	0.12	0.13	0.14	1	0	0	0	
L04AB06	Golimumab (DDD 1.66 mg)				21,672	22,088	23,732	21,502	1	1	1	1	0.50	0.53	0.61	0.58	1	1	1	1	
L04AC	Interleukin inhibitors				40,641	48,846	62,048	72,250	19	18	21	17	0.82	1.04	1.39	1.67	20	22	23	19	
L04AC02	Basiliximab (DDD 40 mg)				349	386	513	489	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100	
L04AC03	Anakinra (DDD 0.10 g)				465	539	587	604	9	9	12	14	0.01	0.01	0.01	0.01	9	9	12	14	
L04AC05	Ustekinumab (DDD 0.54 mg)				13,522	17,729	22,212	26,993	18	24	25	23	0.40	0.56	0.74	0.92	24	31	29	26	
L04AC07	Tocilizumab (DDD 20 mg)				9,065	7,892	10,710	9,327	54	47	59	47	0.15	0.14	0.18	0.17	47	38	49	36	
L04AC08	Canakinumab (DDD 2.70 mg)					156	312	826			100	100			0.00	0.00	0.00		100	100	100

Table continued



ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
L04AC10	Secukinumab (DDD 10 mg)	9,863	9,749	9,883	10,166	0	0	0	0	0.15	0.15	0.16	0.16	0	0	0	0
L04AC11	Siltuximab (DDD 37 mg)	3		38	155	100		100	100	0.00		0.00	0.00	100		100	100
L04AC12	Brodalumab (DDD 15 mg)	134	205	262	385	0	0	0	0	0.00	0.00	0.00	0.01				
L04AC13	Ixekizumab (DDD 2.90 mg)	3,785	4,870	6,710	7,616	0	1	0	0	0.06	0.08	0.11	0.13	0	1	0	0
L04AC14	Sarilumab (DDD 14.30 mg)	731	1,081	1,639	1,941	0	0	6	2	0.01	0.02	0.03	0.03			6	2
L04AC16	Guselkumab (DDD 1.79 mg)	2,715	4,655	5,914	7,181	0	0	0	0	0.04	0.07	0.09	0.12		0	0	0
L04AC18	Risankizumab (DDD 1.67 mg)	8	1,584	3,237	6,467	0	0	0	0	0.00	0.03	0.06	0.11			0	0
L04AC19	Satralizumab			31	78			100	100								
L04AC21	Bimekizumab (DDD 5.70 mg)				21				0				0.00				
L04AD	Calcineurin inhibitors	12,122	11,798	11,371	10,349	5	5	5	5	0.78	0.79	0.79	0.79	5	4	4	5
L04AD01	Ciclosporin (DDD 0.25 g)	4,744	4,418	3,899	3,320	4	4	3	4	0.39	0.36	0.33	0.30	4	4	3	3
L04AD02	Tacrolimus (DDD 5 mg)	7,378	7,380	7,472	7,029	6	5	6	5	0.39	0.42	0.46	0.48	6	5	5	5
L04AX	Other immunosuppressants	64,788	69,698	77,783	53,678	2	2	2	2	7.56	7.69	8.04	8.26	1	1	1	1
L04AX01	Azathioprine (DDD 0.15 g)	861	919	1,018	1,006	1	0	1	0	1.17	1.22	1.36	1.34	1	0	1	0
L04AX02	Thalidomide (DDD 0.10 g)	78	72	71	17	39	25	15	30	0.00	0.00	0.00	0.00	39	25	15	30
L04AX03	Methotrexate (DDD 2.50 mg)	8,337	9,582	10,317	11,169	0	0	0	0	6.04	6.09	6.25	6.46	1	1	1	1
L04AX04	Lenalidomide (DDD 10 mg)	30,185	31,671	35,168	10,888	4	3	4	5	0.10	0.10	0.11	0.15	3	3	4	3
L04AX05	Pirfenidone (DDD 2.40 g)	5,643	6,083	6,100	5,891	1	1	1	1	0.04	0.04	0.04	0.04	1	1	1	1
L04AX06	Pomalidomide (DDD 3 mg)	6,451	8,259	10,598	13,128	4	1	2	1	0.01	0.01	0.02	0.02	3	1	2	1
L04AX07	Dimethyl fumarate (DDD 0.48 g)	13,233	13,112	14,511	11,552	0	0	0	0	0.20	0.22	0.26	0.23	0	0	0	0
L04AX09	Diroximel fumarate (DDD 0.92 g)				27				3				0.00				3



M Musculo-skeletal system

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
M	Musculo-skeletal system	102,349	97,706	99,580	113,008	22	20	20	23	101.80	98.58	99.85	105.71	2	2	2	2
M01	Antiinflammatory and antirheumatic products	46,056	42,895	42,294	45,715	2	2	2	1	80.89	77.43	78.32	83.85	1	1	1	1
M02	Topical products for joint and muscular pain	12,952	14,131	14,572	13,391	1	1	1	1								
M03	Muscle relaxants	15,236	14,648	15,953	17,151	64	62	59	56	5.26	5.14	5.09	4.89	3	2	2	2
M04	Antigout preparations	1,940	1,791	1,490	1,566	2	2	2	3	4.19	4.46	4.46	4.65	2	2	2	2
M05	Drugs for treatment of bone diseases	16,516	16,915	18,001	20,007	12	15	14	16	11.41	11.52	11.97	12.31	5	5	4	5
M09	Other drugs for disorders of the musculo-skeletal system	9,650	7,325	7,270	15,178	98	98	99	83	0.05	0.02	0.02	0.01	72	42	53	79

**M01 Antiinflammatory and antirheumatic products**

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
M01	Antiinflammatory and antirheumatic products	46,056	42,895	42,294	45,715	2	2	2	1	80.89	77.43	78.32	83.85	1	1	1	1
M01A	Antiinflammatory and antirheumatic products, non-steroids	45,917	42,686	42,058	45,440	2	2	2	1	80.84	77.43	78.32	83.85	1	1	1	1
M01AB	Acetic acid derivatives and related substances	2,246	2,120	2,012	1,944	6	6	6	5	3.93	3.75	3.58	3.38	2	2	2	2
M01AB01	Indometacin (DDD 0.10 g)	128	138	122	106	1	1	1	1	0.17	0.18	0.15	0.13	1	1	1	0
M01AB05	Diclofenac (DDD 0.10 g)	1,982	1,862	1,781	1,744	5	4	4	4	3.68	3.51	3.37	3.20	2	2	2	2
M01AB15	Ketorolac (DDD 30 mg)	53	49	49	38	82	84	84	78	0.02	0.02	0.02	0.01	82	84	85	83
M01AB55	Diclofenac, combinations (DDD 2 ED)	83	71	61	55	1	0	0	0	0.06	0.05	0.05	0.04	1	0	0	0
M01AC	Oxicams	363	336	285	261	1	1	1	2	1.11	1.02	0.93	0.81	1	1	1	1
M01AC06	Meloxicam (DDD 15 mg)	363	336	285	261	1	1	1	2	1.11	1.02	0.93	0.81	1	1	1	1
M01AE	Propionic acid derivatives	34,732	32,547	32,690	36,541	1	1	1	1	61.53	58.18	58.63	64.26	1	1	1	1
M01AE01	Ibuprofen (DDD 1.20 g)	30,661	28,990	29,338	32,923	1	1	1	1	52.78	49.97	50.86	56.02	1	1	1	1
M01AE02	Naproxen (DDD 0.50 g)	1,649	1,405	1,433	1,645	2	2	2	1	5.95	5.59	5.32	5.81	2	2	1	1
M01AE03	Ketoprofen (DDD 0.15 g)	462	421	391	387	1	0	0	0	0.67	0.60	0.55	0.52	1	1	1	1
M01AE17	Dexketoprofen (DDD 75 mg)	201	162	172	140	84	82	81	76	0.05	0.05	0.06	0.06	76	63	63	63
M01AE51	Ibuprofen, combinations (DDD 3 ED)	867	691	456	574	0	0	0	0	0.56	0.46	0.31	0.38				
M01AE52	Naproxen and esomeprazole (DDD 0.50 g)	892	878	901	873	0	0	0	0	1.52	1.49	1.53	1.48	0	0	0	0
M01AG	Fenamates	90	81	70	34	0	0	0	0	0.21	0.19	0.16	0.08	0	0	0	0
M01AG01	Mefenamic acid (DDD 1 g)	15	13	3		1	1	1		0.03	0.03	0.01		1	0	1	
M01AG02	Tolfenamic acid (DDD 0.30 g)	75	68	67	34	0	0	0	0	0.18	0.16	0.16	0.08	0	0	0	0

Table continued



ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
M01AH	Coxibs	3,743	3,238	2,651	2,423	3	3	3	3	10.72	11.43	12.24	12.78	1	1	1	1
M01AH01	Celecoxib (DDD 0.20 g)	214	178	155	130	2	2	2	2	0.65	0.61	0.61	0.59	3	3	3	3
M01AH04	Parecoxib (DDD 40 mg)	50	51	53	45	98	99	98	96	0.00	0.00	0.00	0.00	98	99	98	97
M01AH05	Etoricoxib (DDD 60 mg)	3,480	3,008	2,442	2,247	2	1	1	1	10.07	10.82	11.63	12.19	1	1	1	1
M01AX	Other antiinflammatory and antirheumatic agents, non-steroids	4,743	4,364	4,350	4,238	1	0	0	0	3.34	2.86	2.77	2.55	1	1	1	1
M01AX01	Nabumetone (DDD 1 g)	14	8	1		1	1	3		0.03	0.02	0.00		1	1	3	
M01AX05	Glucosamine (DDD 1.50 g)	2,048	1,788	1,758	1,631	1	0	1	1	3.31	2.85	2.76	2.55	1	1	1	1
M01AX25	Chondroitin sulfate	2,681	2,568	2,591	2,607	0	0	0	0								
M01C	Specific antirheumatic agents	139	209	236	276	0	0	0	0	0.05				1			
M01CB	Gold preparations	33				1				0.05				1			
M01CB01	Sodium aurothiomalate (DDD 2.40 mg)	33				1				0.05				1			
M01CX	Other specific antirheumatic agents	210	418	472	552	1	0	0	0								



M02 Topical products for joint and muscular pain

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
M02	Topical products for joint and muscular pain	12,952	14,131	14,572	13,391	1	1	1	1								
M02A	Topical products for joint and muscular pain	12,952	14,131	14,572	13,391	1	1	1	1								
M02AA	Antiinflammatory preparations, non-steroids for topical use	12,045	13,258	13,762	12,891	1	1	1	1								
M02AA07	Piroxicam	864	880	846	776	3	2	1	1								
M02AA10	Ketoprofen	98	96	96	91	25	23	24	20								
M02AA13	Ibuprofen	1,116	760	1,039	882	0	0	0	2								
M02AA15	Diclofenac	9,968	11,522	11,782	11,142	0	0	0	0								
M02AC	Preparations with salicylic acid derivatives	1,813	1,747	1,619	1,001	11	9	10	12								

**M03 Muscle relaxants**

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
M03	Muscle relaxants	15,236	14,648	15,953	17,151	64	62	59	56	5.26	5.14	5.09	4.89	3	2	2	2
M03A	Muscle relaxants, peripherally acting agents	10,167	9,751	10,726	11,795	79	76	72	69								
M03AB	Choline derivatives	500	639	561	531	99	99	99	99								
M03AB01	Suxamethonium	500	639	561	531	99	99	99	99								
M03AC	Other quaternary ammonium compounds	1,860	1,083	847	1,359	99	99	98	99								
M03AC09	Rocuronium bromide	1,759	914	726	1,278	99	99	98	99								
M03AC10	Mivacurium chloride	22	14	15	13	89	87	83	71								
M03AC11	Cisatracurium	80	154	105	68	100	100	100	100								
M03AX	Other muscle relaxants, peripherally acting agents	7,807	8,029	9,318	9,905	73	72	69	63								
M03AX01	Botulinum toxin	7,807	8,029	9,318	9,905	73	72	69	63								
M03B	Muscle relaxants, centrally acting agents	5,068	4,897	5,227	5,356	33	32	31	29	5.26	5.14	5.09	4.89	3	2	2	2
M03BC	Ethers, chemically close to antihistamines	1,244	1,143	1,461	1,704	39	37	28	22	2.82	2.76	2.75	2.61	1	1	1	1
M03BC01	Orphenadrine (citrate) (DDD 0.12 g)	1,097	1,025	1,295	1,499	44	42	31	25	2.51	2.52	2.52	2.41	2	1	1	1
M03BC51	Orphenadrine, combinations (DDD 4 ED)	147	117	166	205	0	0	0	0	0.31	0.24	0.22	0.20	0	0	0	0
M03BX	Other centrally acting agents	3,825	3,755	3,766	3,652	31	31	33	32	2.43	2.39	2.34	2.28	4	3	3	3
M03BX01	Baclofen	1,652	1,617	1,716	1,640	68	69	70	69	0.54	0.53	0.55	0.55	11	9	9	9
M03BX02	Tizanidine (DDD 12 mg)	2,172	2,137	2,050	2,012	2	2	1	1	1.89	1.86	1.78	1.74	2	1	1	1



M04 Antigout preparations

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
M04	Antigout preparations	1,940	1,791	1,490	1,566	2	2	2	3	4.19	4.46	4.46	4.65	2	2	2	2
M04A	Antigout preparations	1,940	1,791	1,490	1,566	2	2	2	3	4.19	4.46	4.46	4.65	2	2	2	2
M04AA	Preparations inhibiting uric acid production	1,897	1,739	1,474	1,496	2	2	2	2	4.18	4.44	4.45	4.62	2	2	2	2
M04AA01	Allopurinol (DDD 0.40 g)	1,567	1,493	1,208	1,215	2	2	2	2	3.92	4.15	4.12	4.28	2	2	2	1
M04AA03	Febuxostat (DDD 80 mg)	330	246	266	281	3	3	3	4	0.26	0.29	0.32	0.34	3	3	3	4
M04AC	Preparations with no effect on uric acid metabolism	43	52	16	70	17	11	22	14	0.02	0.02	0.01	0.03	17	11	22	14
M04AC01	Colchicine (DDD 1 mg)	43	52	16	70	17	11	22	14	0.02	0.02	0.01	0.03	17	11	22	14

**M05 Drugs for treatment of bone diseases**

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
M05	Drugs for treatment of bone diseases	16,516	16,915	18,001	20,007	12	15	14	16	11.41	11.52	11.97	12.31	5	5	4	5
M05B	Drugs affecting bone structure and mineralization	16,516	16,915	18,001	20,007	12	15	14	16	11.41	11.52	11.97	12.31	5	5	4	5
M05BA	Bisphosphonates	2,709	3,199	2,870	3,273	41	54	57	72	3.41	3.26	3.17	3.11	2	2	2	5
M05BA02	Clodronic acid	126	86	78	35	2	2	2	1	0.01	0.01	0.01	0.00	2	1	1	1
M05BA03	Pamidronic acid (DDD 60 mg)	51	43	42	40	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100
M05BA04	Alendronic acid (DDD 10 mg)	953	895	700	466	2	2	1	1	2.31	2.27	2.28	2.20	2	2	1	1
M05BA06	Ibandronic acid	204	168	138	122	6	3	2	2	0.48	0.43	0.38	0.35	2	2	2	2
M05BA07	Risedronic acid (DDD 5 mg)	355	335	317	291	3	3	3	3	0.59	0.54	0.49	0.44	3	3	2	3
M05BA08	Zoledronic acid (DDD 4 mg)	1,020	1,672	1,596	2,320	99	99	99	100	0.00	0.00	0.01	0.12	99	99	99	99
M05BB	Bisphosphonates, combinations	139	121	110	100	1	1	1	1	0.23	0.20	0.18	0.17	1	1	1	1
M05BB03	Alendronic acid and colecalciferol (DDD 10 mg)	139	121	110	100	1	1	1	1	0.23	0.20	0.18	0.17	1	1	1	1
M05BC	Bone morphogenetic proteins	55	46	67	34	100	100	100	100								
M05BC01	Dibotermin alfa	55	46	67	34	100	100	100	100								
M05BX	Other drugs affecting mineralization	13,613	13,550	14,953	16,600	6	6	5	5	7.77	8.06	8.62	9.04	6	6	5	5
M05BX04	Denosumab (DDD 0.33 mg)	13,613	13,550	14,398	14,895	6	6	5	5	7.77	8.06	8.62	9.04	6	6	5	5
M05BX05	Burosumab (DDD 2.50 mg)			555	1,706			2	4								

**M09 Other drugs for disorders of the musculo-skeletal system**

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
M09	Other drugs for disorders of the musculo-skeletal system	9,650	7,325	7,270	15,178	98	98	99	83	0.05	0.02	0.02	0.01	72	42	53	79
M09A	Other drugs for disorders of the musculo-skeletal system	9,650	7,325	7,270	15,178	98	98	99	83	0.05	0.02	0.02	0.01	72	42	53	79
M09AB	Enzymes	1,230	9			96	100			0.00	0.00			96	100		
M09AB02	Collagenase clostridium histolyticum (DDD 0.90 mg)	1,230	9			96	100			0.00	0.00			96	100		
M09AX	Other drugs for disorders of the musculo-skeletal system	8,420	7,316	7,270	15,178	98	98	99	83	0.05	0.02	0.02	0.01	71	42	53	79
M09AX01	Hyaluronic acid (DDD 3.60 mg)	420	150	104	17	68	24	32	0	0.05	0.02	0.01	0.00	68	24	32	
M09AX03	Ataluren (DDD 2.80 g)				2,494				0				0.00				
M09AX07	Nusinersen (DDD 0.10 mg)	7,999	7,166	7,166	12,666	100	100	100	100	0.01	0.01	0.01	0.01	100	100	100	100
M09AX07	Nusinerseeni (DDD 0.10 mg)	750	9,416	7,999	7,166	100	100	100	100	0.00	0.01	0.01	0.01	100	100	100	100



N Nervous system

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
N	Nervous system	306,269	320,435	328,013	344,459	16	16	17	17	278.90	288.20	294.15	304.28	4	4	4	4
N01	Anesthetics	18,946	17,422	17,188	16,468	88	88	86	84								
N02	Analgesics	93,152	95,246	93,432	100,518	11	10	10	10	65.72	68.83	68.73	73.49	6	5	5	5
N03	Antiepileptics	34,003	34,844	35,266	34,687	12	10	10	9	14.30	14.49	14.56	14.33	4	4	4	4
N04	Anti-parkinson drugs	17,289	16,860	16,351	15,251	4	4	4	4	5.27	5.06	5.21	5.18	4	4	4	4
N05	Psycholeptics	70,388	72,917	74,063	74,180	14	14	14	14	84.99	86.24	86.92	86.66	5	5	5	5
N06	Psychoanaleptics	53,905	58,436	64,554	70,947	3	3	3	3	101.15	105.63	111.04	117.04	2	2	2	2
N07	Other nervous system drugs	18,586	24,710	27,159	32,407	24	40	51	55	7.48	7.95	7.68	7.59	17	19	22	24

**N01 Anesthetics**

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
N01	Anesthetics	18,946	17,422	17,188	16,468	88	88	86	84								
N01A	Anesthetics, general	9,673	8,496	7,288	5,873	97	96	96	94								
N01AB	Halogenated hydrocarbons	2,622	2,314	1,959	1,722	97	98	97	95								
N01AB06	Isoflurane	11	12	11	14	100	100	88	100								
N01AB07	Desflurane	588	390	285	161	100	100	100	99								
N01AB08	Sevoflurane	2,023	1,912	1,664	1,546	97	97	96	95								
N01AF	Barbiturates, plain	27	50	27	23	99	99	98	98								
N01AF03	Thiopental	27	50	27	23	99	99	98	98								
N01AH	Opioid anesthetics	1,558	1,698	1,783	1,746	95	94	94	94								
N01AH01	Fentanyl	228	225	235	204	98	99	99	98								
N01AH02	Alfentanil	165	138	123	88	92	87	85	86								
N01AH03	Sufentanil	36	30	30	27	100	100	100	100								
N01AH06	Remifentanil	1,128	1,304	1,395	1,427	95	94	94	94								
N01AX	Other general anesthetics	5,466	4,434	3,519	2,381	97	96	95	93								
N01AX03	Ketamine	53	26	47	42	91	89	93	94								
N01AX10	Propofol	4,000	3,319	2,719	1,660	96	96	95	90								
N01AX14	Esketamine	1,413	1,089	753	679	98	99	98	98								

Table continued



ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
N01B	Anesthetics, local	9,273	8,926	9,900	10,595	80	79	79	79								
N01BA	Esters of amino benzoic acid				25				79								
N01BA04	Chloroprocaine				25				79								
N01BB	Amides	8,797	8,467	9,369	10,010	79	79	79	79								
N01BB01	Bupivacaine	747	565	549	477	87	96	98	96								
N01BB02	Lidocaine	1,769	1,757	2,269	3,017	79	77	79	82								
N01BB03	Mepivacaine	5	5	4	5	10	10	13	18								
N01BB04	Prilocaine		1	7	8		82	98	98								
N01BB09	Ropivacaine	1,537	1,546	1,768	1,978	97	97	97	96								
N01BB10	Levobupivacaine	1,010	975	867	395	99	98	96	94								
N01BB20	Combinations	1,097	1,034	1,057	1,155	48	45	44	44								
N01BB51	Bupivacaine, combinations	44	24	37	37	80	92	88	88								
N01BB52	Lidocaine, combinations	1,117	1,214	1,311	1,360	81	81	80	79								
N01BB54	Prilocaine, combinations	118	149	146	154	62	62	60	62								
N01BB58	Articaine, combinations	1,355	1,196	1,355	1,425	68	66	66	68								
N01BX	Other local anesthetics	476	459	531	561	88	83	83	80								
N01BX04	Capsaicin	476	459	531	561	88	83	83	80								

**N02 Analgesics**

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
N02	Analgesics	93,152	95,246	93,432	100,518	11	10	10	10	65.72	68.83	68.73	73.49	6	5	5	5
N02A	Opioids	25,790	24,778	24,028	22,790	25	24	25	26	13.75	13.30	12.95	12.56	9	8	8	8
N02AA	Natural opium alkaloids	10,188	10,337	10,771	11,150	50	49	47	47	2.37	2.36	2.29	2.34	35	35	33	33
N02AA01	Morphine	1,397	1,642	1,385	1,379	87	87	85	84	0.29	0.31	0.26	0.25	90	91	90	87
N02AA03	Hydromorphone	618	544	581	823	71	70	73	83	0.11	0.09	0.10	0.16	63	63	67	83
N02AA05	Oxycodone	5,089	4,955	5,179	5,397	48	45	45	46	1.68	1.68	1.65	1.65	25	24	23	22
N02AA55	Oxycodone and naloxone (DDD 75 mg)	3,083	3,196	3,627	3,552	32	30	32	27	0.29	0.28	0.29	0.27	33	32	31	24
N02AB	Phenylpiperidine derivatives	3,209	3,061	2,996	2,242	21	17	15	16	0.75	0.67	0.62	0.55	17	14	13	12
N02AB03	Fentanyl	3,209	3,061	2,996	2,242	21	17	15	16	0.75	0.67	0.62	0.55	17	14	13	12
N02AE	Oripavine derivatives	5,124	5,084	4,698	4,257	7	7	6	6	1.48	1.48	1.52	1.49	6	5	5	5
N02AE01	Buprenorphine (DDD 1.20 mg)	5,124	5,084	4,698	4,257	7	7	6	6	1.48	1.48	1.52	1.49	6	5	5	5
N02AJ	Opioids in combination with non-opioid analgesics	3,663	3,230	3,024	2,811	1	1	1	1	6.51	6.26	5.97	5.71	1	1	1	1
N02AJ06	Codeine and paracetamol	3,073	2,749	2,522	2,358	1	1	1	1	5.97	5.69	5.41	5.24	2	1	1	1
N02AJ08	Codeine and ibuprofen (DDD 4 ED)	294	265	254	216	0	0	0	0	0.11	0.11	0.10	0.09	0	0	0	0
N02AJ13	Tramadol and paracetamol (DDD 3 ED)	289	208	239	226	1	1	0	1	0.43	0.46	0.46	0.39	1	1	1	0
N02AJ14	Taramadol and dexketoprofen	8	9	9	11	0	0	0	0								
N02AX	Other opioids	3,605	3,066	2,539	2,329	4	4	4	3	2.64	2.54	2.54	2.46	2	2	2	2
N02AX02	Tramadol (DDD 0.30 g)	3,605	3,066	2,539	2,329	4	4	4	3	2.64	2.54	2.54	2.46	2	2	2	2

Table continued



ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
N02B	Other analgesics and antipyretics	47,031	44,568	41,323	47,934	8	8	9	7	49.15	52.39	52.29	57.36	5	4	4	5
N02BA	Salicylic acid and derivatives	1,506	3,388	2,714	4,492	1	0	0	0	1.02	1.33	1.12	1.39	1	0	0	1
N02BA01	Acetylsalicylic acid	997	1,033	966	991	1	1	1	2	0.77	0.73	0.67	0.66	1	1	1	1
N02BA51	Acetylsalicylic acid, combinations excl. psycholeptics	509	2,355	1,749	3,501	0	0	0	0	0.25	0.59	0.45	0.73	0	0	0	0
N02BE	Anilides	26,725	27,940	26,347	31,473	11	10	12	9	39.16	41.29	40.58	44.79	6	5	5	5
N02BE01	Paracetamol (DDD 3 g)	25,861	27,341	25,989	31,105	11	10	12	10	38.87	41.09	40.46	44.67	6	5	5	5
N02BE51	Paracetamol, combinations excl. psycholeptics (DDD 6 ED)	864	600	358	368	0	0	0	0	0.28	0.20	0.13	0.13		0	0	0
N02BF	Gabapentinoids	18,619	13,050	12,014	11,731	4	4	4	4	8.97	9.77	10.58	11.18	3	3	3	3
N02BF01	Gabapentin (DDD 1.80 g)	6,107	6,487	6,773	7,288	4	4	4	4	3.54	4.20	4.69	5.12	4	4	4	4
N02BF02	Pregabalin (DDD 0.30 g)	12,512	6,563	5,241	4,442	4	3	4	4	5.43	5.57	5.89	6.06	3	3	2	2
N02BG	Other analgesics and antipyretics	181	189	247	239	47	52	57	61	0.00	0.00	0.00	0.00	10	17	15	12
N02BG09	Methoxyflurane	75	88	131	138	99	94	95	96								
N02BG10	Cannabinoids (DDD 8 ED)	105	101	116	101	10	17	15	12	0.00	0.00	0.00	0.00	10	17	15	12

Table continued



ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
N02C	Antimigraine preparations	20,332	25,900	28,081	29,794	2	0	0	0	2.82	3.14	3.50	3.57	1	0	0	0
N02CC	Selective 5ht1-receptor agonists	8,056	7,876	7,700	6,841	1	1	1	1	2.40	2.34	2.51	2.43	1	1	1	1
N02CC01	Sumatriptan	4,820	4,717	4,557	3,931	2	1	2	2	1.55	1.46	1.59	1.55	1	1	1	1
N02CC02	Naratriptan (DDD 2.50 mg)	94	79	76	111	0	0	0	0	0.03	0.03	0.03	0.04	0	0	0	0
N02CC03	Zolmitriptan (DDD 2.50 mg)	909	865	793	885	1	1	1	1	0.19	0.19	0.19	0.21	1	1	1	1
N02CC04	Rizatriptan (DDD 10 mg)	669	700	769	753	0	0	0	0	0.14	0.14	0.16	0.15	0	0	0	0
N02CC05	Almotriptan (DDD 12.50 mg)	448	440	502	551	0	0	0	0	0.11	0.11	0.11	0.12	0	0	0	0
N02CC06	Eletriptan (DDD 40 mg)	543	479	419	353	0	0	0	0	0.23	0.24	0.26	0.29	0	0	0	0
N02CC07	Frovatriptan (DDD 2.50 mg)	574	595	583	256	0	0	0	0	0.16	0.17	0.17	0.07	0	0	0	0
N02CD	Calcitonin gene-related peptide (CGRP) antagonists	12,276	18,024	20,381	22,953	3	0	0	0	0.41	0.80	0.98	1.14	3	0	0	0
N02CD01	Erenumab (DDD 2.50 mg)	12,247	13,284	10,209	9,366	3	0	0	0	0.41	0.63	0.62	0.60	3	0	0	0
N02CD02	Galcanezumab (DDD 4 mg)		288	2,633	3,885		0	0	0		0.01	0.10	0.15			0	0
N02CD03	Fremanezumab (DDD 7.50 mg)	29	4,452	7,539	9,645	0	0	0	0	0.00	0.16	0.27	0.38		0	0	0
N02CD05	Eptinezumab				48				98								
N02CD06	Rimegepant (DDD 37.50 mg)				9				0				0.00				

**N03 Antiepileptics**

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
N03	Antiepileptics	34,003	34,844	35,266	34,687	12	10	10	9	14.30	14.49	14.56	14.33	4	4	4	4
N03A	Antiepileptics	34,003	34,844	35,266	34,687	12	10	10	9	14.30	14.49	14.56	14.33	4	4	4	4
N03AB	Hydantoin derivatives	1,046	723	657	579	89	86	86	86	0.17	0.15	0.13	0.11	12	8	9	8
N03AB02	Phenytoin (DDD 0.30 g)	127	107	96	85	8	4	6	5	0.17	0.14	0.13	0.11	8	4	6	5
N03AB05	Fosphenytoin (DDD 0.45 g)	919	616	561	495	100	100	100	100	0.01	0.01	0.00	0.00	100	100	100	100
N03AE	Benzodiazepine derivatives	501	471	434	276	3	2	2	2	0.69	0.64	0.59	0.38	2	2	2	2
N03AE01	Clonazepam (DDD 8 mg)	501	471	434	276	3	2	2	2	0.69	0.64	0.59	0.38	2	2	2	2
N03AF	Carboxamide derivatives	4,942	4,993	4,900	4,905	4	3	2	2	3.62	3.58	3.50	3.42	2	2	2	2
N03AF01	Carbamazepine (DDD 1 g)	1,159	1,097	1,007	961	7	6	3	4	1.32	1.26	1.18	1.11	3	2	2	2
N03AF02	Oxcarbazepine (DDD 1 g)	3,117	3,180	3,165	3,164	3	2	2	2	2.22	2.25	2.23	2.23	2	2	2	2
N03AF03	Rufinamide (DDD 1.40 g)	220	235	251	273	6	5	3	3	0.02	0.02	0.02	0.02	6	5	3	2
N03AF04	Eslicarbazepine (DDD 0.80 g)	447	481	477	507	2	2	1	2	0.06	0.06	0.06	0.07	2	2	1	2
N03AG	Fatty acid derivatives	4,717	4,700	4,552	3,931	10	9	9	9	3.60	3.57	3.50	3.42	6	6	5	5
N03AG01	Valproic acid (DDD 1.50 g)	4,634	4,617	4,474	3,851	10	9	9	9	3.58	3.55	3.48	3.40	6	6	5	5
N03AG04	Vigabatrin (DDD 2 g)	83	83	78	80	9	9	10	15	0.02	0.02	0.02	0.02	9	9	10	15

Table continued



ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
N03AX	Other antiepileptics	22,798	23,958	24,723	24,995	11	10	9	9	6.22	6.55	6.84	7.00	5	4	4	4
N03AX09	Lamotrigine (DDD 0.30 g)	4,749	4,559	4,517	4,511	3	2	2	2	2.23	2.32	2.41	2.44	3	2	2	2
N03AX11	Topiramate (DDD 0.30 g)	1,567	1,504	1,423	1,348	4	4	3	3	0.36	0.36	0.34	0.33	5	5	4	3
N03AX14	Levetiracetam (DDD 1.50 g)	8,623	8,689	8,156	7,691	10	8	9	8	2.70	2.77	2.83	2.85	6	5	5	5
N03AX15	Zonisamide (DDD 0.20 g)	857	833	801	880	3	2	2	2	0.19	0.19	0.19	0.20	3	2	2	2
N03AX17	Stiripentol (DDD 1 g)	319	341	338	331	1	3	2	2	0.01	0.01	0.01	0.01	1	3	2	2
N03AX18	Lacosamide (DDD 0.30 g)	4,839	5,561	6,050	5,655	22	21	19	19	0.52	0.61	0.67	0.71	7	7	5	5
N03AX22	Perampanel (DDD 8 mg)	884	958	1,021	1,138	7	6	7	5	0.08	0.09	0.10	0.11	5	5	5	4
N03AX23	Brivaracetam (DDD 0.10 g)	960	1,513	1,968	2,268	16	14	9	7	0.11	0.20	0.28	0.34	6	5	3	2
N03AX24	Cannabidiol (DDD 0.70 g)			448	1,163			6	6			0.00	0.01			6	6
N03AX25	Cenobamate (DDD 0.20 g)				11				4				0.00				1



N04 Anti-parkinson drugs

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
N04	Anti-parkinson drugs	17,289	16,860	16,351	15,251	4	4	4	4	5.27	5.06	5.21	5.18	4	4	4	4
N04A	Anticholinergic agents	94	91	87	84	4	5	5	5	0.17	0.16	0.16	0.15	4	5	5	5
N04AA	Tertiary amines	94	91	87	84	4	5	5	5	0.17	0.16	0.16	0.15	4	5	5	5
N04AA02	Biperiden (DDD 10 mg)	94	91	87	84	4	5	5	5	0.17	0.16	0.16	0.15	4	5	5	5
N04B	Dopaminergic agents	17,195	16,770	16,264	15,167	4	4	3	4	5.10	4.90	5.06	5.03	4	4	4	4
N04BA	Dopa and dopa derivatives	13,120	13,127	13,076	12,240	5	4	4	4	2.47	2.31	2.53	2.55	6	5	5	5
N04BA02	Levodopa and decarboxylase inhibitor (DDD 0.60 g)	11,210	10,853	9,853	8,611	5	4	3	4	1.75	1.60	1.84	1.87	6	5	5	4
N04BA03	Levodopa, decarboxylase inhibitor and comt inhibitor (DDD 0.45 g)	1,910	2,274	3,223	3,629	5	5	5	4	0.72	0.71	0.69	0.68	6	5	5	5
N04BC	Dopamine agonists	3,362	2,974	2,524	2,179	3	2	3	2	1.45	1.46	1.43	1.40	2	2	2	2
N04BC01	Bromocriptine (DDD 40 mg)	6	6	0		12	18	27		0.00	0.00	0.00		12	18	27	
N04BC04	Ropinirole (DDD 6 mg)	589	464	331	244	2	2	2	2	0.70	0.68	0.64	0.63	2	2	2	2
N04BC05	Pramipexole (DDD 2.50 mg)	1,802	1,514	1,347	1,209	2	2	2	2	0.64	0.67	0.69	0.68	2	2	2	2
N04BC06	Cabergoline (DDD 3 mg)	71	74	73	78	4	6	6	6	0.01	0.01	0.01	0.01	4	6	6	6
N04BC07	Apomorphine (DDD 20 mg)	329	348	250	157	3	2	3	2	0.01	0.01	0.01	0.01	3	2	3	2
N04BC09	Rotigotine (DDD 6 mg)	566	568	521	490	4	3	3	2	0.08	0.09	0.08	0.07	3	2	3	2
N04BD	Monoamine oxidase type b inhibitors	557	499	459	412	3	3	2	3	1.15	1.10	1.06	1.03	2	3	3	3
N04BD01	Selegiline (DDD 5 mg)	367	341	324	300	2	2	2	3	0.78	0.73	0.71	0.69	2	2	2	3
N04BD02	Rasagiline (DDD 1 mg)	190	158	134	111	5	6	3	3	0.37	0.37	0.35	0.34	3	6	4	4
N04BD03	Safinamide (DDD 75 mg)	0	1	1	1	0	20	0	14	0.00	0.00	0.00	0.00		19		13
N04BX	Other dopaminergic agents	155	169	205	336	9	6	5	4	0.02	0.03	0.03	0.05	9	6	5	4
N04BX02	Entacapone (DDD 1 g)	155	169	174	169	9	6	5	6	0.02	0.03	0.03	0.03	9	6	5	6
N04BX04	Opicapone (DDD 50 mg)			31	167			4	2			0.00	0.03			4	2



N05 Psycholeptics

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
N05	Psycholeptics	70,388	72,917	74,063	74,180	14	14	14	14	84.99	86.24	86.92	86.66	5	5	5	5
N05A	Antipsychotics	50,472	51,762	52,700	52,894	11	11	10	10	22.16	22.94	23.13	23.36	7	7	7	7
N05AA	Phenothiazines with aliphatic side chain	362	347	337	312	6	6	6	6	0.33	0.31	0.28	0.27	6	6	6	6
N05AA02	Levomepromazine	362	347	337	312	6	6	6	6	0.33	0.31	0.28	0.27	6	6	6	6
N05AB	Phenothiazines with piperazine structure	571	568	551	542	5	5	5	5	0.45	0.44	0.42	0.41	5	5	5	5
N05AB03	Perphenazine	551	549	530	520	5	5	5	6	0.43	0.43	0.41	0.40	5	5	5	5
N05AB04	Prochlorperazine	21	19	20	22	2	2	2	1	0.01	0.01	0.01	0.01	2	2	2	1
N05AD	Butyrophenone derivatives	502	499	420	319	49	50	43	29	0.41	0.42	0.39	0.36	23	27	24	23
N05AD01	Haloperidol	346	360	336	319	26	31	29	29	0.39	0.40	0.38	0.36	20	24	22	23
N05AD08	Droperidol (DDD 2.50 mg)	157	139	84		98	97	97		0.02	0.02	0.01		98	97	97	
N05AE	Indole derivatives	1,480	1,551	1,643	1,535	7	7	6	6	0.32	0.33	0.35	0.34	6	6	5	5
N05AE03	Sertindole (DDD 16 mg)	412	387	363	305	6	4	5	5	0.07	0.06	0.06	0.05	5	4	4	5
N05AE04	Ziprasidone	603	592	580	541	4	4	3	3	0.17	0.16	0.16	0.15	3	3	3	3
N05AE05	Lurasidone (DDD 60 mg)	465	572	700	690	13	12	9	8	0.08	0.10	0.13	0.14	12	11	9	8
N05AF	Thioxanthene derivatives	594	579	553	529	12	13	14	14	0.67	0.65	0.60	0.57	8	9	9	10
N05AF01	Flupentixol	70	69	69	72	3	3	3	2	0.06	0.05	0.05	0.05	4	3	2	2
N05AF03	Chlorprothixene	262	247	230	217	4	3	3	4	0.26	0.24	0.22	0.20	4	3	3	3
N05AF05	Zuclopenthixol	263	263	254	240	22	24	27	26	0.36	0.35	0.33	0.32	12	14	14	15

Table continued



ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
N05AH	Diazepines, oxazepines, thiazepines and oxepines	19,820	20,079	20,494	21,021	12	12	11	11	13.92	14.52	14.53	14.56	7	7	6	7
N05AH02	Clozapine (DDD 0.30 g)	3,874	3,884	3,530	3,083	9	9	9	7	2.25	2.36	2.32	2.23	9	9	10	8
N05AH03	Olanzapine (DDD 10 mg)	11,991	12,282	12,562	12,342	16	16	15	16	6.30	6.66	6.70	6.85	9	8	8	9
N05AH04	Quetiapine (DDD 0.40 g)	3,833	3,798	4,294	5,495	3	3	3	3	5.36	5.48	5.50	5.46	4	3	3	3
N05AH05	Asenapine (DDD 20 mg)	122	114	107	101	16	15	13	9	0.02	0.02	0.02	0.02	13	12	10	7
N05AL	Benzamides	100	102	93	91	7	8	7	9	0.04	0.04	0.04	0.04	7	9	7	9
N05AL01	Sulpiride (DDD 0.80 g)	100	102	93	91	7	8	7	9	0.04	0.04	0.04	0.04	7	9	7	9
N05AN	Lithium	615	621	626	617	6	6	6	6	0.98	0.99	0.99	0.98	6	6	6	6
N05AN01	Lithium (DDD 168 mg)	615	621	626	617	6	6	6	6	0.98	0.99	0.99	0.98	6	6	6	6
N05AX	Other antipsychotics	26,426	27,415	27,985	27,928	10	9	9	9	5.04	5.25	5.52	5.83	7	7	7	7
N05AX08	Risperidone	9,332	8,669	7,928	7,266	5	5	5	5	1.83	1.84	1.80	1.76	6	6	6	5
N05AX12	Aripiprazole	7,587	8,269	8,563	8,716	11	10	10	10	2.62	2.75	2.87	3.07	6	6	6	6
N05AX13	Paliperidone	9,436	10,257	10,560	10,460	13	12	11	10	0.58	0.64	0.67	0.70	13	12	11	11
N05AX15	Cariprazine (DDD 3 mg)	61	143	524	837	56	56	22	16	0.01	0.03	0.11	0.19	54	53	25	17
N05AX16	Brexpiprazole (DDD 3 mg)	10	77	410	649	23	23	16	13	0.00	0.01	0.06	0.11	23	24	17	12
N05B	Anxiolytics	5,989	6,916	7,078	6,983	11	25	30	29	16.22	15.48	14.50	14.15	6	6	6	6
N05BA	Benzodiazepine derivatives	4,676	5,588	5,744	5,654	13	30	35	35	14.76	14.03	13.09	12.80	6	6	6	6
N05BA01	Diazepam (DDD 10 mg)	1,411	1,295	1,133	1,070	28	27	22	21	4.30	3.98	3.60	3.61	9	9	8	8
N05BA04	Oxazepam (DDD 50 mg)	1,753	1,698	1,646	1,651	4	3	3	4	4.84	4.70	4.52	4.46	4	4	4	4
N05BA06	Lorazepam (DDD 2.50 mg)	446	1,578	2,065	2,066	25	78	82	81	1.81	1.79	1.73	1.67	10	13	14	14
N05BA09	Clobazam (DDD 20 mg)	113	129	133	143	4	4	4	3	0.33	0.38	0.39	0.42	4	4	4	3
N05BA12	Alprazolam (DDD 1 mg)	953	887	767	724	1	1	1	1	3.47	3.19	2.86	2.65	1	1	1	1

Table continued



ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
N05BB	Diphenylmethane derivatives	727	725	681	657	5	4	4	4	1.22	1.19	1.14	1.08	5	5	4	5
N05BB01	Hydroxyzine (DDD 75 mg)	727	725	681	657	5	4	4	4	1.22	1.19	1.14	1.08	5	5	4	5
N05BE	Azaspirodecanedione derivatives	586	604	653	672	11	12	11	8	0.24	0.25	0.27	0.27	11	12	11	8
N05BE01	Buspirone (DDD 30 mg)	586	604	653	672	11	12	11	8	0.24	0.25	0.27	0.27	11	12	11	8
N05C	Hypnotics and sedatives	13,927	14,239	14,285	14,303	25	21	21	24	46.61	47.82	49.30	49.15	4	4	4	4
N05CD	Benzodiazepine derivatives	3,330	3,472	3,298	2,932	13	15	15	16	5.84	5.29	4.82	4.26	5	6	6	6
N05CD02	Nitrazepam (DDD 5 mg)	112	102	53	35	3	2	1	3	0.31	0.26	0.14	0.09	3	2	1	3
N05CD05	Triazolam	40	33	29	26	0	0	1	0	0.03	0.03	0.03	0.02	0	0	1	0
N05CD07	Temazepam (DDD 20 mg)	1,798	1,800	1,832	1,766	3	3	3	3	5.30	4.78	4.45	3.97	4	4	4	4
N05CD08	Midazolam	1,380	1,536	1,385	1,100	27	30	32	36	0.20	0.22	0.20	0.17	45	55	56	53
N05CD14	Remimazolam				5				100								
N05CF	Benzodiazepine related drugs	2,510	2,505	2,328	2,231	2	2	2	2	16.73	16.02	14.80	13.98	2	2	2	2
N05CF01	Zopiclone (DDD 7.50 mg)	1,912	1,886	1,720	1,629	2	2	2	2	12.13	11.43	10.56	10.00	3	2	3	2
N05CF02	Zolpidem (DDD 10 mg)	598	619	608	602	1	1	1	1	4.60	4.59	4.24	3.98	1	1	1	1
N05CH	Melatonin receptor agonists	5,131	5,662	6,045	6,074	5	4	4	3	23.93	26.29	29.48	30.71	5	4	4	4
N05CH01	Melatonin (DDD 2 mg)	5,131	5,662	6,045	6,074	5	4	4	3	23.93	26.29	29.48	30.71	5	4	4	4
N05CM	Other hypnotics and sedatives	2,956	2,600	2,614	3,066	95	83	84	88	0.11	0.22	0.21	0.20	12	6	6	7
N05CM09	Valerianae radix	147	451	416	381	0	0	0	0	0.09	0.21	0.19	0.19		0	0	
N05CM18	Dexmedetomidine (DDD 1 mg)	2,809	2,149	2,198	2,685	100	100	100	100	0.01	0.01	0.01	0.01	100	100	100	100

**N06 Psychoanaleptics**

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
N06	Psychoanaleptics	53,905	58,436	64,554	70,947	3	3	3	3	101.15	105.63	111.04	117.04	2	2	2	2
N06A	Antidepressants	33,491	36,009	38,181	39,007	2	2	3	3	78.29	81.51	85.23	88.92	2	2	2	1
N06AA	Non-selective monoamine reuptake inhibitors	3,300	3,419	3,599	3,609	2	2	1	2	4.12	3.92	3.94	3.85	2	2	2	2
N06AA04	Clomipramine (DDD 0.10 g)	148	161	158	159	3	4	4	3	0.20	0.22	0.21	0.22	3	4	4	3
N06AA06	Trimipramine (DDD 0.15 g)	61	65	58		3	2	2		0.09	0.09	0.08		3	2	2	
N06AA09	Amitriptyline (DDD 75 mg)	2,492	2,758	2,890	2,900	2	2	1	1	2.89	3.01	3.00	2.98	2	2	1	2
N06AA10	Nortriptyline	422	436	493	550	2	2	2	2	0.58	0.60	0.65	0.66	2	2	2	2
N06AA12	Doxepin (DDD 0.10 g)	176				2				0.36				2			
N06AB	Selective serotonin reuptake inhibitors	6,618	6,819	7,162	7,442	2	2	2	2	43.40	44.57	46.44	48.82	1	1	1	1
N06AB03	Fluoxetine (DDD 20 mg)	1,035	1,089	1,208	1,271	2	2	2	1	4.41	4.50	4.91	5.09	2	1	1	1
N06AB04	Citalopram (DDD 20 mg)	1,463	1,343	1,287	1,233	2	2	2	2	9.11	8.50	8.08	7.64	1	1	1	1
N06AB05	Paroxetine (DDD 20 mg)	701	652	570	509	1	1	1	1	2.32	2.33	2.31	2.28	1	1	1	1
N06AB06	Sertraline (DDD 50 mg)	1,413	1,610	1,676	1,867	2	2	1	1	9.70	10.87	11.93	13.53	2	2	2	2
N06AB08	Fluvoxamine (DDD 0.10 g)	78	76	73	72	1	1	1	1	0.14	0.14	0.13	0.13	1	1	1	1
N06AB10	Escitalopram (DDD 10 mg)	1,929	2,048	2,348	2,489	2	2	2	2	17.72	18.23	19.08	20.16	1	1	1	1
N06AG	Monoamine oxidase type a inhibitors	267	268	260	248	1	1	2	2	0.34	0.34	0.33	0.32	1	1	1	2
N06AG02	Moclobemide (DDD 0.30 g)	267	268	260	248	1	1	2	2	0.34	0.34	0.33	0.32	1	1	1	2

Table continued



ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
N06AX	Other antidepressants	23,306	25,502	27,160	27,708	2	2	3	4	30.43	32.68	34.52	35.92	2	2	2	2
N06AX03	Mianserin (DDD 60 mg)	241	190	180	195	2	2	2	2	0.26	0.20	0.20	0.21	2	2	2	2
N06AX05	Trazodone (DDD 0.30 g)	169	179	187	202	3	3	2	2	0.19	0.20	0.21	0.23	3	3	2	2
N06AX11	Mirtazapine (DDD 30 mg)	4,612	5,077	5,275	5,112	4	4	3	3	8.24	8.47	8.54	8.21	4	3	3	3
N06AX12	Bupropion (DDD 0.30 g)	4,088	4,057	3,204	2,858	1	1	1	1	2.32	2.53	2.69	3.13	1	1	1	1
N06AX16	Venlafaxine (DDD 0.10 g)	6,478	6,982	7,016	7,025	2	2	2	2	11.04	11.67	11.90	12.24	2	2	2	1
N06AX17	Milnacipran (DDD 0.10 g)	51	23			2	1			0.04	0.02			2	1		
N06AX18	Reboxetin (DDD 8 mg)	34	30			2	2			0.03	0.03			2	2		
N06AX21	Duloxetine (DDD 60 mg)	1,228	1,308	2,049	1,696	2	4	3	3	3.93	4.14	4.49	4.71	2	2	2	2
N06AX22	Agomelatine (DDD 25 mg)	860	778	727	646	3	2	3	3	0.91	1.04	1.10	1.09	2	2	2	2
N06AX26	Vortioxetine (DDD 10 mg)	5,547	6,834	8,279	9,327	3	2	2	2	3.47	4.39	5.40	6.09	2	2	2	2
N06AX27	Esketamine (DDD 8 mg)		45	243	648		73	91	84		0.00	0.00	0.01		73	91	84
N06B	Psychostimulants, agents used for adhd and nootropics	13,732	16,115	20,090	24,767	3	2	2	2	5.56	6.70	8.61	10.96	1	1	1	1
N06BA	Centrally acting sympathomimetics	13,332	15,562	19,620	24,238	1	1	1	1	5.51	6.65	8.56	10.91	1	1	1	1
N06BA02	Dexamfetamine (DDD 15 mg)	646	739	817	962	0	0	1	0	0.13	0.15	0.17	0.20	0	0	1	0
N06BA04	Methylphenidate (DDD 30 mg)	7,201	8,107	9,931	11,726	1	1	0	0	4.28	4.95	6.21	7.69	1	1	0	0
N06BA07	Modafinil (DDD 0.30 g)	773	765	771	759	0	0	1	2	0.08	0.08	0.09	0.09	0	0	1	2
N06BA09	Atomoxetine (DDD 80 mg)	1,280	876	836	679	4	4	4	4	0.17	0.20	0.24	0.29	4	4	3	3
N06BA12	Lisdexamfetamine (DDD 30 mg)	3,432	5,075	7,253	9,993	1	1	1	1	0.84	1.27	1.85	2.64	1	1	1	1
N06BA14	Solriamfetol			13	119			0	1								

Table continued



ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
N06BC	Xanthine derivatives	274	253	277	247	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100
N06BC01	Caffeine (DDD 0.40 g)	274	253	277	247	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100
N06BX	Other psychostimulants and nootropics	126	300	192	282	5	0	6	0	0.05	0.05	0.05	0.05	3	2	1	1
N06BX03	Piracetam	54	52	52	53	3	2	1	2	0.05	0.05	0.05	0.05	3	2	1	1
N06BX13	Idebenone (DDD 0.90 g)	73	248	140	229	6	0	8	0	0.00	0.00	0.00	0.00	6		8	
N06C	Psycholeptics and psychoanaleptics in combination	457	439	421	403	1	1	1	1	0.75	0.71	0.68	0.69	1	1	1	1
N06CA	Antidepressants in combination with psycholeptics	457	439	421	403	1	1	1	1	0.75	0.71	0.68	0.69	1	1	1	1
N06CA01	Amitriptyline and psycholeptics	457	439	421	403	1	1	1	1	0.75	0.71	0.68	0.69	1	1	1	1
N06D	Anti-dementia drugs	6,225	5,874	5,862	6,770	5	5	5	4	16.57	16.70	16.52	16.48	4	4	4	3
N06DA	Anticholinesterases	4,362	4,451	4,516	4,777	5	5	4	4	9.84	9.83	9.58	9.43	4	3	3	3
N06DA02	Donepezil (DDD 7.50 mg)	467	649	733	743	4	3	3	3	6.02	5.93	5.52	5.20	3	3	3	3
N06DA03	Rivastigmine	2,643	2,470	2,538	2,868	7	6	6	5	2.23	2.23	2.31	2.34	5	5	4	4
N06DA04	Galantamine (DDD 16 mg)	1,252	1,332	1,245	1,165	3	4	3	3	1.59	1.66	1.75	1.89	3	3	3	3
N06DX	Other anti-dementia drugs	1,863	1,423	1,347	1,994	5	6	5	3	6.73	6.87	6.94	7.05	5	5	4	4
N06DX01	Memantine (DDD 20 mg)	1,863	1,423	1,347	1,994	5	6	5	3	6.73	6.87	6.94	7.05	5	5	4	4

**N07 Other nervous system drugs**

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
N07	Other nervous system drugs	18,586	24,710	27,159	32,407	24	40	51	55	7.48	7.95	7.68	7.59	17	19	22	24
N07A	Parasympathomimetics	460	489	448	525	38	43	36	43	0.27	0.27	0.27	0.29	5	5	5	5
N07AA	Anticholinesterases	445	477	437	513	39	44	37	44	0.27	0.27	0.27	0.29	5	5	5	5
N07AA02	Pyridostigmine	277	271	279	292	3	2	3	3	0.26	0.26	0.27	0.28	3	2	3	2
N07AA51	Neostigmine, combinations (DDD 1 ED)	168	206	158	220	98	99	98	98	0.01	0.01	0.01	0.01	98	99	98	98
N07AX	Other parasympathomimetics	15	12	11	12	1	1	5	9	0.00	0.00	0.00	0.00	1	1	5	9
N07AX01	Pilocarpine	15	12	11	12	1	1	5	9	0.00	0.00	0.00	0.00	1	1	5	9
N07B	Drugs used in addictive disorders	15,374	21,262	24,008	27,371	28	44	57	64	4.39	4.82	4.51	4.47	27	31	36	40
N07BA	Drugs used in nicotine dependence	10,366	11,083	8,934	7,710	4	4	5	5	2.47	2.67	2.23	1.99	6	6	7	7
N07BA01	Nicotine	7,014	7,666	7,666	7,710	6	6	6	5	1.83	2.02	1.99	1.99	7	7	7	7
N07BA03	Varenicline (DDD 2 mg)	3,352	3,418	1,268		1	1	1		0.64	0.65	0.24		1	1	1	
N07BB	Drugs used in alcohol dependence	642	604	567	562	6	6	5	6	0.65	0.63	0.58	0.58	6	7	6	7
N07BB01	Disulfiram (DDD 0.20 g)	410	396	366	356	7	7	6	7	0.55	0.53	0.49	0.47	7	7	6	7
N07BB04	Naltrexone (DDD 50 mg)	157	156	156	170	5	5	5	5	0.09	0.09	0.09	0.10	5	5	5	5
N07BB05	Nalmefene (DDD 18 mg)	75	52	44	36	1	2	0	1	0.01	0.01	0.01	0.01	1	2	0	1
N07BC	Drugs used in opioid dependence	4,366	9,575	14,507	19,100	86	93	91	90	1.27	1.52	1.69	1.91	81	86	86	85
N07BC01	Buprenorphine	1,739	7,415	10,512	13,789	98	97	95	96	0.12	0.53	0.78	1.05	98	97	95	95
N07BC02	Methadone (DDD 25 mg)	1,610	1,586	1,350	1,247	90	90	87	82	0.62	0.61	0.51	0.46	86	86	82	78
N07BC05	Levomethadone (DDD 15 mg)		74	321	680		73	67	77		0.02	0.08	0.17		73	66	76
N07BC51	Buprenorphine, combinations	1,017	500	2,323	3,384	61	52	75	73	0.52	0.36	0.32	0.23	71	71	72	56

Table continued



ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
N07C	Antivertigo preparations	701	706	666	469	1	1	1	1	2.76	2.80	2.82	2.75	1	1	1	1
N07CA	Antivertigo preparations	701	706	666	469	1	1	1	1	2.76	2.80	2.82	2.75	1	1	1	1
N07CA01	Betahistine (DDD 24 mg)	700	705	666	469	1	1	1	1	2.76	2.80	2.82	2.75	1	1	1	1
N07CA52	Cinnarizine, combinations (DDD 90 mg)	1	1	0		6	0	0		0.00	0.00	0.00		6			
N07X	Other nervous system drugs	2,051	2,253	2,037	4,042	6	7	5	0	0.05	0.06	0.07	0.08	4	4	3	2
N07XX	Other nervous system drugs	2,051	2,253	2,037	4,042	6	7	5	0	0.05	0.06	0.07	0.08	4	4	3	2
N07XX02	Riluzole (DDD 0.10 g)	179	210	255	254	8	8	8	5	0.02	0.02	0.02	0.02	8	8	8	5
N07XX04	Sodium oxybate (DDD 7.50 g)	1,367	1,100	605	582	0	0	0	0	0.03	0.03	0.03	0.03	0	0	0	0
N07XX06	Tetrabenazine (DDD 0.10 g)	80	63	56	61	8	7	3	3	0.01	0.00	0.00	0.00	8	7	3	3
N07XX07	Fampridine (DDD 20 mg)	74	106	106	97	10	6	5	2	0.00	0.01	0.01	0.01	6	4	3	2
N07XX08	Tafamidis (DDD 20 mg)	285	654	807	2,811	31	20	9	0	0.00	0.00	0.00	0.01	31	20	5	
N07XX11	Pitolisant (DDD 18 mg)	68	120	209	237	1	0	0	0	0.00	0.00	0.01	0.01	0		0	



P Antiparasitic products, insecticides and repellents

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
P	Antiparasitic products, insecticides and repellents	6,296	5,749	6,329	10,476	3	3	4	4	2.42	2.51	2.41	2.42	2	2	1	2
P01	Antiprotozoals	3,064	2,668	2,468	2,615	3	4	3	3	2.12	2.24	2.16	2.17	2	3	2	2
P02	Anthelmintics	1,679	1,515	1,927	4,455	0	0	4	5	0.29	0.27	0.25	0.25	0	0	0	1
P03	Ectoparasiticides, incl. scabicides, insecticides and repellents	1,553	1,566	1,933	3,407	4	4	4	4								

**P01 Antiprotozoals**

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
P01	Antiprotozoals	3,064	2,668	2,468	2,615	3	4	3	3	2.12	2.24	2.16	2.17	2	3	2	2
P01A	Agents against amoebiasis and other protozoal diseases	743	659	604	597	7	6	6	6	0.30	0.26	0.26	0.24	9	8	7	8
P01AB	Nitroimidazole derivatives	743	659	604	597	7	6	6	6	0.30	0.26	0.26	0.24	9	8	7	8
P01AB01	Metronidazole (DDD 2 g)	743	659	604	597	7	6	6	6	0.30	0.26	0.26	0.24	9	8	7	8
P01B	Antimalarials	2,320	2,009	1,864	2,017	2	4	2	2	1.83	1.98	1.91	1.93	1	2	1	1
P01BA	Aminoquinolines	1,594	1,754	1,691	1,710	1	2	1	1	1.79	1.97	1.90	1.91	1	2	1	1
P01BA02	Hydroxychloroquine (DDD 0.52 g)	1,594	1,754	1,691	1,710	1	2	1	1	1.79	1.97	1.90	1.91	1	2	1	1
P01BB	Biguanides	623	217	136	237	5	20	23	7	0.03	0.01	0.01	0.01	4	19	23	7
P01BB51	Proguanil and atovaquone (DDD 4 ED)	623	217	136	237	5	20	23	7	0.03	0.01	0.01	0.01	4	19	23	7
P01BC	Quinine alkaloids	104	37	37	70	0	4	1	1	0.00	0.00	0.00	0.00	0	4	1	1
P01BC02	Mefloquine (DDD 1 g)	104	37	37	70	0	4	1	1	0.00	0.00	0.00	0.00	0	4	1	1



P02 Anthelmintics

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
P02	Anthelmintics	1,679	1,515	1,927	4,455	0	0	4	5	0.29	0.27	0.25	0.25	0	0	0	1
P02C	Antinematodal agents	1,679	1,515	1,927	4,455	0	0	4	5	0.29	0.27	0.25	0.25	0	0	0	1
P02CF	Avermectines			557	3,290			15	6			0.01	0.04			15	6
P02CF01	Ivermectin (DDD 12 mg)			557	3,290			15	6			0.01	0.04			15	6
P02CX	Other antinematodals	1,679	1,515	1,370	1,165	0	0	0	0	0.29	0.27	0.24	0.20	0	0	0	0
P02CX01	Pyviniium (DDD 0.35 g)	1,679	1,515	1,370	1,165	0	0	0	0	0.29	0.27	0.24	0.20	0	0	0	0

P03 Ectoparasiticides, incl. scabicides, insecticides and repellents

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
P03	Ectoparasiticides, incl. scabicides, insecticides and repellents	1,553	1,566	1,933	3,407	4	4	4	4								
P03A	Ectoparasiticides, incl. scabicides	1,553	1,566	1,933	3,407	4	4	4	4								
P03AC	Pyrethrines, incl. synthetic compounds	1,553	1,566	1,933	3,407	4	4	4	4								
P03AC04	Permethrin	1,553	1,566	1,933	3,407	4	4	4	4								



R Respiratory system

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
R	Respiratory system	152,760	148,602	150,912	169,149	6	6	4	3	189.25	194.04	198.01	205.57	2	2	2	2
R01	Nasal preparations	26,971	23,802	24,113	28,956	1	1	1	1	37.03	33.25	33.71	38.83	1	1	1	1
R02	Throat preparations	7,555	5,708	5,375	9,791	0	0	0	0	3.28	2.51	2.28	3.93	0	0	0	0
R03	Drugs for obstructive airway diseases	91,012	93,802	90,249	92,759	9	8	5	5	79.91	83.82	80.99	83.65	3	3	3	3
R05	Cough and cold preparations	10,667	7,100	6,175	10,980	2	2	2	2	4.77	3.16	2.67	4.74	2	2	2	2
R06	Antihistamines for systemic use	15,862	17,165	18,344	16,650	0	1	0	0	64.26	71.31	78.35	74.42	1	1	1	1
R07	Other respiratory system products	693	1,027	6,656	10,012	100	83	13	6	0.00	0.00	0.00	0.00	100	87	21	11



R01 Nasal preparations

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
R01	Nasal preparations	26,971	23,802	24,113	28,956	1	1	1	1	37.03	33.25	33.71	38.83	1	1	1	1
R01A	Decongestants and other nasal preparations for topical use	20,916	19,755	19,940	23,288	1	1	1	1	35.12	31.97	32.61	37.20	1	1	1	1
R01AA	Sympathomimetics, plain	5,853	5,294	5,349	7,200	1	1	1	1	11.11	9.17	9.57	12.39	1	1	1	1
R01AA05	Oxymetazoline (DDD 0.40 mg)	284	260	253	352	0	0	0	0	0.82	0.75	0.73	1.00	0	0	0	0
R01AA07	Xylometazoline (DDD 0.80 mg)	5,569	5,034	5,096	6,847	1	1	1	1	10.29	8.42	8.84	11.40	1	1	1	1
R01AB	Sympathomimetics, combinations excl. corticosteroids	612	492	517	754	0	0	0	0	0.83	0.64	0.69	1.04	0			
R01AB06	Xylometazoline (DDD 0.80 ml)	612	492	517	754	0	0	0	0	0.83	0.64	0.69	1.04	0			
R01AC	Antiallergic agents, excl. corticosteroids	303	246	351	271	1	0	0	0	0.33	0.22	0.29	0.22	1	0	0	0
R01AC01	Cromoglicic acid (DDD 40 mg)	133	21			1	0			0.19	0.03			1	0		
R01AC02	Levocabastine (DDD 0.60 mg)	98	137	212	167	0	0	0	0	0.07	0.09	0.14	0.10		0	0	0
R01AC03	Azelastine (DDD 0.56 mg)	71	87	138	103	0	0	0	0	0.08	0.09	0.15	0.11				0
R01AD	Corticosteroids	13,708	13,275	13,264	14,628	1	1	1	1	22.50	21.63	21.74	23.26	1	1	1	1
R01AD01	Beclometasone (DDD 0.40 mg)	506	535	527	446	0	0	0	1	1.07	1.04	0.99	0.84	0	0	0	1
R01AD05	Budesonide (DDD 0.20 mg)	186	92			0	0			0.47	0.23			0	0		
R01AD08	Fluticasone (DDD 0.20 mg)	2,368	2,361	2,369	2,455	2	1	1	1	4.48	4.43	4.39	4.62	2	1	1	1
R01AD09	Mometasone (DDD 0.20 mg)	2,290	1,866	1,891	1,829	1	1	1	1	6.34	5.86	6.10	6.12	1	1	1	1
R01AD11	Triamcinolone (DDD 0.22 mg)	506	537	548	474	0	0	0	0	0.63	0.67	0.68	0.61	0	0	0	0
R01AD12	Fluticasone furoate (DDD 0.11 mg)	3,016	2,836	2,763	2,916	0	1	1	1	4.95	4.65	4.61	4.81	0	1	1	1
R01AD58	Fluticasone, combinations (DDD 4 ED)	4,837	5,048	5,166	6,472	1	0	0	1	4.56	4.75	4.95	6.26	1	0	0	1
R01AD59	Mometasone, combinations				36				0								

Table continued



ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption. DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
R01AX	Other nasal preparations	440	449	459	436	10	16	15	14	0.35	0.31	0.32	0.30	4	4	4	4
R01AX03	Ipratropium bromide (DDD 0.24 mg)	164	186	183	171	8	7	8	7	0.12	0.13	0.11	0.12	7	7	6	5
R01AX06	Mupirocin	149	163	162	163	20	35	33	28								
R01AX10	Various (DDD 2 ml)	127	100	114	101	2	3	3	3	0.23	0.18	0.21	0.18	2	3	3	3
R01B	Nasal decongestants for systemic use	6,054	4,047	4,174	5,668	1	1	1	1	1.91	1.28	1.11	1.63	1	1	1	1
R01BA	Sympathomimetics	6,054	4,047	4,174	5,668	1	1	1	1	1.91	1.28	1.11	1.63	1	1	1	1
R01BA01	Phenylpropanolamine (DDD 0.10 g)	52	48	46	46	1	1	0	1	0.13	0.12	0.12	0.11	1	1	0	1
R01BA52	Pseudoephedrine, combinations	6,003	3,999	4,127	5,622	1	1	1	1	1.78	1.15	0.99	1.52	1	1	1	1



R02 Throat preparations

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
R02	Throat preparations	7,555	5,708	5,375	9,791	0	0	0	0	3.28	2.51	2.28	3.93	0	0	0	0
R02A	Throat preparations	7,555	5,708	5,375	9,791	0	0	0	0	3.28	2.51	2.28	3.93	0	0	0	0
R02AA	Antiseptics	4,259	2,967	3,002	5,186	0	0	0	0	1.52	1.06	1.12	1.79	0	0	0	0
R02AA03	Dichlorobenzyl alcohol (DDD 6 ED)	3,636	2,626	2,781	4,658	0	0	0	0	1.51	1.05	1.11	1.79	0	0	0	0
R02AA05	Chlorhexidine	28	12	4	3	9	5	0	0	0.02	0.01	0.00	0.00	9	5		
R02AA20	Various	594	328	217	524	1	2	2	1								
R02AB	Antibiotics	2,232	2,065	1,854	3,388	1	1	1	1	1.18	1.06	0.88	1.49	1	1	1	1
R02AB30	Gramicidin (DDD 6 ED)	2,232	2,065	1,854	3,388	1	1	1	1	1.18	1.06	0.88	1.49	1	1	1	1
R02AX	Other throat preparations	1,065	676	518	1,218	0	0	0	0	0.58	0.38	0.29	0.65				
R02AX01	Flurbiprofen (DDD 44 mg)	275	169	132	325	0	0	0	0	0.06	0.04	0.03	0.08	0			
R02AX03	Benzydamine (DDD 9 mg)	790	507	386	893	0	0	0	0	0.52	0.35	0.26	0.57				

**R03 Drugs for obstructive airway diseases**

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
R03	Drugs for obstructive airway diseases	91,012	93,802	90,249	92,759	9	8	5	5	79.91	83.82	80.99	83.65	3	3	3	3
R03A	Adrenergics, inhalants	53,769	55,920	54,498	55,828	3	3	3	3	45.44	48.11	47.11	50.10	3	3	3	3
R03AC	Selective beta-2-adrenoceptor agonists	7,754	7,567	6,976	7,284	2	3	3	3	14.94	14.87	14.13	15.44	3	4	4	4
R03AC02	Salbutamol	5,515	5,334	4,968	5,379	3	3	3	3	12.60	12.53	12.03	13.37	3	5	4	5
R03AC03	Terbutaline	507	519	457	453	1	1	1	1	1.14	1.16	1.03	1.04	1	1	1	1
R03AC12	Salmeterol (DDD 0.10 mg)	482	481	433	410	1	1	1	1	0.34	0.34	0.31	0.30	1	1	1	1
R03AC13	Formoterol (DDD 24 mcg)	945	966	883	840	1	1	1	1	0.65	0.66	0.60	0.59	1	1	1	1
R03AC18	Indacaterol (DDD 0.15 mg)	183	160	130	107	2	3	2	2	0.14	0.12	0.10	0.08	2	3	2	2
R03AC19	Olodaterol (DDD 5 mcg)	122	107	105	95	3	3	3	2	0.07	0.07	0.06	0.06	3	3	3	2
R03AK	Adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics	37,912	38,253	36,196	35,555	2	2	2	2	27.67	29.87	29.31	30.56	2	2	2	2
R03AK06	Salmeterol and fluticasone	12,393	9,864	7,489	6,077	4	4	4	4	7.11	7.21	6.66	6.41	4	3	3	3
R03AK07	Formoterol and budesonide (DDD 2 ED)	14,420	15,132	14,353	14,318	1	1	1	1	13.71	14.41	13.76	14.37	1	1	1	1
R03AK08	Formoterol and beclometasone (DDD 2 ED)	3,688	4,497	5,034	5,481	2	2	2	2	3.08	3.81	4.27	4.84	2	2	2	2
R03AK10	Vilanterol and fluticasone furoate (DDD 1 ED)	5,262	6,389	7,136	7,642	1	1	1	1	2.37	2.90	3.17	3.51	1	1	1	1
R03AK11	Formoterol and fluticasone	2,148	2,369	2,181	2,032	2	2	2	2	1.41	1.54	1.46	1.43	2	2	2	2
R03AK14	Indacaterol and mometasone		1	3	5		0	0	1								

Table continued



ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption. DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
R03AL	Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids	8,102	10,101	11,326	12,989	7	6	6	5	2.83	3.37	3.67	4.10	9	10	9	9
R03AL01	Fenoterol and ipratropium bromide	277	306	286	323	14	27	23	27	0.46	0.56	0.54	0.62	5	24	21	24
R03AL02	Salbutamol and ipratropium bromide (DDD 3 ED)	411	281	182	192	51	41	38	43	0.30	0.24	0.19	0.19	50	41	38	44
R03AL03	Vilanterol and umeclidinium bromide (DDD 1 ED)	1,120	1,170	1,165	1,162	2	2	3	2	0.37	0.40	0.39	0.40	2	2	3	2
R03AL04	Indacaterol and glycopyrronium bromide (DDD 1 ED)	448	369	339	296	3	2	3	2	0.15	0.13	0.12	0.10	3	2	3	2
R03AL05	Formoterol and aclidinium bromide (DDD 2 ED)	169	142	122	101	2	2	2	2	0.06	0.05	0.04	0.04	2	2	2	2
R03AL06	Olodaterol and tiotropium bromide (DDD 2 ED)	2,165	2,342	2,243	2,183	5	5	5	5	0.74	0.82	0.79	0.77	5	5	5	5
R03AL07	Formoterol and glycopyrronium bromide (DDD 4 ED)	7	21	33	40	2	3	6	2	0.00	0.01	0.01	0.01	2	3	6	2
R03AL08	Vilanterol, umeclidinium bromide and fluticasone furoate (DDD 1 ED)	1,688	2,585	2,874	3,178	2	3	3	3	0.44	0.67	0.78	0.88	2	3	3	3
R03AL09	Formoterol, glycopyrronium bromide and beclometasone (DDD 4 ED)	1,818	2,884	3,969	4,949	6	7	7	5	0.31	0.51	0.80	1.08	9	10	9	8
R03AL11	Formoterol, glycopyrronium bromide and budesonide			87	529			2	5								
R03AL12	Indacaterol, glycopyrronium bromide and mometasone (DDD 1 ED)		1	26	36		0	0	0		0.00	0.01	0.01				0
R03B	Other drugs for obstructive airway diseases, inhalants	28,302	28,235	25,483	24,600	4	3	3	3	25.66	26.56	24.68	24.36	4	3	3	3
R03BA	Glucocorticoids	16,936	17,154	15,279	15,179	3	3	2	2	19.16	20.13	18.83	18.88	2	2	2	2
R03BA01	Beclometasone	2,370	2,426	2,125	2,010	2	2	2	2	2.49	2.53	2.28	2.19	2	2	2	2
R03BA02	Budesonide	4,567	4,728	4,114	4,136	6	4	4	4	4.43	4.55	4.08	4.07	3	3	3	3
R03BA05	Fluticasone	6,512	6,200	5,412	5,391	3	2	2	2	5.39	5.59	5.06	5.10	3	3	2	3
R03BA07	Mometasone (DDD 0.40 mg)	160	150	124	129	1	1	1	0	0.17	0.16	0.13	0.14	1	1	1	0
R03BA08	Ciclesonide (DDD 0.16 mg)	3,328	3,650	3,505	3,513	1	1	1	1	6.68	7.31	7.27	7.38	1	1	1	1

Table continued



ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
R03BB	Anticholinergics	11,366	11,081	10,204	9,421	4	4	4	4	6.49	6.43	5.85	5.48	7	7	6	7
R03BB01	Ipratropium bromide	263	281	239	245	40	45	39	41	0.59	0.54	0.46	0.46	47	46	43	45
R03BB04	Tiotropium bromide	10,326	10,072	9,297	8,534	4	3	3	3	5.54	5.53	5.07	4.70	3	3	3	3
R03BB05	Acclidinium bromide (DDD 0.64 mg)	85	74	61	48	2	2	3	2	0.04	0.04	0.03	0.02	2	2	3	2
R03BB06	Glycopyrronium bromide (DDD 44 mcg)	186	154	133	114	2	1	2	2	0.09	0.08	0.07	0.06	2	1	2	2
R03BB07	Umeclidinium bromide (DDD 55 mcg)	505	501	474	480	2	2	2	2	0.24	0.24	0.23	0.24	2	2	2	2
R03C	Adrenergics for systemic use	104	74	80	89	2	3	1	2	0.03	0.03	0.03	0.02	3	3	1	2
R03CC	Selective beta-2-adrenoceptor agonists	104	74	80	89	2	3	1	2	0.03	0.03	0.03	0.02	3	3	1	2
R03CC02	Salbutamol (DDD 12 mg)	104	74	80	89	2	3	1	2	0.03	0.03	0.03	0.02	3	3	1	2
R03D	Other systemic drugs for obstructive airway diseases	8,837	9,572	10,188	12,242	67	48	20	19	8.77	9.12	9.16	9.17	2	2	2	2
R03DA	Xanthines	260	195	144	128	3	3	3	3	0.70	0.64	0.59	0.53	3	3	3	3
R03DA04	Theophylline (DDD 0.40 g)	194	192	144	128	3	3	3	3	0.68	0.64	0.59	0.53	3	3	3	3
R03DA05	Aminophylline (DDD 0.60 g)	3	1			2	4			0.01	0.00			2	4		
R03DA54	Theophylline, combinations excl. psycholeptics (DDD 12 ED)	63	2			1	4			0.02	0.00			1	4		

Table continued



ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption. DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
R03DC	Leukotriene receptor antagonists	1,327	1,301	1,336	1,360	1	1	1	1	7.89	8.29	8.37	8.40	1	1	1	1
R03DC01	Zafirlukast (DDD 40 mg)	1				5				0.00				5			
R03DC03	Montelukast (DDD 10 mg)	1,326	1,301	1,336	1,360	1	1	1	1	7.89	8.29	8.37	8.40	1	1	1	1
R03DX	Other systemic drugs for obstructive airway diseases	7,251	8,077	8,708	10,755	81	56	23	21	0.18	0.19	0.20	0.23	43	32	16	16
R03DX05	Omalizumab (DDD 16 mg)	3,304	3,347	3,741	4,160	65	40	30	24	0.05	0.05	0.06	0.07	65	40	30	24
R03DX07	Roflumilast (DDD 0.50 mg)	221	217	197	189	5	5	4	6	0.09	0.09	0.08	0.07	5	4	4	5
R03DX08	Reslizumab (DDD 7.10 mg)	363	179	102	68	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100
R03DX09	Mepolizumab (DDD 3.60 mg)	2,593	2,756	3,043	4,160	100	68	14	20	0.03	0.03	0.04	0.06	100	63	14	20
R03DX10	Benralizumab (DDD 0.54 mg)	771	1,577	1,626	2,179	100	74	21	16	0.01	0.02	0.02	0.03	100	71	21	16

**R05 Cough and cold preparations**

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
R05	Cough and cold preparations	10,667	7,100	6,175	10,980	2	2	2	2	4.77	3.16	2.67	4.74	2	2	2	2
R05C	Expectorants, excl. combinations with cough suppressants	4,251	3,077	2,604	4,171	4	5	5	4	2.68	1.91	1.61	2.71	4	4	4	3
R05CA	Expectorants	157	112	111	62	0	0	0	0	0.09	0.06	0.06	0.03	0	0	0	0
R05CA03	Guaifenesin (DDD 0.90 g)	14				0				0.01							
R05CA10	Combinations	144	112	111	62	0	0	0	0	0.08	0.06	0.06	0.03	0	0	0	0
R05CB	Mucolytics	4,093	2,965	2,494	4,109	4	5	5	4	2.58	1.85	1.55	2.67	4	4	4	3
R05CB01	Acetylcysteine	774	562	452	830	4	3	4	3	0.72	0.53	0.42	0.77	4	4	4	3
R05CB02	Bromhexine (DDD 24 mg)	1,357	968	785	1,356	0	0	0	0	1.02	0.72	0.59	0.97	0	0	0	0
R05CB03	Carbocisteine (DDD 1.50 g)	95	58	49	82	0	1	1	1	0.06	0.03	0.03	0.05	0	1	1	1
R05CB06	Ambroxol (DDD 0.12 g)	676	429	335	728	3	4	4	2	0.28	0.18	0.14	0.31	3	4	4	2
R05CB13	Dornase alfa (desoxyribonuclease) (DDD 2.50 mg)	360	388	380	310	10	11	10	15	0.01	0.01	0.01	0.01	10	11	10	15
R05CB15	Erdosteine (DDD 0.60 g)	830	561	492	804	10	11	11	10	0.50	0.37	0.35	0.57	10	11	11	10

Table continued



ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption. DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
R05D	Cough suppressants, excl. combinations with expectorants	2,329	1,561	1,336	2,698	0	1	1	1	1.08	0.69	0.59	1.17	1	1	0	1
R05DA	Opium alkaloids and derivatives	1,839	1,202	1,123	2,307	1	1	1	1	0.91	0.57	0.52	1.06	1	1	1	1
R05DA01	Ethylmorphine (DDD 50 mg)	867	579	495	953	0	1	1	1	0.27	0.16	0.11	0.21	0	1	1	1
R05DA09	Dextromethorphan (DDD 90 mg)	972	622	628	1,355	1	1	0	1	0.65	0.42	0.42	0.85	1	1	0	1
R05DB	Other cough suppressants	490	359	213	391	0	0	0	0	0.16	0.12	0.07	0.12	0	0	0	
R05DB05	Pentoxyverine (DDD 0.10 g)	490	359	213	391	0	0	0	0	0.16	0.12	0.07	0.12	0	0	0	
R05F	Cough suppressants and expectorants, combinations	3,484	1,968	1,660	3,260	1	0	0	0	1.02	0.55	0.47	0.86	1	0	0	0
R05FA	Opium derivatives and expectorants	1,715	589	547	891	1	0	0	0	0.58	0.22	0.21	0.31	1	0	0	0
R05FA02	Opium derivatives and expectorants	1,715	589	547	891	1	0	0	0	0.58	0.22	0.21	0.31	1	0	0	0
R05FB	Other cough suppressants and expectorants	1,769	1,380	1,113	2,369	0	0	0	0	0.43	0.33	0.27	0.54	0	0	0	0
R05FB02	Cough suppressants and expectorants	1,769	1,380	1,113	2,369	0	0	0	0	0.43	0.33	0.27	0.54	0	0	0	0
R05X	Other cold preparations	1,206	988	1,150	1,702	0	0	0	0								

**R06 Antihistamines for systemic use**

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
R06	Antihistamines for systemic use	15,862	17,165	18,344	16,650	0	1	0	0	64.26	71.31	78.35	74.42	1	1	1	1
R06A	Antihistamines for systemic use	15,862	17,165	18,344	16,650	0	1	0	0	64.26	71.31	78.35	74.42	1	1	1	1
R06AA	Aminoalkyl ethers	108	137	159	174	1	1	2	2	0.08	0.10	0.12	0.13	1	1	2	2
R06AA09	Doxylamine (DDD 25 mg)	108	137	159	174	1	1	2	2	0.08	0.10	0.12	0.13	1	1	2	2
R06AE	Piperazine derivatives	8,494	9,335	9,910	9,114	1	1	1	1	35.07	37.91	40.61	39.16	1	1	1	1
R06AE03	Cyclizine		14	35	54		0	0	0		0.00	0.01	0.02		0	0	0
R06AE05	Meclozine (DDD 50 mg)	439	234	235	361	0	0	1	0	0.19	0.09	0.08	0.13	0	0	1	0
R06AE07	Cetirizine (DDD 10 mg)	6,591	7,583	8,199	7,572	1	1	1	1	30.16	32.81	35.39	34.34	1	1	1	1
R06AE09	Levocetirizine (DDD 5 mg)	1,464	1,505	1,441	1,127	0	0	0	0	4.72	5.01	5.14	4.67	0	0	0	0
R06AX	Other antihistamines for systemic use	7,259	7,693	8,275	7,363	0	0	0	0	29.11	33.29	37.62	35.14	0	0	0	0
R06AX13	Loratadine (DDD 10 mg)	635	751	725	644	1	0	0	0	3.07	3.53	3.39	3.03	1	0	0	0
R06AX18	Acrivastine (DDD 24 mg)	144	144	153	147	0	0	0	0	0.08	0.08	0.08	0.08	0	0	0	0
R06AX22	Ebastine (DDD 10 mg)	2,335	2,541	2,676	2,352	0	0	0	0	7.66	9.16	10.10	9.55	0	0	0	0
R06AX26	Fexofenadine (DDD 0.12 g)	1,664	1,733	1,863	1,529	0	0	0	0	3.86	4.20	4.94	4.32	0	0	0	0
R06AX27	Desloratadine (DDD 5 mg)	2,307	2,337	2,658	2,506	1	0	0	1	14.05	15.91	18.67	17.75	0	0	0	0
R06AX29	Bilastine (DDD 20 mg)	174	187	200	185	0	0	0	0	0.39	0.41	0.44	0.41	0	0	0	0



R07 Other respiratory system products

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption. DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
R07	Other respiratory system products	693	1,027	6,656	10,012	100	83	13	6	0.00	0.00	0.00	0.00	100	87	21	11
R07A	Other respiratory system products	693	1,027	6,656	10,012	100	83	13	6	0.00	0.00	0.00	0.00	100	87	21	11
R07AA	Lung surfactants	693	857	864	575	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100
R07AA02	Natural phospholipids (DDD 0.16 g)	693	857	864	575	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100
R07AX	Other respiratory system products		170	5,792	9,437		0	0	0		0.00	0.00	0.00				0
R07AX02	Ivacaftor (DDD 0.30 g)		85	2,014	3,334		0	0	0		0.00	0.00	0.00				0
R07AX30	Ivacaftor and lumacaftor			644	955			0	0								
R07AX31	Ivacaftor and tezacaftor		85	71	298		0	0	0								
R07AX32	Ivacaftor, tezacaftor and elexacaftor			3,064	4,851			0	0								



S Sensory organs

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
S	Sensory organs	67,362	67,879	70,730	82,251	41	44	44	50	30.03	31.28	31.79	31.92	2	2	2	2
S01	Ophthalmologicals	65,277	65,916	68,670	79,863	43	46	46	51	30.03	31.28	31.79	31.92	2	2	2	2
S02	Otologicals	1,887	1,784	1,884	2,207	2	2	2	2								
S03	Ophthalmological and otological preparations	197	180	176	181	8	10	8	9								

**S01 Ophthalmologicals**

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption. DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
S01	Ophthalmologicals	65,277	65,916	68,670	79,863	43	46	46	51	30.03	31.28	31.79	31.92	2	2	2	2
S01A	Antiinfectives	4,434	3,501	3,334	5,181	9	11	11	9								
S01AA	Antibiotics	3,774	2,840	2,707	4,586	9	11	12	9								
S01AA01	Chloramphenicol	3,195	2,426	2,338	3,959	7	9	9	7								
S01AA12	Tobramycin	13	12	13	3	7	8	7	10								
S01AA13	Fusidic acid	415	270	202	434	4	6	4	3								
S01AA26	Azithromycin	60	30	28	55	0	1	1	1								
S01AA27	Cefuroxime	90	103	126	135	92	87	84	85								
S01AD	Antivirals	4	34	49	47	11	11	7	8								
S01AD03	Aciclovir	4	34	49	47	11	11	7	8								
S01AE	Fluoroquinolones	655	627	578	543	8	8	9	11								
S01AE01	Ofloxacin	94	54	47	70	3	4	4	2								
S01AE05	Levofloxacin	549	563	518	454	9	8	9	11								
S01AE07	Moxifloxacin	12	11	12	18	19	19	33	49								
S01AX	Other antiinfectives				5				99								
S01AX18	Povidone-iodine				5				99								

Table continued



ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption. DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
S01B	Antiinflammatory agents	3,622	3,789	3,978	4,022	37	38	37	38								
S01BA	Corticosteroids, plain	2,864	2,993	2,986	3,059	46	48	49	50								
S01BA01	Dexamethasone	1,475	1,558	1,582	1,833	74	73	70	74								
S01BA02	Hydrocortisone	91	113	130	148	0	0	0	1								
S01BA04	Prednisolone	856	838	766	777	2	2	2	2								
S01BA05	Triamcinolone	225	283	277	57	100	100	99	100								
S01BA07	Fluorometholone	217	201	177	164	1	1	1	1								
S01BA15	Fluocinolone acetonide			55	80			100	100								
S01BC	Antiinflammatory agents, non-steroids	758	796	992	963	1	1	1	1								
S01BC03	Diclofenac	82	87	80	119	5	6	5	5								
S01BC10	Nepafenac	621	645	827	719	1	1	1	1								
S01BC11	Bromfenac	55	64	85	125	0	0	0	0								
S01C	Antiinflammatory agents and antiinfectives in combination	1,022	978	1,274	1,388	9	10	8	8								
S01CA	Corticosteroids and antiinfectives in combination	1,022	978	1,274	1,388	9	10	8	8								
S01CA01	Dexamethasone and antiinfectives	743	708	1,026	1,149	10	10	8	7								
S01CA03	Hydrocortisone and antiinfectives	279	270	247	239	7	8	9	10								
S01E	Antiglaucoma preparations and miotics	14,565	14,581	14,395	14,646	3	3	3	3	30.03	31.28	31.79	31.92	2	2	2	2
S01EA	Sympathomimetics in glaucoma therapy	452	422	446	479	30	30	37	41	0.63	0.58	0.55	0.55	9	8	10	10
S01EA03	Apraclonidine (DDD 0.30 ml)	155	148	189	226	79	77	80	81	0.04	0.04	0.05	0.05	64	60	62	62
S01EA05	Brimonidine (DDD 0.20 ml)	297	274	256	253	5	4	5	4	0.59	0.54	0.51	0.50	5	4	5	4

Table continued



ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption. DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
S01EB	Parasympathomimetics	37	41	41	52	49	57	54	60	0.11	0.10	0.09	0.09	13	12	15	13
S01EB01	Pilocarpine	18	16	16	14	13	12	15	13	0.11	0.10	0.09	0.09	13	12	15	13
S01EB09	Acetylcholine	19	25	25	38	83	86	79	77								
S01EC	Carbonic anhydrase inhibitors	1,353	1,386	1,402	1,344	2	2	2	3	2.80	2.88	2.92	2.91	2	3	2	2
S01EC03	Dorzolamide (DDD 0.30 ml)	126	121	111	107	3	3	3	3	0.18	0.18	0.17	0.16	3	3	3	3
S01EC04	Brinzolamide (DDD 0.20 ml)	734	759	768	756	2	3	2	2	2.05	2.12	2.15	2.19	2	3	2	2
S01EC54	Brinzolamide, combinations (DDD 0.20 ml)	492	506	523	482	2	2	2	2	0.57	0.58	0.60	0.55	2	2	2	2
S01ED	Beta blocking agents	7,130	6,928	7,068	7,354	2	2	2	1	15.12	15.95	16.45	17.11	1	1	1	1
S01ED01	Timolol (DDD 0.20 ml)	281	286	275	324	2	2	2	2	0.58	0.51	0.22	0.20	3	3	5	6
S01ED02	Betaxolol (DDD 0.20 ml)	80	78	75	72	3	3	3	3	0.30	0.30	0.29	0.27	3	3	3	3
S01ED51	Timolol, combinations	6,769	6,565	6,718	6,959	2	2	2	1	14.24	15.15	15.94	16.63	1	1	1	1
S01EE	Prostaglandin analogues	5,593	5,804	5,438	5,417	2	2	2	1	11.36	11.78	11.77	11.27	2	2	2	2
S01EE01	Latanoprost (DDD 0.10 ml)	1,817	1,984	1,640	1,684	2	2	2	2	5.00	5.10	5.15	4.94	2	2	2	2
S01EE03	Bimatoprost (DDD 0.10 ml)	915	907	884	815	2	2	2	2	3.54	3.86	3.84	3.59	1	1	1	1
S01EE04	Travoprost (DDD 0.10 ml)	789	686	622	560	2	2	2	2	0.88	0.79	0.72	0.65	3	3	3	3
S01EE05	Tafluprost (DDD 0.30 ml)	2,072	2,227	2,293	2,358	1	1	1	1	1.93	2.03	2.06	2.09	1	1	1	1

Table continued



ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption. DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
S01F	Mydriatics and cycloplegics	610	635	799	767	61	58	59	56								
S01FA	Anticholinergics	533	552	716	683	60	56	58	54								
S01FA01	Atropine	20	28	30	30	18	15	16	21								
S01FA02	Scopolamine	39			0	17			100								
S01FA04	Cyclopentolate	98	113	125	124	50	41	41	39								
S01FA06	Tropicamide	241	272	283	259	54	51	50	45								
S01FA56	Tropicamide, combinations	134	139	279	271	96	87	78	74								
S01FB	Sympathomimetics excl. antiglaucoma preparations	76	82	83	84	72	71	69	69								
S01FB01	Phenylephrine	76	82	83	84	72	71	69	69								
S01G	Decongestants and antiallergics	3,810	3,310	3,970	3,376	1	1	1	1								
S01GA	Sympathomimetics used as decongestants	252	201	212	233	0	0	0	0								
S01GA02	Tetryzoline	252	201	212	233	0	0	0	0								
S01GX	Other antiallergics	3,559	3,109	3,758	3,143	1	1	1	1								
S01GX01	Cromoglicic acid	2,618	2,304	2,660	2,223	1	1	1	1								
S01GX02	Levocabastine	122	176	257	160	0	0	0	0								
S01GX05	Lodoxamide	56	35	44	29	0	0	0	0								
S01GX06	Emedastine	34	27	34	25	0	0	0	1								
S01GX07	Azelastine	26				0											
S01GX08	Ketotifen	640	516	696	645	0	1	1	0								
S01GX09	Olopatadine	63	52	68	61	0	0	0	0								

Table continued



ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption. DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
S01H	Local anesthetics	221	228	215	217	80	78	71	69								
S01HA	Local anesthetics	221	228	215	217	80	78	71	69								
S01HA02	Oxybuprocaine	221	228	215	217	80	78	71	69								
S01J	Diagnostic agents	187	200	203	191	56	58	57	56								
S01JA	Colouring agents	187	200	203	191	56	58	57	56								
S01JA01	Fluorescein	14	17	18	13	98	97	98	100								
S01JA51	Fluorescein, combinations	173	183	186	178	53	54	53	52								
S01L	Ocular vascular disorder agents	24,651	26,776	28,022	37,377	100	100	100	100								
S01LA	Antineovascularisation agents	24,651	26,776	28,022	37,377	100	100	100	100								
S01LA01	Verteporfin	167	161		185	100	100		100								
S01LA04	Ranibizumab	327	299	250	274	100	100	100	100								
S01LA05	Aflibercept	24,157	26,263	27,721	36,796	100	100	100	100								
S01LA06	Brolucizumab		54	50	122		100	100	100								
S01X	Other ophthalmologicals	12,156	11,918	12,481	12,698	3	2	2	2								
S01XA	Other ophthalmologicals	12,156	11,918	12,481	12,698	3	2	2	2								
S01XA02	Retinol	519	526	505	343	3	3	3	1								
S01XA18	Ciclosporin	600	660	740	898	0	1	1	1								
S01XA20	Artificial tears and other indifferent preparations	11,036	10,681	11,152	11,401	3	2	2	2								
S01XA21	Mercaptamine		51	84	55		0	5	100								



S02 Otologicals

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption. DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
S02	Otologicals	1,887	1,784	1,884	2,207	2	2	2	2								
S02A	Antiinfectives	715	735	724	812	2	2	1	2								
S02AA	Antiinfectives	715	735	724	812	2	2	1	2								
S02AA03	Boric acid	691	718	704	780	2	2	1	2								
S02AA15	Ciprofloxacin	24	17	20	33	2	2	2	1								
S02B	Corticosteroids	10	16	26	33	0	0	0	0								
S02BA	Corticosteroids	10	16	26	33	0	0	0	0								
S02BA08	Fluocinolone acetonide	10	16	26	33	0	0	0	0								
S02C	Corticosteroids and antiinfectives in combination	958	919	1,021	1,173	3	3	3	2								
S02CA	Corticosteroids and antiinfectives in combination	958	919	1,021	1,173	3	3	3	2								
S02CA02	Flumetasone and antiinfectives	180	224	94	74	3	3	2	3								
S02CA03	Hydrocortisone and antiinfectives	486	378	427	469	4	4	3	3								
S02CA05	Fluocinolone acetonide and antiinfectives	292	317	500	630	2	2	2	2								
S02D	Other otologicals	204	114	114	189	0	1	0	0								
S02DA	Analgesics and anesthetics	204	114	114	189	0	1	0	0								
S02DA04	Cinchocaine	204	114	114	189	0	1	0	0								

**S03 Ophthalmological and otological preparations**

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
S03	Ophthalmological and otological preparations	197	180	176	181	8	10	8	9								
S03C	Corticosteroids and antiinfectives in combination	197	180	176	181	8	10	8	9								
S03CA	Corticosteroids and antiinfectives in combination	197	180	176	181	8	10	8	9								
S03CA04	Hydrocortisone and antiinfectives	197	180	176	181	8	10	8	9								



V Various

ATC classification

Wholesale price (VAT excluded), thousand euros

Sales to hospitals and other health care units as a proportion (%) of wholesale value

Consumption, DDD/1,000 inhabitants/day

Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day

		2019				2020				2021				2022			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
V	Various	38,868	39,673	41,348	45,168	89	86	85	79	0.19	0.19	0.18	0.16	41	42	44	42
V01	Allergens	3,248	4,979	6,244	7,026	59	46	45	42								
V03	All other therapeutic products	9,764	9,319	8,670	11,130	77	75	76	60	0.19	0.19	0.18	0.16	41	42	44	42
V04	Diagnostic agents	963	897	868	826	87	89	92	90								
V07	All other non-therapeutic products	3,232	3,045	2,873	2,885	95	94	92	94								
V08	Contrast media	21,476	21,382	22,681	23,053	99	99	98	98								
V09	Diagnostic radiopharmaceuticals	183	52	12	247	100	100	100	100								

**V01 Allergens**

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
V01	Allergens	3,248	4,979	6,244	7,026	59	46	45	42								
V01A	Allergens	3,248	4,979	6,244	7,026	59	46	45	42								
V01AA	Allergen extracts	3,248	4,979	6,244	7,026	59	46	45	42								
V01AA02	Grass pollen	704	846	1,067	1,201	0	0	0	0								
V01AA03	House dust mites	43	50	52	60	24	22	24	34								
V01AA05	Tree pollen	2,205	3,736	4,645	5,271	74	53	51	47								
V01AA07	Insects	194	215	267	285	99	99	100	99								
V01AA11	Animals	101	131	212	209	78	78	77	75								
V01AA20	Various	1	1	1	0	92	84	100	100								



V03 All other therapeutic products

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
V03	All other therapeutic products	9,764	9,319	8,670	11,130	77	75	76	60	0.19	0.19	0.18	0.16	41	42	44	42
V03A	All other therapeutic products	9,764	9,319	8,670	11,130	77	75	76	60	0.19	0.19	0.18	0.16	41	42	44	42
V03AB	Antidotes	5,355	5,439	4,884	8,073	96	94	97	61								
V03AB14	Protamine	311	251	317	290	100	100	100	100								
V03AB15	Naloxone	177	252	59	136	89	92	89	91								
V03AB17	Methylthioninium chloride	133	108	112	105	99	99	99	99								
V03AB21	Potassium iodide	257	455	130	3,412	41	44	22	10								
V03AB25	Flumazenil	67	77	37	23	99	99	96	96								
V03AB33	Hydroxocobalamin	152	159	197	124	95	97	99	96								
V03AB34	Fomepizole	140	85	79	77	100	100	99	100								
V03AB35	Sugammadex	3,379	3,431	3,395	3,619	99	99	99	99								
V03AB37	Idarucizumab	278	198	225	198	100	100	100	100								
V03AB38	Andexanet alfa	461	422	333	90	100	100	100	100								
V03AC	Iron chelating agents	1,038	1,011	1,035	502	6	6	7	6								
V03AC01	Deferoxamine	20	19	20	14	88	85	100	96								
V03AC02	Deferiprone	6		9	7	4		31	3								
V03AC03	Deferasirox	1,013	992	1,006	482	4	5	5	4								

Table continued



ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
V03AE	Drugs for treatment of hyperkalemia and hyperphosphatemia	1,210	1,232	1,062	919	18	17	17	17	0.13	0.13	0.12	0.10	19	18	17	17
V03AE01	Polystyrene sulphonate (DDD 45 g)	114	105	106	95	22	23	23	24	0.03	0.03	0.03	0.03	22	23	23	24
V03AE02	Sevelamer (DDD 6.40 g)	381	401	405	388	17	16	16	13	0.04	0.04	0.04	0.04	17	16	15	13
V03AE03	Lanthanum carbonate (DDD 2.25 g)	706	686	458	295	17	15	16	16	0.06	0.06	0.04	0.02	16	15	15	15
V03AE05	Sucroferric oxyhydroxide (DDD 1.50 g)	5	14	25	23	90	11	4	10	0.00	0.00	0.00	0.00	90	11	4	10
V03AE09	Patiromer calcium (DDD 8.40 g)	4	26	68	116	100	45	25	27	0.00	0.00	0.01	0.01	100	45	24	28
V03AE10	Sodium zirconium cyclosilicate (DDD 7.50 g)				2				48				0.00				50
V03AF	Detoxifying agents for cytostatic treatment	2,160	1,636	1,690	1,636	96	94	93	93	0.06	0.06	0.06	0.05	95	95	94	94
V03AF01	Mesna	534	448	459	490	100	100	100	100								
V03AF02	Dexrazoxane (DDD 1.50 g)	365	133	216	160	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100
V03AF03	Calcium folinate (DDD 60 mg)	781	625	517	413	89	84	76	73	0.05	0.06	0.06	0.05	95	95	94	93
V03AF07	Rasburicase (DDD 14 mg)	426	413	469	533	100	100	99	100	0.00	0.00	0.00	0.00	100	100	100	100
V03AF08	Palifermin (DDD 4.20 mg)	15				100				0.00				100			
V03AF10	Sodium levofolinate (DDD 30 mg)	39	18	29	40	100	100	100	100	0.00	0.00	0.00	0.00	100	100	100	100
V03AX	Other therapeutic products	0				100				0.00				100			
V03AX03	Cobicistat (DDD 0.15 g)	0				100				0.00				100			

**V04 Diagnostic agents**

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
V04	Diagnostic agents	963	897	868	826	87	89	92	90								
V04C	Other diagnostic agents	963	897	868	826	87	89	92	90								
V04CD	Tests for pituitary function	108	108	77	86	25	29	32	16								
V04CD01	Metyrapone	108	108	77	86	25	29	32	16								
V04CF	Tuberculosis diagnostics	6	6	3	0	80	80	77	60								
V04CF01	Tuberculin	6	6	3	0	80	80	77	60								
V04CL	Tests for allergic diseases	296	180	179	137	158	163	155	159								
V04CX	Other diagnostic agents	701	694	699	672	98	100	100	100								
V04CX05	13c-urea	18	2			13	2										
V04CX06	Hexaminolevulinate	683	692	699	672	100	100	100	100								

**V07 All other non-therapeutic products**

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a pro- portion (%) of consumption, DDD/1,000 inhabitants/day			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
V07	All other non-therapeutic products	3,232	3,045	2,873	2,885	95	94	92	94								
V07A	All other non-therapeutic products	3,232	3,045	2,873	2,885	95	94	92	94								
V07AB	Solvents and diluting agents, incl. irrigating solutions	6,464	6,089	5,745	5,770	190	188	185	187								

**V08 Contrast media**

ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
V08	Contrast media	21,476	21,382	22,681	23,053	99	99	98	98								
V08A	X-ray contrast media, iodinated	16,339	17,031	17,503	17,617	100	99	99	99								
V08AA	Watersoluble, nephrotropic, high osmolar x-ray contrast media	101	116	123	110	100	100	100	100								
V08AA01	Diatrizoic acid	101	116	123	110	100	100	100	100								
V08AB	Watersoluble, nephrotropic, low osmolar x-ray contrast media	16,238	16,915	17,380	17,507	100	99	99	99								
V08AB02	Iohexol	12,970	13,409	14,099	14,309	100	100	99	99								
V08AB07	Ioversol	11	2			100	100										
V08AB09	Iodixanol	1,193	1,060	1,102	1,126	98	98	97	97								
V08AB10	Iomeprol	2,064	2,445	2,180	2,072	100	100	99	100								
V08B	X-ray contrast media, non-iodinated	0				100											
V08BA	Barium sulfate containing x-ray contrast media	0				100											
V08BA01	Barium sulfate with suspending agents	0				100											

Table continued



ATC classification		Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value				Consumption, DDD/1,000 inhabitants/day				Sales to hospitals and other health care units as a proportion (%) of consumption, DDD/1,000 inhabitants/day			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
V08C	Magnetic resonance imaging contrast media	5,050	4,281	5,106	5,361	96	98	96	94								
V08CA	Paramagnetic contrast media	5,050	4,281	5,106	5,361	96	98	96	94								
V08CA02	Gadoteric acid	4,812	4,045	4,906	5,163	96	97	95	94								
V08CA04	Gadoteridol	48	13	4		95	78	83									
V08CA08	Gadobenic acid	0	0		0	100	100		100								
V08CA09	Gadobutrol	20	16			100	100										
V08CA10	Gadoxetic acid	170	207	196	199	100	100	100	100								
V08D	Ultrasound contrast media	88	70	72	75	100	100	99	100								
V08DA	Ultrasound contrast media	88	70	72	75	100	100	99	100								
V08DA01	Microspheres of human albumin	2	2	1	5	100	100	100	100								
V08DA05	Sulphur hexafluoride	87	68	72	70	100	100	99	100								
V09	Diagnostic radiopharmaceuticals	183	52	12	247	100	100	100	100								
V09C	Renal system	43	15	3	30	100	100	100	100								
V09CA	Technetium (99mTc) compounds	43	15	3	30	100	100	100	100								
V09CA03	Technetium (99mTc) mertiatide	43	15	3	30	100	100	100	100								
V09D	Hepatic and reticulo endothelial system	140	37	9	187	100	100	100	100								
V09DB	Technetium (99mTc), particles and colloids	140	37	9	187	100	100	100	100								
V09DB01	Technetium (99mTc) nanocolloid	140	37	9	187	100	100	100	100								
V09G	Cardiovascular system				30				100								
V09GA	Technetium (99mTc) compounds				30				100								
V09GA02	Technetium (99mTc) tetrofosmin				30				100								



Nicotine replacement therapy

Total

ATC name	Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value			
	2018	2019	2020	2021	2018	2019	2020	2021
Nicotine	57,716	61,368	71,691	75,207	13.80	14.78	17.86	18.83

Pharmacies

ATC name	Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value			
	2018	2019	2020	2021	2018	2019	2020	2021
Nicotine	6,986	6,609	7,228	7,217	1.83	1.65	1.88	1.85
Medicated chewing gums (DDD 30 mg)	2,375	2,044	1,919	1,759	0.77	0.64	0.60	0.56
Losenzes and sublingual tablets (DDD 30 mg)	876	791	727	733	0.16	0.15	0.13	0.14
Transdermal patches (DDD 14 mg)	1,086	1,092	1,146	1,034	0.38	0.39	0.40	0.36
Other formulations	2,649	2,681	3,436	3,691	0.52	0.48	0.74	0.78

Table continued



Other

ATC name	Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value			
	2018	2019	2020	2021	2018	2019	2020	2021
Nicotine	50,344	54,354	64,025	67,541	11.83	13.00	15.84	16.84
Medicated chewing gums (DDD 30 mg)	32,040	32,020	34,644	34,385	8.14	8.22	9.01	8.99
Losenzes and sublingual tablets (DDD 30 mg)	11,022	11,996	13,307	13,410	1.77	1.95	2.17	2.20
Transdermal patches (DDD 14 mg)	127	221	282	303	0.05	0.08	0.10	0.11
Other formulations	7,154	10,117	11,229	19,442	1.87	2.74	4.55	5.54

Hospital

ATC name	Wholesale price (VAT excluded), thousand euros				Sales to hospitals and other health care units as a proportion (%) of wholesale value			
	2018	2019	2020	2021	2018	2019	2020	2021
Nicotine	387	406	438	449	0.13	0.13	0.14	0.14



OTC medicines in outpatient care

ATC classification		Consumption, DDD/1,000 inhabitants/day				Wholesale price (VAT excluded), thousand euros				Retail price (VAT 10% included), thousand euros			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
A	Alimentary tract and metabolism	81.61	84.60	83.18	85.36	60,805	61,457	60,152	61,378	103,447	104,109	101,845	103,995
A01	Stomatological preparations	2.19	2.18	5.35	12.18	1,258	1,299	1,273	1,645	2,241	2,288	2,242	2,871
A01A	Stomatological preparations	2.19	2.18	5.35	12.18	1,258	1,299	1,273	1,645	2,241	2,288	2,242	2,871
A01AA	Caries prophylactic agents			3.30	10.19			179	547			308	934
A01AA01	Sodium fluoride			3.30	10.19			179	547			308	934
A01AB	Antiinfectives for local oral treatment	2.16	2.16	2.03	1.96	1,034	1,138	1,066	1,040	1,853	2,011	1,884	1,835
A01AB03	Chlorhexidine	1.95	1.90	1.82	1.79	819	872	853	871	1,477	1,547	1,514	1,541
A01AB11	Various	0.21	0.26	0.21	0.17	215	266	213	169	376	463	370	294
A01AC	Corticosteroids for local oral treatment					152	112			261	193		
A01AC01	Triamcinolone					152	112			261	193		
A01AD	Other agents for local oral treatment	0.03	0.02	0.02	0.03	72	49	28	58	127	84	49	103
A01AD02	Benzylamine	0.03	0.02	0.02	0.03	72	49	28	58	127	84	49	103
A02	Drugs for acid related disorders	7.10	6.99	7.18	7.53	11,007	11,405	11,785	12,991	19,390	20,009	20,641	22,688
A02A	Antacids	2.20	2.22	2.25	2.34	3,530	3,648	3,819	4,378	6,330	6,523	6,797	7,751
A02AA	Magnesium compounds	0.06	0.05	0.05	0.04	118	111	108	98	206	194	188	171
A02AA04	Magnesium hydroxide	0.06	0.05	0.05	0.04	118	111	108	98	206	194	188	171
A02AD	Combinations and complexes of aluminium, calcium and magnesium compounds	2.15	2.17	2.20	2.29	3,412	3,537	3,711	4,280	6,124	6,330	6,608	7,580
A02AD01	Ordinary salt combinations	2.15	2.17	2.20	2.29	3,412	3,537	3,711	4,280	6,124	6,330	6,608	7,580

Table continued



ATC classification		Consumption, DDD/1,000 inhabitants/day				Wholesale price (VAT excluded), thousand euros				Retail price (VAT 10% included), thousand euros			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
A02B	Drugs for peptic ulcer and gastro-oesophageal reflux disease (gord)	4.90	4.77	4.93	5.19	7,477	7,757	7,965	8,613	13,060	13,486	13,845	14,937
A02BA	H2-receptor antagonists	0.27	0.15	0.14	0.33	514	497	468	794	906	862	811	1,368
A02BA02	Ranitidine	0.17				177				318			
A02BA03	Famotidine	0.10	0.15	0.14	0.13	338	497	468	435	588	862	811	751
A02BA53	Famotidine, combinations				0.20				359				618
A02BC	Proton pump inhibitors	3.52	3.39	3.49	3.53	4,712	4,627	4,706	4,808	8,282	8,102	8,242	8,413
A02BC01	Omeprazole	1.08	0.99	0.91	0.93	1,137	1,044	962	982	1,979	1,812	1,669	1,705
A02BC02	Pantoprazole	1.02	0.99	1.08	1.08	2,260	2,230	2,426	2,450	3,924	3,851	4,203	4,246
A02BC03	Lansoprazole	0.14	0.13	0.12	0.11	227	214	194	178	406	389	345	311
A02BC04	Rabeprazole	0.05	0.05	0.04	0.04	77	79	69	69	137	139	120	120
A02BC05	Esomeprazole	1.23	1.24	1.33	1.37	1,011	1,061	1,055	1,130	1,836	1,912	1,905	2,031
A02BX	Other drugs for peptic ulcer and gastro-oesophageal reflux disease (gord)	1.11	1.22	1.30	1.33	2,251	2,633	2,791	3,010	3,872	4,522	4,792	5,155
A02BX02	Sucralfate	0.23	0.27	0.31	0.34	378	453	517	561	648	774	884	956
A02BX13	Alginic acid	0.88	0.95	0.98	1.00	1,873	2,180	2,274	2,450	3,224	3,747	3,908	4,200
A03	Drugs for functional gastrointestinal disorders	1.15	1.09	1.06	1.13	1,452	1,488	1,304	1,438	2,480	2,531	2,221	2,446
A03A	Drugs for functional gastrointestinal disorders	1.15	1.09	1.06	1.13	1,452	1,488	1,304	1,438	2,480	2,531	2,221	2,446
A03AX	Other drugs for functional gastrointestinal disorders	1.15	1.09	1.06	1.13	1,452	1,488	1,304	1,438	2,480	2,531	2,221	2,446
A03AX13	Silicones	1.15	1.09	1.06	1.13	1,434	1,354	1,115	1,165	2,449	2,307	1,908	1,993
A03AX15	Menthae piperitae aetheroleum					18	134	188	273	31	224	313	453

Table continued



ATC classification		Consumption, DDD/1,000 inhabitants/day				Wholesale price (VAT excluded), thousand euros				Retail price (VAT 10% included), thousand euros			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
A06	Drugs for constipation	36.73	39.48	40.90	40.25	20,852	22,601	23,473	23,657	35,099	37,923	39,372	39,677
A06A	Drugs for constipation	36.73	39.48	40.90	40.25	20,852	22,601	23,473	23,657	35,099	37,923	39,372	39,677
A06AB	Contact laxatives	5.82	5.96	5.68	4.98	3,446	3,468	3,246	3,002	5,899	5,927	5,563	5,143
A06AB02	Bisacodyl	0.87	0.70	0.65	0.62	344	260	246	240	601	455	431	422
A06AB06	Senna glycosides	0.15	0.13	0.12	0.12	60	52	51	55	104	91	89	97
A06AB08	Sodium picosulfate	4.80	5.14	4.90	4.24	2,523	2,688	2,450	2,228	4,342	4,612	4,225	3,840
A06AB56	Senna glycosides, combinations					168	162	145	133	280	270	241	221
A06AB58	Sodium picosulfate, combinations	0.00	0.00	0.00	0.00	351	306	353	346	572	499	576	564
A06AC	Bulk-forming laxatives	3.79	4.21	4.31	4.21	2,716	2,982	3,122	3,101	4,542	4,983	5,220	5,184
A06AC01	Ispaghula (psylla seeds)	3.19	3.63	3.76	3.68	2,481	2,754	2,905	2,893	4,143	4,597	4,850	4,832
A06AC51	Ispaghula, combinations	0.60	0.58	0.56	0.53	235	228	218	207	399	386	369	352
A06AD	Osmotically acting laxatives	25.99	28.13	29.73	29.86	12,719	14,147	15,087	15,498	21,343	23,647	25,198	25,891
A06AD11	Lactulose	12.06	11.99	11.65	11.04	2,439	2,395	2,346	2,199	4,192	4,118	4,042	3,792
A06AD15	Macrogol	12.72	15.09	17.18	18.05	8,820	10,367	11,426	12,070	14,705	17,212	18,950	20,029
A06AD17	Sodium phosphate					46	34	19	14	76	55	31	23
A06AD65	Macrogol, combinations	1.20	1.05	0.90	0.77	1,414	1,351	1,296	1,216	2,371	2,261	2,175	2,047
A06AG	Enemas	1.14	1.17	1.18	1.20	1,971	2,004	2,018	2,056	3,315	3,366	3,391	3,460
A06AG02	Bisacodyl	0.16	0.16	0.17	0.15	266	283	288	260	435	463	474	427
A06AG10	Docosate sodium, incl. combinations	0.03	0.03	0.03	0.03	307	303	310	299	485	480	492	475
A06AG11	Laurilsulfate, incl. combinations	0.96	0.98	0.98	1.02	1,399	1,418	1,420	1,497	2,395	2,423	2,426	2,558

Table continued



ATC classification		Consumption, DDD/1,000 inhabitants/day				Wholesale price (VAT excluded), thousand euros				Retail price (VAT 10% included), thousand euros			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
A07	Antidiarrheals, intestinal antiinflammatory/antiinfective agents	2.15	1.62	1.59	2.02	8,307	6,331	6,298	7,642	14,471	11,009	10,953	13,312
A07B	Intestinal adsorbents	0.05	0.06	0.06	0.06	318	305	285	333	540	515	481	563
A07BA	Charcoal preparations	0.05	0.06	0.06	0.06	318	305	285	333	540	515	481	563
A07BA01	Medicinal charcoal	0.05	0.06	0.06	0.06	318	305	285	333	540	515	481	563
A07C	Electrolytes with carbohydrates	0.01	0.01	0.01	0.00	218	131	136	38	372	224	232	65
A07CA	Oral rehydration salt formulations	0.02	0.01	0.01	0.00	435	263	271	76	744	449	464	129
A07D	Antipropulsives	0.94	0.76	0.77	0.99	3,922	3,254	3,361	3,995	7,047	5,820	5,993	7,136
A07DA	Antipropulsives	0.94	0.76	0.77	0.99	3,922	3,254	3,361	3,995	7,047	5,820	5,993	7,136
A07DA03	Loperamide	0.94	0.76	0.77	0.99	2,903	2,429	2,557	3,360	5,225	4,355	4,564	6,008
A07DA53	Loperamide, combinations					1,019	825	804	635	1,823	1,466	1,429	1,128
A07F	Antidiarrheal microorganisms	1.15	0.79	0.76	0.96	3,430	2,374	2,284	2,982	5,781	3,983	3,842	5,034
A07FA	Antidiarrheal microorganisms	1.15	0.79	0.76	0.96	3,430	2,374	2,284	2,982	5,781	3,983	3,842	5,034
A07FA02	Saccharomyces boulardii	1.15	0.79	0.76	0.96	3,430	2,374	2,284	2,982	5,781	3,983	3,842	5,034
A07X	Other antidiarrheals					418	267	232	294	731	467	405	515
A07XA	Other antidiarrheals					418	267	232	294	731	467	405	515
A07XA04	Racecadotril					418	267	232	294	731	467	405	515
A08	Antiobesity preparations, excl. diet products	0.04	0.04	0.04	0.05	192	182	183	209	303	288	289	331
A08A	Antiobesity preparations, excl. diet products	0.04	0.04	0.04	0.05	192	182	183	209	303	288	289	331
A08AB	Peripherally acting antiobesity products	0.04	0.04	0.04	0.05	192	182	183	209	303	288	289	331
A08AB01	Orlistat	0.04	0.04	0.04	0.05	192	182	183	209	303	288	289	331

Table continued



ATC classification		Consumption, DDD/1,000 inhabitants/day				Wholesale price (VAT excluded), thousand euros				Retail price (VAT 10% included), thousand euros			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
A09	Digestives, incl. enzymes	1.23	1.20	1.28	1.35	3,090	3,036	3,229	3,303	4,923	4,845	5,153	5,272
A09A	Digestives, incl. enzymes	1.23	1.20	1.28	1.35	3,090	3,036	3,229	3,303	4,923	4,845	5,153	5,272
A09AA	Enzyme preparations	1.23	1.20	1.28	1.35	3,090	3,036	3,229	3,303	4,923	4,845	5,153	5,272
A09AA02	Multienzymes (lipase, protease etc.)	1.23	1.20	1.28	1.35	3,090	3,036	3,229	3,303	4,923	4,845	5,153	5,272
A11	Vitamins	16.99	17.11	10.48	6.14	6,159	6,173	3,319	1,347	10,458	10,451	5,625	2,298
A11C	Vitamin A and D, incl. combinations of the two	1.12	1.11	1.33	1.36	127	122	147	153	231	222	267	277
A11CC	Vitamin D and analogues	1.12	1.11	1.33	1.36	127	122	147	153	231	222	267	277
A11CC01	Ergocalciferol (vitamin D ₂)					4				8			
A11CC05	Colecalciferol (vitamin D ₃)	1.12	1.11	1.33	1.36	123	122	147	153	223	222	267	277
A11D	Vitamin B ₁ , plain and in combination with vitamin B ₆ and B ₁₂	4.42	4.06	3.73	3.35	1,094	1,015	894	793	1,842	1,708	1,508	1,334
A11DB	Vitamin B ₁ in comb. with vitamin B ₆ and/or vitamin B ₁₂	8.84	8.12	7.46	6.69	2,189	2,031	1,787	1,585	3,683	3,417	3,017	2,668
A11E	Vitamin B-complex, incl. combinations	9.73	9.78	3.97	0.09	4,652	4,699	1,993	135	7,881	7,927	3,347	220
A11EX	Vitamin B-complex, other combinations	19.47	19.57	7.95	0.18	9,303	9,398	3,986	269	15,762	15,855	6,695	440
A11G	Ascorbic acid (vitamin C), incl. combinations	1.59	2.05	1.32	1.23	106	137	89	83	189	245	158	147
A11GA	Ascorbic acid (vitamin C), plain	1.59	2.05	1.32	1.23	106	137	89	83	189	245	158	147
A11GA01	Ascorbic acid (vitamin C)	1.59	2.05	1.32	1.23	106	137	89	83	189	245	158	147
A11H	Other plain vitamin preparations	0.13	0.12	0.12	0.12	180	200	197	184	316	349	344	320
A11HA	Other plain vitamin preparations	0.13	0.12	0.12	0.12	180	200	197	184	316	349	344	320
A11HA02	Pyridoxine (vitamin B ₆)	0.13	0.12	0.12	0.12	42	38	39	38	72	64	66	64
A11HA30	Dexpanthenol					138	162	158	146	244	285	277	256

Table continued



ATC classification		Consumption, DDD/1,000 inhabitants/day				Wholesale price (VAT excluded), thousand euros				Retail price (VAT 10% included), thousand euros			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
A12	Mineral supplements	14.03	14.89	15.31	14.72	8,488	8,942	9,289	9,147	14,081	14,765	15,349	15,100
A12A	Calcium	8.67	9.30	9.52	8.93	4,020	4,391	4,529	4,296	6,860	7,415	7,664	7,272
A12AA	Calcium	1.07	1.12	1.12	1.10	802	843	837	828	1,388	1,456	1,448	1,431
A12AA04	Calcium carbonate	1.06	1.12	1.12	1.10	788	837	837	828	1,362	1,445	1,448	1,431
A12AA06	Calcium lactate gluconate	0.01	0.00			14	6			26	10		
A12AX	Calcium, combinations with vitamin D and/or other drugs	15.20	16.37	16.80	15.67	6,436	7,096	7,384	6,935	10,944	11,918	12,432	11,683
A12B	Potassium	5.36	5.59	5.80	5.78	4,468	4,551	4,760	4,851	7,221	7,350	7,685	7,828
A12BA	Potassium	5.36	5.59	5.80	5.78	4,468	4,551	4,760	4,851	7,221	7,350	7,685	7,828
A12BA01	Potassium chloride	5.32	5.59	5.80	5.78	4,366	4,551	4,760	4,851	7,057	7,350	7,685	7,828
A12BA51	Potassium chloride, combinations	0.04				102				164			



ATC classification		Consumption, DDD/1,000 inhabitants/day				Wholesale price (VAT excluded), thousand euros				Retail price (VAT 10% included), thousand euros			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
B	Blood and blood forming organs	68.78	67.19	66.73	62.89	12,084	10,890	10,277	9,621	20,797	18,697	17,748	16,621
B01	Antithrombotic agents	63.05	61.57	61.48	58.28	7,221	7,239	7,300	7,030	12,595	12,623	12,695	12,218
B01A	Antithrombotic agents	63.05	61.57	61.48	58.28	7,221	7,239	7,300	7,030	12,595	12,623	12,695	12,218
B01AC	Platelet aggregation inhibitors excl. heparin	63.05	61.57	61.48	58.28	7,221	7,239	7,300	7,030	12,595	12,623	12,695	12,218
B01AC06	Acetylsalicylic acid	63.05	61.57	61.48	58.28	7,221	7,239	7,300	7,030	12,595	12,623	12,695	12,218
B03	Antianemic preparations	5.73	5.62	5.25	4.61	4,796	3,584	2,903	2,501	8,093	5,964	4,932	4,256
B03A	Iron preparations	5.73	5.62	5.25	4.61	4,796	3,584	2,903	2,501	8,093	5,964	4,932	4,256
B03AA	Iron bivalent, oral preparations	4.01	4.02	3.75	3.38	3,421	2,277	1,666	1,488	5,829	3,814	2,898	2,589
B03AA01	Ferrous glycine sulfate	2.95	3.15	2.91	2.65	2,851	1,859	1,321	1,183	4,859	3,103	2,303	2,063
B03AA07	Ferrous sulfate	1.07	0.88	0.84	0.73	570	418	345	304	970	710	596	526
B03AB	Iron trivalent, oral preparations	1.72	1.60	1.50	1.23	1,375	1,306	1,237	1,014	2,264	2,151	2,034	1,667
B03AB05	Ferric oxide polymaltose complexes	1.72	1.60	1.50	1.23	1,375	1,306	1,237	1,014	2,264	2,151	2,034	1,667
B05	Blood substitutes and perfusion solutions					67	67	74	90	109	110	121	147
B05B	I.v. solutions					67	67	74	90	109	110	121	147
B05BB	Solutions affecting the electrolyte balance					67	67	74	90	109	110	121	147
B05BB01	Electrolytes					67	67	74	90	109	110	121	147



ATC classification		Consumption, DDD/1,000 inhabitants/day				Wholesale price (VAT excluded), thousand euros				Retail price (VAT 10% included), thousand euros			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
C	Cardiovascular system	0.10	0.10	0.09	0.09	3,678	3,691	4,058	4,217	6,244	6,257	6,861	7,126
C04	Peripheral vasodilators	0.10	0.10	0.09	0.09	74	75	66	62	123	123	108	102
C04A	Peripheral vasodilators	0.10	0.10	0.09	0.09	74	75	66	62	123	123	108	102
C04AD	Purine derivatives	0.10	0.10	0.09	0.09	74	75	66	62	123	123	108	102
C04AD03	Pentoxifylline	0.10	0.10	0.09	0.09	74	75	66	62	123	123	108	102
C05	Vasoprotectives					3,604	3,616	3,992	4,155	6,122	6,134	6,753	7,024
C05A	Agents for treatment of hemorrhoids and anal fissures for topical use					2,116	2,109	2,430	2,490	3,625	3,605	4,142	4,228
C05AA	Corticosteroids					2,024	2,109	2,430	2,490	3,462	3,605	4,142	4,228
C05AA04	Prednisolone					2,024	2,109	2,430	2,490	3,462	3,605	4,142	4,228
C05AX	Other agents for treatment of hemorrhoids and anal fissures for topical use					92				163			
C05AX03	Other preparations, combinations					92				163			
C05B	Antivaricose therapy					1,488	1,507	1,562	1,666	2,497	2,529	2,610	2,795
C05BA	Heparins or heparinoids for topical use					1,488	1,507	1,562	1,666	2,497	2,529	2,610	2,795
C05BA01	Organo-heparinoid					1,488	1,507	1,562	1,666	2,497	2,529	2,610	2,795



ATC classification		Consumption, DDD/1,000 inhabitants/day				Wholesale price (VAT excluded), thousand euros				Retail price (VAT 10% included), thousand euros			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
D	Dermatologicals					23,360	21,348	22,322	22,100	40,414	36,980	38,588	38,133
D01	Antifungals for dermatological use					4,038	4,209	4,166	4,442	6,931	7,216	7,138	7,603
D01A	Antifungals for topical use					4,038	4,209	4,166	4,442	6,931	7,216	7,138	7,603
D01AA	Antibiotics					43	46	43	49	76	81	76	87
D01AA02	Natamycin					43	46	43	49	76	81	76	87
D01AC	Imidazole and triazole derivatives					2,732	2,890	2,881	3,084	4,687	4,949	4,932	5,276
D01AC01	Clotrimazole					247	223	213	189	436	392	376	334
D01AC02	Miconazole					909	922	931	999	1,571	1,593	1,608	1,725
D01AC07	Tioconazole					4	29	26	20	6	50	45	35
D01AC08	Ketoconazole					1,045	1,143	1,153	1,287	1,768	1,928	1,945	2,172
D01AC10	Bifonazole						39	29	39		69	51	67
D01AC20	Imidazoles/triazoles in combination with corticosteroids					528	535	529	550	905	917	907	943
D01AE	Other antifungals for topical use					1,262	1,273	1,242	1,308	2,168	2,186	2,130	2,240
D01AE15	Terbinafine					1,262	1,273	1,242	1,308	2,168	2,186	2,130	2,240
D02	Emollients and protectives					2,357	49	52	48	3,945	86	92	83
D02A	Emollients and protectives					2,357	49	52	48	3,945	86	92	83
D02AE	Carbamide products					1,271	29	32	32	2,124	52	57	56
D02AE01	Carbamide					1,271	29	32	32	2,124	52	57	56
D02AX	Other emollients and protectives					2,172	40	42	32	3,640	67	70	53

Table continued



ATC classification	Consumption, DDD/1,000 inhabitants/day				Wholesale price (VAT excluded), thousand euros				Retail price (VAT 10% included), thousand euros			
	2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
D03 Preparations for treatment of wounds and ulcers					6,508	6,678	6,994	6,788	11,400	11,652	12,168	11,788
D03A Cicatrizants					6,508	6,678	6,994	6,788	11,400	11,652	12,168	11,788
D03AX Other cicatrizants					6,508	6,678	6,994	6,788	11,400	11,652	12,168	11,788
D03AX03 Dexpanthenol					6,508	6,678	6,994	6,788	11,400	11,652	12,168	11,788
D04 Antipruritics, incl. antihistamines, anesthetics, etc.					425	379	644	499	776	696	1,130	878
D04A Antipruritics, incl. antihistamines, anesthetics, etc.					425	379	644	499	776	696	1,130	878
D04AA Antihistamines for topical use					425	379	644	499	776	696	1,130	878
D04AA04 Tripelennamine					425	379	644	499	776	696	1,130	878
D06 Antibiotics and chemotherapeutics for dermatological use					3,028	2,839	2,935	3,146	5,257	4,924	5,087	5,437
D06A Antibiotics for topical use					1,202	1,167	1,280	1,409	2,114	2,051	2,245	2,455
D06AX Other antibiotics for topical use					1,202	1,167	1,280	1,409	2,114	2,051	2,245	2,455
D06AX04 Neomycin					1,202	1,167	1,280	1,409	2,114	2,051	2,245	2,455
D06B Chemotherapeutics for topical use					1,826	1,672	1,655	1,737	3,143	2,873	2,842	2,982
D06BB Antivirals					1,621	1,480	1,468	1,540	2,799	2,550	2,530	2,652
D06BB03 Aciclovir					1,114	1,089	1,095	1,141	1,925	1,882	1,890	1,969
D06BB06 Penciclovir					245	195	190	192	427	334	329	331
D06BB53 Aciclovir, combinations					262	196	183	207	448	334	312	351
D06BX Other chemotherapeutics					205	192	187	197	344	322	312	330
D06BX01 Metronidazole					205	192	187	197	344	322	312	330

Table continued



ATC classification		Consumption, DDD/1,000 inhabitants/day				Wholesale price (VAT excluded), thousand euros				Retail price (VAT 10% included), thousand euros			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
		D07	Corticosteroids, dermatological preparations					5,225	5,312	5,586	5,438	9,179	9,321
D07A	Corticosteroids, plain					3,535	3,677	3,946	3,921	6,246	6,488	6,956	6,889
D07AA	Corticosteroids, weak (group i)					3,535	3,677	3,946	3,921	6,246	6,488	6,956	6,889
D07AA02	Hydrocortisone					3,535	3,677	3,946	3,921	6,246	6,488	6,956	6,889
D07B	Corticosteroids, combinations with antiseptics					731	711	701	678	1,280	1,243	1,225	1,184
D07BA	Corticosteroids, weak, combinations with antiseptics					731	711	701	678	1,280	1,243	1,225	1,184
D07BA04	Hydrocortisone and antiseptics					731	711	701	678	1,280	1,243	1,225	1,184
D07C	Corticosteroids, combinations with antibiotics					659	653	665	574	1,115	1,106	1,125	972
D07CA	Corticosteroids, weak, combinations with antibiotics					659	653	665	574	1,115	1,106	1,125	972
D07CA01	Hydrocortisone and antibiotics					659	653	665	574	1,115	1,106	1,125	972
D07X	Corticosteroids, other combinations					300	272	274	264	538	484	491	468
D07XA	Corticosteroids, weak, other combinations					300	272	274	264	538	484	491	468
D07XA01	Hydrocortisone					300	272	274	264	538	484	491	468
D08	Antiseptics and disinfectants					331	315	302	297	578	555	530	523
D08A	Antiseptics and disinfectants					331	315	302	297	578	555	530	523
D08AC	Biguanides and amidines					29	4	6	2	46	7	10	3
D08AC02	Chlorhexidine					29	4	5		45	7	7	
D08AC52	Chlorhexidine, combinations					0	0	1	2	0	0	2	3
D08AG	Iodine products					302	311	296	295	532	548	521	520
D08AG02	Povidone-iodine					302	311	296	295	532	548	521	520
D09	Medicated dressings					110	108	106	91	176	173	170	147
D09A	Medicated dressings					110	108	106	91	176	173	170	147
D09AB	Zinc bandages					110	108	106	91	176	173	170	147
D09AB01	Zinc bandage without supplements					110	108	106	91	176	173	170	147

Table continued



ATC classification		Consumption, DDD/1,000 inhabitants/day				Wholesale price (VAT excluded), thousand euros				Retail price (VAT 10% included), thousand euros			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
D10	Anti-acne preparations					450	460	459	433	762	777	777	728
D10A	Anti-acne preparations for topical use					450	460	459	433	762	777	777	728
D10AE	Peroxides					450	460	459	433	762	777	777	728
D10AE01	Benzoyl peroxide					450	460	459	433	762	777	777	728
D11	Other dermatological preparations					887	1,000	1,078	918	1,410	1,580	1,699	1,434
D11A	Other dermatological preparations					887	1,000	1,078	918	1,410	1,580	1,699	1,434
D11AC	Medicated shampoos					107	113	107		187	198	188	
D11AC03	Selenium compounds					107	113	107		187	198	188	
D11AX	Other dermatologicals					780	886	971	918	1,222	1,382	1,512	1,434
D11AX01	Minoxidil					780	886	971	918	1,222	1,382	1,512	1,434



ATC classification		Consumption, DDD/1,000 inhabitants/day				Wholesale price (VAT excluded), thousand euros				Retail price (VAT 10% included), thousand euros			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
G	Genito urinary system and sex hormones	11.04	10.79	9.67	8.72	12,756	12,696	9,208	7,909	21,052	20,928	15,258	13,164
G01	Gynecological antiinfectives and antiseptics	0.55	0.51	0.51	0.52	1,959	1,785	1,808	1,918	3,330	3,037	3,077	3,266
G01A	Antiinfectives and antiseptics, excl. combinations with corticosteroids	0.55	0.51	0.51	0.52	1,959	1,785	1,808	1,918	3,330	3,037	3,077	3,266
G01AF	Imidazole derivatives	0.55	0.51	0.51	0.52	1,959	1,785	1,808	1,918	3,330	3,037	3,077	3,266
G01AF02	Clotrimazole	0.42	0.41	0.43	0.45	1,783	1,664	1,707	1,833	3,025	2,828	2,902	3,119
G01AF04	Miconazole	0.13	0.09	0.08	0.06	176	121	101	85	305	208	175	147
G03	Sex hormones and modulators of the genital system	6.79	6.59	5.57	5.07	9,316	9,491	6,055	4,901	15,273	15,528	9,955	8,088
G03A	Hormonal contraceptives for systemic use	0.04	0.04	0.04	0.04	1,055	942	853	938	1,751	1,591	1,438	1,579
G03AD	Emergency contraceptives	0.04	0.04	0.04	0.04	1,055	942	853	938	1,751	1,591	1,438	1,579
G03AD01	Levonorgestrel	0.03	0.02	0.02	0.03	506	456	419	454	863	779	718	778
G03AD02	Ulipristal	0.02	0.02	0.02	0.02	549	486	434	483	888	812	720	801
G03C	Estrogens	6.75	6.54	5.53	5.02	8,261	8,549	5,202	3,963	13,522	13,937	8,518	6,509
G03CA	Natural and semisynthetic estrogens, plain	6.75	6.54	5.53	5.02	8,261	8,549	5,202	3,963	13,522	13,937	8,518	6,509
G03CA03	Estradiol	1.08	1.07	0.53	0.34	5,979	5,891	2,836	1,756	9,686	9,547	4,601	2,856
G03CA04	Estriol	5.67	5.48	5.01	4.68	2,282	2,658	2,366	2,206	3,836	4,390	3,916	3,653
G04	Urologicals	3.69	3.69	3.59	3.13	1,481	1,420	1,344	1,090	2,449	2,364	2,226	1,810
G04B	Urologicals	3.05	3.13	3.08	2.91	986	999	983	936	1,648	1,683	1,640	1,560
G04BX	Other urologicals	3.05	3.13	3.08	2.91	986	999	983	936	1,648	1,683	1,640	1,560
G04BX01	Magnesium hydroxide	3.05	3.13	3.08	2.91	986	999	983	936	1,648	1,683	1,640	1,560
G04C	Drugs used in benign prostatic hypertrophy	0.64	0.56	0.51	0.23	495	421	361	154	801	681	586	250
G04CX	Other drugs used in benign prostatic hypertrophy	0.64	0.56	0.51	0.23	495	421	361	154	801	681	586	250
G04CX02	Sabalisserrulataefructus	0.64	0.56	0.51	0.23	495	421	361	154	801	681	586	250



ATC classification		Consumption, DDD/1,000 inhabitants/day				Wholesale price (VAT excluded), thousand euros				Retail price (VAT 10% included), thousand euros			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
H	Systemic hormonal preparations, excl. sex hormones and insulins	0.57	0.46	0.46	0.46	837	677	688	669	1,606	1,227	1,239	1,207
H02	Corticosteroids for systemic use	0.57	0.46	0.46	0.46	837	677	688	669	1,606	1,227	1,239	1,207
H02A	Corticosteroids for systemic use, plain	0.57	0.46	0.46	0.46	837	677	688	669	1,606	1,227	1,239	1,207
H02AB	Glucocorticoids	0.57	0.46	0.46	0.46	837	677	688	669	1,606	1,227	1,239	1,207
H02AB09	Hydrocortisone	0.57	0.46	0.46	0.46	837	677	688	669	1,606	1,227	1,239	1,207



ATC classification		Consumption, DDD/1,000 inhabitants/day				Wholesale price (VAT excluded), thousand euros				Retail price (VAT 10% included), thousand euros			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
J	Antifungals for systemic use	0.19	0.18	0.19	0.19	2,371	1,986	1,994	2,101	4,183	3,551	3,503	3,689
J02	Antimycotics for systemic use	0.09	0.09	0.09	0.09	1,123	909	893	899	2,016	1,662	1,604	1,614
J02A	Antimycotics for systemic use	0.09	0.09	0.09	0.09	1,123	909	893	899	2,016	1,662	1,604	1,614
J02AC	Triazole and tetrazole derivatives	0.09	0.09	0.09	0.09	1,123	909	893	899	2,016	1,662	1,604	1,614
J02AC01	Fluconazole	0.09	0.09	0.09	0.09	1,123	909	893	899	2,016	1,662	1,604	1,614
J05	Antivirals for systemic use	0.10	0.10	0.10	0.11	1,248	1,077	1,101	1,202	2,167	1,889	1,899	2,075
J05A	Direct acting antivirals	0.10	0.10	0.10	0.11	1,248	1,077	1,101	1,202	2,167	1,889	1,899	2,075
J05AB	Nucleosides and nucleotides excl. reverse transcriptase inhibitors	0.10	0.10	0.10	0.11	1,248	1,077	1,101	1,202	2,167	1,889	1,899	2,075
J05AB01	Aciclovir	0.04	0.04	0.04	0.04	323	286	280	315	579	515	495	558
J05AB11	Valaciclovir	0.06	0.06	0.06	0.06	925	791	821	887	1,588	1,375	1,405	1,518



ATC classification		Consumption, DDD/1,000 inhabitants/day				Wholesale price (VAT excluded), thousand euros				Retail price (VAT 10% included), thousand euros			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
M	Musculo-skeletal system	24.62	23.02	23.44	26.63	33,850	33,201	33,662	35,906	59,755	58,131	59,013	63,213
M01	Antiinflammatory and antirheumatic products	24.62	23.02	23.44	26.63	23,058	21,296	21,309	24,539	41,679	38,349	38,453	44,275
M01A	Antiinflammatory and antirheumatic products, non-steroids	24.62	23.02	23.44	26.63	23,058	21,296	21,309	24,539	41,679	38,349	38,453	44,275
M01AE	Propionic acid derivatives	24.62	23.02	23.44	26.63	23,058	21,296	21,309	24,539	41,679	38,349	38,453	44,275
M01AE01	Ibuprofen	23.86	22.38	22.97	26.08	21,820	20,277	20,536	23,634	39,454	36,522	37,057	42,632
M01AE02	Naproxen	0.03	0.02	0.03	0.03	73	56	62	65	127	97	108	114
M01AE03	Ketoprofen	0.17	0.15	0.14	0.14	298	272	256	265	567	517	487	502
M01AE51	Ibuprofen, combinations	0.56	0.46	0.31	0.38	867	691	456	574	1,531	1,214	801	1,026
M02	Topical products for joint and muscular pain					10,792	11,905	12,353	11,367	18,076	19,782	20,561	18,938
M02A	Topical products for joint and muscular pain					10,792	11,905	12,353	11,367	18,076	19,782	20,561	18,938
M02AA	Antiinflammatory preparations, non-steroids for topical use					9,937	11,072	11,583	10,897	16,625	18,369	19,254	18,137
M02AA07	Piroxicam					437	447	405	372	754	771	698	641
M02AA13	Ibuprofen					1,116	760	1,034	867	1,915	1,304	1,749	1,481
M02AA15	Diclofenac					8,384	9,865	10,144	9,658	13,956	16,294	16,808	16,015
M02AC	Preparations with salicylic acid derivatives					1,711	1,665	1,540	941	2,902	2,826	2,612	1,602



ATC classification		Consumption, DDD/1,000 inhabitants/day				Wholesale price (VAT excluded), thousand euros				Retail price (VAT 10% included), thousand euros			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
N	Nervous system	10.84	13.03	12.10	13.97	23,851	27,488	25,024	31,563	31,073	36,230	31,842	43,229
N01	Anesthetics					287	295	334	339	495	507	575	584
N01B	Anesthetics, local					287	295	334	339	495	507	575	584
N01BB	Amides					287	295	334	339	495	507	575	584
N01BB20	Combinations					287	295	334	339	495	507	575	584
N02	Analgesics	7.62	8.57	7.36	9.16	16,465	18,977	16,447	22,915	29,656	33,943	29,415	40,821
N02B	Other analgesics and antipyretics	7.62	8.57	7.36	9.16	16,446	18,965	16,435	22,900	29,622	33,922	29,394	40,794
N02BA	Salicylic acid and derivatives	1.02	1.32	1.12	1.38	1,496	3,377	2,704	4,476	2,666	5,916	4,742	7,799
N02BA01	Acetylsalicylic acid	0.77	0.73	0.66	0.65	988	1,022	955	975	1,774	1,831	1,710	1,743
N02BA51	Acetylsalicylic acid, combinations excl. psycholeptics	0.25	0.59	0.45	0.73	508	2,354	1,748	3,501	891	4,085	3,032	6,056
N02BE	Anilides	6.60	7.24	6.24	7.78	14,950	15,589	13,732	18,424	26,957	28,006	24,652	32,995
N02BE01	Paracetamol	6.32	7.05	6.13	7.66	14,089	14,995	13,385	18,063	25,433	26,965	24,044	32,361
N02BE51	Paracetamol, combinations excl. psycholeptics	0.28	0.20	0.12	0.12	861	593	346	361	1,524	1,041	608	634
N02C	Antimigraine preparations	0.00	0.00	0.00	0.00	19	12	12	15	34	21	21	26
N02CC	Selective 5ht1-receptor agonists	0.00	0.00	0.00	0.00	19	12	12	15	34	21	21	26
N02CC01	Sumatriptan	0.00	0.00	0.00	0.00	19	12	12	15	34	21	21	26
N05	Psycholeptics	1.52	2.58	2.89	2.95	490	989	1,025	1,008	922	1,779	1,851	1,824
N05C	Hypnotics and sedatives	1.52	2.58	2.89	2.95	490	989	1,025	1,008	922	1,779	1,851	1,824
N05CH	Melatonin receptor agonists	1.42	2.37	2.70	2.76	343	538	609	627	669	1,018	1,147	1,180
N05CH01	Melatonin	1.42	2.37	2.70	2.76	343	538	609	627	669	1,018	1,147	1,180
N05CM	Other hypnotics and sedatives	0.09	0.21	0.19	0.19	147	451	416	381	254	761	705	644
N05CM09	Valerianae radix	0.09	0.21	0.19	0.19	147	451	416	381	254	761	705	644



ATC classification		Consumption, DDD/1,000 inhabitants/day				Wholesale price (VAT excluded), thousand euros				Retail price (VAT 10% included), thousand euros			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
P	Antiparasitic products, insecticides and repellents	0.29	0.27	0.24	0.20	3,170	3,026	3,232	4,424	5,118	4,886	5,214	7,134
P02	Anthelmintics	0.29	0.27	0.24	0.20	1,678	1,515	1,370	1,164	2,722	2,453	2,217	1,888
P02C	Antinematodal agents	0.29	0.27	0.24	0.20	1,678	1,515	1,370	1,164	2,722	2,453	2,217	1,888
P02CX	Other antinematodals	0.29	0.27	0.24	0.20	1,678	1,515	1,370	1,164	2,722	2,453	2,217	1,888
P02CX01	Pyvvinium	0.29	0.27	0.24	0.20	1,678	1,515	1,370	1,164	2,722	2,453	2,217	1,888
P03	Ectoparasiticides, incl. scabicides, insecticides and repellents					1,492	1,511	1,862	3,260	2,396	2,432	2,997	5,246
P03A	Ectoparasiticides, incl. scabicides					1,492	1,511	1,862	3,260	2,396	2,432	2,997	5,246
P03AC	Pyrethrines, incl. synthetic compounds					1,492	1,511	1,862	3,260	2,396	2,432	2,997	5,246
P03AC04	Permethrin					1,492	1,511	1,862	3,260	2,396	2,432	2,997	5,246



ATC classification		Consumption, DDD/1,000 inhabitants/day				Wholesale price (VAT excluded), thousand euros				Retail price (VAT 10% included), thousand euros			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
R	Respiratory system	44.19	42.88	46.77	51.39	32,526	29,048	29,756	39,573	57,650	51,036	52,226	69,407
R01	Nasal preparations	14.36	12.13	12.96	16.44	8,401	7,703	8,109	10,565	15,338	13,767	14,494	18,841
R01A	Decongestants and other nasal preparations for topical use	14.36	12.13	12.96	16.44	8,401	7,703	8,109	10,565	15,338	13,767	14,494	18,841
R01AA	Sympathomimetics, plain	10.99	9.08	9.51	12.31	5,799	5,244	5,317	7,153	10,751	9,447	9,665	12,973
R01AA05	Oxymetazoline	0.81	0.75	0.73	1.00	283	260	253	352	516	474	461	641
R01AA07	Xylometazoline	10.17	8.33	8.77	11.31	5,516	4,984	5,064	6,801	10,235	8,973	9,205	12,332
R01AB	Sympathomimetics, combinations excl. corticosteroids	0.83	0.64	0.69	1.04	612	492	517	754	1,097	892	915	1,339
R01AB06	Xylometazoline	0.83	0.64	0.69	1.04	612	492	517	754	1,097	892	915	1,339
R01AC	Antiallergic agents, excl. corticosteroids	0.33	0.22	0.29	0.22	301	246	351	271	533	422	602	463
R01AC01	Cromoglicic acid	0.19	0.03			132	21			242	38		
R01AC02	Levocabastine	0.07	0.09	0.14	0.10	98	137	212	167	168	234	363	284
R01AC03	Azelastine	0.08	0.09	0.15	0.11	71	87	138	103	123	151	239	178
R01AD	Corticosteroids	1.99	2.01	2.28	2.70	1,565	1,624	1,813	2,289	2,727	2,824	3,106	3,884
R01AD01	Beclometasone	0.30	0.31	0.30	0.16	208	231	230	153	354	393	390	256
R01AD08	Fluticasone	0.62	0.59	0.64	0.61	608	621	674	644	1,064	1,086	1,160	1,110
R01AD09	Mometasone	0.72	0.70	0.91	0.82	418	403	521	468	735	708	892	805
R01AD11	Triamcinolone	0.36	0.40	0.43	0.36	331	369	389	322	574	638	664	552
R01AD58	Fluticasone, combinations				0.75				702				1,161
R01AX	Other nasal preparations	0.23	0.18	0.20	0.18	124	98	111	99	229	181	206	182
R01AX10	Various	0.23	0.18	0.20	0.18	124	98	111	99	229	181	206	182

Table continued



ATC classification		Consumption, DDD/1,000 inhabitants/day				Wholesale price (VAT excluded), thousand euros				Retail price (VAT 10% included), thousand euros			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
R02	Throat preparations	3.27	2.50	2.28	3.92	7,531	5,686	5,357	9,758	13,285	9,976	9,374	17,091
R02A	Throat preparations	3.27	2.50	2.28	3.92	7,531	5,686	5,357	9,758	13,285	9,976	9,374	17,091
R02AA	Antiseptics	1.52	1.06	1.12	1.79	4,250	2,960	2,998	5,181	7,520	5,202	5,263	9,100
R02AA03	Dichlorobenzyl alcohol	1.51	1.05	1.11	1.79	3,636	2,626	2,781	4,658	6,387	4,603	4,870	8,162
R02AA05	Chlorhexidine	0.02	0.01	0.00	0.00	25	12	4	3	46	21	8	5
R02AA20	Various					588	323	213	520	1,087	578	385	933
R02AB	Antibiotics	1.17	1.06	0.87	1.48	2,216	2,050	1,840	3,360	3,897	3,588	3,205	5,862
R02AB30	Gramicidin	1.17	1.06	0.87	1.48	2,216	2,050	1,840	3,360	3,897	3,588	3,205	5,862
R02AX	Other throat preparations	0.58	0.38	0.29	0.65	1,065	676	518	1,218	1,869	1,186	906	2,128
R02AX01	Flurbiprofen	0.06	0.04	0.03	0.08	275	169	132	325	470	288	226	555
R02AX03	Benzydamine	0.52	0.35	0.26	0.57	790	507	386	893	1,399	898	680	1,573

Table continued



ATC classification		Consumption, DDD/1,000 inhabitants/day				Wholesale price (VAT excluded), thousand euros				Retail price (VAT 10% included), thousand euros			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
R05	Cough and cold preparations	3.36	2.44	2.06	3.71	6,827	5,122	4,449	8,295	11,974	8,958	7,794	14,525
R05C	Expectorants, excl. combinations with cough suppressants	1.90	1.39	1.13	1.94	2,465	1,813	1,495	2,646	4,346	3,183	2,631	4,650
R05CA	Expectorants	0.09	0.06	0.06	0.03	157	112	111	62	287	201	197	111
R05CA03	Guaifenesin	0.01				14				25			
R05CA10	Combinations	0.08	0.06	0.06	0.03	143	112	111	62	262	201	197	111
R05CB	Mucolytics	1.81	1.33	1.07	1.91	2,307	1,701	1,385	2,584	4,059	2,982	2,434	4,539
R05CB01	Acetylcysteine	0.69	0.51	0.40	0.75	744	543	436	809	1,302	951	763	1,418
R05CB02	Bromhexine	1.01	0.72	0.59	0.97	1,346	959	780	1,353	2,361	1,683	1,375	2,382
R05CB03	Carbocisteine	0.06	0.03	0.03	0.05	94	57	48	81	164	100	84	142
R05CB06	Ambroxol	0.06	0.06	0.05	0.15	123	142	120	341	231	249	211	597
R05D	Cough suppressants, excl. combinations with expectorants	0.80	0.53	0.49	0.96	1,454	978	838	1,738	2,579	1,731	1,492	3,109
R05DA	Opium alkaloids and derivatives	0.64	0.41	0.41	0.84	964	619	626	1,347	1,712	1,097	1,115	2,416
R05DA09	Dextromethorphan	0.64	0.41	0.41	0.84	964	619	626	1,347	1,712	1,097	1,115	2,416
R05DB	Other cough suppressants	0.16	0.12	0.07	0.12	490	359	213	391	867	634	377	693
R05DB05	Pentoxyverine	0.16	0.12	0.07	0.12	490	359	213	391	867	634	377	693
R05F	Cough suppressants and expectorants, combinations	0.65	0.52	0.44	0.80	2,305	1,837	1,541	3,060	4,024	3,205	2,692	5,325
R05FA	Opium derivatives and expectorants	0.22	0.19	0.18	0.26	544	461	430	697	972	824	768	1,241
R05FA02	Opium derivatives and expectorants	0.22	0.19	0.18	0.26	544	461	430	697	972	824	768	1,241
R05FB	Other cough suppressants and expectorants	0.43	0.33	0.27	0.54	1,761	1,376	1,112	2,363	3,052	2,381	1,924	4,084
R05FB02	Cough suppressants and expectorants	0.43	0.33	0.27	0.54	1,761	1,376	1,112	2,363	3,052	2,381	1,924	4,084
R05X	Other cold preparations					1,206	988	1,150	1,702	2,051	1,678	1,956	2,882

Table continued



ATC classification		Consumption, DDD/1,000 inhabitants/day				Wholesale price (VAT excluded), thousand euros				Retail price (VAT 10% included), thousand euros			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
R06	Antihistamines for systemic use	23.19	25.81	29.47	27.32	9,767	10,536	11,840	10,955	17,053	18,335	20,565	18,951
R06A	Antihistamines for systemic use	23.19	25.81	29.47	27.32	9,767	10,536	11,840	10,955	17,053	18,335	20,565	18,951
R06AE	Piperazine derivatives	15.87	17.62	19.76	18.80	6,023	6,524	7,212	6,923	10,490	11,331	12,621	12,014
R06AE03	Cyclizine		0.00	0.01	0.02		14	34	54		25	61	96
R06AE05	Meclozine	0.19	0.09	0.08	0.13	439	233	232	360	765	414	400	622
R06AE07	Cetirizine	15.10	16.90	18.99	18.10	5,238	5,928	6,569	6,252	9,127	10,289	11,520	10,859
R06AE09	Levocetirizine	0.59	0.63	0.68	0.55	347	350	377	257	598	602	639	437
R06AX	Other antihistamines for systemic use	7.32	8.19	9.71	8.52	3,744	4,012	4,629	4,032	6,564	7,004	7,944	6,937
R06AX13	Loratadine	1.19	1.37	1.39	1.19	374	437	436	376	677	780	759	653
R06AX18	Acrivastine	0.08	0.08	0.08	0.08	144	144	152	147	260	260	275	265
R06AX22	Ebastine	2.87	3.26	3.73	3.27	1,455	1,568	1,761	1,538	2,474	2,653	3,014	2,625
R06AX26	Fexofenadine	2.14	2.27	2.73	2.37	1,194	1,216	1,435	1,225	2,131	2,147	2,441	2,108
R06AX27	Desloratadine	1.05	1.21	1.78	1.62	576	647	844	746	1,021	1,164	1,455	1,285



ATC classification		Consumption, DDD/1,000 inhabitants/day				Wholesale price (VAT excluded), thousand euros				Retail price (VAT 10% included), thousand euros			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
S	Sensory organs					15,225	14,437	15,400	15,224	25,658	24,254	25,746	25,431
S01	Ophthalmologicals					14,562	13,826	14,814	14,495	24,519	23,206	24,742	24,182
S01G	Decongestants and antiallergics					3,310	2,894	3,426	2,992	5,736	5,010	5,829	5,090
S01GA	Sympathomimetics used as decongestants					251	201	212	233	452	356	370	406
S01GA02	Tetryzoline					251	201	212	233	452	356	370	406
S01GX	Other antiallergics					3,059	2,693	3,215	2,759	5,284	4,654	5,459	4,685
S01GX01	Cromoglicic acid					2,601	2,286	2,644	2,208	4,474	3,938	4,480	3,737
S01GX02	Levocabastine					122	175	257	160	211	304	443	276
S01GX05	Lodoxamide					56	35	44	29	98	61	76	51
S01GX07	Azelastine					26				43			
S01GX08	Ketotifen					254	197	270	361	457	351	460	620
S01X	Other ophthalmologicals					11,252	10,932	11,388	11,503	18,783	18,196	18,913	19,092
S01XA	Other ophthalmologicals					11,252	10,932	11,388	11,503	18,783	18,196	18,913	19,092
S01XA02	Retinol					503	512	492	340	866	882	848	587
S01XA20	Artificial tears and other indifferent preparations					10,750	10,420	10,896	11,162	17,917	17,314	18,066	18,505
S02	Otologicals					663	612	586	729	1,139	1,048	1,004	1,249
S02A	Antiinfectives					460	498	473	541	790	852	808	925
S02AA	Antiinfectives					460	498	473	541	790	852	808	925
S02AA03	Boric acid					460	498	473	541	790	852	808	925
S02D	Other otologicals					203	114	113	188	350	196	196	324
S02DA	Analgesics and anesthetics					203	114	113	188	350	196	196	324
S02DA04	Cinchocaine					203	114	113	188	350	196	196	324




ATC classification		Consumption, DDD/1,000 inhabitants/day				Wholesale price (VAT excluded), thousand euros				Retail price (VAT 10% included), thousand euros			
		2019	2020	2021	2022	2019	2020	2021	2022	2019	2020	2021	2022
V	Various					246	359	226	3,174	405	591	372	5,349
V03	All other therapeutic products					151	257	102	3,065	247	422	166	5,168
V03A	All other therapeutic products					151	257	102	3,065	247	422	166	5,168
V03AB	Antidotes					151	257	102	3,065	247	422	166	5,168
V03AB21	Potassium iodide					151	257	102	3,065	247	422	166	5,168
V07	All other non-therapeutic products					95	102	124	109	157	169	205	181
V07A	All other non-therapeutic products					95	102	124	109	157	169	205	181
V07AB	Solvents and diluting agents, incl. irrigating solutions					190	204	247	218	314	338	411	362
V07A	All other non-therapeutic products					89	95	102	124	147	157	169	205
V07AB	Solvents and diluting agents, incl. irrigating solutions					177	190	204	247	293	314	338	411



Figures on sales statistics


Figure 7.1. Consumption and sales of proton pump inhibitors (A02BC) in 2006–2022

DDD/1,000 inhabitants/day



- Esomeprazole (A02BC05)
- Rabeprazole (A02BC04)
- Lansoprazole (A02BC03)
- Pantoprazole (A02BC02)
- Omeprazole (A02BC01)

Wholesale price (VAT excluded) thousand euros



- Proton pump inhibitors (A02BC)
- Esomeprazole (A02BC05)
- - Rabeprazole (A02BC04)
- - Lansoprazole (A02BC03)
- Pantoprazole (A02BC02)
- Omeprazole (A02BC01)



Figure 7.2. Consumption of drugs for acid related disorders (A02) by hospital district in 2022

Whole country 75.47 DDD/1,000 inhabitants/day






Figure 7.3. Consumption and sales of insulins and analogues (A10A) in 2006–2022

DDD/1,000 inhabitants/day



- Insulins and analogues for injection, long-acting (A10AE)
- Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting (A10AD)
- Insulins and analogues for injection, intermediate-acting (A10AC)
- Insulins and analogues for injection, fast-acting (A10AB)


Wholesale price (VAT excluded) thousand euros




- Insulins and analogues (A10A)
- Insulins and analogues for injection, long-acting (A10AE)
- - - Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting (A10AD)
- Insulins and analogues for injection, intermediate-acting (A10AC)
- Insulins and analogues for injection, fast-acting (A10AB)

Figure 7.4. Consumption and sales of Blood glucose lowering drugs (A10B) in 2006–2022

DDD/1,000 inhabitants/day



Wholesale price (VAT excluded) thousand euros



- Sodium-glucose co-transporter 2 (SGLT2) inhibitors (A10BK)
- Glucagon-like peptide-1 (GLP-1) analogues (A10BJ)
- Dipeptidyl peptidase 4 (DPP-4) inhibitors (A10BH)
- Thiazolidinediones (A10BG)
- Combinations of oral blood glucose lowering drugs (A10BD)
- Sulfonylureas (A10BB)
- Biguanides (A10BA)

- Blood glucose lowering drugs, excl. Insulins (A10B)
- - - Sodium-glucose co-transporter 2 (SGLT2) inhibitors (A10BK)
- . . . Glucagon-like peptide-1 (GLP-1) analogues (A10BJ)
- . . . Dipeptidyl peptidase 4 (DPP-4) inhibitors (A10BH)
- Thiazolidinediones (A10BG)
- - - Combinations of oral blood glucose lowering drugs (A10BD)
- . . . Sulfonylureas (A10BB)
- . . . Biguanides (A10BA)

Figure 7.5. Consumption and sales of most common antihypertensives in 2006–2022







Figure 7.6. Consumption and sales of agents acting on renin-angiotensin system (C09) in 2006–2022



- Angiotensin II antagonists, combinations (C09D)
- Angiotensin II antagonists (C09C)
- ACE inhibitors, combinations (C09B)
- ACE inhibitors, plain (C09A)



- Angiotensin II antagonists, combinations (C09D)
- - - Angiotensin II antagonists (C09C)
- · - · - ACE inhibitors, combinations (C09B)
- · · ACE inhibitors, plain (C09A)

Figure 7.7. Consumption of agents acting on renin-angiotensin system (C09) by hospital district in 2022

Whole country 287.23 DDD/1,000 inhabitants/day








Figure 7.8. Consumption and sales of statins (C10AA) in 2006–2022

DDD/1,000 inhabitants/day



- Rosuvastatin (C10AA07)
- Atorvastatin (C10AA05)
- Fluvastatin (C10AA04)
- Pravastatin (C10AA03)
- Lovastatin (C10AA02)
- Simvastatin (C10AA01)

Wholesale price (VAT excluded) thousand euros



- Rosuvastatin (C10AA07)
- Atorvastatin (C10AA05)
- Fluvastatin (C10AA04)
- Pravastatin (C10AA03)
- Lovastatin (C10AA02)
- Simvastatin (C10AA01)

Figure 7.9. Consumption of lipid modifying agents reducers (C10) by hospital district in 2022

Whole country 190.46 DDD/1,000 inhabitants/day




Figure 7.10. Consumption of hormonal contraceptives in 2006–2022

DDD/day




Figure 7.11. Consumption of hormone replacement therapy drugs (G03C, G03F) among women aged over 45 by hospital district in 2022

Whole country 114.00 DDD/1,000 women aged over 45/day




Figure 7.12. Consumption of antibacterials (J01) in 2006–2022

DDD/1,000 inhabitants/day




Figure 7.13. Consumption of antibacterials (J01) by hospital district in 2022

Whole country 12.50 DDD/1,000 inhabitants/day




Figure 7.14. Consumption of analgesics (M01A, N02A and N02B) in 2006–2022

DDD/1,000 inhabitants/day




Figure 7.15. Consumption of most common OTC analgesics in 2006–2022




Figure 7.16. Consumption of opioids (N02A, N07BC) in 2006–2022





Figure 7.17. Consumption of most common hypnotics (N05C) in 2006–2022



1 Only products with marketing authorization.

Figure 7.18. Consumption of hypnotics (N05C) in outpatient care by hospital district in 2022

Whole country 47.39 DDD/1,000 inhabitants/day




Figure 7.19. Consumption of antidepressants (N06A) in 2006–2022




Figure 7.20. Consumption of most common antidepressants (N06A) in 2006–2022




Figure 7.21. Consumption of antidepressants (N06A) in outpatient care by hospital district in 2022

Whole country 87.60 DDD/1,000 inhabitants/day





Figure 7.22. Consumption of inhaled drugs for obstructive airway diseases in 2006–2022


DDD/1,000 inhabitants/day



- Anticholinergics (R03BB)
- Glucocorticoids (R03BA)
- Adrenergics in combination with anticholinergics (R03AL)
- Adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics (R03AK)
- Long-acting beta-2-adrenoreceptor agonists (R03AC12, R03AC13, R03AC18¹, R03AC19²)
- Short-acting beta-2-adrenoreceptor agonists (R03AC02, R03AC03)

1 From 2010.
2 From 2014.

Wholesale price (VAT excluded) thousand euros




- Anticholinergics (R03BB)
- ⋯ Glucocorticoids (R03BA)
- Adrenergics in combination with anticholinergics (R03AL)
- - - Adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics (R03AK)
- Long-acting beta-2-adrenoreceptor agonists (R03AC12, R03AC13, R03AC18¹, R03AC19²)
- ⋯ Short-acting beta-2-adrenoreceptor agonists (R03AC02, R03AC03)


1 From 2010.
2 From 2014.

Figure 7.23. Consumption of drugs for obstructive airway diseases (R03) by hospital district in 2022

Whole country 83.65 DDD/1,000 inhabitants/day



Appendices





Appendix 1. Alterations to ATC classification, valid as of January 2023

Substance	Previous ATC code	New ATC code
Covid-19 vaccines	J07BX03	deleted
Sitimagene ceradenovec	L01XX37	L01XL01
Talimogene laherparepvec	L01XX51	L01XL02
Axicabtagene ciloleucel	L01XX70	L01XL03
Tisagenlecleucel	L01XX71	L01XL04
Mirogabalin	N02BG11	N02BF03
Gabapentin	N03AX12	N02BF01
Pregabalin	N03AX16	N02BF02



Appendix 2. Alterations to defined daily doses (DDD), valid as of January 2023

Substance	Previous DDD	New DDD	ATC code
Sodium selenite	0.2 mg P	deleted 1)	A12CE02
Magnesium sulfate	1 g P	deleted 1)	A12CC02
Magnesium chloride	0.8 g P	deleted 1)	A12CC01
Calcium laevulate	1 g P	deleted 1)	A12AA30
Calcium chloride	0.2 g P	deleted 1)	A12AA07
Calcium gluconate	3 g P	deleted 1)	A12AA03
Calcium glubionate	2.75 g P	deleted 1)	A12AA02
Baricitinib	4 mg O	3 mg O	L04AA37

1 Parenteral DDDs in A12 are deleted. All parenteral solutions of electrolytes should be classified in B05B or in B05X.



Appendix 3. Deflators for converting expenditure items to 2022 money, 2000–2022

In the tables of the Finnish Statistics on Medicines, the euro amounts are presented in the current currency for each year. If necessary, the effects of changes in the money value may be eliminated by changing the euro amounts by means of a conversion factor appropriate to the monetary value on a given date (a so-called deflation coefficient). The coefficients below have been calculated from indices based on the situation on 31 December 2022.

Year	Consumer price index	Consumer health index/health care
2000	1,4400	1,5208
2001	1,4035	1,4862
2002	1,3820	1,4171
2003	1,3701	1,3739
2004	1,3675	1,3454
2005	1,3559	1,3201
2006	1,3321	1,3118
2007	1,2996	1,3175
2008	1,2489	1,2963
2009	1,2489	1,2533

Year	Consumer price index	Consumer health index/health care
2010	1,2339	1,2301
2011	1,1930	1,2190
2012	1,1604	1,2150
2013	1,1438	1,1941
2014	1,1312	1,1590
2015	1,1339	1,1234
2016	1,1294	1,0514
2017	1,1215	1,0338
2018	1,1094	1,0214
2019	1,0984	1,0122

Year	Consumer price index	Consumer health index/health care
2020	1,0951	1,0041
2021	1,0714	1,0056
2022	1,0000	1,0000

Source: Statistics Finland.